



Phosphorylation	  of	  Olig2	  and	  the	  control	  of	  stem	  	  






A	  thesis	  submitted	  to	  University	  College	  London	  for	  the	  	  
degree	  of	  Doctor	  of	  Philosophy	  
	  
	  
	   	  




I,	   Alexander	   Sinclair-­‐Wilson,	   confirm	   that	   the	   work	   presented	   in	   this	   thesis	   is	   my	   own.	  
Where	   information	   has	   been	   derived	   from	   other	   sources,	   I	   confirm	   that	   this	   has	   been	  
indicated	  in	  the	  thesis.	  
	  




I	  would	   like	   to	   thank	  Prof.	  William	  D.	  Richardson,	   in	  whose	   lab	   I	  have	  worked	  for	   the	   last	  
four	   years.	   The	   support	   and	   guidance	   I	   have	   received	   has	   been	   vital	   and	   I	   am	   extremely	  
grateful	  for	  his	  outstanding	  supervision.	  I	  am	  also	  indebted	  to	  all	  the	  members	  –	  past	  and	  
present	   –	   of	   the	   Richardson	   Lab.	   In	   particular,	   Dr	   Huiliang	   Li	   and	   Dr	   Ursula	   Grazini	   have	  
been	  wonderful	  teachers	  and	  I	  have	  learnt	  a	  tremendous	  amount	  working	  alongside	  them	  
both.	  Matthew	  Grist	  and	  Ulla	  Dennehy	  have	  provided	  excellent	  technical	  support	  in	  the	  lab	  
and	  BSU,	  respectively.	  Finally,	  Paul,	  Eleni,	  Sarah,	  Marcio,	  Alex	  and	  Alejandra	  each	  deserve	  a	  
mention	  for	  the	  huge	  part	  they	  have	  all	  played	  in	  making	  the	  time	  I	  have	  spent	  at	  UCL	  so	  
interesting	  and	  enjoyable.	  
	  
At	  Yale,	  Prof.	  Anne	  Eichmann	  and	  Prof.	  Jean-­‐Leon	  Thomas	  provided	  the	  unique	  opportunity	  
to	   work	   in	   the	   United	   States.	   The	   engaging	   research	   I	   did	   and	   attentive	   supervision	   I	  
received	   as	   a	  member	   of	   the	   Eichmann	   and	   Thomas	   Labs	  made	   the	   time	   I	   spent	   at	   Yale	  
brilliant.	  Of	  the	  many	  people	  I	  worked	  alongside	  so	  easily	  and	  enjoyably,	  Jinah	  Han	  deserves	  
a	  special	  thank	  you	  for	  looking	  after	  me	  and	  making	  me	  feel	  so	  welcome.	  
	  
Finally,	   I	   would	   like	   to	   thank	  my	   dad,	   Jonathan,	  my	  mum,	   Charlotte	   and	  my	   little	   sister,	  
Rosa,	  as	  well	  as	  my	  close	   friends	   (Yas,	  Rohin,	   Jamie,	  Charlie,	  Steve,	  Tom,	  Suni,	  Cian,	  Ollie,	  
Will	  and	  Anya)	  for	  their	  support	  and	  encouragement	  over	  the	  years.	  




Oligodendrocytes	   (OLs)	   are	   the	   myelinating	   cells	   of	   the	   central	   nervous	   system	   (CNS),	  
ensheathing	   axons	   and	   enabling	   the	   rapid	   conduction	   of	   nerve	   impulses.	   In	   CNS	  
development,	   lineage-­‐restricted	   OL	   precursors	   (OLPs)	   arise	   in	   discrete	   regions	   of	   the	  
ventricular	  zone	  under	  strict	  spatial	  and	  temporal	  control.	  In	  the	  embryonic	  spinal	  cord,	  for	  
example,	   the	   majority	   of	   OLPs	   derive	   from	   a	   subpopulation	   of	   neural	   stem	   cells	   (NSCs)	  
residing	   in	   the	   ventral	   progenitor	   of	   motor	   neurons	   (pMN)	   domain.	   These	   pMN	   domain	  
NSCs	  are	  characterized	  by	  expression	  of	  the	  basic	  helix-­‐loop-­‐helix	  (HLH)	  transcription	  factor	  
Olig2	   and	   are	   also	   responsible	   for	   the	   generation	  of	   all	   spinal	  motor	  neurons	   (MNs).	  MN	  
generation	  precedes	  OLP	  generation	  and	  it	  has	  been	  shown	  that	  phosphorylation	  of	  serine	  
147	  (S147)	  in	  the	  HLH	  domain	  of	  Olig2	  is	  a	  key	  modulator	  of	  the	  MN-­‐OLP	  fate	  switch.	  During	  
MN	   production,	   Olig2	   is	   phosphorylated	   at	   S147	   and	   forms	   Olig2:Olig2	   homodimers.	  
Dephosphorylation	   at	   S147	   induces	   Olig2	   homodimer	   dissociation	   and	   formation	   of	  
heterodimers,	  and	  activates	  the	  MN-­‐OLP	  fate	  switch.	  In	  this	  Thesis,	  I	  present	  the	  results	  of	  
my	   research	   into	   the	   mechanisms	   that	   regulate	   the	   dephosphorylation	   of	   Olig2	   and	  
mediate	  the	  impact	  this	  has	  on	  stem	  cell	  fate	  choice.	  Analysing	  the	  genomic	  binding	  sites	  of	  
phosphorylated	   wild-­‐type	   Olig2	   and	   a	   constitutively	   dephosphorylated	   mutant	   form	   of	  
Olig2	  (Olig2-­‐S147A),	  I	  have	  revealed	  that	  S147	  phosphorylation	  has	  a	  major	  impact	  on	  Olig2	  
gene	  target	  choice.	   I	  have	  also	  explored	   the	   role	  of	  angiogenesis	   in	   regulation	  of	   the	   fate	  
switch	  –	  both	  in	  vitro	  and	  in	  vivo	  using	  mouse	  and	  zebrafish	  models	  of	  development	  –	  and	  I	  
have	   identified	   an	   inhibitory	   phosphatase	   component	   that	   is	   down-­‐regulated	   over	   the	  
period	   of	   the	   fate	   switch	   and	   is	   a	   candidate	   regulator	   of	   Olig2	   S147	   dephosphorylation.	  
Finally,	  I	  have	  performed	  computational	  analysis	  of	  Olig2	  phosphorylation	  and	  designed	  and	  
	   v	  
constructed	   genetic	   tools	   for	   studying	   the	   regulation	   and	   function	   of	   an	   additional	   Olig2	  
phospho-­‐acceptor	  site	  at	  S263.	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1.1	   BACKGROUND	  
	  
The	  mammalian	  central	  nervous	  system	  (CNS)	  is	  composed	  of	  two	  major	  neural	  cell	  classes:	  
neurons	   and	   glia.	   Neurons	   receive,	   process	   and	   transmit	   electrical	   and	   chemical	   signals	   as	  
part	   of	   an	   extensive	   network	   of	   interacting	   cells.	   Glia	   provide	   the	   necessary	   metabolic,	  
structural	   and	   functional	   support	   for	   development	   and	   maintenance	   of	   the	   integrated	  
neuronal	  system	  (Verkhratsky	  &	  Butt,	  2007).	  Despite	  making	  up	  more	  than	  80%	  of	  the	  cells	  in	  
the	  CNS,	   the	   role	  of	   glia	  was,	   throughout	  most	  of	   the	   twentieth	   century,	   considered	   to	  be	  
static	  and	  not	  to	  contribute	  to	  the	  activity	  of	  the	  neuronal	  network	  other	  than	  in	  a	  supporting	  
role.	   Improvements	   in	   our	   understanding	   of	   glia	   have,	   however,	   demonstrated	   critical	  
functions	   in	   dynamically	   regulating	   neural	   circuitry,	   raising	   awareness	   of	   these	   cells	   and	  
provoking	  an	  intense	  interest	  in	  glial	  cell	  biology.	  
	  
CNS	   glia	   are	   subdivided	   into	   microglia	   –	   CNS-­‐resident	   immune	   cells	   derived	   from	   the	  
embryonic	  mesoderm	  –	  and	  macroglia	  –	  a	  variety	  of	  cell	  types	  that,	  like	  neurons,	  are	  derived	  
from	  the	  neuroectoderm	  (Jessen	  &	  Richardson,	  2001).	  Macroglia	  are	  principally	  comprised	  of	  
astrocytes	  and	  oligodendrocytes.	  Oligodendrocytes	  (OLs)	  are	  the	  specialized	  cells	  responsible	  
for	   ensheathing	   axons	   of	   CNS	   neurons	   in	   multilayered	   myelin	   (De	   Robertis	   et	   al.,	   1958).	  
Oligodendrocytes	   (literally	   ‘cells	   with	   several	   branches’)	   extend	   processes	   to	   axons	   of	  
different	   proximate	   neurons	   and	   elaborate	  multiple	   myelin	   sheaths	   (Figure	   1).	   Bundles	   of	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myelinated	  axons	  form	  the	  major	  component	  of	  CNS	  “white	  matter”	  tissue,	  visibly	  different	  
from	   “grey	  matter”	   (primarily	   unmyelinated	   neuronal	   cell	   bodies)	   (Fields,	   2008).	   The	   lipid-­‐
rich	  myelin	  sheath	  electrically	  insulates	  the	  myelinated	  axon	  fibre	  and	  allows	  rapid	  saltatory	  
transmission	   of	   action	   potentials	   along	   the	   axon	   (Moore	   et	   al.,	   1978).	   Briefly,	   action	  
potentials	   are	   conducted	   almost	   instantaneously	   between	   nodes	   of	   Ranvier,	   the	  
unmyelinated	  segments	  of	  axon	  between	  myelinated	  internodes,	  where	  activation	  of	  clusters	  
of	  voltage-­‐gated	  sodium	  channels	  depolarizes	  the	  axon	  and	  regenerates	  the	  action	  potential.	  
	  
	  
Figure	   1.	   Myelinating	   oligodendrocytes.	   A.	   Schematic	   representation	   of	   a	   myelinating	  
oligodendrocyte.	  B.	  Electron	  micrograph	  of	  the	  cross-­‐section	  through	  a	  myelinated	  axon.	  
	  
Evolution	  of	  myelin	  
	  
In	  an	  evolutionary	  context,	  accelerated	  transmission	  of	  electrical	  signals	  along	  nerve	  fibres	  –	  
enabling	  a	  quicker,	  more	  sophisticated	  stimulus-­‐response	  –	  would	  have	  conferred	  an	  obvious	  
selective	  advantage	  for	  both	  primitive	  predators	  and	  their	  potential	  prey.	  Over	  the	  course	  of	  
evolution,	   two	   principal	   mechanisms	   have	   developed	   for	   increasing	   the	   speed	   of	   nerve	  
impulse	   conduction:	   expansion	   of	   axon	   diameter	   and	  myelination	   (reviewed	   by	  Hartline	  &	  
Coleman,	  2007).	  Increasing	  the	  axon	  diameter	  accelerates	  conduction	  speed	  by	  reducing	  the	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internal	   resistance	  of	   the	   fibre	   (conduction	   speed	   increases	  proportionally	  with	   the	   square	  
root	   of	   axon	  diameter)	   (Hodgkin,	   1954).	  Giant	   axons	   are	   found	   across	   a	   range	  of	   different	  
taxa,	   often	   in	   time-­‐critical	   neural	   circuits.	   In	   the	   Annelids	   or	   ringed	   worms,	   for	   example,	  
signaling	  along	  longitudinal	  giant	  axons	  is	  necessary	  for	  eliciting	  a	  rapid	  escape	  response	  but	  
is	   not	   involved	   in	   normal	  movement.	   Despite	   increasing	   conduction	   speed,	   however,	   giant	  
axons	  are	  spatially	  inefficient	  and	  extremely	  metabolically	  costly.	  
	  
Myelin	   and	   pseudo-­‐myelin	   sheaths,	   the	   alternative	   evolutionary	   mechanism	   for	   boosting	  
conduction	  speeds,	  have	  been	  described	  in	  both	  vertebrates	  and	  invertebrates,	  respectively	  
(Gunther,	   1976;	   Bullock	   et	   al.,	   1984).	   The	   different	   myelinated	   taxa	   are	   widely	   separated	  
phylogenetically,	   suggesting	   that	   superficially	   similar	   myelin	   structures	   have	   evolved	  
independently	   in	   different	   lineages.	   Vertebrate	   myelin	   may	   have	   arisen	   in	   the	   first	  
Gnathostomes	   (jawed	   fish)	   (Bullock	   et	   al.,	   1984).	   Absent	   in	   jawless	   fish	   (lampreys	   and	  
hagfish),	  the	  co-­‐emergence	  of	  myelinated	  cranial	  nerves	  and	  hinged	  jaws	  might	  underlie	  the	  
evolution	  of	  predation.	  An	  alternative	  hypothesis	   is	   that	  OL	  myelin	   first	  evolved	  to	   insulate	  
the	   axons	   of	   motor	   neurons	   (MNs)	   and	   enable	   rapid	   escape	   behaviour	   (Li	   &	   Richardson,	  
2008).	  In	  support	  of	  this	  hypothesis	  is	  the	  intimate	  developmental	  relationship	  between	  MNs	  
and	  OLs	   in	   the	   vertebrate	   CNS	   and	   the	   fact	   that	   pseudo-­‐myelin	   in	   invertebrate	   lineages	   is	  
primarily	   associated	   with	   circuits	   involved	   in	   rapid	   escape	   or	   startle	   reactions	   (see	  
Oligodendrocyte	  Development	  below).	  
	  
The	  myelin	   sheath	   reduces	   the	   transverse	   capacitance	   across	   the	   axon	  plasma	  membrane.	  
Typically,	  myelin	  insulation	  improves	  conduction	  speeds	  by	  at	  least	  a	  factor	  of	  10	  (equivalent	  
to	  a	  ~100-­‐fold	  increase	  in	  unmyelinated	  axon	  diameter),	  and	  significantly	  reduces	  the	  energy	  
cost	   of	   neuronal	   activity	   (Harris	   &	   Attwell,	   2012).	   Fast	   and	   efficient	   signal	   transmission	  
enables	   coordination	   of	   more	   complex	   neuronal	   networks	   in	   physically	   larger	   nervous	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systems,	  with	  much	   greater	   information	  processing	   capacity,	   and	  ultimately	  proved	   critical	  
for	  the	  evolution	  of	  intelligence.	  
	  
CNS	  myelin	  and	  disease	  
	  
In	   humans,	   OL	   loss	   and	   demyelination	   are	   hallmark	   pathologies	   of	   a	   variety	   of	  
neurodegenerative	   diseases	   (including	   multiple	   sclerosis	   and	   leukodystrophies)	   and	   white	  
matter	  injuries.	  
	  
Multiple	   sclerosis	   (MS).	   MS	   is	   a	   chronic	   inflammatory	   degenerative	   disease	   of	   the	   CNS	  
characterized	   by	   demyelination,	   OL	   death	   and	   axonal	   degeneration	   (Compston	   &	   Coles,	  
2002).	  MS	   is	   believed	   to	   be	   triggered	   by	   autoimmune	   attack	   on	  OLs	   and	  myelin,	   although	  
whether	  the	  immune	  involvement	  is	  the	  cause	  or	  a	  result	  of	  demyelination	  is	  still	  unclear.	  MS	  
affects	   over	   two	   million	   people	   worldwide,	   predominantly	   in	   North	   America,	   Europe	   and	  
Australia,	  and	  is	  a	   leading	  cause	  of	  disability	  among	  young	  adults.	  Patients	  typically	  present	  
with	   a	   relapsing-­‐remitting	   course	   of	   the	   disease	   characterized	   by	   acute	   neurological	  
symptoms	  (days	  to	  several	  months)	  followed	  by	  periods	  of	  complete	  or	  partial	  recovery	  (Milo	  
&	   Kahana,	   2010).	   Between	   10	   and	   15%	   of	   patients	   follow	   a	   primary	   progressive	   disease	  
course	   in	   which	   neurological	   symptoms	   accumulate	   steadily	   from	   the	   point	   of	   onset	  
(Compston	   &	   Coles,	   2008).	   Over	   time,	   relapsing-­‐remitting	   MS	   frequently	   develops	   a	  
secondary-­‐progressive	  character,	  with	  neurological	  disabilities	  accumulating	  in	  the	  patient	  in	  
a	   manner	   similar	   to	   the	   primary-­‐progressive	   form.	   Although	   widely	   considered	   an	  
autoimmune	   disease	   directed	   against	   CNS	  myelin	   or	  OLs,	   the	   underlying	   causes	   of	  MS	   are	  
unknown.	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The	  hallmark	  feature	  of	  MS	  is	  the	  formation	  of	  numerous	  white	  matter	   lesions	  (or	  sclerotic	  
plaques),	   the	   direct	   consequence	   of	   oligodendrocyte	   death	   and	   the	   loss	   of	   myelin.	   One	  
particularly	  interesting	  pathophysiology	  –	  one	  very	  relevant	  to	  glial	  biologists	  –	  is	  the	  limited	  
capacity	   in	   MS	   sufferers	   to	   remyelinate	   axons	   and	   repair	   lesions	   (Chandran,	   2008).	  
Myelination	  remains	  dynamic	  in	  the	  mature	  CNS,	  and	  although	  the	  poor	  OL	  response	  in	  the	  
disease	   context	   is	   not	   fully	   understood,	   inducing	   effective	   remyelination	   in	  MS	   lesions	   has	  
major	  therapeutic	  potential.	  
	  
Leukodystrophies.	   Leukodystrophies	   are	   a	   large	   and	   divergent	   family	   of	   genetic	   disorders	  
characterized	   by	   progressive	   disturbances	   in	   white	   matter	   development	   (Costello	   et	   al.,	  
2009).	  The	  symptoms	  of	  different	  leukodystrophies	  vary	  greatly,	  reflecting	  the	  wide	  range	  of	  
underlying	   genetic	   causes.	   	   Most	   commonly,	   delayed	   cognitive	   development	   presents	   in	  
infants	   and	   children	  and	  progressively	  deteriorates,	  often	  affecting	  movement,	   speech	  and	  
behaviour.	   Similarly	   to	   MS,	   myelin	   repair	   is	   an	   attractive	   therapeutic	   target	   (Kondo	   &	  
Duncan,	  2009).	  Indeed,	  in	  a	  mouse	  model	  of	  congenital	  dysmyelination,	  engrafted	  OL	  lineage	  
cells	  derived	  from	  human	  embryonic	  stem	  cells	  robustly	  myelinated	  the	  deficient	  brain	  and	  
significantly	  extended	  the	  survival	  of	  hypomyelinated	  mice	  (Wang	  et	  al.,	  2013).	  	  
	  
White	   matter	   injury	   (WMI).	  White	   matter	   injury	   can	   occur	   as	   a	   consequence	   of	   different	  
traumatic	  episodes	  typically	  involving	  a	  diminished	  oxygen/blood	  supply	  to	  all	  or	  part	  of	  the	  
brain	   (Volpe,	   2003;	   Khwaja	  &	   Volpe,	   2008).	   In	   periventricular	   leukomalacia	   (PVL),	   preterm	  
newborns	  suffer	  major	  OL	  damage	  around	  the	   lateral	  ventricles.	  The	  cerebral	  white	  matter	  
injury	   is	   commonly	   associated	  with	   neurodevelopmental	   impairment	   and	   cerebral	   palsy	   or	  
epilepsy	  later	  in	  life.	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The	  severity	  and	  incidence	  of	  OL/white	  matter	  diseases	  is	  associated	  with	  an	  enormous	  social	  
and	   economic	   burden.	   Improving	   our	   understanding	   of	   OL	   biology	   in	   both	   normal	   and	  
disease	  contexts	  will	  enable	  the	  essential	  generation	  of	  new	  diagnostic	  and	  therapeutic	  tools.	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1.2	   OLIGODENDROCYTE	  SPECIFICATION	  
	  
Oligodendrocyte	  lineage	  and	  markers	  
	  
OL	   lineage	   cells	   derive	   from	   the	   neuroepithelium	   of	   the	   developing	   CNS	   (Kessaris	   et	   al.,	  
2001).	   The	   first	   OL	   precursors	   (OLPs)	   appear	   late	   in	   embryonic	   neurogenesis	   from	  
multipotent	  neuroepithelial	  stem	  cells	  in	  the	  ventral	  ventricular	  zone	  of	  the	  embryonic	  spinal	  
cord	   (Rowitch,	  2004;	  Richardson	  et	  al.,	  2006).	  OLPs	   transition	   through	  a	  number	  of	  distinct	  
intermediate	  progenitor	  stages	  on	  the	  way	  to	  becoming	  mature,	  myelinating	  OLs	   (Figure	  2)	  
(Nishiyama	  et	  al.,	  2009).	  The	  stereotypical	  morphologies	  and	  molecular	  markers	  associated	  
with	  the	  different	  stages	  of	  OL	  development	  are	  outstanding	  tools	  for	  researching	  OL	  biology	  
both	  in	  vivo	  and	  in	  vitro.	  
	  
	  
Figure	   2.	  Multi-­‐stage	   oligodendrocyte	   development	   and	   lineage	  marker	   expression.	  OLPs	  derive	   from	  
neural	   stem	   cells	   in	   the	   ventricular	   zone	  of	   the	   developing	   CNS.	  Differentiation	   of	  OLPs	   to	  mature	   and	  
myelinating	   OLs	   involves	   stepwise	   transition	   through	   several	   intermediate	   stages.	   Different	   progenitor	  
cell-­‐types	   are	   associated	   with	   stereotypical	   morphologies	   and	   expression	   of	   stage-­‐specific	   protein	  
markers.	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Origins	  of	  OLPs	  
	  
The	  prevailing	  view	  among	  glial	  biologists	  was,	  until	  at	   least	  the	  early	  1990s,	  that	  OLs	  arose	  
from	   all	   parts	   of	   the	   embryonic	   ventricular	   zone.	   It	   has	   been	   clearly	   demonstrated	   since,	  
however,	  that	  while	  mature	  OLs	  are	  widely	  and	  evenly	  distributed	  throughout	  the	  adult	  CNS,	  
fate-­‐restricted	   OLPs	   are	   in	   fact	   born	   from	   discrete	   areas	   of	   the	   ventricular	   zone	   during	  
development	  (Richardson	  et	  al.,	  2006).	  Newly	  specified	  OLPs	  migrate	  away	  from	  the	  specific	  
germinal	   zones,	   eventually	   colonizing	   the	   entire	   CNS,	   before	   differentiating	   to	   become	  
mature	  and	  myelinating	  OLs.	  	  
	  
Embryonic	  spinal	  cord	  
The	   ventricular	   zone	   of	   the	   mammalian	   embryonic	   spinal	   cord	   is	   divided	   into	   distinct	  
progenitor	   domains	   along	   its	   dorsal-­‐ventral	   axis	   (Figure	   3)	   (Jessell,	   2000).	   Neuroepithelial	  
stem	   cells	   resident	   in	   the	   different	   regions	   express	   domain-­‐specific	   combinations	   of	  
transcription	   factors	   (TFs)	   and	   generate	   characteristic	   subtypes	   of	   specialized	   neurons	   and	  
glia.	  Along	  the	  caudal	  neural	   tube,	   the	  antecedent	  structure	   to	   the	  spinal	  cord,	   the	  protein	  
morphogen	   Sonic	   hedgehog	   (Shh)	   is	   secreted	   from	   the	   ventral	   notochord	   and	   floorplate	  
(Dessaud	  et	  al.,	   2008).	   The	   concentration	  and	   length	  of	  exposure	   to	  Shh,	  which	  diminishes	  
with	   distance	   from	   the	   ventral	   midline,	   differentially	   regulates	   transcription	   of	   various,	  
frequently	  cross-­‐repressive	  TFs.	  Collectively,	  specific	  TF	  expression	  profiles	  define	  five	  distinct	  
progenitor	   domains	   across	   the	   ventral	   spinal	   cord	   –	   ventral-­‐most	   p3	   -­‐	   pMN	   -­‐	   p2	   -­‐	   p1	   -­‐	   p0	  
(Figure	  3).	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Figure	   3.	   Ventral	   patterning	   of	   the	   embryonic	   spinal	   cord.	   The	   ventricular	   zone	   of	   the	   embryonic	  
spinal	   cord	   is	   patterned	   along	   its	   dorsal-­‐ventral	   axis	   into	  distinct	   progenitor	   domains.	   In	   the	   ventral	  
portion,	   graded	   sonic	   hedgehog	   (Shh)	   signaling	   induces	   segmental	   expression	   of	   different	  
combinations	   of	   transcription	   factors	   (TFs).	   Specific	   combinations	   initiate	   unique	   developmental	  
programmes	   and	   generate	   particular	   neuronal	   and	   glial	   subtypes	   within	   the	   discrete	   progenitor	  
domains.	  (BMPs,	  bone	  morphogenetic	  proteins;	  FP,	  floorplate;	  RP,	  roofplate.)	  
	  
Stem	   cells	   of	   the	   pMN	   (progenitor	   of	   motor	   neuron)	   neuroepithelial	   domain	   specifically	  
express	   the	   basic	   helix-­‐loop-­‐helix	   TF	  Olig2,	   along	  with	  more	   broadly	   induced	   TFs	   Pax6	   and	  
Nkx6.1	   (Ericson	   et	   al.,	   1997;	   Briscoe	   et	   al.,	   2000;	   Vallstedt	   et	   al.,	   2001;	   Zhou	  &	   Anderson,	  
2002).	   This	  Olig2-­‐positive	  progenitor	  pool	   contributes	  approximately	  80%	  of	   the	  OLs	   in	   the	  
adult	   spinal	   cord.	   The	   restricted	   source	   of	   most	   OLs	   was,	   however,	   first	   identified	   in	   rats	  
before	  the	  discovery	  of	  the	  Olig	  genes	  (Warf	  et	  al.,	  1991;	  Pringle	  &	  Richardson,	  1993;	  Noll	  &	  
Miller,	   1993;	   Yu	   et	   al.,	   1994;	   Timsit	   et	   al.,	   1995).	   Early	   in	   vitro	   experiments	   showed	   OL	  
development	   in	   explant	   cultures	   derived	   from	   ventral	   but	   not	   dorsal	   rat	   spinal	   cord,	  
suggesting	  that	  the	  capacity	  of	  spinal	  cord	  progenitors	  to	  generate	  OLPs	  varies	  with	  position	  
along	  the	  dorsal-­‐ventral	  axis	   (Warf	  et	  al.	  1991).	  RNA	   in	  situ	  hybridization	   (ISH)	  experiments	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then	  established	   transient,	   focal	   expression	  of	  OL	   lineage	  markers	   (platelet-­‐derived	  growth	  
factor	  receptor	  alpha	  [PDGFRA]	  and	  2ʹ′,3ʹ′-­‐cyclic-­‐nucleotide	  3ʹ′-­‐phosphodiesterase	  [CNP])	  in	  the	  
ventral	   spinal	   cord	   at	   embryonic	   day	   14	   (E14),	   consistent	   with	   the	   notion	   of	   spatially	  
restricted	  OLP	  generation	  (Pringle	  &	  Richardson,	  1993;	  Yu	  et	  al.,	  1994).	  The	  discovery	  in	  2000	  
and	  subsequent	  characterization	  of	  OL	  lineage	  genes	  Olig1	  &	  Olig2	  specifically	  delineated	  the	  
pMN	  domain	  and	  confirmed	  the	  restricted,	  ventral	  origin	  of	  OLPs	  (Lu	  et	  al.,	  2000;	  Zhou	  et	  al.,	  
2000;	  Lu	  et	  al.,	  2002;	  Zhou	  et	  al.,	  2002).	  
	  
The	  contribution	  of	  a	  small	  fraction	  –	  now	  understood	  to	  be	  ~20%	  –	  of	  OL	  lineage	  cells	  from	  
dorsal	  neuroepithelium	  after	  the	  emergence	  at	  E12.5	  in	  mouse	  of	  pMN	  OLPs	  continued	  to	  be	  
a	   controversial	   idea	   until	   2005	   (Richardson	   et	   al.,	   2000;	   Spassky	   et	   al.,	   2000;	   reviewed	   by	  
Richardson	   et	   al.,	   2006).	   Analysis	   of	   OL	   marker	   activation	   in	   Shh-­‐null	   and	   Nkx6.1/Nkx6.2	  
compound-­‐null	   mouse	   lines,	   both	   lacking	   pMN-­‐derived	   OLs,	   revealed	   Shh-­‐independent	  
production	  of	  OLPs	  from	  dorsal	  progenitor	  cell	  populations	  (Cai	  et	  al.,	  2005;	  Vallstedt	  et	  al.,	  
2005).	   These	   observations	   were	   independently	   supported	   by	   Cre-­‐lox	   fate	   mapping	  
experiments	   in	   Dbx-­‐CreERT2:Reporter	   transgenic	   mice;	   OLPs	   (Sox10+;	   Olig2+)	   derived	   from	  
Dbx-­‐positive	   neuroepithelium	   (spanning	   the	   dorsoventral	   midline)	   were	   identified	   at	   late	  
embryonic	  (E16.5	  &	  E18.5)	  stages	  (Fogarty	  et	  al.,	  2005).	  	  
	  
In	  brief,	  OLPs	  primarily	  arise	   in	  the	  ventral	  pMN	  domain	  of	  the	  developing	  spinal	  cord,	   first	  
appearing	   around	   E14	   in	   rat	   and	   E12.5	   in	   mouse.	   At	   approximately	   E15	   in	   mouse,	   a	  
subsequent	  Shh-­‐independent	  wave	  of	  OLP	  generation	  begins	  from	  more	  dorsal	  regions	  of	  the	  
ventricular	   zone.	   Oligodendrogenesis	   continues	   until	   late	   gestation,	   with	   newly	   born	   OLPs	  
migrating	  away	  from	  the	  ventricular	  germinal	  zone	  and	  populating	  the	  entire	  spinal	  cord.	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Forebrain	  
Aside	  from	  the	  embryonic	  spinal	  cord,	  research	   into	  the	  origins	  of	  OLPs	  has	  focused	  on	  the	  
developing	  forebrain.	  The	  first	  indication	  that	  OLPs	  derive	  from	  specific	  regions	  of	  the	  rostral	  
neural	   tube	   came	   from	   the	   RNA	   ISH	   experiments	   described	   above	   (Pringle	   &	   Richardson,	  
1993).	  Labeling	  coronal	  sections	  of	  E15	  rat	  forebrain,	  Pringle	  &	  Richardson	  observed	  intense	  
PDGFRA	   signal	   in	   the	   ventral	   forebrain	   pre-­‐optic	   area	   (beneath	   the	   Foramen	   of	   Monro).	  
Additional	   experiments	   from	   the	  Richardson	   Lab	   followed	   the	  distribution	  of	  OLPs	   through	  
the	  developing	   rat	   telencephalon	   from	  E14.5-­‐E20.5	  and	  elucidated	  a	  major	   role	   for	   ventral	  
Shh	   signaling	   in	   forebrain	  oligodendrogenesis	   (Tekki-­‐Kessari	   et	   al.,	   2001).	  Considering	  what	  
was	   known	   by	   2001	   about	  OLP	   specification	   in	   the	   rodent	   spinal	   cord,	   this	   data	   appeared	  
consistent	   with	   a	   restricted	   origin	   of	   OLPs	   in	   the	   ventral	   forebrain.	   The	   data	   did	   not,	  
however,	  exclude	  the	  possibility	  of	  OLP	  production	  from	  additional	  sources	  within	  or	  outside	  
the	  telencephalon.	  
	  
Research	   from	   a	   number	   of	   labs	   pointed	   to	   oligodendrogenesis	   from	   outside	   the	  MGE.	   In	  
vitro	   clonal	   analysis	   and	   Dlx2	   lineage	   tracing	   in	   vivo	   showed	   widespread	   subpallial	   OLP	  
production	   from	  the	   lateral	  and	  caudal	  ganglionic	  eminences	   (LGE	  and	  CGE),	  as	  well	  as	   the	  
medial	   ganglionic	   eminence	   (MGE)	   (He	   et	   al.,	   2001;	  Marshall	   et	   al.,	   2002).	   Examination	   of	  
Emx1-­‐Cre:Reporter	   transgenic	   mice	   also	   revealed	   local	   OLP	   generation	   in	   the	   developing	  
cerebral	   cortex	   (Gorski	   et	   al.,	   2002).	   These	   observations,	   along	  with	   the	   results	   from	  early	  
retroviral	  fate	  mapping	  experiments	  that	  appeared	  to	  demonstrate	  postnatal	  OL	  specification	  
in	  the	  forebrain	  subventricular	  zone,	  fuelled	  skepticism	  over	  the	  ventral	  origins	  of	  OLs	  in	  the	  
forebrain	   (Levison	   et	   al.,	   1993).	   In	   2006,	   Kessaris	   et	   al.	   resolved	   the	   issue	   using	   three	  Cre-­‐
Reporter	  mouse	   lines	  to	   label	  and	  trace	  distinct	   forebrain	  stem	  cell	  populations	   in	  the	  MGE	  
(Nkx2.1-­‐expressing),	   the	   LGE/CGE	   (Gsh2-­‐expressing)	   and	   in	   the	   cortex	   (Emx1-­‐expressing)	  
(Kessaris	   et	   al.,	   2006).	   The	   analysis	   revealed	   precise	   spatio-­‐temporal	   control	   of	   OLP	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production	   from	   multiple	   sites.	   MGE-­‐derived	   OLPs	   first	   emerged	   around	   E11.5,	   with	  
subsequent	   specification	   from	   the	   LGE/CGE	   at	   ~E15	   and	   from	   the	   cortex	   after	   birth.	  
Experimentally	  observed	  as	  three	  distinct	  oligodendrogenic	  phases,	  forebrain	  OLP	  production	  
probably	  proceeds	  as	  a	  continuous	  wave,	  moving	  from	  ventral	  to	  dorsal	  over	  time.	  
	  
OL	   development	   in	   the	   forebrain	  mimics	   the	   spinal	   cord.	   The	   first	  OLPs	   arise	   from	   ventral	  
progenitors	   through	   a	   Shh	   signaling-­‐dependent	   process.	   Specification	   from	   more	   dorsal	  
progenitors	   occurs	   later	   and	   independently	   of	   Shh.	   Surprisingly,	   MGE-­‐derived	   OLs	   (the	  
earliest-­‐born)	   are	   eliminated	   after	   birth	   and	   are	   largely	   absent	   from	   the	   adult	   forebrain,	  
though	   the	   mechanism(s)	   and	   explanation	   for	   their	   removal	   have	   not	   been	   discovered	  
(Kessaris	  et	  al.,	  2006).	  	  
	  
Behaviour	  of	  ventrally	  versus	  dorsally	  derived	  OLPs	  
After	  the	  early	  morphological	  classification	  of	  different	  OL	  subtypes	  by	  Del	  Rio	  Hortega	  in	  the	  
1920s,	   identification	   of	   different	   OL	   populations	   originating	   from	   different	   VZ	   territories	  
reinforced	  suggestions	  of	   functional	  heterogeneity	  among	  OLs.	   In	   the	   forebrain,	  Kessaris	  et	  
al.	   (2006)	   adapted	   their	   Cre-­‐Reporter	   strategy	   to	   eliminate	   OLPs	   derived	   from	   specific	  
progenitor	  populations.	  This	  demonstrated	  that	  targeted	  ablation	  of	  any	  population	  of	  OLPs	  
(for	   example	   the	   LGE/CGE-­‐derived	   pool)	   was	   effectively	   compensated	   for	   by	   expansion	   of	  
neighbouring	  populations	  of	  OLPs,	  indicating	  functional	  redundancy	  among	  OLs,	  regardless	  of	  
origin.	   More	   recently,	   research	   in	   the	   spinal	   cord	   has	   examined	   whether	   ventrally	   versus	  
dorsally	  derived	  OLPs	  possess	  different	  electrophysiological	  properties	  (Tripathi	  et	  al.,	  2011).	  
Tripathi	   et	   al.	   generated	  a	   transgenic	  dual	   reporter	  mouse	   line	   that	  differentially	   labels	  OL	  
lineage	  cells	  according	  to	  place	  of	  birth.	  All	  OLPs	  were	  morphologically	  indistinguishable,	  and	  
although	   two	   electrophysiological	   subtypes	   were	   identified	   –	   spiking	   and	   non-­‐spiking	   –	  
neither	   subtype	   was	   linked	   to	   a	   particular	   developmental	   origin.	   This	   study,	   however,	   did	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identify	   population-­‐specific	   patterns	   of	   migration	   and	   myelination.	   Compared	   to	   ventrally	  
derived	   OLPs,	   dorsal	   progenitors	   migrate	   less	   widely	   from	   their	   sources,	   predominantly	  
settling	  and	  myelinating	  axons	   in	   the	  dorsal	   tract.	  Furthermore,	   the	  proportion	  of	  ventrally	  
derived	  OLs	  in	  the	  dorsal	  spinal	  cord	  decreases	  from	  roughly	  45%	  at	  P13	  to	  less	  than	  20%	  at	  
P67,	   indicating	   that	   the	   dorsally	   derived	   cells	   possess	   some	   selective	   advantage	   and	   are	  
capable	  of	  displacing	  ventrally	  derived	  OLs	  from	  regions	  of	  shared	  occupancy.	  
	  
A	  motor	  neuron-­‐oligodendrocyte	  connection	  
	  
In	   the	   developing	   CNS,	   neuroepithelial	   stem	   cells	   resident	   in	   different	   regions	   of	   the	  
ventricular	   zone	   generate	   particular	   subtypes	   of	   neurons	   and	   glia	   (Briscoe	   et	   al.,	   2000;	  
Jessell,	   2000).	  While	   the	   periods	   of	   neurogenesis	   and	   gliogenesis	   vary	   substantially	   among	  
different	   germinal	   zones,	   neuronal	   specification	   always	   precedes	   glial	   specification;	   stem	  
cells	   in	  a	  given	   region	  produce	  neurons	  before	  switching	   to	  produce	  glia.	   In	   the	  embryonic	  
spinal	   cord,	   ventrally	   derived	   OLPs	   arise	   from	   the	   same	   progenitor	   domain	   –	   the	   pMN	  
domain	  –	  that	  previously	  gives	  rise	  to	  all	  adult	  motor	  neurons	  (MNs)	  (Kessaris	  et	  al.,	  2001).	  In	  
the	   mouse,	   MNs	   are	   born	   from	   ~E9.5	   -­‐	   ~E12.5	   with	   pMN-­‐derived	   OLPs	   first	   emerging	  
immediately	  after	  the	  end	  of	  neurogenesis	  (Figure	  4).	  
	  
The	  production	  of	  different	  neuronal	  subtypes	  at	  specific	  dorsal-­‐ventral	  positions	  across	  the	  
spinal	  cord,	   including	  a	  ventral	  origin	  of	  MN	  precursors,	  was	  described	   in	  chick	  embryos	  as	  
early	  as	  1970	  (Langman	  &	  Haden,	  1970).	  By	  1991,	  tissue-­‐grafting	  experiments	  demonstrated	  
the	   role	  of	  polarizing	   floor	  plate	  and	  notochord	  activity	   in	   controlling	   the	  pattern	  of	  motor	  
neuron	   specification,	   though	   the	   mechanisms	   and	   diffusible	   signal(s)	   remained	   unclear	  
(Yamada	   et	   al.,	   1991).	   Echelard	   et	   al.	   (1993)	   identified	   three	   mammalian	   relatives	   of	   the	  
Drosophila	  polarity	  gene	  hedgehog:	  Desert	  hedgehog,	   Indian	  hedgehog	  and	  Sonic	  hedgehog	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(Shh)	   (Echelard	   et	   al.,	   1993).	   Examining	   the	   pattern	   of	   endogenous	   Shh	   signaling	   and	   the	  
effect	  of	  ectopic	  Shh	  expression	  (under	  control	  of	  the	  Wnt-­‐1	  regulatory	  element;	  Wnt1:Shh)	  
revealed	   a	   role	   in	   floor	   plate	   induction	   and	   CNS	   polarity.	   Research	   from	   several	   different	  
groups	   subsequently	   confirmed	   the	   restricted	   ventral	   origin	  of	  motor	  neuron	  development	  
and	   its	   sensitivity	   to	   graded	   Shh	   from	   the	   notochord	   and	   floor	   plate	   (Marti	   et	   al.,	   1995;	  
Roelink	  et	  al.,	  1995;	  Tanabe	  et	  al.,	  1995;	  Chiang	  et	  al.,	  1996;	  Ericson	  et	  al.,	  1996).	  	  
	  
	  
Figure	  4.	  Sequential	  generation	  of	  motor	  neurons	  and	  oligodendrocyte	  precursors.	  From	  E9.5	  –	  E12.5	  
in	  mouse,	  neural	  stem	  cells	  (NSCs)	  resident	  in	  the	  ventral	  pMN	  domain	  of	  the	  developing	  spinal	  cord	  
divide	  and	  differentiate	  to	  produce	  motor	  neurons	   (MNs).	  At	  ~E12.5,	   the	  fate	  of	  pMN	  NSCs	  changes	  
and	  a	  programme	  of	  OLP	  specification	  replaces	  the	  early	  programme	  of	  MN	  production.	  	  
	  
	  
The	  pattern	  of	  PDGFRA-­‐positive	  OLP	  development	  and	  the	  demonstration	  of	  its	  dependence	  
on	   Shh	   signaling	   raised	   the	   possibility	   that	  MNs	   and	  OLPs	   are	   descended	   from	   a	   common	  
population	   of	   neuroepithelial	   precursors	   (Pringle	   &	   Richardson,	   1993;	   Pringle	   et	   al.,	   1996;	  
Richardson	  et	  al.,	  1997;	  Richardson	  et	  al.,	  2000).	  Initial	  recombinant	  retroviral	  examination	  of	  
MN	   genealogy	   in	   the	   chick	   spinal	   cord	   pointed	   to	   lineal	   relationships	   of	   MNs	   with	   both	  
astrocytes	  and	  putative	  OLs	  (Leber	  et	  al.,	  1990).	  Analysis	   in	  mouse	  spinal	  cord	  by	  Sun	  et	  al.	  
(1998)	   found	   that	   OLPs	   and	   Islet2-­‐positive/Lim3-­‐positive	   MNs	   originate	   from	   the	   most	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ventral	  Pax6-­‐expressing	  cells,	  and	  that	  the	  generation	  of	  both	  cell	  types	  is	  similarly	  altered	  in	  
mice	  lacking	  functional	  Pax6	  (Sun	  et	  al.,	  1998).	   Identification	  of	  the	  OL-­‐lineage	  transcription	  
factor	  Olig2	  provided	  firm	  evidence	  for	  common	  MN	  and	  OL	  origins	  (Lu	  et	  al.,	  2000;	  Zhou	  et	  
al.,	  2000;	  Takebayashi	  et	  al.,	  2000;	  Lu	  et	  al.,	  2002;	  Takebayashi	  et	  al.,	  2002).	  The	  pMN-­‐specific	  
expression	  of	  Olig2	  over	  the	  course	  of	  both	  MN	  and	  OLP	  specification,	  and	  the	  discovery	  of	  
its	   fundamental	   role	   in	   both	   developmental	   phases,	   clearly	   demonstrated	   that	   MN	   and	  
ventral	  OL	  generation	  occurs	  sequentially	  from	  the	  same	  Olig2-­‐positive	  neuroepithelium.	  
	  
The	  precise	  NSC	  lineage	  relationship	  between	  MNs	  and	  OLPs	  is	  not	  yet	  fully	  understood.	  As	  
opposed	   to	  MNs	  and	  OLPs	  deriving	   in	   sequence	   from	  a	  uniform	  population	  of	  multipotent	  
Olig2+	  NSCs,	  the	  restricted	  ventral	  origin	  of	  both	  cell	  types	  and	  their	  common	  developmental	  
requirement	  for	  transcription	  factor	  Olig2	  might	  in	  fact	  disguise	  distinct	  pre-­‐MN	  and	  pre-­‐OLP	  
progenitor	   populations	   within	   the	   pMN	   domain	   (Rowitch	   et	   al.,	   2004).	   In	   this	   model,	  
neuronal	   lineage-­‐restricted	  Olig2+	   precursors	   (or	   neuroblasts)	   generate	  MNs	  before	  Olig2+	  
glioblasts	   –	   dormant	   throughout	   MN	   generation	   –	   generate	   OLPs.	   In	   support	   of	   this	  
hypothesis,	   lineage	   tracing	   analysis	   in	   the	   caudal	   forebrain	   using	   Plp-­‐CreERT2:Reporter	  
transgenic	  mice	   identified	   the	   progeny	   of	   E9.5	   or	   E13.5	   progenitors	   and	   indicates	   neurons	  
and	  glia	  are	  sequentially	  generated	  from	  two	  unique	  subpopulations	  of	  progenitor	  (Delauney	  
et	   al.,	   2008).	   In	   contrast	   to	   this	   segregative	  model	  of	  MN	  and	  OLP	  development,	  however,	  
retroviral	   lineage	  tracing	  experiments	  performed	  in	  the	  embryonic	  chick,	  along	  with	  in	  vitro	  
clonal	   analysis	   of	   cultured	   NSCs	   derived	   from	   embryonic	   rat	   spinal	   cord,	   suggest	   a	   shared	  
MN/OL	   lineage	   (Leber	   et	   al.,	   1995;	   Kalyani	   et	   al.,	   1997).	   Moreover,	   Park	   et	   al.	   (2004)	  
performed	  in	  vivo	  clonal	  analysis	  of	  Olig2+	  pMN	  NSCs	  in	  zebrafish	  that	  demonstrated	  the	  MN	  
and	  OL	   lineages	  have	  not	  diverged	  at	  the	  onset	  of	  neurogenesis,	   favouring	  a	   ‘switching’	   (as	  
opposed	  to	  a	  ‘segregating’)	  model	  of	  development	  (Rowitch	  et	  al.,	  2004).	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  1.3	   ANGIOGENESIS	   &	   THE	   MOTOR	   NEURON-­‐OLIGODENDROCYTE	   PRECURSOR	   FATE	  
SWITCH	  
	  
The	   precise	   sequential	   generation	   of	  MNs	   and	  OLPs	   from	   the	   ventral	   population	   of	   Oig2+	  
NSCs	   in	   the	  developing	   spinal	   cord	   indicates	   stringent	   regulation	  of	   the	   switch	   from	  motor	  
neurogenesis	   to	   oligodendrogenesis	   (referred	   to	   hereafter	   as	   the	  MN-­‐OLP	   fate	   switch).	   In	  
pMN	   domain-­‐resident	   NSCs,	   however,	   the	   trigger(s)	   of	   the	   MN-­‐OLP	   fate	   switch	   have	   not	  
been	   established	   and	   there	   remain	   a	   number	   of	   legitimate	   hypotheses.	   For	   example,	   the	  
timing	  of	  the	  spinal	  MN-­‐OLP	  fate	  switch	  might	  be	  cell	  autonomous,	  with	  pMN	  domain	  NSCs	  
‘hardwired’	   to	   switch	   at	   a	   specific	   developmental	   time	   point	   (near	   E12.5	   in	   mice)	   from	  
generating	  MNs	  to	  generating	  OLPs.	  Alternatively,	  instructive	  cues	  might	  induce	  the	  MN-­‐OLP	  
fate	  switch	  in	  a	  non-­‐cell	  autonomous	  manner.	  In	  this	  case,	  overlying	  developmental	  changes	  
would	   signal	   –	   directly	   or	   indirectly	   –	   to	   pMN	   NSCs	   and	   alter	   the	   programme	   of	   fate	  
specification.	  In	  the	  embryonic	  CNS,	  tissue	  angiogenesis	  occurs	  around	  the	  time	  of	  the	  MN-­‐
OLP	  fate	  switch	  and	  is	  a	  promising	  candidate	  developmental	  cue	  that	  might	  crucially	  regulate	  
NSC	   fate	   in	   the	   pMN	   domain.	   In	   the	   following	   section,	   I	   focus	   on	   the	   potential	   role	   of	  
angiogenesis	   in	   governing	   the	   timing	   of	   spinal	   OLP	   formation	   and	   highlight	   the	   potential	  
mechanisms	  of	  an	  angiogenesis-­‐dependent	  MN-­‐OLP	  fate	  switch.	  
	  
Development	  of	  the	  vascular	  pattern	  within	  the	  spinal	  cord	  has	  been	  visualized	  in	  a	  range	  of	  
animal	  models,	   including	  sheep,	  pig	  and	  chick	  embryos,	  by	   India	   ink	   injection	   (Sterzi,	  1904;	  
Hoskins,	  1914;	  Watterson	  &	  Feeney,	  1946).	  These	  classic	  experiments	  revealed	  a	  consistent	  
spatio-­‐temporal	   pattern	   of	   invasion	   from	   somatic	   tissue	   outside	   the	   CNS:	   blood	   vessels	  
approach	   the	   cord	   at	   the	   ventro-­‐lateral	   border	   and	   sequentially	   invade	   the	   ventral,	   lateral	  
and	  finally	  dorsal	  surfaces.	  We	  now	  understand	  vascular	  endothelial	  cells	  (ECs)	   invade	  from	  
the	  perineural	  vascular	  plexus	   (PNVP)	  and	   follow	  vascular	  endothelial	  growth	   factor	   (VEGF)	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gradients,	  growing	  toward	  the	  ventricular	  neuroepithelium	  where	  these	  signaling	  factors	  are	  
produced	   (reviewed	   by	   Eichmann	   &	   Thomas,	   2013).	   At	   the	   leading	   edge	   of	   a	   developing	  
vessel,	  “tip”	  cells	  extend	  filopodia	  toward	  hypoxic	  regions	  producing	  VEGF.	  Binding	  of	  VEGF	  
to	   VEGF	   receptor	   2	   (VEGFR2)	   expressed	   on	   tip	   cell	   filopodia	   triggers	   Notch-­‐signaling	   to	  
adjacent	  ECs.	   In	  these	  neighbouring	  ECs,	  Notch	  signal	  activation	  induces	  differentiation	  into	  
follower	  “stalk”	  cells.	  Stalk	  cells,	  insensitive	  to	  VEGF,	  proliferate	  to	  form	  the	  capillary	  lumen,	  
enabling	  blood	  flow	  and	  tissue	  oxygenation.	  
	  
A	  possible	  role	  for	  MNs	  in	  regulating	  vascular	  sprouting	  from	  the	  PNVP	  has	  been	  described	  by	  
Nagase	   et	   al.	   (2005).	   Islet-­‐1/2-­‐positive	  MN	   columns	   in	   the	   ventral	   and	   lateral	   neural	   tube	  
express	   VEGF	   immediately	   before	   vascular	   invasion.	   Moreover,	   in	   whole	   mouse	   embryo	  
cultures,	  blockade	  of	  Shh	  signaling	  by	  cyclopamine	  administration	  from	  E8.5	  both	  eliminated	  
MN	  induction	  and	  impaired	  vascular	  sprouting,	  suggesting	  that	  MNs	  might	  directly	  regulate	  
spinal	  cord	  angiogenesis	  via	  expression	  of	  VEGF.	  An	  extension	  of	   this	   idea	   is	   therefore	   that	  
MNs,	  by	   inducing	  spinal	  cord	  angiogenesis,	   indirectly	  regulate	  the	  timing	  of	  OLP	  production	  
from	  pMN	  NSCs.	  It	  should	  be	  noted,	  however,	  that	  the	  vascular	  phenotype	  observed	  in	  these	  
experiments	   might	   not	   be	   the	   result	   of	   MN	   deficiency	   but	   of	   an	   additional,	   independent	  
effect	  of	  cyclopamine	  treatment	  and	  blocking	  Shh	  signaling.	  
	  
Angiogenic	  regulation	  of	  NSC	  fate	  choice	   in	  the	  developing	  spinal	  cord	  could	  occur	  through	  
one	  or	  a	  combination	  of	  three	  principal	  mechanisms:	  1.	  Changing	  tissue	  oxygen	  (O2)	  tension;	  
2.	  Endocrine	  signaling;	  3.	  EC-­‐NSC	  signaling	  (either	  contact-­‐dependent	  or	  paracrine	  signaling).	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1.	   Changing	  tissue	  oxygen	  tension	  
	  
Oxygen	   is	   an	   important	   regulator	   of	   progenitor	   cell	   behaviour	   throughout	   embryonic	   and	  
postnatal	   development	   (Mohyeldin	   et	   al.,	   2010).	   The	   limited	   diffusion	   distance	   of	   oxygen	  
(estimated	  at	   approximately	  150	  µm	   in	   various	  mammalian	   tissues)	  means	   that	  before	   the	  
establishment	   of	   the	   circulatory	   system,	   early	   mammalian	   development	   predominantly	  
occurs	   in	   an	   oxygen-­‐poor	   environment	   (Krogh,	   1919).	   Hypoxia-­‐inducible	   factor	   1	   (HIF1),	   a	  
heterodimeric	   bHLH	   TF	   containing	   an	   O2-­‐sensitive	   alpha	   subunit	   (HIF1A)	   and	   the	  
constitutively	   expressed	   beta	   subunit	   (HIF1B),	   is	   the	   primary	   intracellular	   mediator	   of	   the	  
hypoxic	   response	   (Wang	   &	   Semenza,	   1993;	   Wang	   &	   Semenza,	   1995).	   In	   normoxic	   cells,	  
oxygen-­‐dependent	  prolyl	  hydroxylation	  of	  HIF1A	  induces	  interaction	  with	  von	  Hippel-­‐Lindau	  
tumour	   suppressor	   (VHL)	   protein,	   the	   recognition	   component	   of	   an	   E3	   ubiquitin	   ligase	  
complex,	  which	  rapidly	  targets	  the	  alpha	  subunit	  for	  proteasomal	  degradation	  (Weidemann	  
&	   Johnson,	  2008).	  Under	   low	  oxygen	   conditions,	   stable	  HIF1A	  accumulates	   in	   the	  nuclei	  of	  
hypoxic	  cells,	  forming	  the	  functional	  HIF1A:HIF1B	  dimers	  that	  bind	  and	  regulate	  expression	  of	  
hypoxia-­‐responsive	  target	  genes.	  Homozygous	  knockout	  of	  either	  HIF1A	  or	  HIF1B	  subunit	   is	  
embryonic	  lethal	  by	  E11	  in	  mice	  and	  clearly	  demonstrates	  the	  importance	  of	  the	  HIF	  pathway	  
during	   development	   (Iyer	   et	   al.,	   1998;	   Ramirez-­‐Bergeron	   et	   al.,	   2006).	   Indeed,	   neural	   cell-­‐
specific	  knockout	  of	  HIF1A	  with	  a	  Nestin	  promoter-­‐driven	  Cre	  results	   in	  major,	  though	  non-­‐
lethal,	  CNS	  defects	  (Tomita	  et	  al.,	  2003).	  	  
	  
In	  culture,	  spontaneous	  differentiation	  of	  human	  embryonic	  stem	  cells	  (hESCs)	  is	  reduced	  in	  
low	   (3-­‐5%	   v/v)	   [O2]	   (Ezashi	   et	   al.,	   2005).	   There	   is	   also	   considerable	   in	   vitro	   evidence	   of	  
hypoxia	  regulating	  NSC	  differentiation,	  along	  glial	  and	  neuronal	  lineages.	  Studer	  et	  al.	  (2000)	  
found	   rodent	   embryonic	   CNS	   precursor	   cells	   showed	   enhanced	   survival	   and	   proliferation	  
under	  low	  [O2]	  compared	  to	  atmospheric	  (~20%)	  levels.	  Differentiation	  of	  rat	  precursors	  into	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tyrosine	  hydroxylase-­‐positive	  dopaminergic	  neurons	   is	  also	  selectively	  promoted	  in	   lowered	  
[O2].	   In	   addition,	   research	   using	   Nestin-­‐positive	   human	   subventricular	   zone	   precursors	  
demonstrated	   a	   similar	   effect	   on	   proliferation	   of	   near-­‐physiological	   (5%)	   [O2]	   versus	  
atmospheric	   [O2]	   (Erecinska	   &	   Silver,	   2001;	   Pistollato	   et	   al.,	   2007).	   Expansion	   in	   5%	   [O2]	  
yields	  greater	  cell	  numbers	  and	  a	  higher	  proportion	  with	  CD133-­‐/CD24-­‐positive	  stem	  cell-­‐like	  
character,	   while	   high	   [O2]	   triggers	   mitotic	   arrest	   and	   stimulated	   astrocyte	   and	   OL	  
differentiation.	   Comparable	   results	   were	   obtained	   using	  mouse	   cortical	   precursor	   cultures	  
(Chen	  et	  al.,	  2007).	  Overall,	  the	  data	  from	  these	  in	  vitro	  culture	  experiments	  support	  the	  idea	  
that	  [O2]	  can	  regulate	  NSC	  development.	  
	  
At	  the	  molecular	  level,	  O2	  availability	  and	  HIF	  modulate	  Wnt/β-­‐catenin	  and	  Notch	  signaling,	  
important	  pathways	  for	  both	  neural	  stem	  cell	  and	  OL	  development.	  In	  mouse	  embryonic	  and	  
neural	  stem	  cells,	  hypoxic	  exposure	  stimulates	  HIF1-­‐dependent	  activation	  of	  Wnt/β-­‐catenin	  
signaling	  and	  upregulation	  of	  Wnt	  target	  genes	   (Mazumdar	  et	  al.,	  2010).	   In	  vivo,	   regions	  of	  
active	  Wnt/β-­‐catenin	  signaling	  correlate	  strongly	  with	  low	  O2	  tension	  in	  both	  the	  embryonic	  
and	  adult	  mouse	  brain.	  In	  addition,	  in	  the	  dentate	  gyrus	  of	  the	  adult	  hippocampus,	  a	  primary	  
neurogenic	  stem	  cell	  niche,	  inducible	  deletion	  of	  HIF1A	  reduces	  Wnt	  signaling	  and	  suppresses	  
neurogenesis.	  These	  findings	  indicate	  that	  under	  low	  oxygen	  conditions,	  HIF1	  influences	  NSC	  
function	  through	  direct	  regulation	  of	  Wnt/β-­‐catenin	  signaling.	  In	  embryonic	  OL	  development,	  
Wnt	   signaling	   has	   been	   shown	   to	   negatively	   regulate	   specification	   of	   OLPs	   in	   both	   the	  
telencephalon	   and	   spinal	   cord	   (Langseth	   et	   al.,	   2010;	   Dai	   et	   al.,	   2014).	   In	   the	   embryonic	  
telencephalon,	   inhibition	   of	   Wnt	   signaling,	   by	   electroporation	   of	   either	   a	   soluble	   Wnt	  
antagonist	   or	   a	   dominant-­‐negative	   transcriptional	   regulator,	   prompts	   precocious	   and	  
excessive	  OLP	  production	  (Langseth	  et	  al.,	  2010).	  In	  addition,	  transgenic	  β-­‐catenin	  activation	  
in	   the	  pMN	  domain	  of	  mutant	   embryonic	   spinal	   cords	   results	   in	   generation	  of	   significantly	  
fewer	   Sox10-­‐/PDGFRA-­‐positive	  OLPs	   (Langseth	   et	   al.,	   2010).	   Therefore,	   oxygen	   delivery	   via	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the	  nascent	  vasculature	  might,	  through	  HIF1	  degradation,	  relieve	  pMN	  domain-­‐resident	  NSCs	  
from	  Wnt-­‐mediated	  suppression	  of	  OL	  specification,	  and	  trigger	  the	  MN-­‐OLP	  fate	  switch.	  	  
	  
The	  Notch	  pathway	  is	  a	  direct	  cell-­‐cell	  signaling	  system	  with	  crucial	  roles	  in	  controlling	  stem	  
cell	   self-­‐renewal	  and	   fate	  choice	   in	   the	  vertebrate	  CNS	   (Louvi	  &	  Artavanis-­‐Tsakonas,	  2006).	  
Notch	  receptors	  interact	  with	  ligands	  –	  including	  Delta	  and	  Jagged	  –	  expressed	  on	  the	  surface	  
of	  adjacent	  cells.	  Ligand	  binding	  induces	  a	  series	  of	  internal	  proteolytic	  cleavages,	  liberating	  
the	  Notch	  intracellular	  domain	  (Notch	  ICD),	  which	  translocates	  to	  the	  nucleus	  and	  activates	  
Notch	  downstream	  genes,	  such	  as	  the	  Hes	  and	  Hey	  TFs.	  Gustafsson	  et	  al.	   (2005)	  elucidated	  
an	   important	   role	   for	  Notch	   in	  underpinning	   the	   link	  between	  hypoxia	  and	  maintenance	  of	  
the	  undifferentiated	  cell	   state.	   In	   vitro,	  blocking	   the	  Notch	  pathway	   in	   cultured	   rat	   cortical	  
precursors	   revealed	   hypoxia-­‐induced	   inhibition	   of	   differentiation	   requires	   functional	   Notch	  
signaling.	  Exploring	   the	  mechanism	  of	   the	  Notch-­‐mediated	  effect	  of	  hypoxia,	  Gustafsson	  et	  
al.	   (2005)	   found	   that	   under	   low	   [O2],	   HIF1A	   physically	   interacts	  with	   the	   Notch1	   ICD.	   The	  
Notch1-­‐ICD:HIF1A	  transcriptional	  complex	  stabilizes	  the	  Notch1	  ICD	  and	  activates	  expression	  
of	   Notch	   target	   genes.	   Subsequent	   research	   has	   provided	   additional	   insight	   into	   the	  
importance	   and	   precise	   nature	   of	   crosstalk	   between	   the	   Notch	   and	   hypoxia	   signaling	  
pathways	   (Wang	   et	   al.,	   2006;	   Zheng	   et	   al.,	   2008;	   Sahlgren	   et	   al.,	   2008;	   Chen	   et	   al.,	   2010;	  
Mukherjee	  et	  al.,	  2011).	  
	  
In	   differentiating	   NSCs,	   expression	   of	   proneuronal	   bHLH	   TFs	   Mash1	   and	   the	   Neurogenins	  
induce	   expression	   of	   Notch	   ligands,	   which	   activate	   Notch	   signaling	   in	   neighbouring	   cells	  
(Kageyama	  et	  al.,	  2005).	  The	  Notch-­‐induced	  Hes	  genes	  –	  homologues	  of	  Drosophila	  Hairy	  and	  
Enhancer	   of	   split	   –	   encode	   repressor	   bHLH	   TFs	   that	   directly	   antagonize	   proneuronal	   TF	  
activity	   through	  repression	  of	   transcription	  and	   inhibition	  at	   the	  protein	   level.	   In	   restricting	  
the	   commitment	   of	   NSCs	   to	   neuronal	   fates,	   Notch	   signaling	   and	   Hes	   TFs	   serve	   critical	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functions	   in	  maintaining	  neural	   stem	   cell	   populations	   for	   successive	  developmental	   phases	  
such	   as	   oligodendrogenesis.	   In	   the	   optic	   nerve,	   Notch1	   signaling	   in	   OLPs	   –	   activated	   by	  
Jagged1	  expressed	  on	  the	  axons	  of	  retinal	  ganglion	  cells	  –	  inhibits	  OL	  differentiation	  (Wang	  et	  
al.,	   1998).	   In	   line	   with	   this	   observation,	   Notch1	   deficiency	   in	   vivo	   causes	   premature	  
differentiation	   of	   OLPs	   into	   myelinating	   OLs	   (Givogri	   et	   al.,	   2002).	   In	   chick	   and	   mouse	  
embryos,	   the	   Notch	   ligand	   Jagged2	   (JAG2)	   is	   transiently	   expressed	   in	   pMN	   domain	   cells	  
under	   the	   control	  of	   Shh	   signaling.	   JAG2-­‐mediated	  activation	  of	  Notch	   signaling	   inhibits	  OL	  
gene	   expression,	   and	   forced	   up-­‐	   or	   down-­‐regulation	   of	   JAG2	   suggests	   that	   JAG2-­‐Notch	  
signaling	   is	   both	   necessary	   and	   sufficient	   to	   block	   the	  MN-­‐OLP	   fate	   switch.	   Similar	   to	   the	  
oxygen-­‐mediated	   attenuation	   of	   Wnt	   signaling	   and	   the	   potential	   effect	   on	  
oligodendrogenesis	  described	  above,	  spinal	  cord	  angiogenesis	  and	  the	  consequent	   increase	  
in	  pMN	  oxygen	  tension	  might	  inhibit	  hypoxia-­‐induced	  Notch	  pathway	  activation	  and	  thereby	  
permit	  OLP	  formation.	  
	  
2.	  	   Endocrine	  signaling	  	  
	  
Endocrine	   signaling	   molecules	   (protein	   and	   steroid	   hormones),	   secreted	   directly	   into	   the	  
blood,	   travel	   through	   the	   circulatory	   system	   and	   trigger	   specific	   responses	   in	   hormone	  
receptor-­‐expressing	   target	   cells.	   Endocrine	   signaling	  plays	  a	  major	   role	   in	   the	  development	  
and	  function	  of	  a	  wide	  variety	  of	  tissues,	   including	  the	  CNS.	  Indeed,	  a	  number	  of	  endocrine	  
factors	   are	   known	   regulators	   of	  OL	   differentiation.	   Vascularization	  of	   the	   embryonic	   spinal	  
cord	  might,	  therefore,	  permit	  delivery	  of	  hormone(s)	  that	  trigger	  the	  MN-­‐OLP	  fate	  switch.	  	  
	  
Thyroid	  hormone	  T3	  signaling	  has	  profound	  effects	  on	  OL	  development.	  Hypothyroid	  humans	  
and	   rodents	   display	   reduced	   myelin	   phenotypes,	   while	   increasing	   thryoid	   hormone	   levels	  
both	  in	  vitro	  and	  in	  vivo	  enhances	  OL	  differentiation	  and	  myelin	  synthesis	  (Walters	  &	  Morell,	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1981;	  Leung	  et	  al.,	  1992;	  Rodriguez-­‐Pena	  et	  al.,	  1993;	  Barres	  et	  al.,	  1994;	  Jagannathan	  et	  al.,	  
1998;	   Marta	   et	   al.,	   1998;	   Pombo	   et	   al.,	   1998).	   In	   addition	   to	   thyroid	   hormone,	   steroid	  
hormone	   signals	   –	   notably	   glucocorticoids	   and	   progesterone	   –	   and	   the	   peptide	   hormone	  
insulin-­‐like	  growth	  factor	  (IGF)-­‐1	  promote	  OL	  maturation	  and	  myelin	  formation.	  In	  the	  adult	  
mouse	   brain,	   glucocorticoid	   receptor	   (GR),	   along	   with	   its	   cofactor	   steroid	   receptor	   co-­‐
activator	  1	  (SRC-­‐1),	  are	  expressed	   in	  >95%	  NG2-­‐positive	  OLPs	  (Matsusue	  et	  al.,	  2014).	  After	  
early	   post-­‐natal	   adrenalectomy	   (surgical	   removal	   of	   the	   corticosteroid-­‐producing	   adrenal	  
glands)	   rats	   develop	   a	   hypomyelinated	   CNS	   phenotype,	   while	   corticosteroid	   treatment	  
induces	  expression	  of	  differentiation	  markers	  MBP	  and	  PLP	  in	  OLP	  cultures	  and	  inhibits	  OLP	  
proliferation	   in	   vivo	   (Preston	   &	   McMorris,	   1984;	   Alonso,	   2000;	   Clarner	   et	   al.,	   2011).	  
Myelinogenic	   effects	   have	   also	   been	   described	   for	   progesterone,	   a	   steroid	   hormone	  
classically	   known	   for	   its	   role	   in	   reproduction.	   In	   rat	   cerebellar	   slice	   cultures,	   progesterone	  
significantly	  stimulates	  OLP	  proliferation	  and	  increases	  the	  rate	  of	  myelination	  (Ghoumari	  et	  
al.,	   2003;	   Ghoumari	   et	   al.,	   2005).	   Finally,	   similar	   to	   the	   action	   of	   progesterone,	   IGF1	  
promotes	  proliferation	  and	  OL	  differentiation	  in	  rat	  OLPs	  in	  vitro,	  as	  well	  as	  myelination	  in	  rat	  
brain	  aggregate	  cultures	  (McMorris	  &	  Dubois-­‐Dalcq,	  1988;	  Mozell	  &	  McMorris,	  1991).	  
	  
In	  contrast	   to	   the	  extensive	  data	   regarding	  OL	  differentiation	  and	  myelination,	  very	   little	   is	  
known	  about	  the	  role(s)	  of	  endocrine	  signaling	  in	  OLP	  specification.	  It	  remains	  an	  interesting	  
idea	   that	   hormones	   released	   from	   either	   maternal	   or	   embryonic	   sources	   and	   delivered	  
through	  the	  developing	  vasculature	  might	  transform	  NSC	  behaviour	  and	  trigger	  the	  MN-­‐OLP	  
fate	  switch.	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3.	  	   Endothelial	  cell-­‐neural	  stem	  cell	  signaling	  
	  
Besides	  the	  delivery	  of	  a	  fate	  switch-­‐inducing	  agent	  carried	  in	  the	  blood	  (whether	  oxygen	  or	  
endocrine),	  spinal	  cord	  angiogenesis	  might	  enable	  direct	  signaling	  from	  vascular	  ECs	  to	  pMN	  
domain	   NSCs.	   In	   this	   case,	   EC-­‐NSC	   contact	   or	   secretion	   of	   EC-­‐derived	   paracrine	   factor(s)	  
might	   direct	   NSC	   fate	   choice,	   with	   expansion	   of	   the	   vascular	   network	   into	   the	   ventral	  
ventricular	  zone	  thereby	  timing	  the	  MN-­‐OLP	  fate	  switch.	  
	  
EC-­‐NSC	  contact-­‐dependent	  signaling.	  Contact-­‐dependent	  –	  or	  juxtacrine	  –	  signaling	  between	  
ECs	   of	   the	   developing	   spinal	   cord	   vasculature	   and	   pMN-­‐resident	   NSCs	   could	   potentially	  
induce	   the	   MN-­‐OLP	   fate	   switch.	   In	   the	   mouse	   embryonic	   cortex,	   radial	   glial	   neural	  
progenitors	  are	  in	  contact	  with	  and	  interact	  with	  nascent	  blood	  vessels	  (Ma	  et	  al.,	  2013).	  In	  
the	  adult	  subventricular	  zone,	  NSCs	  are	  closely	  apposed	  to	  vascular	  ECs,	  and	  disruption	  of	  the	  
NSC-­‐EC	  contact	  in	  co-­‐culture	  assays	  affects	  NSC	  proliferation	  and	  differentiation	  (Shen	  et	  al.,	  
2008;	  Tavazoie	  et	  al.,	  2008).	  One	  highly	  conserved	  juxtacrine	  cell-­‐cell	  signaling	  pathway	  with	  
established	   roles	   in	   neural	   development	   is	   the	  Notch	   pathway.	   As	   described	   above,	  Notch	  
receptor	  activation	  by	  JAG1	  and	  JAG2	  ligands	  has	  been	  reported	  to	  inhibit	  OLP	  differentiation	  
and	  specification,	  respectively	  (Wang	  et	  al.,	  1998;	  Rabadan	  et	  al.,	  2012).	  Indeed,	  in	  the	  pMN	  
domain	  of	  the	  developing	  spinal	  cord,	  JAG2-­‐Notch	  signaling	  during	  neurogenesis	  maintains	  a	  
reservoir	  of	  multipotent	  progenitors,	  and	  JAG2	  deficiency	  induces	  premature	  OLP	  formation	  
in	   the	   pMN	   domain.	   There	   are,	   however,	   a	   number	   of	   studies	   suggesting	   Notch	   signaling	  
actually	  induces	  OLP	  formation.	  In	  mutant	  zebrafish	  embryos	  lacking	  both	  DeltaA	  and	  DeltaD	  
Notch	  ligands,	  excess	  MNs	  develop	  from	  the	  pMN	  domain	  at	  the	  expense	  of	  OLPs,	  which	  are	  
entirely	  absent	   (Park	  et	  al.,	  2003).	  Conversely,	  expression	  of	  a	   constitutively	  active	   form	  of	  
Notch	   results	   in	   reduced	   MN	   formation	   and	   increased	   OLP	   numbers	   (Park	   et	   al.,	   2003).	  
Notch-­‐induced	   OL	   specification	   has	   also	   been	   described	   for	   Olig2+	   radial	   glia	   in	   adult	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zebrafish	  spinal	  cord	  (Kim	  et	  al.,	  2008).	  Vascular	  endothelial	  cells	  prominently	  express	  Notch	  
ligands	  JAG1	  and	  Dll4,	  and	  might	   in	  principle	  trigger	  OLP	  formation	  through	  Notch	  pathway	  
activation	  in	  pMN	  NSCs	  (Hellstrom	  et	  al.,	  2007;	  High	  et	  al.,	  2008).	  The	  observation	  of	  JAG2-­‐
dependent	   inhibition	   of	   OLP	   generation	   in	   the	   mouse	   pMN	   domain	   appears	   difficult	   to	  
reconcile	  with	  this	  hypothesis	  and	  with	  the	  zebrafish	  data	  (Wang	  et	  al.,	  1998;	  Rabadan	  et	  al.,	  
2012).	   One	   possibility	   is	   that	   different	   Notch	   ligands	   induce	   specific	   developmental	  
responses;	  for	  instance,	  while	  JAG2-­‐Notch	  signaling	  between	  neighbouring	  pMN	  cells	  blocks	  
premature	   OLP	   formation,	   Dll4-­‐Notch	   signaling	   from	   ECs	   to	   NSCs	   might	   initiate	   OL	   gene	  
activation.	  
	  
Endothelial	  paracrine	  factors.	  As	  part	  of	  the	  neurovascular	  niche,	  ECs	  are	  understood	  to	  be	  a	  
rich	  source	  of	  molecular	  trophic	  signals	  with	  important	  roles	  in	  regulating	  adult	  neural	  stem	  
cell	  homeostasis	  and	  function	  (Leventhal	  et	  al.,	  1999;	  Shen	  et	  al.,	  2004;	  Lok	  et	  al.,	  2007).	   In	  
addition	   to	   the	   well-­‐documented	   involvement	   in	   neurogenic	   progenitor	   cell	   behaviour,	  
recent	  research	  has	  elucidated	  analogous	  communication	  between	  the	  vascular	  endothelium	  
and	  OL	  lineage	  cells.	  Brain-­‐derived	  neurotrophic	  factor	  (BDNF),	  related	  to	  the	  canonical	  nerve	  
growth	   factor	   (NGF),	   is	   secreted	   from	   cortical	   ECs	   and	   is	   known	   to	   regulate	   NSC	   and	   OL	  
development.	  BDNF	  promotes	  OLP	  proliferation	  and	  differentiation	  in	  vivo	  and	  in	  vitro,	  and	  
these	   effects	   are	  mediated	   through	   Trkb	   and	   the	  MAP	   kinase	   pathway	   (Van’t	   Veer	   et	   al.,	  
2009;	  Vondran	  et	  al.,	  2010;	  Xiao	  et	  al.,	  2010).	  Furthermore,	  in	  cultured	  NSCs	  derived	  from	  the	  
cortices	  of	  newborn	  mice,	  BDNF	  enhances	  commitment	  to	  the	  OL	  lineage	  (Chen	  et	  al.,	  2013).	  
	  
Similar	  to	  BDNF,	  FGF-­‐2	  is	  expressed	  by	  ECs	  and	  has	  potent	  effects	  on	  OL	  differentiation	  (Issa	  
et	  al.,	  2005).	   In	  the	  ventral	  embryonic	  forebrain,	   loss-­‐of-­‐function	  experiments	  revealed	  that	  
FGF	   signaling	   through	   FGFR1	   and	   FGFR2	   is	   necessary	   for	  OLP	   generation,	  while	   exogenous	  
FGF	  administration	  in	  vitro	  and	  in	  vivo	  suggests	  that	  FGF	  signaling	  is	  sufficient	  to	  induce	  OLP	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production	   (Kessaris	  et	  al.,	  2004;	  Furusho	  et	  al.,	  2011;	  Chandran	  et	  al.,	  2003;	  Naruse	  et	  al.,	  
2006;	   Azim	   et	   al.,	   2012).	   Treating	   neural	   progenitor	   cell	   cultures	   derived	   from	   spinal	   cord	  
with	  FGF2	  triggers	  Olig2	  expression	  and	  OLP	  generation,	  and	  microinjection	  of	  FGF-­‐2	  into	  the	  
ventricles	  of	  the	  mouse	  fetal	  forebrain	  results	  in	  ectopic	  induction	  of	  OLPs	  in	  vivo	  (Chandran	  
et	  al.,	  2003;	  Naruse	  et	  al.,	  2006).	  
	  
Whether	  BDNF	  and/or	  FGF	  are	  a)	  synthesized	  and	  released	  from	  the	  embryonic	  spinal	  cord	  
vasculature,	   and	  b)	   affect	  OLP	   specification	   from	  pMN-­‐resident	  NSCs,	   is	   yet	   to	  be	  properly	  
investigated.	   In	   more	   rostral	   brain	   structures,	   however,	   the	   expression	   of	   these	   soluble	  
signals	  from	  vascular	  ECs	  and	  their	  important	  roles	  in	  OL	  development	  exemplify	  how	  spinal	  





The	  mechanism(s)	  governing	  the	  timing	  of	  the	  MN-­‐OLP	  fate	  switch	  are	  yet	  to	  be	  established.	  
The	   timing	  of	   spinal	   angiogenesis	   and	   the	   significant	   involvement	  of	  a	  number	  of	   vascular-­‐
related	  signals	  –	  including	  both	  long-­‐	  and	  short-­‐range	  signaling	  factors	  –	  in	  controlling	  neural	  
stem	  cell	  proliferation	  and	  differentiation,	  as	  well	  as	  OL	  development	  more	  specifically,	  hints	  
at	  a	  possible	  regulatory	  role	  in	  the	  MN-­‐OLP	  fate	  switch.	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1.3	   TRANSCRIPTION	  FACTOR	  OLIG2	  
	  
At	  a	  molecular	  level,	  several	  transcriptional	  regulators	  of	  OL	  development	  and	  function	  have	  
been	   identified.	  Olig1	  and	  Olig2	  are	  members	  of	   the	  basic	  helix-­‐loop-­‐helix	   (bHLH)	   family	  of	  
transcription	   factors.	   These	   proteins	   are	   characterized	   by	   a	   common	   structural	   motif	   (the	  
bHLH	   domain)	   and	   are	   key	   regulators	   of	   cell-­‐type	   specification	   and	   tissue	   development	   in	  
vertebrates	  and	   invertebrates.	   The	  proneuronal	   functions	  of	   several	  Drosophila	  bHLH	  gene	  
homologs,	  including	  Mash1	  (Mouse	  Achaete-­‐scute	  homolog	  1)	  and	  the	  Neurogenin	  family	  of	  
Atonal-­‐related	  transcription	  factors,	  were	  established	  before	  identification	  of	  the	  Olig	  genes	  
(Johnson	  et	   al.,	   1990;	   Sommer	  et	   al.,	   1996).	   In	   the	  human	  and	  mouse	  genomes,	  Olig1	   and	  
Olig2	   both	   lie	   in	   the	   same	   50	   kb	   region	   of	   the	   genome,	   indicating	   duplication	   of	   a	   single	  
ancestral	  Olig	   gene.	   The	   absence	   of	  Olig1	   homologues	   in	   more	   primitive	   non-­‐mammalian	  
vertebrates	   suggests	   Olig2	   is	   the	   primal	   variant.	   Olig2	   is	   expressed	   throughout	  
oligodendrocyte	   development	   and	   is	   considered	   a	   master	   regulator	   of	   OL	   lineage	  
commitment	  and	  progression.	  Alongside	  its	  oligodendrogenic	  function,	  Olig2	  is	  expressed	  in	  
a	  variety	  of	  distinct	  neuroepithelial	   stem	  cell	  populations	  and	  plays	  a	  key	   role	   in	   regulating	  
neuronal	  as	  well	  as	  glial	  development.	   	   Indeed,	  closer	  examination	  of	  Olig	  gene	   function	   in	  
Olig1-­‐/Olig2-­‐single	  and	   -­‐compound	  knockout	  mouse	   lines	  distinguished	   the	  critical	   function	  
of	  Olig2	  for	  neural	  tube	  patterning	  and	  MN	  specification,	  as	  well	  as	  in	  OL	  development	  (Lu	  et	  
al.,	  2002;	  Park	  et	  al.,	  2002;	  Takebayashi	  et	  al.,	  2002;	  Zhou	  et	  al.,	  2002).	  A	  third	  member	  of	  the	  
Olig	  family,	  Olig3,	  has	  been	  identified.	  Its	  transient	  and	  isolated	  expression	  in	  distinct	  regions	  
of	  the	  CNS,	  however,	  indicates	  non-­‐overlapping	  functions	  with	  Olig1	  and	  Olig2	  (Takebayashi	  
et	  al.,	  2000;	  Takebayashi	  et	  al.,	  2002).	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Role	  in	  spinal	  cord	  patterning	  
	  
Olig2	  expression	  in	  the	  ventral	  embryonic	  spinal	  cord	  is	  essential	  for	  the	  establishment	  of	  the	  
pMN	  domain.	  In	  Olig2	  knockout	  (Olig2-­‐KO)	  mice,	  the	  Irx3-­‐positive	  p2	  and	  Nkx2.2-­‐positive	  p3	  
domains,	   spatially	   separated	   by	   the	   intermediate	   pMN	   domain	   in	   wild-­‐type	   embryos,	   are	  
immediately	  apposed	  (Lu	  et	  al.,	  2002).	  The	  absence	  of	  the	  pMN	  in	  Olig2-­‐deficient	  mutants	  is	  
a	   consequence	   of	   ventral	   expansion	   of	   the	   p2	   domain,	  which	   subsumes	   territory	   normally	  
occupied	   by	   Olig2-­‐positive	   MN	   progenitor	   cells.	   In	   normal	   spinal	   cord	   development,	   the	  
induction	   of	   Olig2	   in	   the	   ventral	   ventricular	   zone	   is	   mediated	   by	   Shh	   signaling	   from	   the	  
notochord	  and	  floorplate	  (Lu	  et	  al.,	  2000;	  Zhou	  et	  al.,	  2000).	  Global	  deletion	  of	  Shh	  eliminates	  
ventral	  Olig2	  expression,	  while	   transgenic	   Shh	  production	   in	   the	  dorsal	   spinal	   cord	   in	  Wnt-­‐
1:Shh	  mice	   is	   accompanied	   by	   ectopic	   expression	   of	   Olig2	   (Rowitch	   et	   al.,	   1999;	   Lu	   et	   al.,	  
2000).	   However,	   Cre-­‐recombinase	   labeling	   indicates	   that	   the	   range	   of	   Shh-­‐dependent	  
induction	  of	  Olig2	  initially	  includes	  the	  putatively	  Olig2-­‐negative	  p2	  and	  p3	  domains	  (Dessaud	  
et	   al.,	   2007;	   Dessaud	   et	   al.,	   2010).	   Concerted	   down-­‐regulation	   of	   Olig2	   in	   the	  
neuroepithelium	   surrounding	   the	   pMN	   then	   refines	   the	   early,	   broad	   pattern	   of	   Olig2	  
expression	  exclusively	  to	  the	  pMN	  domain	  by	  the	  onset	  of	  neurogenesis	  at	  ~E9.5.	  
	  
Sonic	   hedgehog-­‐dependent	   induction	   and	   subsequent	   refinement	   of	   Olig2	   expression	  
delineates	   the	   ventral	   pMN	  domain	   in	   the	   nascent	   spinal	   cord.	   After	   establishment	   of	   the	  
pMN	   domain,	   resident	   Olig2-­‐positive	   neuroepithelial	   stem	   cells	   divide	   and	   differentiate	   to	  
generate	  MNs	  followed	  by	  OLs.	  Olig2	   is	  absolutely	  necessary	  for	  formation	  of	  the	  pMN	  and	  
remains	   critically	   important	   for	   regulating	   commitment	   to	  both	   the	  MN	  and	  OL	   lineages	   in	  
the	  spinal	  cord.	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Role	  in	  motor	  neuron	  specification	  
	  
Before	  the	  discovery	  of	  the	  Olig	  genes,	  mapping	  the	  spatiotemporal	  pattern	  of	  MN	  and	  OLP	  
development	  strongly	  indicated	  the	  two	  cell	  types	  arise	  in	  sequence	  from	  a	  single	  region	  of	  
the	  developing	  spinal	   cord,	   the	  pMN	  domain	   (reviewed	   in	  Richardson	  et	  al.,	  1997	  &	  2000).	  
Despite	   the	   evidence,	   however,	   no	   pMN-­‐specific	   factor	   distinguishing	   the	   common	  
progenitors	   and	   linking	   both	   MN	   and	   OLP	   specification	   had	   been	   identified.	   Preliminary	  
characterization	  of	  Olig2	  confirmed	  restricted	  expression	   in	  ventral	  neuroepithelium	  before	  
the	  emergence	  of	  Olig2/PDGFRA	  double-­‐positive	  OLPs	  during	  the	  period	  of	  MN	  generation,	  
indicating	  a	  possible	  involvement	  of	  Olig2	  in	  MN	  production.	  	  
	  
Olig1	   and	   Olig2	   single-­‐knockout	   and	   double-­‐knockout	   (dKO)	   mouse	   lines	   resolved	   the	  
developmental	  requirements	  for	  both	  genes	  and	  validated	  the	  particular	  importance	  of	  Olig2	  
for	  MN	  specification	  (Lu	  et	  al.,	  2002;	  Zhou	  et	  al.,	  2002).	  Olig1/2-­‐dKO	  mice	  fail	  completely	  to	  
generate	  MNs	   and	  OL	   lineage	   cells	   throughout	   the	   CNS.	   Comparison	  with	   an	  Olig2	   single-­‐
knockout	  (Olig2-­‐KO),	  in	  which	  PDGFRA/Sox10	  double-­‐positive	  OLPs	  were	  identified	  in	  limited	  
numbers	  in	  regions	  of	  the	  rostral	  CNS,	   indicates	  that	  Olig1	  can	  partially	  compensate	  for	  the	  
absence	  of	  Olig2	  outside	  the	  spinal	  cord.	  In	  the	  spinal	  cords	  of	  Olig2-­‐KO	  mice,	  however,	  MN	  
development	  is	  entirely	  replaced	  by	  additional	  V2	  interneuron	  generation	  from	  the	  enlarged	  
p2	   domain.	   In	   contrast	   to	  Olig2,	  Olig1	   was	   found	   to	   be	   expendable	   for	   spinal	  MN	   and	  OL	  
specification	  (Paes	  de	  Faria	  et	  al.,	  2014).	  
	  
Despite	   the	   requirement	   for	  Olig2	   in	  MN	   formation,	   research	   in	   2005	   revealed	   that	  Olig2,	  
after	   initially	   priming	   pMN	   progenitors	   for	   neuronal	   lineage	   commitment,	   inhibits	  
differentiation	   of	   post-­‐mitotic	   MNs	   (Lee	   et	   al.,	   2005).	   The	   observations	   helped	   to	   explain	  
both	   the	   limited	   capacity	   of	   ectopic	  Olig2	   to	   trigger	  MN	  generation	   and	   the	   abrupt	   down-­‐
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regulation	  of	  Olig2	  in	  newly	  born	  MNs	  (Mizuguchi	  et	  al.,	  2001;	  Novitch	  et	  al.,	  2001;	  Du	  et	  al.,	  
2006).	  The	  data	  suggest	  that	  the	  transition	  of	  individual	  MN	  progenitors	  to	  post-­‐mitotic	  MNs	  
in	   the	   pMN	   domain	   is	   determined	   by	   the	   relative	   abundance	   of	   nuclear	   Olig2	   and	   pro-­‐
neuronal	   bHLH	   transcription	   factor	   Neurogenin	   2	   (Ngn2).	   Olig2highNgn2low	   promotes	  
maintenance	  of	  the	  progenitor	  state	  over	  commitment	  to	  the	  MN	  lineage,	  and	  vice	  versa.	  Lee	  
et	  al.	  (2005)	  propose	  that	  Olig2	  performs	  essential	  dual	  functions	  in	  MN	  development.	  Early	  
on,	   Olig2	   is	   required	   for	   the	   establishment	   of	   the	   pMN	   domain	   and	   for	   early	   neurogenic	  
instruction.	   Thereafter,	  Olig2	  blocks	   commitment	   to	   the	  MN	   lineage	   in	   a	   selection	  of	   pMN	  
progenitors	  by	  opposing	  the	  activity	  of	  pro-­‐neuronal	  factors	  such	  as	  Ngn2.	  
	  
Role	  in	  oligodendrocyte	  specification	  
	  
Since	   its	   identification	   in	   the	   year	   2000,	   in	   vivo	   and	   in	   vitro	   characterization	   has	   clearly	  
demonstrated	  that	  Olig2	  is	  absolutely	  critical	  for	  embryonic	  OL	  specification	  (Lu	  et	  al.,	  2002;	  
Park	   et	   al.,	   2002;	   Zhou	   et	   al.,	   2002).	   ISH	   mapping	   experiments	   confirmed	   focal	   Olig2	  
expression	   in	   the	  ventral	  oligodendrogenic	  neuroepithelium	  before	   the	  emergence	  of	  OLPs	  
(Lu	  et	  al.,	  2000).	  At	  later	  embryonic	  stages,	  Olig2	  is	  faithfully	  co-­‐expressed	  with	  OLP	  markers	  
Sox10	   and	   PDGFRA.	   	   In	   the	   spinal	   cords	   of	   Olig2-­‐KO	   mice,	   both	   ventral	   and	   dorsal	   OLP	  
populations	  fail	  to	  develop.	  Interestingly,	  discrete	  clusters	  of	  Sox10/PDGFRA	  double-­‐positive	  
cells	  do	  emerge	  in	  more	  rostral	  structures	  in	  the	  Olig2-­‐KO	  that	  are	  entirely	  absent	  in	  Olig1/2-­‐
dKO	   mice,	   indicating	   that	   Olig1	   can	   partially	   compensate	   for	   Olig2	   deficiency	   in	   specific	  
regions	  of	  the	  CNS	  (Lu	  et	  al.,	  2002).	  Consistent	  with	  this	  observation,	  targeted	  ablation	  of	  the	  
Olig2	  gene	  in	  dorsal	  multipotent	  progenitors	  in	  the	  telencephalon	  does	  not	  entirely	  prohibit	  
formation	   of	   OLPs	   (Yue	   et	   al.,	   2006).	   In	   the	   embryonic	   spinal	   cord,	   however,	   Olig2	   is	  
absolutely	   essential	   for	   OL	   lineage	   specification	   –	   a	   feature	   that	   appears	   highly	   conserved	  
among	  different	  species	  (Lu	  et	  al.,	  2002).	   In	  the	  zebrafish	  spinal	  cord,	  for	  example,	  MN	  and	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OL	   development	   follows	   an	   almost	   identical	   spatiotemporal	   structure,	   and	   is	   similarly	  
abolished	  upon	  loss	  of	  Olig2	  (Park	  et	  al.,	  2002).	  	  
	  
Beyond	   the	   requirement	   for	  OL	   specification,	   the	   sufficiency	   of	  Olig2	   to	   induce	  OL	   lineage	  
commitment	  proved	  a	  more	  contentious	  question.	  In	  both	  mouse	  and	  human	  fetal	  stem	  cell	  
cultures,	   Olig2	   over-­‐expression	   triggers	   differentiation	   to	   myelination-­‐competent	   OLPs	   in	  
vitro	   and	   after	   engraftment	   into	   the	   dysmyelinated	   brains	   of	   shiverer	  mice	   (Copray	   et	   al.,	  
2006;	   Maire	   et	   al.,	   2009).	   In	   vivo	   studies	   performed	   in	   chick	   have,	   however,	   yielded	  
conflicting	  results.	  Early	  Olig2	  electroporation	  experiments	  clearly	  indicated	  that	  ectopic	  OLP	  
formation	   required	   misexpression	   of	   Olig2	   in	   combination	   with	   Nkx2.2,	   and	   that	   neither	  
factor	   alone	  was	  adequate	   (Sun	  et	   al.,	   2001;	   Zhou	  et	   al.,	   2001).	   In	  direct	   contrast	   to	   these	  
results,	   research	   published	   in	   2007,	   adopting	   a	   very	   similar	   electroporation	   strategy,	  
identified	   ectopic	   and	   precocious	   Sox10-­‐positive	   OLPs	   four	   days	   after	   introduction	   of	   an	  
Olig2-­‐only	  expression	  construct,	  suggesting	  Olig2	  on	  its	  own	  is	  sufficient	  for	  OL	  fate	  selection	  
(Liu	   et	   al.,	   2007).	   The	   authors	   suggest	   that	   the	   different	   observations	   might	   be	   a	  
consequence	  of	  variation	  in	  the	  intensity	  and	  duration	  of	  exogenous	  Olig2	  expression.	  	  
	  
Role	  in	  oligodendrocyte	  differentiation	  
	  
The	   sustained	   expression	   of	  Olig2	   along	   the	  OL	   lineage	   gave	   an	   early	   indication	   that	  Olig2	  
might	   function	   in	  OL	  differentiation.	  More	  recent	   research	  has	  validated	  the	   importance	  of	  
Olig2	  in	  regulating	  maturation,	  as	  well	  as	  uncovering	  the	  dynamic	  nature	  of	  its	  involvement	  –	  
Olig2	  performs	  specific	  roles	  depending	  on	  the	  stage	  from	  OLP	  to	  myelinating	  OL	  (Yue	  et	  al.,	  
2006;	  Mei	  et	  al.,	  2013).	  In	  cell	  culture	  experiments,	  antisense	  knockdown	  of	  Olig2	  in	  cultures	  
derived	   from	   rodent	   spinal	   cord	   significantly	   delays	   induction	   of	   late-­‐stage	   OL	   lineage	  
markers	  GalC	  and	  proteolipid	  protein	  (PLP)	  (Fu	  et	  al.,	  2002).	  Co-­‐suppression	  of	  transcription	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factor	  (TF)	  Nkx2.2	  and	  Olig2	  in	  these	  cultures	  also	  has	  an	  additive	  inhibitory	  effect,	  suggesting	  
both	   transcription	   factors	   synergistically	   and	   positively	   regulate	   OL	   differentiation.	   In	   vivo,	  
conditional	   deletion	   in	   early	   cortical	   progenitors	   in	   mice	   indicates	   progression	   of	   OLPs	   to	  
myelinating	   OLs	   requires	   Olig2	   (Yue	   et	   al.,	   2006).	   Olig2-­‐deficiency	   does	   not	   prevent	  
generation	  of	  cortical	  OLPs	  but	  does	  result	  in	  a	  marked	  reduction	  in	  the	  expression	  of	  myelin	  
genes	   and	   severe	   hypomyelination.	   In	   support	   of	   a	   central	   and	   positive	   regulatory	   role	   in	  
driving	  OL	  differentiation,	  prolonged	  misexpression	  of	  Olig2	  (for	  five	  days)	  in	  the	  chick	  spinal	  
cord	  induces	  mature	  OL	  markers	  myelin	  basic	  protein	  (MBP)	  and	  PLP	  (Liu	  et	  al.,	  2007).	  	  
	  
This	  straightforward	  view	  of	  Olig2	  promoting	  differentiation	  was	  called	  into	  question	  by	  the	  
results	  of	  comprehensive	  immunostaining	  for	  OL	  lineage	  TFs	  Olig1,	  Olig2,	  Sox10	  and	  Nkx2.2	  
(Kitada	   &	   Rowitch,	   2006).	   Analysis	   of	   Olig2	   expression	   alongside	   established	   OL	   lineage	  
markers	   in	   the	   adult	   mouse	   spinal	   cord	   found	   terminal	   differentiation	   of	   mature	   OLs	  
coincides	   with	   down-­‐regulation	   of	   Olig2.	   The	   functional	   significance	   of	   the	   observation,	  
however,	  was	  unclear.	  Mei	  et	  al.	  (2013)	  directly	  addressed	  the	  question	  of	  diversity	  of	  Olig2	  
function	   in	   early	   postnatal	   OLPs	   versus	   OLs,	   and	   characterized	   a	   complex	   and	   dynamic	  
influence	  on	  differentiation.	  Stage-­‐specific	  deletion	  under	  either	  CNP	  promoter	  (OLP-­‐specific)	  
or	  PLP	  promoter	  (immature	  OL-­‐specific)	  Cre	  drivers	  revealed	  divergent	  functions	  of	  Olig2	  at	  
different	   points	   along	   the	   lineage.	   In	   the	   early	   phase	  of	  OLP	  development,	  Olig2	  positively	  
regulates	   differentiation,	   stimulating	   progression	   towards	   becoming	   a	   mature	   OL.	   In	  
contrast,	   Olig2	   appears	   to	   inhibit	   myelination,	   arresting	   pre-­‐myelinating	   OLs	   immediately	  
before	  the	  final	  stage	  of	  maturation.	  	  
	  
The	  existing	  data	  indicate	  that	  Olig2	  is	  initially	  a	  necessary	  positive	  regulator	  of	  commitment	  
to	  and	  early	  progression	  along	  the	  OL	  lineage.	  At	  later	  stages	  of	  OL	  differentiation,	  the	  role	  of	  
Olig2	  appears	   to	   transform	   from	  pro-­‐	   to	  anti-­‐maturation,	  with	  development	  of	  myelinating	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OLs	   requiring	  a	   reduction	   in	   the	   level	  of	  Olig2.	  Despite	  down-­‐regulation	  of	  Olig2	   in	  mature	  
OLs	  in	  the	  adult	  CNS,	  however,	  Olig2	  continues	  to	  be	  expressed	  and	  localized	  to	  the	  nucleus	  
throughout	   the	  OL	   lineage.	  This	  observation	   is	  difficult	   to	   reconcile	  with	   the	   reported	  anti-­‐
maturation	  role	  of	  Olig2	  in	  immature	  OLs,	  and	  suggests	  there	  are	  important	  facets	  of	  Olig2-­‐
mediated	  regulation	  of	  OL	  differentiation	  that	  are	  still	  to	  be	  discovered.	  Indeed,	  the	  precise	  
function	  of	  Olig2	  in	  mature	  and	  myelinating	  OLs	  is	  yet	  to	  be	  addressed	  in	  vivo.	  	  
	  
Additional	  roles	  of	  Olig2:	  forebrain	  neurogenesis	  and	  astrogliogenesis	  
	  
Forebrain	  neurogenesis	  
Analysis	   of	   the	   localisation	   and	   distribution	   of	   Olig2-­‐positive	   cells	   at	   different	   embryonic	  
stages	  established	  a	  dynamic	   spatiotemporal	  pattern	  of	  Olig2	  expression	   in	   the	  developing	  
mouse	  forebrain	  (Takebayashi	  et	  al.,	  2000;	  Furusho	  et	  al.,	  2006;	  Kessaris	  et	  al.,	  2006;	  Ono	  et	  
al.,	   2008).	   In	   the	   telencephalon,	  Olig2	  expression	  begins	   at	   E10.5	   in	   the	   ventral	   ventricular	  
zone,	   localizing	   to	   the	   medial	   ganglionic	   eminence	   (MGE),	   septum	   and	   anterior	  
entopeduncular	   area	   (AEP)	   until	   E12.5.	   By	   E17.5,	   Olig2-­‐positive	   cells	   are	   distributed	  
throughout	   the	   parenchyma	   of	   the	   telencephalon	   but	   remain	   clustered	   in	   the	   ventral	  
ventricular	   zone	   [including	   the	   lateral	   ganglionic	   eminence	   (LGE)].	   The	   progeny	   of	   Olig2-­‐
expressing	   stem	   cells	   in	   the	   forebrain	   have	   been	   characterized	   by	   short-­‐	   and	   long-­‐term	  
lineage	   tracing	   experiments	   using	   an	   inducible	   Olig2-­‐Cre-­‐Reporter	   system	   (Furosho	   et	   al.,	  
2006;	  Miyoshi	  et	  al.,	  2007;	  Ono	  et	  al.,	  2008).	  	  
	  
In	   the	   basal	   forebrain,	   Olig2	   lineage	   cells	   generate	   excitatory	   cholinergic	   (choline	   acetyl-­‐
transferase-­‐	   (ChAT-­‐)	   positive)	   neurons	   (Furosho	   et	   al.,	   2006).	   In	   the	   MGE,	   labeling	   Olig2-­‐
expressing	  cells	  at	  different	  time	  points	  revealed	  that	  different	  inhibitory	  cortical	  interneuron	  
subtypes	   are	   generated	   in	   strict	   temporal	   sequence	   (Miyoshi	   et	   al.,	   2007).	   In	   addition,	   a	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considerable	  number	  of	  excitatory	  glutamatergic	  neurons	  derive	  from	  Olig2	  progenitors	  and	  
are	   found	   in	   the	  adult	  hypothalamus	   (Ono	  et	  al.,	  2008).	  These	   fate-­‐mapping	  studies	  clearly	  
show	  that	  Olig2-­‐positive	  cells	   in	  the	  embryonic	  forebrain	  contribute	  to	  a	  number	  of	  distinct	  
neuronal	   populations	   –	   both	   excitatory	   and	   inhibitory	   –	   and	   that	   subtype	   generation	   is	  
spatially	  and	  temporally	  determined.	  	  
	  
The	   nature	   of	   Olig2	   function	   in	   different	   forebrain	   progenitor	   populations	   at	   different	  
embryonic	   time	  points	  has	  not	  been	   fully	  elucidated.	   In	  Olig2-­‐null	  mice,	   the	  effect	  of	  Olig2	  
deficiency	   on	   neuronal	   specification	   varies	   according	   to	   neuronal	   subtype.	   For	   cholinergic	  
neuron	  development	   in	   the	  basal	   forebrain,	  Olig2	   knockout	   leads	   to	  an	  approximately	  40%	  
reduction	  at	  E18.5	  in	  mice	  (Furosho	  et	  al.,	  2006).	  In	  contrast,	  the	  number	  and	  distribution	  of	  
GABAergic	  interneurons	  appears	  unchanged	  in	  E18.5	  Olig2-­‐null	  mutant	  embryos	  (Ono	  et	  al.,	  
2008).	  A	   recent	   study	  using	  Olig1-­‐null	  mice,	  however,	   indicates	   that	  Olig1	   is	   a	   repressor	  of	  
Dlx1/2	  and	  a	  negative	  regulator	  of	  interneuron	  production	  in	  the	  mammalian	  brain	  (Silbereis	  
et	  al.,	  2014).	  Nonetheless,	  while	   the	  details	  of	  Olig2	   function	   in	   forebrain	  neurogenesis	  are	  




Lineage	   tracing	   experiments	   performed	   in	   transgenic	   mice	   demonstrated	   that	   Olig2-­‐
expressing	   pMN	   domain	   stem	   cells	   in	   the	   embryonic	   spinal	   cord	   contribute	   a	   subset	   of	  
astrocytes	   that	   localize	   to	   the	   ventral	   pial	   surface	   (Masahira	   et	   al.,	   2006).	   Olig2	   has	   been	  
detected	   in	  astrogenic	  populations	  of	  both	  embryonic	  and	  postnatal	  progenitor	   cells	  but	   is	  
absent	   from	   mature	   astrocytes	   (Lu	   et	   al.,	   2000;	   Zhou	   et	   al.,	   2000;	   Marshall	   et	   al.,	   2005;	  
Masahira	  et	  al.,	  2006;	  Cai	  et	  al.,	  2007;	  Chen	  et	  al.,	  2008;	  Ono	  et	  al.,	  2008;	  Zhu	  et	  al.,	  2011).	  
Indeed,	  development	  of	  fully	  mature	  astrocytes	  from	  neural	  progenitors	  in	  vitro	  is	   inhibited	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by	   forced	   expression	   of	   Olig2	   (Fukuda	   et	   al.,	   2004;	   Setoguchi	   &	   Kondo,	   2004).	   In	   contrast	  
however,	   retroviral	   introduction	   of	   either	   normal	   or	   dominant-­‐negative	   forms	   of	   Olig2	   in	  
mice	   demonstrated	   wild-­‐type	   Olig2	   promotes	   astrocytic	   over	   neuronal	   development	   in	  
progenitor	  cells	   in	  the	  neonatal	  subventricular	  zone	  (Marshall	  et	  al.,	  2005).	  Taken	  together,	  
the	  results	  suggest	  that	  Olig2	  might	  initially	  promote	  formation	  of	  immature	  astrocytes	  while	  
removal	   of	   Olig2	   is	   necessary	   for	   the	   later	   steps	   of	   astrocyte	   differentiation.	  More	   recent	  
research	   in	   vivo	   has	   described	   transient	   Olig2	   expression	   in	   immature	   astrocytes	   and	  
subsequent	  down-­‐regulation	  over	  later	  stages	  of	  differentiation	  (Cai	  et	  al.,	  2007).	  In	  addition	  
to	   the	   temporal	   variation	  along	   the	  astrocyte	   lineage,	   targeted	  Olig2	   knockout	   in	  mice	  has	  
revealed	  spatial	  differences	   in	  Olig2	  function	  (Cai	  et	  al.,	  2007;	  Zhu	  et	  al.,	  2012).	  Conditional	  
Olig2	  deletion	  using	  a	  human	  GFAP	  promoter-­‐driven	  Cre	  has	  been	  reported	  to	  generate	  an	  
astrocyte	  deficit	  in	  the	  cortical	  and	  spinal	  white	  matter	  (Zhuo	  et	  al.,	  2001;	  Cai	  et	  al.,	  2007).	  In	  
contrast,	  conditional	  Olig2	  deletion	   in	  neocortical	  NG2	  cells	  using	  an	  NG2-­‐Cre	   line	  triggered	  
protoplasmic	   astrocyte	   formation	   at	   the	   expense	   of	   OLs,	   suggesting	   that	   Olig2	   inhibits	  
astrocyte	  specification	  in	  NG2	  cells	  (Zhu	  et	  al.,	  2012).	  It	  therefore	  appears	  that,	  similar	  to	  its	  
roles	   in	   forebrain	   and	   spinal	   cord	   neurogenesis,	   the	   involvement	   of	   Olig2	   in	   astrocyte	  
development	  differs	  according	  to	  cell	  maturity	  and	  region-­‐specific	  subtype.	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1.4	   REGULATION	  OF	  OLIG2	  EXPRESSION	  IN	  THE	  EMBRYONIC	  SPINAL	  CORD	  
	  
The	   first	   two	   Olig	   genes	   (Olig1/2)	   were	   first	   isolated	   in	   the	   year	   2000,	   screening	   for	  
transcription	  factor	  determinants	  of	  OL	  fate.	  Research	  since	  has	  examined	  the	  central	  role	  of	  
the	   ancestral	   variant	   Olig2	   in	   CNS	   development.	   Olig2	   is	   critical	   for	   proper	   neural	   tube	  
patterning	  and	  for	  regulating	  both	  motor	  neuron	  and	  oligodendrocyte	  development,	  as	  well	  
as	   anterior	   neurogenesis.	   In	   the	   following	   section,	   I	   describe	   the	   mechanisms	   underlying	  
regulation	  of	  expression	  of	  Olig2	  in	  the	  establishment	  of	  the	  pMN	  domain,	  the	  generation	  of	  
MNs	  and	  the	  development	  of	  both	  ventral	  and	  dorsal	  OL	  populations	  in	  the	  embryonic	  spinal	  
cord	  (see	  Origins	  of	  OLPs	  above).	  	  
	  
Regulation	  of	  Olig2	  expression	  in	  establishment	  of	  the	  pMN	  domain	  
	  
Induction	  of	  Olig2	  expression.	  Before	   the	  onset	  of	  neurogenesis	   in	   the	  neural	   tube,	  protein	  
morphogen	  Shh	  emanating	  from	  the	  ventral	  notochord	  and	  floorplate	  induces	  expression	  of	  
progenitor	   domain-­‐specific	   combinations	   of	   transcription	   factors	   (Briscoe	   et	   al.,	   2000).	   Shh	  
signaling	  directly	  represses	  class	  I	  homeodomain	  transcription	  factor	  genes	  Pax6,	  Pax7,	  Irx3,	  
Dbx1	   and	   Dbx2,	   and	   activates	   class	   II	   homeodomain	   factor	   genes	  Nkx6.1	   and	  Nkx2.2.	   The	  
duration	  and	  intensity	  of	  exposure	  of	  an	  individual	  cell	  to	  Shh	  diminishes	  with	  distance	  from	  
the	  floorplate.	  As	  a	  result,	  the	  precise	  combinatorial	  expression	  of	  homeodomain	  proteins	  is	  
determined	  by	   a	   cell’s	   position	   along	   the	  dorsal-­‐ventral	   axis	   of	   the	   spinal	   ventricular	   zone.	  
Strong	  Nkx6.1	  (class	   II)	  and	  weak	  Pax6	  (class	   I)	  expression	   initially	  characterize	  presumptive	  
pMN	  domain	  cells	  (Ericson	  et	  al.,	  1997;	  Qiu	  et	  al.,	  1998;	  Mizuguchi	  et	  al.,	  2001;	  Novitch	  et	  al.,	  
2001;	  Balaskas	  et	  al.,	  2012).	  Transcription	  of	  Olig2	   is	   indirectly	   regulated	  by	  Shh	  via	  Nkx6.1	  
(Novitch	  et	  al.,	  2001;	  Vallstedt	  et	  al.,	  2001;	  Liu	  et	  al.,	  2003).	  Olig2	  expression	   in	  the	  ventral	  
ventricular	   zone	   is	   significantly	   reduced	   in	   Nkx6.1-­‐null	   mice	   and	   completely	   absent	  
CHAPTER	  1	  Introduction	   	   	  
  
	   36	  
phenocopy	  of	  Shh-­‐null	  mutants)	  from	  Nkx6.1/Nkx6.2	  (Nkx6-­‐)	  double-­‐knockout	  spinal	  cord	  at	  
E10.5	  and	  E12.5.	  In	  addition,	  gain-­‐of-­‐function	  experiments	  in	  embryonic	  chick	  demonstrated	  
that	   ectopic	   Nkx6.1	   induces	  misexpression	   of	   Olig2	   (Novitch	   et	   al.,	   2001;	   Liu	   et	   al.,	   2003).	  
After	   broad	   Nkx6.1-­‐mediated	   induction	   of	   Olig2	   across	   the	   ventral	   third	   of	   the	   spinal	  
ventricular	  zone	  (including	  in	  the	  presumptive	  p2	  and	  p3	  domains),	  transcriptional	  and	  post-­‐
transcriptional	  repression	  in	  p2	  and	  p3	  progenitor	  cells	  refines	  the	  dorsal	  and	  ventral	  limits	  of	  
Olig2	  expression	  to	  the	  pMN	  domain.	  
	  
Refinement	  of	  Olig2	  expression.	   In	  the	  ventral	  p3	  domain,	  sustained	  exposure	  of	  progenitor	  
cells	  to	  Shh	  initiates	  expression	  of	  class	  II	  homeodomain	  TF	  Nkx2.2,	  which	  silences	  Olig2	  gene	  
transcription	  (Briscoe	  et	  al.,	  1999;	  Briscoe	  et	  al.,	  2000).	  Nkx2.2-­‐null	  mice	  lack	  the	  p3	  domain	  
and	  do	  not	  generate	  V3	   interneurons,	   instead	  producing	  additional	  MNs	  from	  an	  expanded	  
Olig2-­‐positive	   pMN	  domain	   (Novitch	   et	   al.,	   2001;	  Qi	   et	   al.,	   2001).	   In	   normal	   development,	  
mutually	   repressive	   interaction	   between	   Nkx2.2	   and	   Pax6	   at	   the	   transcriptional	   level,	  
potentially	   combined	   with	   a	   cross-­‐inhibitory	   physical	   interaction	   of	   Olig2	   and	   Nkx2.2	  
proteins,	   restricts	   dorsal	   expansion	   of	   the	   p3	   domain	   and	   defines	   the	   p3/pMN	   boundary	  
(Ericson	   et	   al.,	   1997;	   Briscoe	   et	   al.,	   2000;	   Sun	   et	   al.,	   2003).	   The	   dorsal	   extent	   of	   Olig2	  
expression	   is	   refined	   through	   the	   cross-­‐repressive	   transcriptional	   relationship	   between	   the	  
p2	  domain-­‐specific	  class	  I	  TF	  Irx3	  and	  Olig2	  itself	  (Mizuguchi	  et	  al.,	  2001;	  Novitch	  et	  al.,	  2001).	  
Analogous	   to	   the	   neurogenic	   phenotype	   of	   animals	   lacking	   Nkx2.2,	   in	   Olig1/2	   double-­‐
knockout	  (Olig1/2-­‐dKO)	  mice,	  ventral	  expansion	  of	  the	  Irx3-­‐positive	  p2	  domain	  abolishes	  the	  
pMN	   (Zhou	   et	   al.,	   2002).	   Conversely,	   in	   the	   chick	   neural	   tube,	   electroporation	   of	   an	  Olig2	  
expression	   construct	   silences	   Irx3	   and	   triggers	   ectopic	   MN	   production	   (likewise,	   Irx3	  
electroporation	   effectively	   represses	   Olig2	   and	   promotes	   V2	   interneuron	   generation)	  
(Mizuguchi	  et	  al.,	  2001;	  Novitch	  et	  al.,	  2001).	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On	   top	   of	   transcription	   factor-­‐mediated	   regulation,	   more	   recent	   research	   has	   shown	  
involvement	   of	   the	   RNA	   interference	   (RNAi)	   pathway	   in	   fine-­‐tuning	   the	   pattern	   of	   Olig2	  
(Chen	   et	   al.,	   2011).	   In	   E9.5	   mice,	   microRNA	   cluster	   mir-­‐17~92	   is	   upregulated	   in	   the	   p2	  
domain.	  As	  part	  of	  the	  RNA-­‐induced	  silencing	  complex,	  mature	  mir-­‐17	  specifically	  hybridizes	  
with	   the	  3’	   untranslated	   region	   (UTR)	  of	  Olig2	  messenger	  RNA,	   targeting	   the	   transcript	   for	  
degradation	   and	   precluding	   Olig2	   protein	   synthesis.	  Mir-­‐17~92-­‐null	  mutants	   exhibit	   errant	  
Olig2	  expression	  in	  the	  p2	  domain,	  a	  phenotype	  also	  observed	  in	  Dicer	  mutants	  incapable	  of	  
generating	  functional	  miRNAs	  from	  primary	  immature	  transcripts.	  
	  
Regulation	  of	  Olig2	  expression	  in	  motor	  neuron	  specification	  
	  
Adult	   MNs	   derive	   exclusively	   from	   multipotent	   Olig2-­‐expressing	   stem	   cells	   of	   the	   pMN	  
domain	   (Lu	   et	   al.,	   2002;	   Takebayashi	   et	   al.,	   2002;	   Zhou	   et	   al.,	   2002).	   During	   development,	  
post-­‐mitotic	   immature	  MNs	  migrate	  away	   from	  the	  ventricular	   zone,	   settling	   in	   the	  ventral	  
and	  lateral	  horns	  of	  the	  spinal	  cord,	  before	  undergoing	  the	  final	  stages	  of	  differentiation.	  The	  
transition	  from	  uncommitted	  progenitor	  to	  post-­‐mitotic	  immature	  MN	  is	  associated	  with	  the	  
rapid	   down-­‐regulation	   of	  Olig2	   (Lu	   et	   al.,	   2000;	   Zhou	   et	   al.,	   2000;	  Mizuguchi	   et	   al.,	   2001;	  
Novitch	   et	   al.,	   2001).	   The	   transcription	   factor(s)	   responsible	   for	   negatively	   regulating	  Olig2	  
gene	   expression	   are	   not	   known.	   Expression	   of	   Olig2	   with	   the	   motor	   neuron	   determinant	  
Homeobox	  9	  (Hb9)	  is	  temporally	  non-­‐overlapping,	  indicating	  that	  upregulation	  of	  Hb9	  might	  
directly	  or	  indirectly	  silence	  Olig2	  gene	  transcription	  (Lee	  et	  al.,	  2005).	  The	  swift	  removal	  of	  
Olig2	   protein	   from	   differentiating	   MNs	   also	   suggests	   that	   additional,	   cooperative	  
mechanisms	  might	  be	  involved,	  perhaps	  including	  mir-­‐17~92	  microRNAs.	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Regulation	  of	  Olig2	  expression	  in	  dorsal	  oligodendrocyte	  specification	  
	  
Approximately	   20%	   of	  OLs	   in	   the	   spinal	   cord	   derive	   from	   stem	   cells	   resident	   in	   the	   dorsal	  
ventricular	   zone	   (Richardson	  et	   al.,	   2006;	   Tripathi	   et	   al.,	   2011).	   Production	  of	   dorsal	  Olig2-­‐
positive	   cells	   begins	   around	   E14.5,	   approximately	   2	   days	   after	   the	   emergence	   of	   the	   first	  
pMN-­‐derived	   OLPs.	   In	   contrast	   to	   Shh-­‐	   and	   Nkx6.1-­‐mediated	   ventral	   induction	   of	   Olig2,	  
specification	  of	  OLPs	  from	  dorsal	  dp3,	  dp4	  and	  dp5	  progenitor	  domains	  persists	  in	  both	  Shh-­‐
null	  and	  Nkx6-­‐null	  mutant	  mice	  (Cai	  et	  al.,	  2005;	  Vallstedt	  et	  al.,	  2005;	  Fogarty	  et	  al.,	  2005).	  
The	   demonstration	   in	   2005	   of	   Shh-­‐	   and	   Nkx6-­‐independent	   induction	   of	   Olig2	   in	   dorsal	  
oligodendrogenesis	   posed	   the	   question	   of	   how	   Olig2	   expression	   is	   initiated	   in	   these	  
precursors.	  
	  
In	   the	   dorsal	   aspects	   of	   the	   developing	   spinal	   cord,	   specification	   of	   neural	   identity	   is	  
predominantly	  determined	  by	  graded	  bone	  morphogenetic	  protein	  (BMP)	  signaling	  from	  the	  
roofplate,	  analogous	  to	  the	  ventral	  Shh	  countergradient	  (reviewed	  by	  Ulloa	  &	  Briscoe,	  2007;	  
Chizhikov	  &	  Millen,	  2004).	  In	  vitro	  and	  in	  vivo,	  BMPs	  inhibit	  OLP	  formation	  while	  exposure	  of	  
dorsal	  progenitors	  to	  BMP	  antagonists	  Noggin	  and	  Chordin	  triggers	  precocious	  OLP	  formation	  
(Mekki-­‐Dauriac	  et	  al.,	  2002;	  Miller	  et	  al.,	  2004;	  Vallstedt	  et	  al.,	  2005).	  A	  progressive	  reduction	  
in	  BMP	  concentration	  during	  development	  is	  therefore	  thought	  to	  relieve	  repression	  of	  OLP	  
genetic	  programmes,	  including	  Olig2	  expression.	  
	  
In	  cultures	  of	  dorsal	  cord	  neural	  progenitors,	   treatment	  with	   fibroblast	  growth	   factor	   (FGF)	  
activates	   Olig2	   expression	   and	   stimulates	   OL	   production,	   an	   observation	   that	   remains	  
unaffected	  by	  co-­‐administration	  of	  cyclopamine,	  a	  potent	  inhibitor	  of	  Hh	  signaling	  (Chandran	  
et	  al.,	  2003;	  Kessaris	  et	  al.,	  2004).	   In	  addition,	  a	   small	  molecule	  antagonist	  of	  FGF	  receptor	  
signaling	  blocks	  induction	  of	  Olig2	  and	  OL	  development	  in	  dorsal	  Pax7-­‐expressing	  progenitors	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(Chandran	   et	   al.,	   2003).	   In	   vivo	   evidence	   for	   FGF-­‐mediated	   regulation	   of	   Olig2	   gene	  
expression	   came	   in	   2010	   from	   research	   into	   the	   control	   of	   neural	   cell	   diversity	   in	   the	  
zebrafish	  hindbrain	  (Esain	  et	  al.,	  2010).	  The	  data	  confirm	  that	  dynamic	  BMP	  activity	  and	  FGF	  
signaling	  combine	  to	  regulate	  dorsal	  Olig2	  expression.	  
	  
In	   vitro	   research	   has	   explored	   the	  molecular	  mechanism	   underlying	   regulation	   of	   Olig2	   by	  
BMP	   and	   FGF	   (Bilican	   et	   al.,	   2008).	   The	   experiments	   –	   also	   performed	   using	   isolated	   rat	  
dorsal	   spinal	   cord	   progenitors	   –	   revealed	   that	   the	   intracellular	   BMP	   signaling	   intermediate	  
SMAD4	   associates	  with	   the	  Olig2	   promoter	   and	   its	   dissociation	   from	   this	   genomic	   binding	  
site	  correlates	  with	  Olig2	   transcription.	   Induction	  of	  Olig2	  after	  FGF2	  addition	  also	  requires	  
mitogen	   activated	   protein	   kinase	   (MAPK)	   pathway-­‐dependent	   sequestration	   of	   BMP-­‐
activated	   SMAD1	   in	   the	   cytoplasm	   (Bilican	   et	   al.,	   2008).	   In	   vivo,	   regulation	   of	   sub-­‐cellular	  
localisation	   of	   BMP	   signaling	   factors	   by	   downstream	   effectors	   of	   FGF	   might	   critically	  
modulate	  BMP	  signaling	  and	  thereby	  permit	  Olig2	  gene	  expression	  and	  OLP	  specification	   in	  
the	  dorsal	  spinal	  cord.	  
	  
Regulation	  of	  Olig2	  expression	  in	  oligodendrocyte	  differentiation	  
	  
Nuclear	   Olig2,	   expressed	   in	   multipotent	   pMN	   NSCs	   and	   upregulated	   in	   dorsal	   progenitors	  
upon	  OL	  fate	  specification,	  is	  continuously	  expressed	  over	  OL	  lineage	  development	  (Lu	  et	  al.,	  
2000;	   Zhou	   et	   al.,	   2000).	   Variation	   in	   the	   level	   of	   Olig2	   expression	   has,	   however,	   been	  
observed	   in	   vivo	   and	   down-­‐regulation	   is	   proposed	   to	   regulate	   critical	   final	   steps	   in	   OL	  
maturation	  (see	  Introduction	  to	  TF	  Olig2:	  OL	  differentiation)	  (Kitada	  &	  Rowitch,	  2006;	  Mei	  et	  
al.,	   2013).	   The	  pathways	  underlying	   this	   in	   vivo	  adjustment	   in	  Olig2	   synthesis	  have	  not	   yet	  
been	  identified.	  In	  vitro,	  cultured	  OLPs	  purified	  from	  adult	  spinal	  cord	  express	  BMP	  receptor	  
subunits	  Ia,	  Ib	  and	  II,	  and	  treatment	  with	  BMP2	  and	  4	  results	  in	  reduced	  Olig2	  expression	  and	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blocks	  OL	  differentiation	   (Cheng	  et	   al.,	   2007).	   Inhibition	  of	  OL	  differentiation	   is	   rescued	  by	  
forced	  Olig2	  expression,	  indicating	  BMP-­‐induced	  down-­‐regulation	  of	  Olig2	  might	  regulate	  OL	  
development	   in	   vivo,	   preserving	   a	  pool	   of	   responsive	   and	  proliferative	  Olig2low	  OLPs	   in	   the	  
adult.	  
	  
Olig2	  sub-­‐cellular	  localization	  and	  astrocyte	  development	  
	  
Long-­‐term	   fate-­‐mapping	   experiments	   using	   an	   inducible	   Olig2-­‐Cre-­‐Reporter	   mouse	   line	  
demonstrated	  that	  Olig2+	  pMN	  NSCs	  generate	  a	  discrete	  population	  of	  astrocytes	  (Masahira	  
et	   al.,	   2006).	   Olig2	   is	   absent	   from	   mature	   astrocytes	   and	   its	   role	   in	   regulating	   pMN	  
astrogliogenesis	  is	  not	  clear.	  One	  possibility	  is	  that	  repression	  of	  Olig2	  in	  pMN	  NSCs	  initiates	  a	  
phase	   of	   pMN	   astrocyte	   production.	   In	   the	   ventral	   embryonic	   forebrain,	   astrocyte	  
specification	   from	   Olig2-­‐expressing	   progenitors	   requires	   down-­‐regulation	   of	   Olig2	   for	  
activation	  of	  astrocyte	   lineage	  genes	  such	  as	  glial	   fibrillary	  acidic	  protein	   (GFAP)	   (Fukuda	  et	  
al.,	   2004).	   Moreover,	   conditional	   deletion	   of	   Olig2	   in	   postnatal	   NG2	   cells	   is	   sufficient	   to	  
trigger	  a	  developmental	  fate	  switch	  from	  OL	  to	  astrocyte	  production	  in	  some	  regions	  of	  the	  
CNS	   (Zhu	   et	   al.,	   2012).	   The	   pathways	   underlying	   regulation	   of	   this	   Olig2-­‐dependent	   fate	  
switch	  have	  not	  been	  identified.	  	  
	  
An	  additional	  mechanism	  for	  modulating	  TF	  activity	   is	  regulation	  of	  nuclear	  versus	  cytosolic	  
distribution	   within	   the	   cell.	   In	   astrocytes	   born	   from	   Olig2-­‐positive	   stem	   cells	   in	   the	  
subventricular	  zone	  of	  adult	  mice,	  Olig2	  is	  localized	  exclusively	  to	  the	  cytoplasm,	  suggesting	  
that	   nuclear-­‐cytoplasmic	   translocation	   might	   attenuate	   Olig2	   function	   and	   thereby	   permit	  
astrocyte	   development	   (Setoguchi	   &	   Kondo,	   2004).	   In	   cell	   culture,	   redistribution	   of	   Olig2	  
requires	  nuclear	  export	  signal	  receptor	  CRM1	  and	  is	  necessary	  for	  ciliary	  neurotrophic	  factor-­‐	  
(CNTF-­‐)	   induced	   astrocyte	   differentiation	   (Setoguchi	   &	   Kondo,	   2004).	   The	   reported	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mechanism	   involves	   CNTF-­‐mediated	   activation	   of	   phosphoinositide	   3-­‐kinase	   and	   Akt	  
intracellular	   signaling	   pathways;	   Akt-­‐dependent	   phosphorylation	   of	   Olig2	   at	   serine	   30	  
induces	   nuclear-­‐cytoplasmic	   translocation	   of	   Olig2	   via	   nuclear	   export	   receptor	   CRM1	  
recognition	  of	  an	  Olig2	  nuclear	  export	  signal	  peptide.	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1.5	   MOLECULAR	  MECHANISMS	  OF	  OLIG2	  FUNCTION	  
	  
The	  uninterrupted	  expression	  of	  Olig2	  from	  early	  multipotent	  stem	  cells,	  through	  neurogenic	  
and	   oligodendrogenic	   phases	   of	   pMN	   development,	   to	   widely	   distributed,	   mature	   and	  
myelinating	  OLs	  suggests	  that	  Olig2	  is	  performing	  particular	  roles	  in	  different	  developmental	  
contexts.	  Basic	  HLH	  transcription	  factors	  typically	  function	  through	  cofactor	  dimerization	  and	  
regulation	   of	   expression	   of	   specific	   target	   genes,	   primarily	   binding	   E-­‐box	   consensus	  
sequences	   in	  DNA.	  Here	   I	   describe	  what	   is	   understood	  of	   the	  molecular	   functions	  of	  Olig2	  
during	  spinal	  MN	  specification	  and	  OL	  development.	  
	  
Olig2	  regulation	  of	  motor	  neuron	  formation	  
	  
Novitch	  et	  al.	  (2001)	  and	  Mizugutchi	  et	  al.	  (2001)	  explored	  the	  pre-­‐oligodendrogenic	  role	  of	  
Olig2	   in	  MN	   induction.	   Gain-­‐of-­‐function	   experiments	   demonstrated	  Olig2	   upregulates	   pan-­‐
neuronal	   bHLH	   gene	  Neurogenin2	   (Ngn2),	   and	  motor	   neuron-­‐specific	   homeodomain	   genes	  
MNR2	   and	   Lim3.	   Interestingly,	   introduction	   of	   either	   an	  Olig2	   ‘Activator’	   construct	   –	  Olig2	  
bHLH	  domain	   fused	   to	   the	  herpes	   simplex	   virus	   protein	   16	   transactivation	  domain	  –	   or	   an	  
Olig2	   	   ‘Repressor’	   construct	   –	   Olig2	   bHLH	   fused	   to	   the	   repressor	   domain	   of	   Drosophila	  
Engrailed	   protein	   –	   indicated	   that	   Olig2-­‐mediated	   gene	   activation	   relies	   on	   transcriptional	  
repressor	  activity.	  Expression	  of	  the	  Olig2	  Activator	  within	  the	  pMN	  domain	  resulted	  in	  loss	  
of	   Isl1-­‐/Isl2-­‐positive	   MNs,	   while	   the	   Olig2	   Repressor	   mimicked	   wild-­‐type	   Olig2	   activity,	  
presumably	   via	   indirect	   de-­‐repression	   of	   pan-­‐neuronal	   (Ngn2)	   and	   motor	   neuron-­‐specific	  
(MNR2	  and	  Lim3)	  determinants	  (Mizugutchi	  et	  al.,	  2001;	  Novitch	  et	  al.,	  2001).	  
	  
Further	  work	  has	   revealed	  additional	  complexities	   in	   the	   role	  of	  Olig2	   in	  MN	  development.	  
Besides	   indirectly	   activating	   transcriptional	   programmes	   associated	   with	  MN	   specification,	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Olig2	  also	  inhibits	  differentiation	  of	  post-­‐mitotic	  MNs	  (Lee	  et	  al.,	  2005).	  DNA	  binding	  studies	  
showed	   that	   the	  Ngn2:E47	  activator	   complex	  and	  Olig2	   target	   the	   same	  E-­‐box	  elements	  of	  
pro-­‐MN	  differentiation	  genes	  such	  as	  Homeobox	  gene	  Hb9,	  activating	  and	  suppressing	  Hb9	  
expression,	   respectively.	   Dimerization	   is	   necessary	   for	   bHLH	   transcription	   factor	   activity	  
(Massari	   et	   al.,	   2000;	   Jones,	   2004).	   Yeast-­‐two-­‐hybrid	   and	   co-­‐immunoprecipitation	   assays	  
detected	  preferential	  formation	  of	  Olig2:Olig2	  homodimers,	  along	  with	  both	  Olig2:Ngn2	  and	  
Olig2:E47	  heterodimers	   (Lee	  et	  al.,	  2005).	  Repressive	  Olig2	  homodimers	  competitively	  bind	  
pro-­‐MN	   gene	   regulatory	   elements,	   while	   Olig2	   hetero-­‐interactions	   with	   Ngn2	   and	   E47	  
‘squelches’	   the	   cofactors	   away	   from	   one	   another	   and	   inhibits	   formation	   of	   the	   functional	  
Ngn2:E47	   activator	   complex	   (Figure	   5).	   These	   observations	   helped	   to	   explain	   the	   limited	  
capacity	  of	  ectopic	  Olig2	  to	  trigger	  MN	  differentiation	  and	  the	  abrupt	  extinction	  of	  Olig2	   in	  
newborn	   MNs	   (Mizuguchi	   et	   al.,	   2001;	   Novitch	   et	   al.,	   2001).	   On	   the	   basis	   of	   the	   gene	  
regulation	  and	  protein-­‐protein	  interaction	  data,	  Lee	  et	  al.	  (2005)	  propose	  a	  revised	  model	  of	  
Olig2	   function	   in	   the	   pMN	   domain	   (Figure	   5).	   During	   the	   neurogenic	   phase,	   Olig2	   primes	  
pMN-­‐resident	   stem	   cells	   for	   neuronal	   differentiation	   by	   de-­‐repressing	   genes	   such	   as	  Ngn2	  
and	  Lim3.	  In	  Ngn2/Olig2	  double-­‐positive	  cells,	  Olig2	  antagonizes	  Ngn2	  through	  occupancy	  of	  
common	   gene	   regulatory	   elements	   and	   co-­‐activator	   sequestration,	   thereby	   preventing	  
further	  MN	   differentiation.	   The	   transition	   of	   individual	   pMN	   cells	   from	  MN	   progenitors	   to	  
post-­‐mitotic	   MNs	   depends	   on	   the	   relative	   abundance	   of	   nuclear	   Olig2	   and	   Ngn2;	  
Olig2high/Ngn2low	  promotes	  maintenance	  of	  the	  progenitor	  state	  over	  neuronal	  commitment,	  
and	  vice	  versa	  (Figure	  5).	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Figure	  5.	   Lee	  et	  al.	   (2005)	  model	   for	  Olig2	  and	  Ngn2	   function	   in	  MN	  specification.	  Olig2	  and	  Ngn2	  
suppress	   and	   activate	  MN	  gene	  expression,	   respectively.	   The	   relative	   abundance	  of	  Olig2	   and	  Ngn2	  
determines	  NSC	   commitment	   to	   become	   post-­‐mitotic	  MNs.	   In	  Olig2high/Ngn2low	   NSCs	   (left):	   1.	   Olig2	  
homodimers	  bind	  E-­‐box	  motifs	  at	  MN	  genes	  and	  repress	  gene	  transcription;	  2.	  Olig2	  squelches	  Ngn2	  
and	   E47	   thereby	   preventing	   pro-­‐MN	   Ngn2:E47	   complex	   formation.	   In	   Olig2low/Ngn2high	   post-­‐mitotic	  
MN	  progenitors	  (right):	  1.	  Ngn2:E47	  heterodimers	  displace	  Olig2	  from	  E-­‐box	  motifs	  at	  MN	  genes	  and	  
activate	  gene	  transcription.	  
	  
Ligon	   et	   al.	   (2007)	   characterized	   an	   additional	   Olig2-­‐dependent	  mechanism	   for	   preserving	  
the	   replication-­‐competent	  progenitor	  pool.	   In	  neurosphere	  cultures	  derived	   from	  wild-­‐type	  
or	  Olig2-­‐null	  embryonic	  rats,	  the	  absence	  of	  Olig2	  is	  associated	  with	  a	  significant	  reduction	  in	  
proliferation	   rate,	   suggesting	   that	   Olig2	   promotes	   cell	   cycle	   progression.	   Computational	  
analysis	  predicted	  that	  the	  p53-­‐inducible	  inhibitor	  of	  cell	  cycle	  progression	  p21WAF/CIP1	  (p21)	  is	  
a	   direct	   target	   of	   Olig2.	   Chromatin	   immunoprecipitation	   (ChIP)	   of	   Olig2	   bound	   genomic	  
fragments	  confirmed	  Olig2	  occupancy	  of	  the	  p21	  promoter	  in	  neural	  progenitor	  cell	  cultures.	  
Finally,	   in	   a	   human	   glioma	   cell	   line,	   forced	   expression	   of	   Olig2	   suppresses	   activation	   of	   a	  
p21/luciferase	   reporter	   construct,	   suggesting	   that	   Olig2	   opposes	   post-­‐mitotic	   MN	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differentiation	  by	  direct	  transcriptional	  repression	  of	  the	  p21	  gene	  and	  inhibition	  of	  cell	  cycle	  
exit.	  
	  
Examining	   the	   gene	   regulatory	   network	   regulating	   NSC	   development,	   Mateo	   et	   al.	   (2015)	  
reported	   the	   results	  of	  high-­‐throughput	  Olig2	  ChIP-­‐seq	   from	  primary	   cultures	  of	  NSCs.	   The	  
genome-­‐wide	   location	   analysis	   revealed	   that	  Olig2	   occupies	   the	   cis-­‐regulatory	   elements	   of	  
genes	  required	  for	  neuronal	  differentiation	  and	  quiescence.	  Integrating	  the	  ChIP-­‐seq	  results	  
with	   data	   from	   parallel	   DNA	   microarray	   analysis	   of	   Olig2-­‐expressing	   and	   Olig2-­‐null	   NSC	  
cultures	   established	   a	   dual	   role	   for	   Olig2	   in	   transcriptional	   regulation.	   Olig2	   deficiency	  
induced	   upregulation	   and	   down-­‐regulation	   of	   distinct	   Olig2	   target	   genes,	   indicating	   that	  
Olig2	  acts	  as	  both	  a	   transcriptional	   activator	  and	   repressor.	  Moreover,	   gene	  ontology	   (GO)	  
analysis	   revealed	   enrichment	   of	   several	   GO	   terms	   relating	   to	   neuronal	   differentiation	  
(including	  “neurogenesis”)	  among	  Olig2-­‐repressed	  genes.	  Conversely,	  the	  GO	  analysis	  found	  
Olig2-­‐activated	   genes	   are	   significantly	   associated	   with	   biological	   processes	   including	   “cell	  
cycle”	  and	  “DNA	  replication”,	  consistent	  with	  a	  role	  for	  Olig2	  in	  promoting	  NSC	  proliferation.	  
Overall,	   the	   data	   highlight	   the	   dual	   functionality	   of	  Olig2	   as	   a	   transcriptional	   activator	   and	  
repressor	  in	  promoting	  NSC	  self-­‐renewal	  and	  inhibiting	  neuronal	  differentiation.	  
	  
Olig2	   is	  essential	   for	  MN	  development,	  though	  its	  role	   in	  regulating	  MN	  generation	   is	  more	  
complex	   than	  was	   first	   appreciated.	   Olig2	   appears	   to	   act	   as	   an	   early	   positive	   regulator	   of	  
neuronal	   differentiation,	   activating	   genes	   such	   as	   Ngn2,	   before	   switching	   to	   anatagonize	  
neuronal	  differentiation,	  acting	  instead	  to	  preserve	  the	  undifferentiated	  stem	  cell	  state	  and	  
maintain	   a	   reservoir	   of	   non-­‐restricted	   pMN	   progenitors	   for	   the	   gliogenic	   phase	   of	  
development.	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Olig2	  regulation	  of	  oligodendrogenesis	  
	  
Electroporation	   of	   Olig2	   into	   the	   chick	   spinal	   cord	   is	   sufficient	   to	   trigger	   ectopic	   and	  
precocious	   OL	   differentiation	   (Liu	   et	   al.,	   2007).	   Genetic	   evidence	   from	   these	   experiments	  
indicates	   that	   High	   Mobility	   Group	   (HMG)	   box	   TF	   Sox10	   acts	   downstream	   of	   Olig2	   and	  
directly	  mediates	  Olig2	   function.	   Introduction	  of	   Sox10	  alone	  mimics	   the	  effects	  of	   ectopic	  
Olig2	   expression	   –	   inducing	   OL	   markers	   MBP	   and	   PLP	   –	   but	   on	   an	   accelerated	   timeline.	  
Kuspert	   et	   al.	   (2011)	   identified	   the	   conserved	   upstream	  U2	   enhancer	   of	   Sox10	   gene	   as	   an	  
Olig2	  target	  and	  important	  regulatory	  element	  in	  OL	  development.	  The	  expression	  pattern	  of	  
a	  U2-­‐lacZ	   transgene	   that	   specifically	   labels	  U2-­‐active	   cells	   revealed	   that	   the	  U2	   enhancer	  
drives	   Sox10	   expression	   in	   OLPs	   after	   the	   initial	   induction	   of	   Sox10	   expression.	   The	   U2	  
enhancer	  is	  also	  silenced	  during	  terminal	  differentiation	  and	  remains	  inactive	  in	  mature	  OLs,	  
suggesting	   that	   additional	   regulatory	   regions	   drive	   both	   early	   and	   late	   stage	   Sox10	  
transcription	   in	   OLs	   in	   vivo.	   Although	   the	   U2	   enhancer	   is	   not	   active	   immediately	   post-­‐
specification	  and	   in	  mature	  OLs,	  both	  of	  which	  are	  Sox10+	  stages	  of	  the	  OL	   lineage,	  the	  U2	  
enhancer	  is	  necessary	  for	  Sox10	  gene	  expression	  in	  committed	  OLPs.	  In	  vitro,	  electromobility	  
shift	  (EMS)	  and	  luciferase	  reporter	  assays	  confirmed	  that	  Olig2:E47	  dimer	  binding	  at	  the	  U2	  
enhancer	   site	   triggers	   enhancer	   activation.	   In	   vivo,	   analysis	   of	   a	   transgenic	  mutant	  U2mut-­‐
lacZ	  reporter	  mouse	  line,	  lacking	  the	  principal	  Olig2	  target	  sequence	  within	  the	  U2	  enhancer,	  
revealed	  diminished	  U2	   activation	   in	   E16.5	   spinal	   cords	   and	   the	   importance	  of	   the	   site	   for	  
Olig2-­‐binding	  and	  U2	  activity	  in	  vivo.	  
	  
In	  addition	  to	  transcriptional	  regulation	  of	  Sox10,	  yeast	  two-­‐hybrid	  screens	  for	  mouse	  Sox10	  
binding	  partners	   identified	  Olig2,	  suggesting	  the	  two	  TFs	  might	  physically	   interact	   in	  Sox10-­‐
positive	   OLPs	   in	   vivo	   (Wissmuller	   et	   al.,	   2006).	   Interestingly,	   in	   zebrafish,	   Olig1	   alone	  
specifically	   associates	   with	   Sox10	   and	   enhances	   Sox10-­‐mediated	   activation	   of	   MBP	  
CHAPTER	  1	  Introduction	   	   	  
  
	   47	  
expression	   in	   vivo	   (Li	   et	   al.,	   2007).	   It	   is	   possible	   that	   Olig2	   and	   Sox10	   engage	   in	   a	   similar	  
manner	   to	   regulate	  MBP	   transcription	  and	  promote	  OL	  differentiation	   in	  mice,	   though	   this	  
has	  not	  as	  yet	  been	  described	  in	  vivo.	  
	  	  
Since	   the	   introduction	   of	   next	   generation	   DNA	   sequencing	   technologies,	   results	   from	  
independent	  genome-­‐wide	  Olig2	  target-­‐mapping	  experiments	  have	  been	  published	  (Weng	  et	  
al.,	  2012;	  Yu	  et	  al.,	  2013;	  Mateo	  et	  al.,	  2015).	  Weng	  et	  al.	  (2012)	  performed	  Olig1	  and	  Olig2	  
ChIP-­‐seq	   using	   purified	   rat	   OLs.	   The	   data	   identified	   5439	   distinct	   candidate	   Olig2	   binding	  
sites.	   Comparison	   with	   the	   Olig1	   dataset	   revealed	   Smad-­‐interacting	   protein	   1	   (Sip1)	   is	   a	  
common	  gene	  target	  of	  both	  Olig	  TFs,	  with	  multiple	  Olig2	  binding	  sites	  within	  the	  Sip1	  gene.	  
The	   effects	   on	   Sip1	   expression	   of	   either	   Olig2	   deficiency	   in	   vivo	   or	   of	   forced	   Olig2	   over-­‐
expression	   in	   cultured	   neural	   progenitors	   clearly	   suggest	   Olig2	   directly	   activates	   Sip1	  
transcription.	  In	  OLPs,	  Sip1	  –	  a	  member	  of	  the	  zinc	  finger	  homeobox	  family	  of	  TFs	  –	  indirectly	  
blocks	  BMP-­‐induced	  expression	  of	  Inhibitor	  of	  Differentiation	  TFs	  ID2	  and	  ID4.	  This	  process,	  
mediated	   largely	   through	   Sip1-­‐mediated	   transcriptional	   activation	   of	   the	   BMP	   signaling	  
inhibitor	  Smad7,	   is	   critical	   for	  OL	  maturation	  and	  myelinogenesis,	   but	  not	   for	   formation	  of	  
PDGFRA-­‐positive	  OLPs.	  
	  
Olig2	  is	  itself	  a	  key	  target	  of	  BMP/ID	  pathway-­‐mediated	  inhibition	  of	  OL	  differentiation.	  The	  
BMP	   signaling	   effectors	   ID2	   and	   ID4	   directly	   interact	   with	   Olig2,	   sequestering	   Olig2	   away	  
from	   its	   genomic	   targets	   and	   disrupting	   its	   pro-­‐OL	   function	   (Samanta	   &	   Kessler,	   2004).	  
Olig2/Sip1-­‐dependent	   silencing	   of	   ID2	   and	   ID4	   expression,	   therefore,	   upregulates	   Olig2	  
activity,	  forming	  a	  positive	  feedback	  loop	  driving	  OL	  lineage	  progression,	  while	  BMP-­‐induced	  
IDs	   sensitize	   individual	   cells	   to	   BMP	   signaling	   by	   repressing	   Olig2	   function	   and	   thereby	  
prevent	  OLP	  differentiation.	  As	  both	  a	   regulator	  and	   target	   in	  BMP	  signaling,	  Olig2	   thereby	  
facilitates	  crosstalk	  between	  the	  pro-­‐	  and	  anti-­‐OL	  differentiation	  pathways.	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Yu	   et	   al.	   (2013)	   carried	   out	   Olig2	   ChIP-­‐seq	   experiments	   in	   OLPs,	   immature	   OLs	   (iOLs)	   and	  
mature	  OLs	  (mOLs),	  characterized	  according	  to	  stage-­‐specific	  combinatorial	  expression	  of	  OL	  
lineage	  genes	  CNP,	  Mag,	  PLP	  and	  MBP.	  The	  three	  datasets	  consist	  of	  21901,	  25787	  and	  2759	  
Olig2	  binding	   sites	   in	  OLPs,	   iOLs,	   and	  mOLs	   respectively,	   confirming	   the	  dynamic	  nature	  of	  
Olig2	   target	  choice	  over	   the	  course	  of	  OL	  differentiation.	  Parallel	  genome-­‐wide	  mapping	  of	  
Brg1	  –	  the	  central	  ATPase	  subunit	  of	  the	  SWI/SNF	  chromatin	  remodeler	  complex	  –	  revealed	  
Brg1	  is	  predominantly	  associated	  with	  genomic	  sites	  pre-­‐occupied	  by	  Olig2	  in	  immature	  OLs,	  
including	  at	  the	  established	  U2	  enhancer	  of	  Sox10	   (Kuspert	  et	  al.,	  2011).	  Brg1	  and	  Olig2	  co-­‐
occupancy	  correlates	  strongly	  with	  histone	  modifications	  marking	  active	  transcription	   (such	  
as	  histone	  3	  lysine	  27	  (H3K27)	  acetylation),	  and	  RNAi	  knockdown	  of	  Brg1	  in	  culture	  reduces	  
OL	   lineage	   gene	   expression.	   Furthermore,	   Olig2	   and	   Brg1	   co-­‐immunoprecipitate	   in	   iOLs,	  
suggesting	   that	  Olig2	   physically	   recruits	   Brg1	   to	   its	  OL	   gene	   E-­‐box	  binding	   sites	   to	   activate	  
gene	  expression	  and	  promote	  the	  OLP	  to	  iOL	  transition.	  In	  mature	  OLs,	  Brg1	  and	  Olig2	  do	  not	  
co-­‐localize	   at	   common	   sites	   and	   instead	   regulate	   distinct	   target	   genes.	   The	   mechanisms	  
underlying	  the	  transient	  nature	  of	  Olig2/Brg1	  cooperation	  have	  not	  been	  investigated.	  
	  
Opposing	   roles	   for	  Olig2	   at	   different	   points	   along	   the	  OL	   lineage	   –	   promoting	  OLP-­‐iOL	   but	  
inhibiting	  iOL-­‐mOL	  transitions	  –	  were	  described	  in	  2013	  based	  on	  the	  results	  of	  stage-­‐specific	  
Olig2	  deletion	  in	  mice	  in	  vivo	  (Mei	  et	  al.,	  2013).	  Mei	  et	  al.	  reported	  that	  the	  pro-­‐	  and	  anti-­‐OL	  
functions	   of	   Olig2	   correlate	  with	   contrasting	   effects	   on	   Olig1	   expression.	  Olig2	   ablation	   in	  
OLPs	   results	   in	  a	   reduction	   in	  Olig1	  expression,	  while	  similar	  ablation	   in	   iOLs	   is	   reported	   to	  
trigger	   excessive	   Olig1	   expression.	   In	   combination,	   the	   observations	   suggest	   that	   Olig2	  
encourages	  OLP	  differentiation	  via	  activation	  of	  expression	  of	  Olig1,	  before	  repressing	  Olig1	  
in	   iOLs	  to	  restrict	   late-­‐stage	  lineage	  progression.	  The	  observation	  in	  vitro	  that	  forced	  up-­‐	  or	  
down-­‐regulation	  of	  Olig1	  is	  sufficient	  to	  rescue	  the	  effect	  of	  Olig2	  ablation	  in	  OLPs	  and	  iOLs,	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respectively,	  suggests	  Olig2-­‐mediated	  regulation	  of	  Olig1	  expression	  might	  be	  an	   important	  
component	  of	  Olig2	  function.	  For	  both	  the	  OLP-­‐specific	  activation	  and	  iOL-­‐specific	  repression	  
of	   Olig1	   expression,	   however,	   the	   mechanism	   underlying	   the	   proposed	   regulatory	   role	   of	  
Olig2	   (transcriptional	  or	  post-­‐transcriptional;	  direct	  or	   indirect)	   is	  not	  known.	   In	  addition,	   it	  
should	   be	   noted	   that	   analysis	   of	  Olig1-­‐null	  mice	   has	   confirmed	  Olig1	   is	   expendable	   for	  OL	  
development,	   indicating	   Olig1	   is	   non-­‐essential	   for	   Olig2-­‐mediated	   regulation	   of	   OL	   lineage	  
progression	  (Mei	  et	  al.,	  2013;	  Paes	  de	  Faria	  et	  al.,	  2014).	  
	  
Additional	   Olig2	   cofactors	   have	   been	   identified	   in	   vitro.	   Co-­‐immunoprecipitation	   assays	  
performed	  in	  transfected	  Cos7	  cells	  have	  shown	  Olig2	  physically	  interacts	  with	  both	  Nkx2.2,	  a	  
homeodomain	  TF	  necessary	   for	  OL	  differentiation,	  and	  the	  transcriptional	  activator	  p300,	  a	  
histone	  acetyltransferase	  (Sun	  et	  al.,	  2003;	  Fukuda	  et	  al.,	  2004).	  The	  functional	  significance	  of	  
these	  interactions	  in	  OL	  lineage	  cells	  in	  vivo	  has	  not	  been	  established.	  
	  
While	  our	  understanding	  is	  far	  from	  complete,	  research	  to	  date	  has	  revealed	  Olig2	  performs	  
a	  number	  of	  functions	  in	  different	  cell	  types	  at	  different	  developmental	  stages.	  This	  variety	  in	  
function	   is	  underscored	  by	  a	  diverse	  and	  dynamic	   range	  of	  molecular	  operations,	   including	  
direct	  activation	  and	  suppression	  of	  target	  gene	  transcription,	  hetero-­‐complex	  formation	  and	  
regulation	  of	  cofactor	  function	  at	  the	  protein	  level.	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1.6	   OLIG2	  PHOSPHORYLATION	  
	  
Discovery	   of	   the	   different	   developmental	   and	   molecular	   functions	   of	   Olig2	   has	   been	  
accompanied	   by	   research	   into	   the	   mechanisms	   directing	   its	   stage-­‐	   and	   cell	   type-­‐specific	  
activity.	   Post-­‐translational	  modifications	   (PTMs)	   at	   specific	   amino	   acid	   residues	   –	   including	  
serine/threonine	  phosphorylation	  –	  coordinate,	  often	   in	  combination,	   the	  precise	   functions	  
of	  transcription	  factors,	  altering	  secondary	  and	  tertiary	  structure	  and	  modulating	  sub-­‐cellular	  
localization,	   DNA	   binding,	   stability	   and	   association	   with	   coregulator	   proteins	   (Benayoun	   &	  
Veitia,	  2009;	  Filtz	  et	  al.,	  2014).	  Mouse	  Olig2	  contains	  more	  than	  60	  serine/threonine	  residues	  
(of	  323	  total),	   suggesting	   that	  post-­‐translational	  addition	  and	  removal	  of	  phosphate	  groups	  
might	   be	   critical	   for	  modulating	   the	   different	   functions	   of	  Olig2	   (Li	   et	   al.,	   2011;	   Sun	   et	   al.,	  
2011).	   Two-­‐dimensional	   PAGE	   and	   western	   blot	   (WB)	   analysis	   of	   Olig2	   before	   and	   after	  
treatment	  with	  calf	  intestinal	  phosphatase	  has	  confirmed	  phosphorylation	  at	  multiple	  sites	  in	  
vivo	  (Li	  et	  al.,	  2011).	  Summarized	  below,	  research	  from	  several	  labs	  has	  begun	  to	  characterize	  





Figure	   6.	   Serine	   phosphorylation	   sites	   conserved	   in	   human	   and	   mouse	   Olig2.	   Olig2	   contains	   a	  
number	  of	  established	  phospho-­‐acceptor	  serine	  residues,	   including	  the	  N-­‐terminal	  triple-­‐serine	  motif	  
(TSM),	  S85	  and	  S87	  within	  the	  serine-­‐threonine-­‐rich	  (STR)	  domain	  and	  S147	  within	  the	  bHLH	  domain.	  
The	  TSM	  and	  S147	  are	  also	  entirely	  conserved	  in	  chicken,	  Xenopus	  laevis	  and	  zebrafish.	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Serine-­‐threonine-­‐rich	  domain	  phosphorylation	  
	  
The	   amino-­‐terminal	   half	   of	   mammalian	   Olig2	   contains	   a	   string	   of	   12	   contiguous	  
serine/threonine	   residues,	   known	  as	   the	   serine-­‐threonine-­‐rich	   (STR)	  domain.	  Huillard	  et	   al.	  
(2010),	  examining	  the	  role	  of	  the	  prolific	  serine/threonine	  kinase	  casein	  kinase	  2	  (CK2)	  in	  NSC	  
proliferation	  and	  OLP	  specification,	   identified	  Olig2	  as	  a	  CK2	  substrate.	   In	  vitro,	   radioactive	  
32P	   incorporation	   demonstrated	   CK2-­‐dependent	   phosphorylation	   of	   an	   N-­‐terminal	   Olig2	  
fragment	  (amino	  acids	  1-­‐177),	  while	  subsequent	  Edman	  degradation	  isolated	  the	  STR	  domain	  
as	   the	   target	  within	   the	  phosphorylated	  Olig2(1-­‐177)	  peptide.	  Of	   the	  12	  constituent	  amino	  
acids	   that	   form	   the	   STR	   domain,	   S85	   and	   S87	   were	   identified	   as	   the	   major	   phospho-­‐
acceptors,	   along	   with	   minor	   sites	   S84,	   T86	   and	   S88.	   Experiments	   conducted	   with	  
neurosphere	  cultures	  suggest	  that	  the	  STR	  domain	  is	  required	  for	  the	  pro-­‐OL	  activity	  of	  Olig2.	  
However,	   Huillard	   et	   al.	   (2010)	   did	   not	   characterize	   the	   impact	   of	   STR	   domain	  
phosphorylation	  on	  Olig2	  function	  either	  in	  vitro	  or	  in	  vivo.	  
	  
Serine	  30	  phosphorylation	  
	  
Setoguchi	   and	   Kondo	   revealed	   phosphorylation-­‐dependent	   regulation	   of	   Olig2	   intracellular	  
localization	   (Setoguchi	   &	   Kondo,	   2004).	   CNTF-­‐stimulated	   Akt	   activation	   induces	   Olig2	  
translocation	   from	   the	   nucleus	   to	   the	   cytoplasm	   –	   an	   essential	   process	   for	   NSC	   astrocyte	  
differentiation	  in	  vitro	  –	  via	  nuclear	  export	  signal	  (NES)	  receptor	  CRM1.	  In	  an	  in	  vitro	  kinase	  
assay,	   Akt	   phosphorylates	   wild-­‐type	   Olig2,	   while	   a	   phospho-­‐null	   mutant	   form	   of	   Olig2	   in	  
which	   serine	   30	   is	  mutated	   to	   an	   alanine	   (Olig2-­‐S30A)	   remains	   unmodified,	   indicating	   that	  
Akt	  directly	   targets	  Olig2	  S30.	   In	   transfected	  cultures	  of	  COS	  cells	  and	  primary	  NSCs,	  Olig2-­‐
S30A	  is	  predominantly	  nuclear,	  in	  contrast	  to	  largely	  cytoplasmic	  wild-­‐type	  Olig2,	  and	  mutant	  
expression	   is	   associated	   with	   a	   reduced	   capacity	   for	   generating	   GFAP+	   astrocytes	   in	   the	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presence	  of	  CNTF.	  Taken	  together	  the	  results	  indicate	  Akt-­‐mediated	  phosphorylation	  of	  Olig2	  
at	  serine	  30	  triggers	  Olig2	  expulsion	  from	  the	  nucleus	  and	  regulates	  astrocyte	  differentiation	  
from	  NSCs	  in	  the	  adult	  subventricular	  zone	  (Setoguchi	  &	  Kondo,	  2004).	  
	  
Amino	  terminal	  triple-­‐serine	  phosphorylation	  
	  
Sun	  et	  al.	  (2011)	  mapped	  bona	  fide	  phosphorylation	  sites	  in	  endogenous	  Olig2	  purified	  from	  
primary	   human	   glioma	   xenografts	   and	   neurosphere	   cultures	   by	   mass	   spectrometry	   (MS).	  
High-­‐confidence	   phosphorylation	   sites	   were	   identified	   in	   both	   mouse	   and	   human	   Olig2	   at	  
S10,	   S13	   and	   S14,	   constituting	   a	   highly	   conserved	   triple-­‐serine	   motif	   within	   the	   amino	  
terminal	  domain.	  Phosphorylation	  of	  the	  Olig2	  S10/13/14	  motif	  is	  developmentally	  regulated	  
and	  an	  important	  positive	  regulator	  of	  neural	  progenitor	  cell	  proliferation.	  Using	  an	  antibody	  
that	   specifically	   recognizes	   the	   phosphorylated	   Olig2	   triple-­‐serine	   motif,	   Sun	   et	   al.	   (2011)	  
observed	   a	   decrease	   in	   Olig2	   S10/13/14	   phosphorylation	   at	   postnatal	   versus	   earlier	  
embryonic	   stages	   of	   development.	   	   In	   secondary	   neurosphere	   assays	   measuring	   the	  
proliferative	  capacity	  of	  NSCs,	  the	  population	  growth	  of	  Olig2-­‐null	  cells	  complemented	  with	  a	  
triple	   phospho-­‐null	   Olig2	   expression	   construct	   (S10/13/14	   all	   mutated	   to	   either	   valine	   or	  
glycine)	   was	   markedly	   limited.	   In	   contrast,	   S10/13/14	   substitution	   with	   the	   negatively	  
charged	   amino	   acid	   glutamate	   in	   a	   triple	   phospho-­‐mimetic	   Olig2	  mutant	   rescued	   the	   pro-­‐
mitogenic	   function	   of	   Olig2,	   suggesting	   S10/13/14	   phosphorylation	   is	   crucial	   for	   Olig2-­‐
mediated	   regulation	   of	   NSC	   proliferation.	   Consistent	   with	   these	   results,	   the	   oncogenic	  
potential	  –	  after	   inoculation	   into	   the	  mouse	  brain	  –	  of	   triple	  phospho-­‐null	  Olig2-­‐expressing	  
tumour	   neurospheres	   is	   significantly	   lower	   than	   wild-­‐type	   Olig2-­‐expressing	   neurospheres.	  
The	  findings	  of	  Sun	  et	  al.	  (2011)	  indicate	  phosphorylation	  of	  Olig2	  at	  its	  amino	  terminal	  triple-­‐
serine	   motif	   regulates	   proliferation	   and	   potentially	   entry	   into	   post-­‐mitotic	   phases	   of	  
differentiation	  of	  neural	  progenitors	  over	  the	  course	  of	  development.	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Research	   published	   more	   recently	   from	   the	   same	   group	   investigated	   precisely	   how	  
phosphorylation	  of	  the	  triple-­‐serine	  motif	  influences	  Olig2	  activity	  (Meijer	  et	  al.,	  2014).	  In	  the	  
DNA-­‐binding	  mutant	  Olig2-­‐N114H	  –	   in	  which	  mutation	  of	  bHLH	  asparagine	  114	   to	  histidine	  
abolishes	   the	   DNA-­‐binding	   capability	   of	   Olig2	   –	   S10/13/14	   triple-­‐serine	  mutation	   does	   not	  
affect	  neural	  progenitor	  cell	  proliferation	  in	  vitro,	  indicating	  that	  the	  pro-­‐mitogenic	  effects	  of	  
S10/13/14	   phosphorylation	   require	   Olig2:DNA	   interaction.	   RNA-­‐seq	   analysis	   uncovered	  
important,	  growth-­‐/proliferation-­‐related	  differences	  in	  the	  gene	  expression	  profiles	  of	  Olig2-­‐
null	  NSCs	  transduced	  with	  either	  triple	  phospho-­‐null	  or	  phospho-­‐mimetic	  Olig2	  variants.	  ChIP	  
analyses	  performed	  on	  the	  same	  cells,	  however,	  found	  no	  difference	  in	  genomic	  binding	  site	  
occupancy	   between	   the	   Olig2	   mutants,	   indicating	   that	   Olig2	   S10/13/14	   phosphorylation	  
regulates	  gene	  transcription	  but	  not	  E-­‐box	  target	  recognition.	  Exploring	  the	  phosphorylation	  
state-­‐specific	   regulation	   of	   a	   constant	   set	   of	   gene	   targets,	   Meijer	   et	   al.	   (2014)	   describe	  
differential	   intranuclear	   compartmentalization	   (open	   versus	   condensed	   chromatin)	   of	  
endogenous	   S10/13/14	   phosphorylated	   and	   dephosphorylated	   Olig2	   in	   wild-­‐type	   NSC	  
cultures.	  Phospho-­‐Olig2	  is	  enriched	  in	  open	  chromatin,	  while	  Olig2	  isolated	  from	  condensed	  
chromatin	   structures	   is	   typically	   dephosphorylated.	   This	   uneven	   distribution	   of	   different	  
Olig2	   isoforms	   is	   accompanied	   by	   differential	   access	   to	   coregulator	   proteins.	   Tandem	  
antibody	  purification	   and	  MS	  of	  Olig2	  binding	  partners	   identified	  open	   chromatin	   fraction-­‐
specific	   cofactors,	   including	   HDAC1,	   and	   condensed	   chromatin-­‐specific	   cofactors,	   including	  
NF1A,	   both	   of	   which	   were	   confirmed	   by	   co-­‐immunoprecipitation	   from	   different	   nuclear	  
fractions.	  
	  
The	   successive	   studies	   by	   Sun	   et	   al.	   (2011)	   and	   Meijer	   et	   al.	   (2014)	   characterize	   a	  
developmentally	   regulated	   phosphorylation	   of	   Olig2	   at	   a	   highly	   conserved	   amino	   terminal	  
triple-­‐serine	  motif.	  In	  the	  nuclei	  of	  neural	  progenitors,	  phosphorylated	  Olig2	  is	  concentrated	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in	  regions	  of	  transcriptionally	  active	  open	  chromatin,	  where	   interaction	  with	  compartment-­‐
specific	   protein	   partners	   regulates	   gene	   expression,	   promoting	   cell	   cycle	   progression	   and	  
progenitor	   cell	   proliferation.	  Dephosphorylation	   triggers	   intranuclear	   relocalization	  of	  Olig2	  
to	   condensed	   chromatin,	   and	   interaction	   with	   different	   cofactors.	   The	   precise	   function	   of	  
these	  interactions	  in	  transcriptionally	  inert	  chromatin	  structures	  is	  not	  fully	  understood.	  
	  
Basic	  helix-­‐loop-­‐helix	  domain	  serine	  147	  phosphorylation	  
	  
Post-­‐translational	  modification	  of	  the	  bHLH	  domain	  regulates	  cofactor	  dimerization	  and	  DNA	  
binding	   in	   a	   number	   of	   different	   TFs	   (for	   example,	   Ngn2	   [Hindley	   et	   al.,	   2012]	   and	   Twist	  
[reviewed	   by	   Xue	  &	   Hemmings,	   2012]).	   Phosphorylation	   of	   Olig2	   at	   serine	   147	   (S147)	   has	  
been	  identified	  by	  Li	  et	  al.	  (2011)	  as	  a	  key	  determinant	  of	  pMN	  domain-­‐resident	  NSC	  fate	  in	  
the	  embryonic	  spinal	  cord,	  regulating	  the	  developmental	  switch	  from	  MN	  to	  OLP	  production	  
(see	  Oligodendrocyte	   Specification	   above).	   Alignment	   of	   the	   Olig2	   protein	   sequences	   from	  
different	   species	   and	   in	   silico	   motif	   analysis	   identified	   an	   evolutionarily	   conserved	   and	  
predicted	  protein	  kinase	  A	  (PKA)	  target	  site	  within	  the	  bHLH	  domain,	  S147.	   In	  vitro	  analysis	  
comparing	  wild-­‐type	  Olig2	  and	  an	  Olig2	  phospho-­‐null	   (Olig2-­‐S147A)	  mutant	   confirmed	   that	  
Olig2	  can	  be	  phosphorylated	  at	  S147.	  Visualizing	  the	  phosphorylation	  state	  of	  S147	   in	  E9.5,	  
E11.5	   and	   E13.5	   mice	   spinal	   cord	   by	   western	   blot,	   using	   an	   antibody	   that	   specifically	  
recognizes	   the	   phospho-­‐S147	   form	   of	   Olig2,	   revealed	   that	   endogenous	   Olig2	   is	   initially	  
phosphorylated	  at	  S147	  during	   the	  MN	  specification	  phase	  and	  dephosphorylated	  over	   the	  
MN-­‐OLP	  fate	  switch.	  
	  
In	   order	   to	   study	   the	   role	   of	   Olig2	   phosphorylation	   at	   S147	   in	   vivo,	   Li	   et	   al.	   generated	   a	  
transgenic	  mouse	  line	  expressing	  the	  phospho-­‐null	  Olig2-­‐S147A	  mutant	  protein	  on	  an	  Olig2-­‐
null	  background	  (Olig2-­‐S147A).	  These	  Olig2-­‐S147A	  mice	  display	  a	  similar	  patterning	  defect	  to	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Olig2-­‐null	  mutants,	  in	  which	  ventral	  expansion	  of	  the	  Olig2-­‐negative,	  Irx3-­‐positive	  p2	  domain	  
completely	   supplants	   the	   pMN	   domain	   (Lu	   et	   al.,	   2002).	   As	   a	   consequence,	   Olig2-­‐S147A	  
mutant	   mice	   die	   at	   birth	   having	   failed	   to	   generate	   MNs.	   This	   evidence	   suggests	   S147	  
phosphorylation	   is	   necessary	   for	   Olig2	   to	   perform	   its	   early	   patterning	   and	   neurogenic	  
functions	   in	   the	  developing	   spinal	   cord.	  Unlike	   in	  Olig2	  deficient	   embryos,	   however,	  which	  
also	  entirely	  lack	  spinal	  cord	  Sox10-­‐/PDGFRA-­‐positive	  OLPs,	  sparse	  OLP	  formation	  is	  observed	  
in	  Olig2-­‐S147A	  mutant	  spinal	  cords	  by	  E18.5,	  suggesting	   that	  Olig2	  S147	  phosphorylation	   is	  
not	  required	  for	  OL	  development.	  In	  fact,	  forced	  expression	  of	  Olig2-­‐S147A	  in	  both	  the	  dorsal	  
chick	   neural	   tube	   and	   cultured	   P19	   cells	   induces	   OLP	   formation	   at	   greater	   efficiency	   than	  
wild-­‐type	   Olig2.	   In	   differentiating	   P19	   cell	   cultures	   transfected	   with	   wild-­‐type	   Olig2	   Hb9-­‐
positive	  MNs	  also	  arise	  in	  significant	  numbers,	  and	  these	  are	  virtually	  absent	  under	  the	  same	  
conditions	  when	   expressing	   the	  Olig2-­‐S147A	  mutant	   form	   of	  Olig2.	   In	   pMN-­‐resident	  NSCs,	  
phospho-­‐S147	  Olig2	  therefore	  appears	  to	  establish	  the	  pMN	  domain	  and	  potentially	  regulate	  
MN	   generation.	   Dephosphorylation	   of	   Olig2	   S147	   at	   ~E12.5	   in	   mice	   then	   arrests	   the	  
programme	  of	  MN	  specification	  and	  initiates	  the	  successor	  programme	  of	  OLP	  formation.	  	  
	  
As	  well	  as	  elucidating	  the	  developmental	   impact	  of	  Olig2	  (de)phosphorylation	  at	  S147,	  Li	  et	  
al.	   (2011)	   performed	   preliminary	   in	   vitro	   experiments	   to	   identify	   the	   underlying	  molecular	  
mechanisms.	  Computational	  analysis	  of	  the	  Olig2	  primary	  structure	  revealed	  that	  S147	  in	  its	  
primary	  structure	  context	  conforms	  to	  the	  PKA	  target	  consensus	  motif.	  To	  assay	  the	  effect	  of	  
PKA	   activity	   on	   Olig2	   S147	   phosphorylation,	   Olig2-­‐S147A	   and	   wild-­‐type	   Olig2	   expression	  
constructes	  were	  transfected	  either	  alone	  or	  in	  combination	  with	  a	  dominant-­‐negative	  form	  
of	   PKA	   (dnPKA)	   into	   Cos	   7	   cells,	   and	   the	   phosphorylation	   patterns	   compared	   by	   two-­‐
dimensional	   PAGE	   and	   WB.	   The	   dnPKA	   altered	   the	   wild-­‐type	   phospho-­‐Olig2	   signal	   to	  
resemble	  that	  of	  Olig2-­‐S147A,	  indicating	  that	  PKA	  can	  phosphorylate	  Olig2	  S147	  in	  vitro.	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The	  position	  of	  S147	  within	  the	  bHLH	  domain	  implied	  that	  S147	  phosphorylation	  might	  affect	  
TF	  dimerization	  and/or	  DNA-­‐binding.	  Differences	  in	  the	  co-­‐immunoprecipitation	  of	  wild-­‐type	  
or	   phospho-­‐null	  mutant	  Olig2	  with	   the	   established	  Olig2	   cofactors	  Ngn2,	   Sox10,	  Olig1	   and	  
Olig2	   itself	   indicated	   that	  S147	  phosphorylation	  alters	   the	  dimerization	  properties	  of	  Olig2.	  
Wild-­‐type	   Olig2	   forms	   homodimers	   and	   Olig2:Olig1	   heterodimers,	   while	   Olig2-­‐S147A	  
preferentially	   binds	   Ngn2.	   These	   phospho-­‐dependent	   changes	   in	   co-­‐factor	   choice	   were	  
confirmed	   in	  a	  mammalian	  two-­‐hybrid	  system.	  An	  electro-­‐mobility	  shift	  assay	  (EMSA)	  using	  
the	   known	   Olig2	   target	   E-­‐box	   within	   the	   Hb9	   promoter	   also	   revealed	   a	   diminished	   DNA	  
binding	   activity	   of	   the	   mutant	   Olig2-­‐S147A.	   Interestingly,	   however,	   in	   a	   luciferase	   assay	  
measuring	   the	   activity	   of	   the	  Hb9	   promoter,	   phospho-­‐null	   mutant	   Olig2	   acted	   as	   a	   more	  
potent	  repressor	  of	  Ngn2-­‐mediated	  transcription	  than	  wild-­‐type	  Olig2,	  suggesting	  that	  Olig2-­‐
S147A:Ngn2	  dimer	   formation	   is	  sufficient	   to	  silence	  Hb9	   transcription	   independent	  of	  Olig2	  
occupancy	  of	  the	  Hb9	  promoter.	   It	  should	  be	  noted,	  however,	  that	  the	  Olig2-­‐S147A	  mutant	  
might	  not	  accurately	  model	   the	  dephosphorylated	   form	  of	  wild-­‐type	  Olig2.	   In	  other	  words,	  
the	   S147A	   mutation	   might	   alter	   the	   molecular	   properties	   of	   Olig2	   independent	   of	  
phosphorylation.	  Li	  et	  al.	   (2011)	  propose	  that	  the	  stability,	  nuclear	   localisation	  and	  capacity	  
of	  the	  mutant	  protein	  to	  bind	  known	  transcriptional	  partners	  and	  drive	  spinal	  OLP	  formation	  
indicates	  that	  Olig2-­‐S147A	  does	  not	  represent	  a	  loss-­‐of-­‐function	  mutant.	  Nonetheless,	  in	  the	  
absence	   of	   a	   comparative	   analysis	   of	   the	   protein-­‐	   and	   DNA-­‐binding	   properties	   of	  
dephosphorylated	   wild-­‐type	   Olig2	   and	   the	   Olig2-­‐S147A	   mutant,	   the	   veracity	   of	   the	  
phosphonull	   mutant	   model	   remains	   to	   be	   fully	   established.	   This	   could,	   for	   example,	   be	  
addressed	   in	   vitro	   using	   the	   Cos7	   cell	   system,	   co-­‐transfecting	   wild-­‐type	   or	   phosphonull	  
mutant	  Olig2	  with	  a	  dnPKA	  –	  shown	  by	  Li	  et	  al.	   (2011)	   to	  dephosphorylate	  Olig2	  at	  S147	  –	  
and	  examining	  the	  activity	  of	  the	  dephosphorylated	  wild-­‐type	  and	  mutant	  Olig2	  proteins.	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Unifying	   the	   in	   vivo	   and	   in	   vitro	   data,	   Li	   et	   al.	   (2011)	   propose	   a	  model	   of	   how	   reversible	  
phosphorylation	   of	   Olig2	   S147	   might	   sequentially	   regulate	   MN	   and	   OLP	   fates	   in	   the	  
embryonic	   spinal	   cord	   (Figure	   7).	   During	   the	   initial	   patterning	   and	   neurogenic	   phases	   of	  
development,	  Olig2	   is	  phosphorylated	  at	  S147,	  preferentially	   forming	  Olig2	  homodimers.	   In	  
this	   state,	   pro-­‐neuronal	   TFs,	   such	   as	  Ngn2,	   activate	   a	   programme	   of	  MN	   gene	   expression,	  
while	  phospho-­‐S147	  Olig2	  homodimers	  bind	  and	  repress	  OL	  lineage	  genes.	  At	  the	  time	  of	  the	  
MN-­‐OLP	   fate	   switch,	   Olig2	   S147	   dephosphorylation	   –	   catalyzed	   by	   an	   as	   yet	   unidentified	  
phosphatase	  enzyme	  –	  induces	  a	  change	  in	  Olig2	  cofactor	  choice	  from	  homo-­‐	  to	  heterodimer	  
formation.	   Dephosphorylated	   Olig2	   complexes	   with	   Ngn2	   and	   presumably	   additional	   co-­‐
regulator	   proteins	   and	   –	   through	   a	   combination	   of	   DNA-­‐independent	   (pro-­‐MN	   TF	  
sequestration)	   and	   DNA-­‐dependent	   (OL	   gene	   activation)	   mechanisms	   –	   replaces	   the	  
programme	  of	  neurogenesis	  with	  a	  programme	  of	  oligodendrogenesis.	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Figure	   7.	   Li	   et	   al.	   (2011)	  model	   of	   Olig2-­‐mediated	   NSC	   fate	   specification.	  MN	  generation:	  Olig2	   –	  
expressed	   in	   pMN	   domain-­‐resident	   NSCs	   –	   is	   phosphorylated	   at	   S147.	   Phospho-­‐Olig2	   forms	  
homodimers,	   repressing	  OL	   lineage	  gene	  expression	  and	  enabling	  activation	  of	  MN	   lineage	  genes	  by	  
pro-­‐neuronal	   TFs	   such	   as	   Ngn2.	   OLP	   generation:	   Over	   the	   MN-­‐OLP	   fate	   switch,	   Olig2	   is	  
dephosphorylated	  at	  S147.	  Dephospho-­‐Olig2	  forms	  heterodimers,	  sequestering	  pro-­‐neuronal	  TFs	  such	  
as	  Ngn2	  to	  inactivate	  MN	  lineage	  genes	  and	  activating	  OL	  lineage	  genes	  in	  complex	  with	  additional	  co-­‐
regulator	  proteins.	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1.7	   SUMMARY	  
	  
Our	  understanding	  of	   the	   importance	  of	  myelinating	  OLs	   for	   proper	  CNS	   function,	   and	   the	  
profound	   consequences	   of	   OL	   loss	   in	   neurodevelopmental	   disease,	   has	   nurtured	   a	  
longstanding	  interest	  in	  OL	  biology.	  Over	  the	  last	  twenty	  years,	  advancements	  in	  the	  genetic	  
tools	  available	  to	  researchers	  have	  yielded	  major	  improvements	  in	  our	  understanding	  of	  OL	  
development.	   OLPs	   arise	   in	   specific	   regions	   and	   at	   specific	   developmental	   stages	   in	   the	  
embryonic	  brain	  and	  spinal	  cord,	  before	  migrating	  and	  settling	  in	  all	  parts	  of	  the	  CNS.	  Cycling	  
OLPs,	  a	  reservoir	  of	  which	  is	  maintained	  throughout	  life,	  transition	  through	  a	  series	  of	  well-­‐
characterized	   progenitor	   phases	   on	   their	   way	   to	   becoming	  mature,	  myelinating	   OLs.	   Basic	  
HLH	  TF	  Olig2	  is	  continuously	  expressed	  along	  the	  OL	  lineage,	  performing	  a	  variety	  of	  different	  
functions	   to	   regulate	   OL	   lineage	   progression.	   Besides	   dynamic	   expression	   of	   co-­‐regulator	  
proteins,	   post-­‐translational	   modification	   of	   Olig2	   –	   notably	   serine	   phosphorylation	   –	  
determines	  its	  activity	  at	  different	  stages	  of	  development.	   In	  the	  embryonic	  spinal	  cord,	  for	  
example,	   Olig2	   is	   expressed	   early	   in	   multipotent	   NSCs	   resident	   in	   a	   discrete	   ventral	  
progenitor	  domain,	  the	  pMN	  domain,	  responsible	  for	  generating	  all	  the	  MNs	  and	  ~80%	  of	  the	  
OLs	   in	   the	   adult	   spinal	   cord.	   Initially,	  Olig2	   is	   reversibly	   phosphorylated	   at	   S147	  within	   the	  
bHLH	  domain	  and	  Olig2-­‐expressing	  NSCs	  exclusively	   form	  MNs.	  Dephosphorylation	  of	   S147	  
then	  alters	  the	  DNA-­‐binding	  and	  dimerization	  properties	  of	  Olig2	  and	  induces	  a	  switch	  in	  NSC	  
fate	  in	  the	  pMN	  domain	  from	  MN	  to	  OL	  lineages.	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1.8	   PROJECT	  AIMS	  
	  
Upstream	  regulation	  of	  Olig2	  and	  the	  MN-­‐OLP	  fate	  switch	  
	  
In	  light	  of	  recent	  advances	  in	  our	  understanding	  of	  the	  intimate	  lineal	  relationship	  of	  ventral	  
spinal	  OLPs	  with	  MNs	   and	   the	   integral	   role	   of	  Olig2	   in	   regulating	  NSC	   fate	   and	  OL	   lineage	  
progression,	   a	   number	   of	   key	   questions	   have	   emerged.	   Olig2	   S147	   dephosphorylation	   is	   a	  
critical	  mediator	  of	  the	  MN-­‐OLP	  fate	  switch.	  At	  a	  molecular	  level,	  however,	  the	  intracellular	  
signaling	   pathway(s)	   and	   phosphatase	   enzyme(s)	   that	   mediate	   removal	   of	   the	   S147	  
phosphate	  group	  have	  not	  been	  established.	  Furthermore,	  the	  broad	  developmental	  changes	  
that	   induce	   S147	   dephosphorylation	   and	   trigger	   the	   MN-­‐OLP	   fate	   switch	   remain	   entirely	  
unknown.	  Whether,	  for	  example,	  the	  timing	  of	  the	  fate	  switch	  is	  intrinsic	  to	  cells	  of	  the	  pMN	  
domain	   or	   regulated	   via	   external	   changes	   that	   influence	   pMN	   NSC	   behaviour	   is	   unclear.	   I	  
therefore	  intended	  to	  examine	  the	  molecular	  and	  developmental	  regulation	  of	  Olig2	  and	  the	  
MN-­‐OLP	  fate	  switch.	  The	  aims	  of	  my	  project	  in	  this	  regard	  were	  as	  follows:	  
	  
1.	   Explore	   the	   role	   of	   spinal	   cord	   angiogenesis	   and	   changing	   tissue	   oxygen	   tension	   in	  
triggering	  the	  MN-­‐OLP	  fate	  switch.	  
2.	   Identify	   the	  phosphatase	  enzyme	   catalyzing	  Olig2	   S147	  dephosphorylation	  over	   the	   fate	  
switch.	  
	  
Olig2-­‐mediated	  regulation	  of	  OL	  specification	  and	  differentiation	  
	  
The	   molecular	   mechanisms	   underlying	   Olig2-­‐mediated	   regulation	   of	   NSC	   fate	   and	   OL	  
development	  are	  only	  partially	  understood.	  While	  S147	  dephosphorylation	  has	  been	  shown	  
to	  alter	  the	  cofactor	  binding	  properties	  of	  Olig2,	  the	  effects	  on	  Olig2	  gene	  target	  specificity	  
CHAPTER	  1	  Introduction	   	   	  
  
	   61	  
have	   yet	   to	   be	   examined	   in	   detail	   (Li	   et	   al.,	   2011).	   Establishing	   precisely	   how	   Olig2	   S147	  
dephosphorylation	   induces	   the	   profound	   change	   in	  NSC	  behaviour	   observed	  over	   the	  MN-­‐
OLP	   fate	   switch	   will	   be	   fundamental	   to	   improving	   our	   understanding	   of	   MN	   and	   OL	  
formation.	   On	   top	   of	   the	   known	   phospho-­‐modifications	   of	   Olig2,	   additional	   Olig2	   post-­‐
translational	   modifications	   and	   their	   impacts	   on	   Olig2	   function	   and	   cell	   development	   also	  
have	   yet	   to	   be	   explored.	   Overall,	   further	   research	   into	   Olig2	   phosphorylation	   will	   provide	  
valuable	  detail	  regarding	  the	  molecular	  regulation	  of	  neural	  development.	  I	  therefore	  aimed	  
to:	  
	  
1.	   Identify	  genomic	  binding	  sites	  of	  Olig2	  and	  establish	  if	  S147	  phosphorylation	  state	  affects	  
gene	  target	  specificity.	  	  	  
2.	  Analyse	  Olig2	  phosphorylation	  in	  silico	  and	  characterize	  the	  role	  of	  Olig2	  carboxyl	  terminus	  
(S263)	  phosphorylation	  (Figure	  6),	  detected	  at	  high	  confidence	  in	  previous	  MS	  analysis	  and	  a	  
putative	  target	  of	  P38	  mitogen-­‐activated	  protein	  kinase	  (MAPK)	  (Sun	  et	  al.,	  2011;	  Bulavin	  et	  
al.,	  2001).	  
	  
These	   four	   aims	   form	   the	   structure	   of	   the	   following	   Results	   section,	   with	   the	   background	  
specific	  to	  each	  aim	  	  introduced	  at	  the	  beginning	  of	  the	  respective	  chapter.	  
	  
All	   together	   this	   research	   will	   significantly	   improve	   our	   understanding	   of	   oligodendrocyte	  
development	   in	   the	   embryonic	   spinal	   cord,	   and	   will	   provide	   important	   insights	   into	   the	  
mechanisms	  of	  stem	  cell	  fate	  choice.	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CHAPTER	  2	  
MATERIALS	  &	  METHODS	  
	  
	  
2.1	   GENERAL	  
	  
Chemicals	  and	  reagents	  were	  purchased	  from	  Sigma-­‐Aldrich	  Co	  Ltd,	  unless	  otherwise	  stated.	  
Falcon	   sterile	   plastic-­‐ware	   was	   purchased	   from	   Marathon	   Ltd.	   RNase/Dnase-­‐free	  
microcentrifuge	   tubes	  were	   purchased	   from	   Starlab.	   All	  water	   used	  was	   purified	   using	   the	  
MilliQ	   system	   (Millipore).	   Sterilization	   of	   solutions	   was	   performed	   by	   autoclaving	   at	   15	  
lb/sq.in	  for	  20	  mins.	  
	  
2.2	   BACTERIAL	  BIOLOGY	  
	  
For	   standard	   cloning,	   plasmids	  were	  maintained	   in	   Escherichia	   coli	   (E.coli)	   strain	   XL1-­‐Blue.	  	  
For	  Phage	  artificial	  chromosome	  (PAC)	  cloning	  E.coli	  strain	  EL250	  was	  used.	  	  The	  EL250	  strain	  
(available	  via	  MTA	  from	  Neal	  G.	   	  Copeland)	   is	  a	  modified	  DH10B	  strain	  (Gibco)	  containing	  a	  
replication	   defective	   λ	   prophage	   (Yu	   et	   al.,	   2000),	   containing	   genes	   with	   temperature-­‐
sensitive	  homologous	  recombination	  functions	  and	  the	  arabinose-­‐inducible	  Flp-­‐recombinase	  
gene	  (Lee	  et	  al.,	  2001).	  
	  
Bacteria	   were	   grown	   in	   Luria-­‐Bertani	   (LB)	   broth	   in	   a	   shaking	   incubator	   (250	   rotations	   per	  
minute	  [rpm])	  or	  on	  LB	  agar	  plates,	  at	  37	  oC	  when	  XL1-­‐Blue	  strains	  were	  used	  and	  at	  32	  oC	  
when	  EL250	  strains	  were	  used.	   	  When	  appropriate,	   LB	  broth	  or	  LB-­‐agar	  was	  supplemented	  
with	   antibiotics:	   Ampicillin	   (final	   concentration	   of	   100	   μg/ml	   for	   plasmid	   transformed	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bacteria	  and	  20	  μg/ml	   for	  PAC	   transformed	  bacteria),	  Kanamycin	   (final	   concentration	  of	  15	  
μg/ml	   for	   plasmid	   transformed	   bacteria	   and	   12.5	   μg/ml	   for	   PAC	   transformed	   bacteria)	   or	  
Chloramphenicol	   (final	   concentration	  of	  30	  μg/ml	   for	  plasmid	   transformed	  bacteria	   and	  15	  
μg/ml	  for	  PAC	  transformed	  bacteria).	  
For	  long-­‐term	  storage,	  glycerol	  stocks	  of	  bacterial	  cultures	  were	  made	  by	  adding	  15%	  v/v	  of	  
glycerol	  and	  1.5ml	  aliquots	  were	  stored	  at	  -­‐80oC.	  
	  
Preparation	  of	  electrocompetent	  bacteria	  
	  
400	  ml	  or	  50	  ml	  of	  LB	  broth	  was	  inoculated	  with	  5	  ml	  or	  1	  ml	  of	  overnight	  culture	  of	  XL1-­‐Blue	  
and	  EL250	  strain,	  respectively.	  	  When	  optical	  density	  at	  600	  nm	  (OD600)	  reached	  0.5-­‐0.8,	  the	  
cultures	  were	  cooled	  down	  in	  ice	  water	  for	  5	  min,	  transferred	  into	  several	  falcon	  tubes	  and	  
centrifuged	  at	  2200	  rpm	  for	  8	  min	  at	  4	   oC.	   	  Each	  pellet	  was	  re-­‐suspended	   in	  1	  ml	  of	  sterile	  
water	  and	  transferred	   to	  1.5	  ml	  microcentrifuge	   tubes.	   	  The	  suspension	  was	  centrifuged	  at	  
13000	  rpm	  for	  20	  seconds	  at	  4	  oC	  and	  the	  pellet	  gently	  re-­‐suspended	  in	  1	  ml	  of	  water.	  	  This	  
wash	  was	  repeated	  three	  times.	  	  If	  being	  used	  immediately,	  the	  final	  pellet	  was	  re-­‐suspended	  
in	  50	  μl	  of	  sterile	  water.	  	  For	  long	  term	  storage	  the	  pellet	  was	  re-­‐suspended	  in	  50	  μl	  of	  water	  
containing	   10%	   v/v	   glycerol,	   transferred	   into	   pre-­‐cooled	   cryo-­‐tubes,	   snap-­‐frozen	   in	   liquid	  
nitrogen	  and	  stored	  at	  -­‐80	  oC.	  
	  
Transformation	  of	  electrocompetent	  bacteria	  
	  
50	  μl	  of	  electrocompetent	  bacteria	  was	   thawed	  on	   ice	  and	  mixed	  with	  1	  µl	  of	  DNA	   (either	  
ligation	   reaction	  or	  mini/maxi	  prep	  DNA).	   	   The	  mixture	  was	   transferred	   to	  a	   chilled	  0.1	   cm	  
electroporation	   cuvette	   (Bio-­‐Rad).	   	   Electroporation	   was	   performed	   with	   a	   Gene	   Pulser	  
electroporator	   equipped	  with	  Pulse	  Controller	   (Bio-­‐Rad	   Laboratories	   Ltd)	   set	   to	   1.8	   kV	   (for	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EL250)	  or	  2.5	  kV	  (for	  XL1-­‐Blue),	  200	  Ω,	  25	  μF.	  Electroporated	  bacteria	  were	  resuspended	   in	  
250	  μl	  LB	  broth	  and	  incubated	  at	  correct	  temperature	  (37	  oC	  for	  1	  hr	  for	  XL1-­‐Blue	  or	  32	  oC	  for	  
2	  hr	  for	  EL250)	  before	  plating	  on	  antibiotic-­‐supplemented	  LB	  agar	  plates.	  	  When	  using	  blue-­‐
white	  selection	   to	  screen	   for	   recombinant	  plasmids,	  20	  μl	  of	  X-­‐gal	   (50	  mg/ml)	  and	  10	  μl	  of	  
IPTG	  (0.1	  M)	  were	  added	  to	  LB	  agar	  plates	  and	  white	  colonies	  were	  selected.	  
	  
2.3	   DNA	  &	  RNA	  PREPARATION	  
	  
Small-­‐scale	  plasmid	  preparation	  (mini	  prep)	  
	  
For	  preparation	  of	  small	  quantities	  (<2	  mg)	  of	  plasmid	  DNA,	  the	  following	  mini	  prep	  protocol	  
was	  used.	  2	  ml	   LB	  broth	  containing	   the	  appropriate	  antibiotic	  was	   inoculated	  with	  a	   single	  
colony	  of	  transformed	  bacteria	  and	  incubated	  in	  a	  shaking	  incubator	  (250	  rpm)	  at	  37	  oC.	  After	  
overnight	  (o/n)	  incubation,	  1.5	  ml	  of	  bacteria	  was	  transferred	  to	  a	  microcentrifuge	  tube	  and	  
centrifuged	  at	  13000	  rpm	  for	  2	  min.	  	  The	  pellet	  was	  re-­‐suspended	  in	  100	  µl	  of	  Solution	  I	  (50	  
mM	   glucose,	   25	  mM	   Tris-­‐HCl,	   pH	   8.0,	   10	  mM	   EDTA,	   pH	   8.0).	   	   200	   µl	   of	   Solution	   II	   (0.2	   N	  
NaOH,	  1%	  w/v	  SDS)	  was	  added	  and	  the	  solution	  mixed	  by	  inversion	  to	  lyse	  the	  cells.	  	  150	  µl	  
of	   Solution	   III	   (3	   M	   potassium	   acetate,	   11.5%	   v/v	   glacial	   acetic	   acid)	   was	   added	   and	   the	  
samples	   mixed	   then	   centrifuged	   at	   13000	   rpm	   for	   10	   min	   at	   RT.	   	   The	   supernatant	   was	  
transferred	   to	   a	   new	  microcentrifuge	   tube	   and	   900	   µl	   of	   100%	   ethanol	   (EtOH;	   stored	   at	   -­‐
20oC)	  added.	  The	  samples	  were	  centrifuged	  at	  13000	  rpm	  for	  10	  min.	   	  The	  DNA	  pellet	  was	  
washed	   with	   200	   µl	   of	   70%	   EtOH	   then	   centrifuged	   for	   1	   min	   at	   13000	   rpm.	   	   The	   DNA	  
precipitate	  was	  re-­‐suspended	  in	  50	  µl	  of	  H2O	  and	  stored	  at	  -­‐20	  oC.	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Large-­‐scale	  plasmid	  preparation	  (maxi	  prep)	  
	  
For	  preparation	  of	  large	  quantities	  (>1	  mg)	  of	  plasmid	  DNA,	  the	  following	  maxi	  prep	  protocol	  
was	  used.	  50	  ml	  LB	  was	   inoculated	  with	  200	  µl	  of	  overnight	  culture	  and	  grown	  in	  a	  shaking	  
incubator	   (250	  rpm)	  at	  37	  oC.	   	  After	  o/n	   incubation,	   the	  culture	  was	   transferred	  to	  a	  50	  ml	  
falcon	  tube	  and	  centrifuged	  at	  4000	  rpm	  for	  10	  min	  at	  4	  oC.	  	  The	  pellet	  was	  re-­‐suspended	  in	  4	  
ml	  Solution	  I	  and	  held	  on	  ice	  for	  5	  min.	  8ml	  of	  Solution	  II	  was	  added,	  mixed	  by	  inversion	  and	  
incubated	  at	  RT	  for	  5	  min.	  6ml	  of	  Solution	  III	  was	  added,	  mixed	  by	  inversion	  and	  incubated	  on	  
ice	  for	  10	  min.	  The	  solution	  was	  centrifuged	  at	  4000	  rpm	  for	  15	  min	  at	  4	  oC.	  	  	  The	  supernatant	  
was	  filtered	  through	  a	  double	  sheet	  of	  autoclaved	  muslin	  into	  a	  fresh	  50	  ml	  Falcon	  tube.	  17	  
ml	   isopropanol	  was	  added	  to	  the	  supernatant	  and	  the	  solution	   incubated	  on	   ice	  for	  15	  min	  
before	  centrifugation	  at	  4000	  rpm	  for	  15	  min	  at	  4	  oC.	  	  The	  DNA	  pellet	  was	  re-­‐suspended	  in	  2	  
ml	  of	  TE	  buffer	  and	  2.5	  ml	  of	  4.4	  M	  LiCl	  added.	  The	  mixture	  was	  incubated	  on	  ice	  for	  1	  hour	  
then	  centrifuged	  at	  4000	  rpm	  for	  15	  min	  at	  4	  oC.	  	  The	  supernatant	  was	  transferred	  to	  a	  new	  
falcon	  and	  9	  ml	  of	  100%	  EtOH	  added.	  The	  DNA	  was	  precipitated	  by	  incubating	  at	  RT	  for	  10-­‐15	  
min	   and	   collected	  by	   centrifugation	   at	   4000	   rpm	   for	   15	  min	   at	   4	   oC.	   	   	   The	  DNA	  pellet	  was	  
washed	  with	   70%	   EtOH	   then	   re-­‐suspended	   in	   400	   µl	   TE	   buffer.	   	   The	   DNA	   suspension	  was	  
transferred	   to	   a	   new	   microcentrifuge	   tube	   and	   treated	   with	   5µl	   of	   4	   mg/ml	   DNase-­‐free	  
RNase	  A	  for	  15	  min	  at	  37	  oC.	  	  	  10	  µl	  of	  20%	  Sodium	  Dodecyl	  Sulphate	  (SDS)	  were	  then	  added	  
and	   the	   mixture	   incubated	   at	   70	   oC	   for	   exactly	   10min.	   	   This	   was	   followed	   by	   phenol-­‐
chloroform	  extraction	  (see	  below).	  
	  
Large-­‐scale	  PAC	  preparation	  (PAC	  maxi	  prep)	  
	  
NB:	   To	   avoid	   PAC	   DNA	   shearing,	   large	   pipette	   tips	   were	   used	   and	   the	   solutions	  mixed	   by	  
gentle	  inversion.	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400	  ml	  LB	  broth	  supplemented	  with	  antibiotic	  was	   inoculated	  with	  500	  µl	  of	  a	  5	  ml	  starter	  
culture	  (EL250	  E.	  coli	  transformed	  with	  PAC	  DNA	  and	  grown	  o/n	  at	  32	  oC).	  	  The	  maxi	  culture	  
was	  grown	  at	  32	  oC	  in	  a	  shaking	  incubator	  (250	  rpm).	  	  After	  o/n	  incubation,	  the	  culture	  was	  
transferred	  to	  50	  ml	  falcon	  tubes	  and	  centrifuged	  at	  3750	  rpm	  for	  10	  min	  at	  4	  oC.	  	  Each	  pellet	  
was	  re-­‐suspended	  in	  8	  ml	  of	  PAC	  Solution	  I	  (PI)	  (50	  mM	  Tris-­‐HCl	  pH	  8.0,	  10	  mM	  EDTA	  pH	  8.0,	  
100	  µg/ml	  RNase	  A).	   	  An	  equal	  volume	  (8	  ml)	  of	  PAC	  Solution	   II	   (PII)	   (0.2	  N	  NaOH,	  1%	  SDS)	  
was	  added	  and	  mixed.	  The	  mixture	  was	   incubated	  at	  RT	   for	  5	  min.	  8	  ml	  of	  PAC	  Solution	   III	  
(PIII)	   (3	   M	   potassium	   acetate,	   11.5%	   w/v	   glacial	   acetic	   acid)	   was	   added	   and	   mixed.	   The	  
mixture	  was	  incubated	  on	  ice	  for	  1	  hr.	  	  The	  suspensions	  were	  centrifuged	  at	  3750	  rpm	  for	  15	  
min	  at	  4	  oC	  and	  the	  supernatants	  filtered	   into	  fresh	  falcon	  tubes	  through	  a	  double	  sheet	  of	  
autoclaved	  muslin.	  24	  ml	  ice-­‐cold	  isopropanol	  was	  added,	  mixed	  and	  the	  solutions	  incubated	  
for	  5	  min	  at	  RT.	  DNA	  was	  pelleted	  by	  centrifugation	  at	  3750	   rpm	  for	  15	  min	  at	  4	   oC.	   	  Each	  
DNA	  pellet	  was	  re-­‐suspended	  in	  2	  ml	  TE	  buffer.	  2.5	  ml	  of	  4.4	  M	  LiCl	  was	  added	  followed	  by	  
incubation	  on	  ice.	  	  After	  30-­‐60	  min,	  the	  mixture	  was	  centrifuged	  at	  3750	  rpm	  for	  15	  min	  at	  4	  
oC	   and	   the	   supernatants	   from	  an	   individual	   400	  ml	   PAC	  maxi	   culture	   collected	   and	  pooled	  
into	   a	   single	   falcon	   tube.	   	   18	  ml	   of	   100%	   EtOH	  were	   added	   to	   each	   “pooled”	   falcon	   tube,	  
mixed	  and	  centrifuged	  at	  3750	  rpm	  for	  15	  min	  at	  4	  oC.	  	  PAC	  DNA	  pellets	  were	  washed	  with	  5	  
ml	  RT	  70%	  EtOH	  and	  re-­‐suspended	  in	  0.5	  ml	  TE	  buffer.	  	  12.5	  µl	  of	  20%	  SDS	  was	  added	  to	  each	  
tube	  and	  the	  solutions	  incubated	  at	  70	  oC	  for	  precisely	  10	  min.	  	  Phenol/chloroform	  extraction	  
of	  DNA	  followed	  by	  EtOH	  precipitation	  was	  performed	  as	  described	  below.	  	  The	  pellets	  were	  
air-­‐dried	  until	   the	  edge	  of	   the	  DNA	  pellets	   turned	   translucent	   then	   re-­‐suspended	   in	  200	  µl	  
water	  and	  stored	  at	  4	  oC.	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Phenol-­‐chloroform	  extraction	  
	  
An	  equal	  volume	  of	  phenol:chloroform:isoamylalcohol	  (IAA)	  (25:24:1)	  was	  added	  to	  the	  DNA-­‐
containing	  solution	  and	  mixed	  by	  gentle	  inversion.	  The	  mixture	  was	  centrifuged	  at	  13000	  rpm	  
for	   2-­‐5	   min	   at	   room	   temperature	   (RT).	   	   The	   aqueous	   phase	   was	   transferred	   to	   a	   clean	  
microcentrifuge	  tube.	  	  An	  equal	  volume	  of	  chloroform:IAA	  (24:1)	  was	  added	  and	  the	  mixture	  
centrifuged	  at	  13000	  rpm	  for	  1-­‐2	  min	  at	  RT.	   	  For	  PAC	  DNA	  the	  phenol:chloroform	  step	  was	  
performed	  twice.	  	  The	  aqueous	  phase	  was	  transferred	  to	  a	  fresh	  microcentrifuge	  tube	  and	  3	  
M	  sodium	  acetate	  (pH	  5.3)	  was	  added	  to	  a	  final	  concentration	  of	  0.3	  M.	  	  A	  double	  volume	  of	  
100%	  EtOH	  was	  added	  and	  the	  mixture	  centrifuged	  at	  13000	  rpm	  for	  15-­‐30	  min	  at	  4	  oC.	  	  	  The	  
DNA	  pellet	  was	  washed	  with	  70%	  EtOH	  then	  re-­‐suspended	  in	  an	  appropriate	  buffer.	  With	  the	  
exception	  of	  PAC	  DNA	  –	  stored	  at	  4oC	  to	  avoid	  shearing	  –	  DNA	  was	  stored	  at	  -­‐20oC.	  
	  
Agarose	  gel	  DNA	  purification	  
	  
The	  QIAquick	  Gel	  Extraction	  Kit	  was	  used	  according	  to	  the	  manufacturer’s	  instructions.	  	  DNA	  
fragments	  were	   initially	   separated	   and	   visualized	   by	   agarose	   gel	   electrophoresis	   (see	   DNA	  
analysis).	  	  
	  
Genomic	  DNA	  extraction	  from	  mouse	  tissue	  
	  
Mouse	  ear	  (postnatal)	  and	  tail	  (embryonic)	  biopsy	  samples	  were	  digested	  at	  55	  oC	  in	  250	  µl	  of	  
extraction	  buffer	  (100	  mM	  Tris-­‐HCl,	  pH	  8.5,	  5	  mM	  EDTA,	  pH	  8.0,	  200	  mM	  NaCl,	  0.2%	  w/v	  SDS)	  
containing	  0.48	  mg/ml	  Proteinase	  K.	  	  After	  o/n	  incubation,	  100	  µl	  of	  6	  M	  ammonium	  acetate	  
was	   added	   and	   the	   samples	   mixed	   by	   vortexing	   then	   incubated	   for	   15	   min	   on	   ice.	   	   The	  
solutions	   were	   then	   centrifuged	   at	   13000	   rpm	   for	   15	   min	   at	   4	   oC	   and	   the	   supernatant	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transferred	  to	  a	  clean	  microcentrifuge	  tube.	  250	  µl	  of	   isopropanol	  was	  added	  and	  the	  DNA	  
precipitated	  by	  centrifuging	  at	  13000	  rpm	  for	  3	  min	  at	  RT.	  	  The	  DNA	  pellet	  was	  washed	  with	  
70%	  EtOH	  then	  re-­‐suspended	  in	  50	  µl	  of	  water.	  	  Purified	  genomic	  DNA	  samples	  were	  stored	  




RNA	  was	  extracted	  from	  cultured	  NSCs	  using	  Trizol	  (Invitrogen)	  following	  the	  manufacturer’s	  
instructions.	  Purified	  RNA	  was	  stored	  at	  -­‐80	  oC.	  
	  
Complementary	  DNA	  synthesis	  
	  
Complementary	   DNA	   (cDNA)	   synthesis	   was	   performed	  with	   random	   hexamer	   primers	   and	  
using	   SuperScript	   II	   reverse	   transcriptase	   (Invitrogen)	   following	   the	   manufacturer’s	  
instructions.	  
	  




PCR	  was	  used	   to	  genotype	  animals.	   Each	  PCR	   reaction	  contained:	  1	  X	  PCR	  buffer	   (500	  mM	  
KCl,	   100	   mM	   Tris-­‐HCl	   pH	   9.0,	   1%	   (v/v)	   Triton	   X-­‐100),	   1.5	   mM	   MgCl2,	   0.2	   mM	   dNTPs	  
(Amersham	   Pharmacia	   Biotech),	   20	   pmole	   of	   each	   primer	   (Table	   1),	   1	   μl	   of	   Taq	   DNA	  
Polymerase	  (purified	  by	  Matthew	  Grist)	  and	  2	  μl	  of	  genomic	  DNA	  made	  up	  to	  a	  final	  volume	  
of	  25	  μl	  with	  water.	  	  	  The	  PCR	  conditions	  were	  as	  follows:	  94	  oC,	  4	  min;	  40	  cycles	  of	  [94	  oC,	  30	  
s;	  the	  primer	  pair-­‐specific	  annealing	  temperature	  (typically	  60	  oC),	  45	  s;	  72	  oC,	  1	  min];	  72	  oC,	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10	  min.	  After	  the	  last	  step,	  PCR	  reactions	  were	  held	  at	  4	  oC.	  PCR	  products	  were	  visualized	  by	  




ChIP	  DNA	   and	   cDNA	   (qRT-­‐PCR)	   samples	  were	   analysed	   by	   qPCR	  using	   gene-­‐specific	   primer	  
sets	  (Table	  1)	  and	  the	  SYBR	  Green	  PCR	  Master	  Mix	  (Invitrogen)	  in	  25	  μl	  reactions	  according	  to	  
the	   manufacturer’s	   instructions.	   The	   samples	   were	   amplified	   using	   a	   Mastercycler	   Ep	  
Realplex	  system	  (Eppendorf).	  For	  ChIP	  analysis,	  Input	  DNA	  was	  serially	  diluted	  1:8,	  1:64	  and	  
1:256	  in	  water.	  For	  each	  primer	  set,	  ChIP	  and	  diluted	  Input	  DNA	  samples	  were	  amplified	  by	  
qPCR	   in	   triplicate.	   ChIP	   enrichment	   was	   calculated	   using	   the	   Percentage	   Input	   method	  
(Invitrogen	  –	  ChIP	  Analysis).	  Briefly,	  the	  Input	  DNA	  Ct	  values	  were	  adjusted	  for	  dilution.	  The	  
ChIP	  and	  adjusted	   Input	  Ct	   values	  were	   then	  used	   to	   calculate	   the	  percentage	  of	   Input	   for	  
each	  ChIP	  sample.	  For	  quantitative	  RT-­‐PCR,	  cDNA	  samples	  were	  amplified	  using	  gene-­‐specific	  
primer	  sets	   in	   triplicate.	  Enrichment	  was	  calculated	  by	  normalization	  to	  the	  reference	  gene	  
GAPDH	  (Invitrogen	  –	  qPCR	  Education).	  
	  
Agarose	  gel	  electrophoresis	  
	  
Agarose	   gels	   were	  made	   by	   dissolving	   1%	   w/v	   agarose	   in	   TAE	   buffer	   (0.04	  M	   Tris,	   1	   mM	  
EDTA,	  0.35%	  v/v	  glacial	  acetic	  acid)	   then	  adding	  0.5	  μg/ml	  ethidium	  bromide.	  DNA	  samples	  
were	   supplemented	   with	   loading	   buffer	   (50%	   glycerol,	   1	   mM	   EDTA	   pH	   8.0,	   0.125%	  
bromophenole	   blue,	   0.125%	   xylene	   cyanol).	   15	   μl	   of	   samples	   and	   5	   μl	   of	   Hyperladder	   I	  
(Bioline)	  were	  loaded	  and	  run	  in	  a	  Peqlab	  Biotechnologie	  GmbH	  gel	  tank	  at	  100-­‐150	  V.	  Gels	  
were	   visualized	   under	   UV	   illumination	   and	   the	   DNA	   properties	   evaluated	   relative	   to	   the	  
Hyperladder	  I	  standards.	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Pulse-­‐field	  gel	  electrophoresis	  
	  
To	   separate	   PAC	   DNA	   fragments	   of	   >15	   kb,	   pulse	   field	   gel	   electrophoresis	   (PFGE)	   was	  
performed	  using	  contour-­‐clamped	  homogenous	  electric	  field	  electrophoresis	  cell	  powered	  by	  
a	  CHEF	  DR	  II	  control	  module	  and	  CHEF	  DR	  II	  drive	  module	  (Bio-­‐Rad).	  	  Agarose	  gels	  were	  made	  
by	  dissolving	  1%	  w/v	  agarose	   in	  0.5	  X	  TBE	  buffer	   (45	  mM	  Tris-­‐borate,	  1	  mM	  EDTA	  pH	  8.0).	  	  
DNA	  samples	  were	  mixed	  with	  10%	  loading	  buffer	  and	  loaded	  into	  the	  gel	  along	  with	  2	  mm	  
of	  Pulse	  Marker™	  (0.1-­‐200	  kb).	  	  DNA	  was	  run	  for	  12	  hours	  in	  a	  6	  V/cm	  field	  with	  initial	  switch	  
time	  of	  2.1	  s	  and	  a	  final	  switch	  time	  of	  10	  s	  at	  4	  oC	   in	  2	  L	  of	  0.5	  x	  TBE.	   	  After	  completion	  of	  




The	   concentration	   of	   DNA	   was	   determined	   using	   either	   NanoDrop	   1000	   V3.6.0	   or	   Qubit	  
(Invitrogen)	   spectrophotometers	   or	   the	   Agilent	   2100	   Biolanalyzer,	   following	   the	  




DNA	   Sequencing	   was	   performed	   by	   the	  Wolfson	   Institute	   for	   Biomedical	   Research	   (WIBR)	  
Scientific	   Support	   Services	   team	  on	  a	  Beckman	  Coulter	  CEQ	  8000	  Genetic	  Analysis	   System.	  	  
DNA	  samples	  were	  prepared	  by	  maxi	  or	  mini	  prep	  (see	  above)	  and	  submitted	  with	  necessary	  
primers	  according	  to	  instructions	  provided	  by	  the	  service.	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Restriction	  digestion	  and	  DNA	  ligation	  
	  
Restriction	  enzymes	  and	  buffers	  were	  purchased	  from	  New	  England	  Biolabs	  (NEB)	  and	  used	  
according	  to	  the	  manufacturer’s	  instructions.	  	  
	  
Ligation	  reactions	  were	  performed	  with	  T4	  DNA	  Ligase	  (NEB)	  using	  gel	  purified	  backbone	  and	  




Olig2	  S263	  mutagenesis	  was	  performed	  using	  the	  QuikChange	  Site-­‐Directed	  Mutagenesis	  Kit	  
(Agilent)	   according	   to	   the	   manufacturer’s	   instructions.	   Briefly,	   the	   Olig2	   ORF	   in	   pcDNA4.1	  
(pcDNA4.1-­‐Olig2WT)	  was	  mutated	  at	  S263	  using	  mutagenic	  oligonucleotide	  primers	  (Table	  1)	  
and	  the	  high	  fidelity	  PfuTurbo	  DNA	  polymerase.	  Thermal	  cycling	  (16	  X	  [94	  °C	  for	  30	  s,	  58	  °C	  
for	   1	   min	   and	   68	   °C	   for	   10	   min])	   and	   incorporation	   of	   the	   primers	   generated	   a	   mutated	  
plasmid	   containing	   staggered	   nicks.	   The	   product	  was	   treated	  with	  DpnI	   (37	   °C	   for	   1	   hr)	   to	  
selectively	   digest	   the	   parental	   pcDNA4.1-­‐Olig2	   template.	   The	   DpnI-­‐treated	   nicked	   DNA	  
containing	   the	   desired	  mutation	   (pcDNA4.1-­‐Olig2S263A)	  was	   then	   transformed	   into	   XL1-­‐Blue	  
supercompetent	  cells	  for	  plasmid	  preparation	  and	  sequencing,	  as	  describe	  above.	  
	  
2.5	   CELL	  CULTURE	  AND	  TRANSFECTION	  
	  
Primary	  NSC	  culture	  	  
	  
Primary	  adherent	  NSC	  cultures	  were	  derived	  from	  the	  dissociated	  cortices	  of	  E13.5	  mice,	  as	  
previously	   described	   in	   Pollard	   et	   al.,	   2006.	   Isolated	   cortices	   were	   dissected	   using	   Leica	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Dissection	  Microscope	   (Fisher	   Scientific)	   and	  mechanically	  dissociated	   in	  1	  ml	  NSC	  medium	  
(DMEM/F-­‐12	   (Invitrogen)	   supplemented	  with:	   1	   X	   PenStrep	   (Invitrogen),	   1	   X	   non-­‐essential	  
amino	   acids	   (NEAA)	   (Invitrogen),	   0.12	   mg/ml	   bovine	   serum	   albumin	   (BSA),	   0.1%	   2-­‐
mercaptoethanol,	  0.5	  X	  B27	  (Invitrogen),	  0.5	  X	  N2	  (Invitrogen),	  10	  ng/ml	  FGF-­‐2	  (Invitrogen),	  
10	   ng/ml	   EGF	   (Invitrogen),	   1	   µg/ml	   Laminin).	   The	   cell	   suspensions	  were	   passed	   through	   a	  
sterile	  100	  µm	  nylon	  cell	  strainer	  and	  plated	  on	  poly-­‐D-­‐lysine	  coated	  culture	  dishes	  (1	  X	  6	  cm	  
plate	  /	  embryo).	  Cells	  were	  cultured	  in	  NSC	  medium	  at	  37	  oC	  with	  20%	  (v/v)	  O2	  and	  passaged	  
at	  80%	  confluency.	  
	  
For	   primary	   NSC	   culture	   differentiation,	   NSC	   medium	   was	   replaced	   with	   Differentiation	  
medium	   (DMEM/F-­‐12	   (Invitrogen)	   supplemented	  with:	   1	   X	   PenStrep	   (Invitrogen),	   1	   X	   non-­‐
essential	  amino	  acids	  (NEAA)	  (Invitrogen),	  0.12	  mg/ml	  bovine	  serum	  albumin	  (BSA),	  0.1%	  2-­‐
mercaptoethanol,	  0.5	  X	  B27	  (Invitrogen),	  0.5	  X	  N2	  (Invitrogen),	  20	  ng/ml	  FGF-­‐2	  (Invitrogen),	  
10	  ng/ml	  PDGF-­‐AA	  (Invitrogen),	  1	  µg/ml	  Laminin).	  
	  
For	   hypoxic	   culture,	   NSC	   cultures	   in	   NS	   or	   Differentiation	   medium	   were	   cultured	   in	   a	  
specialized	  hypoxic	  chamber	  at	  37	  oC	  with	  2-­‐4%	  (v/v)	  O2	  and	  83.5%	  (v/v)	  N2.	  
	  
For	  anisomycin	  treatment,	  NSCs	  were	  cultured	  in	  Differentiation	  medium	  supplemented	  with	  
2	  µg/ml	  anisomycin.	  
	  
P19	  and	  C6	  cell	  culture	  
	  
C6	   cells	   were	   cultured	   at	   37	   oC	   in	   DMEM	   (Invitrogen)	   supplemented	   with:	   1	   X	   PenStrep	  
(Invitrogen),	  1	  X	  non-­‐essential	  amino	  acids	  (NEAA)	  (Invitrogen),	  10%	  (v/v)	  fetal	  bovine	  serum	  
(FBS)	  (Invitrogen).	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P19	   cells	   were	   cultured	   at	   37oC	   in	   MEM	   (Invitrogen)	   supplemented	   with:	   1	   X	   PenStrep	  





Transfection	   of	   plasmid	   DNA	   was	   performed	   with	   FuGENE®	   HD	   Transfection	   Reagent	  
(Promega)	  according	  to	  the	  manufacturer’s	  instructions.	  
	  




Human	   Olig2	   protein	   sequence	   (Q13516)	   was	   processed	   by	   online	   services	   NetPhos	  
(http://cbs.dtu.dk/services/NetPhos)	   and	   NetPhosK	   (http://cbs.dtu.dk/services/NetPhosK)	  




Olig2	   protein	   sequences	   from	   human	   [Q13516],	   mouse	   [Q9EQW6],	   chick	   [Q90XB3]	   and	  
zebrafish	  [Q6P0J2])	  were	  aligned	  using	  ClustalOmega	  (ebi.ac.uk/Tools/msa/clustalo/).	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2.7	   CHROMATIN	  IMMUNOPRECIPITATION	  
	  
For	   ChIP-­‐qPCR,	   the	   input	   NSC	   cultures	   each	   comprised	   ~1-­‐2	   X	   107	   cells.	   For	   ChIP-­‐seq,	   the	  
input	  NSC	  cultures	  each	  comprised	  ~1	  X	  108	  cells.	  
	  
Crosslinking:	   Adherent	   NSC	   cultures	   (see	   above)	   were	   treated	   with	   DMEM/F-­‐12	  
supplemented	   with	   1%	   formaldehyde	   (5	   ml	   /	   10	   cm	   plate)	   and	   incubated	   at	   RT.	   After	  
precisely	   10	  min,	   the	   crosslinking	   reaction	  was	   stopped	  by	   addition	  of	   1.25	  M	  glycine	   to	   a	  
final	   concentration	   of	   0.125	   M.	   Crosslinked	   NSC	   cultures	   were	   then	   rinsed	   once	   with	  
DMEM/F-­‐12	  (5	  ml	  /	  10	  cm	  plate)	  and	  treated	  with	  0.25%	  Trypsin	  (Invitrogen)	  in	  DMEM/F-­‐12	  
(5	  ml	  /	  10	  cm	  plate)	  and	  incubated	  at	  37	  oC.	   	  After	  20	  min,	  crosslinked	  NSCs	  were	  collected	  
using	   a	   P1000	   Gilson	   pipette	   and	   transferred	   to	   a	   15	   ml	   falcon.	   The	   cell	   suspension	   was	  
centrifuged	  at	  300	  g	  for	  10	  min	  at	  4	  	  oC.	  The	  cell	  pellet	  was	  re-­‐suspended	  in	  1	  ml	  ice-­‐cold	  PBS	  
and	  transferred	  to	  a	  1	  ml	  microcentrifuge	  tube.	  The	  cell	  suspension	  was	  centrifuged	  at	  300	  g	  
for	  10	  min	  at	  4	  	  oC	  and	  the	  supernatant	  discarded.	  
	  
Cell	   lysis	   and	   sonication:	   Formaldehyde-­‐crosslinked	  NSC	  pellets	  were	   re-­‐suspended	   in	   1	  ml	  
Lysis	  buffer	  1	  (50	  mM	  Hepes	  KOH	  pH	  7.5,	  140	  mM	  NaCl,	  1	  mM	  EDTA,	  10%	  glycerol,	  0.5%	  NP-­‐
40,	  0.25%	  Triton	  X-­‐100)	  supplemented	  with	  Complete	  protease	  inhibitor	  cocktail	  (Roche)	  and	  
incubated	  for	  10	  min	  at	  4	  oC.	  Nuclei	  were	  pelleted	  by	  centrifugation	  at	  3000	  rpm	  for	  10	  min	  
at	  4	  oC.	  The	  isolated	  nuclei	  were	  rinsed	  with	  1	  ml	  Lysis	  buffer	  2	  (10	  mM	  Tris-­‐HCl	  pH	  8.0,	  200	  
mM	   NaCl,	   1	   mM	   EDTA,	   0.5	   mM	   EGTA)	   supplemented	   with	   Complete	   protease	   inhibitor	  
cocktail	  (Roche)	  and	  re-­‐pelleted	  by	  centrifugation	  at	  3000	  rpm	  for	  10	  min	  at	  4	  oC.	  Nuclei	  were	  
re-­‐suspended	  in	  1	  ml	  Lysis	  buffer	  3	  (10	  mM	  Tris-­‐HCl	  pH	  8.0;	  100	  mM	  NaCl;	  1	  mM	  EDTA;	  0.5	  
mM	  EGTA;	  0.1%	  sodium	  deoxycholate;	  0.5%	  N-­‐lauryl	  sarcosine)	  supplemented	  with	  Complete	  
protease	  inhibitor	  cocktail	  (Roche).	  The	  nuclei	  suspension	  was	  sonicated	  over	  10,	  20,	  30,	  40	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or	   50	   rounds	   of	   30	   s	   on,	   30	   s	   off	   at	   4	   oC	   in	   a	   Bioruptor	   (Diagenode)	   to	   generate	   DNA	  
fragments	  in	  the	  200-­‐1000	  bp	  range.	  Genome	  fragmentation	  was	  assessed	  by	  de-­‐crosslinking	  
(see	   below)	   and	   agarose	   gel	   electrophoresis	   (see	   above).	   Insoluble	   debris	   was	   pelleted	   by	  
centrifugation	  at	  13000	   rpm	   for	  15	  min	  at	  4	   oC	  and	   the	   supernatant	   transferred	   to	  a	   fresh	  
microcentrifuge	  tube.	  	  
	  
Clearing:	  50	  µl	  Protein	  A	  Agarose	  beads	  (Roche)	  per	  ChIP	  were	  rinsed	  with	  Lysis	  buffer	  3	  then	  
added	   to	   the	   nuclear	   lysate	   and	   incubated	   at	   4	   oC	   on	   a	   rotator	   set	   at	   8	   rpm.	   After	   1	   hr,	  
clearing	  beads	  were	  pelleted	  by	   centrifugation	  at	  10000	   rpm	   for	  30	   s	  at	  4	   oC	  and	   the	  1	  ml	  
supernatant	   transferred	   to	   a	   fresh	  microcentrifuge	   tube.	   At	   this	   stage,	   a	   5%	   (50	   µl)	   Input	  
sample	   was	   taken	   from	   each	   nuclear	   lysate	   and	   stored	   on	   ice	   until	   de-­‐crosslinking	   (see	  
below).	  50	  µl	  of	  Lysis	  buffer	  3	  was	  added	  to	  the	  remaining	  950	  µl	  of	  nuclear	  lysate	  to	  restore	  
the	  volume	  to	  1	  ml.	  
	  
ChIP-­‐qPCR	  Immunoprecipitation:	  To	  each	  1	  ml	  cleared	  nuclear	  lysate	  sample,	  2	  µl	  rabbit	  anti-­‐
Olig2	  antibody	  (Millipore;	  AB9610)	  was	  added	  and	  the	  mixture	  incubated	  at	  4	  oC	  on	  a	  rotator	  
set	   at	   8	   rpm.	   After	   3	   hr,	   50	   µl	   pre-­‐rinsed	   Protein	   A	   Agarose	   beads	   were	   added	   and	   the	  
mixture	  incubated	  o/n	  at	  4	  oC	  on	  a	  rotator	  set	  at	  8	  rpm.	  
	  
ChIP-­‐seq	  Immunoprecipitation:	  To	  each	  1	  ml	  cleared	  nuclear	  lysate	  sample,	  10	  µl	  rabbit	  anti-­‐
Olig2	  antibody	   (Millipore;	  AB9610)	  plus	  1	  µl	   rabbit	   anti-­‐Olig2	   (Stiles	   lab;	   Ligon	  et	   al.,	   2004)	  
was	  added	  and	  the	  mixture	  incubated	  at	  4	  oC	  on	  a	  rotator	  set	  at	  8	  rpm.	  After	  3	  hr,	  50	  µl	  pre-­‐
rinsed	   Protein	   A	   Agarose	   beads	   were	   added	   and	   the	   mixture	   incubated	   o/n	   at	   4	   oC	   on	   a	  
rotator	  set	  at	  8	  rpm.	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Washes,	  elution	  and	  de-­‐crosslinking:	  After	  o/n	  immunoprecipitation,	  Protein	  A	  agarose	  beads	  
were	  pelleted	  by	  centrifugation	  at	  10000	  rpm	  for	  30	  s	  at	  4	  oC.	  The	  beads	  were	  washed	  twice	  
at	  4	  oC	  for	  10	  min	  each	  in	  1	  ml	  of	  each	  of	  the	  following	  buffers:	  Wash	  buffer	  1	  (0.1%	  SDS,	  1%	  
Triton	  X-­‐100,	  2	  mM	  EDTA,	  20	  mM	  Tris-­‐HCl	  pH	  8.0,	  150	  mM	  NaCl),	  Wash	  buffer	  2	  (0.1%	  SDS,	  
1%	  Triton	  X-­‐100,	  2	  mM	  EDTA,	  20	  mM	  Tris-­‐HCl	  pH	  8.0,	  500	  mM	  NaCl)	  and	  LiCl	  Wash	  Buffer	  
(0.25	  M	  LiCl,	  1%	  NP-­‐40,	  0.7	  %	  sodium	  deoxycholate,	  1	  mM	  EDTA,	  10	  mM	  Tris	  pH	  8.0).	  After	  
each	  wash,	  beads	  were	  pelleted	  by	   centrifugation	  at	  10000	   rpm	   for	  30	   s	  at	   4	   oC.	  After	   the	  
final	  wash,	  the	  bead	  pellet	  was	  rinsed	  once	  in	  1	  ml	  TE	  buffer	  (10	  mM	  Tris-­‐HCl	  pH	  8.0,	  1	  mM	  
EDTA)	  then	  pelleted	  by	  centrifugation.	  The	  immunoprecipitated	  materials	  were	  eluted	  from	  
the	  beads	  by	  adding	  200	  µl	  Elution	  buffer	  (10	  mM	  Tris-­‐HCl	  pH	  8.0;	  1	  mM	  EDTA;	  1	  %	  SDS)	  to	  
each	  ChIP	  reaction	  and	  incubating	  at	  65	  oC	  for	  20	  min	  with	  vortexing	  every	  2	  min.	  The	  beads	  
were	   pelleted	   by	   centrifugation	   at	   RT	   and	   the	   200	   µl	   eluate	   transferred	   to	   a	   fresh	  
microcentrifuge	  tube.	  150	  µl	  of	  Elution	  buffer	  was	  also	  added	  to	  each	  saved	   Input	  material	  
(50	   µl)	   and	   these	   200	   µl	   samples	   were	   processed	   together	   with	   the	   ChIP	   samples.	   One	  
volume	  (200	  µl)	  of	  TE	  buffer	  was	  added	  to	  each	  sample.	  For	  protein	  and	  RNA	  digestion	  and	  
de-­‐crosslinking,	  proteinase	  K	  and	  RNase	  A	  were	  added	  to	  final	  concentrations	  of	  0.2	  mg/ml	  
and	  0.2	  mg/ml,	  respectively,	  and	  the	  mixtures	  incubated	  at	  65	  oC	  for	  4	  hr.	  
	  
ChIP	  DNA	   Purification:	   The	   Input/ChIP	  DNA	   in	   each	   ~400	   µl	   sample	  was	   purified	   using	   the	  
ChIP	  DNA	  Purification	  Kit	  (Active	  Motif)	  and	  eluted	  in	  20	  µl	  water.	  Purified	  DNA	  samples	  were	  
then	   analysed	   by	   qPCR	   (see	   above)	   or	   quantified	   and	   submitted	   to	   Source	   Bioscience	   for	  
library	  generation	  and	  Illumina	  Sequencing	  according	  to	  the	  instructions	  provided	  by	  Source	  
Bioscience.	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ChIP	  optimization	  with	  Olig2-­‐expressing	  P19	  cells	  
	  
For	  each	  ChIP	  optimization	   IP,	  1	  X	  107	  Olig2-­‐expressing	  P19	  cells	  were	   lysed,	   sonicated	  and	  
cleared	  as	  described	  above	  for	  NSCs.	  Immunoprecipitation	  was	  performed	  with	  2,	  5	  or	  10	  µl	  
of	  Millipore	   rabbit	   anti-­‐Olig2	   antibody	   (AB9610)	   and	   0.25,	   0.5	   or	   1.0	   µl	   of	   Stiles	   lab	   rabbit	  
anti-­‐Olig2	  antibody	  (Ligon	  et	  al.,	  2004).	  The	  antibody	  binding	  solution	  was	  initially	  incubated	  
for	  3	  hr	  at	  4	  oC	  or	  o/n	  at	  4	  oC.	  After	  antibody	  incubation,	  25,	  50	  or	  100	  µl	  Protein	  A	  Agarose	  
beads	  were	  added.	  Depending	  on	  the	  initial	  incubation	  time,	  the	  antibody	  and	  bead	  mixture	  
was	  incubated	  o/n	  (after	  3	  hr	  antibody	  incubation)	  or	  for	  3	  hr	  (after	  o/n	  antibody	  incubation).	  
The	   Protein	  A	  Agarose	   beads	  were	   pelleted	   and	  washed	   as	   described	   above	   for	  NSC	   ChIP.	  
Immunoprecipitated	   proteins	   were	   eluted	   and	   denatured	   using	   NuPAGE	   Sample	   Reducing	  
Agent	   (Invitrogen)	   and	   NuPAGE	   LDS	   Sample	   Buffer	   (Invitrogen),	   according	   to	   the	  
manufacturer’s	  instructions.	  The	  beads	  were	  pelleted	  by	  centrifugation	  and	  the	  supernatant	  
extracted	  and	  stored	  at	  -­‐20	  oC	  for	  PAGE/WB	  analysis	  (see	  below).	  
	  




For	  transfected	  C6	  cells	  (see	  above),	  IP	  was	  performed	  at	  48	  hr	  post-­‐transfection	  with	  1	  X	  6	  
cm	  plate	  at	  80%	  confluency	  per	  IP.	  
	  
For	   primary	   NSC	   cultures	   (see	   above),	   IP	   was	   performed	   using	   1	   X	   10	   cm	   plate	   at	   80%	  
confluency	  per	  IP.	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Immunoprecipitation	   was	   performed	   according	   to	   instructions	   provided	   with	   Protein	   A	  
Agarose	  beads	  (Roche).	  For	  protein	  phosphorylation-­‐dependent	  analysis,	  Complete	  protease	  
inhibitor	   cocktail	   (Roche)	  was	   supplemented	  with	   PhosSTOP	  phosphatase	   inhibitor	   cocktail	  
(Roche)	  according	  the	  manufacturer’s	  instructions.	  
	  
Protein	   samples	   were	   eluted	   and	   denatured	   using	   NuPAGE	   Sample	   Reducing	   Agent	  
(Invitrogen)	   and	   NuPAGE	   LDS	   Sample	   Buffer	   (Invitrogen),	   according	   to	   the	  manufacturer’s	  
instructions.	   After	   elution,	   IP	   beads	   were	   pelleted	   by	   centrifugation	   and	   the	   supernatant	  
extracted	  and	  stored	  at	  -­‐20	  oC	  for	  PAGE/WB	  analysis	  (see	  below).	  
	  
Polyacrylamide	  gel	  electrophoresis	  (PAGE)	  
	  
Resolving	   (12%	   bis/acrylamide,	   0.375	   Tris-­‐HCl	   pH	   8.8,	   0.1%	   SDS)	   and	   stacking	   (5%	  
bis/acrylamide,	  0.125	  M	  Tris-­‐HCl	  pH	  6.8,	  0.1%	  SDS)	   gels	  were	  polymerized	  using	   fresh	  10%	  
ammonium	  persulfate	  (final	  concentration	  0.1%)	  and	  TEMED	  (final	  concentration	  0.1%)	  and	  
cast	   using	   the	   BioRad	   Hand	   Casting	   system,	   according	   to	   the	   manufacturer’s	   instructions.	  
Gels	  were	  loaded	  into	  the	  Mini-­‐PROTEAN	  Tetra	  cell	  (Biorad).	  
	  
Protein	   samples	   eluted	   in	   NuPAGE	   Sample	   Reducing	   Agent	   (Invitrogen)	   and	   NuPAGE	   LDS	  
Sample	  Buffer	  (Invitrogen)	  were	  incubated	  at	  85	  oC	  for	  10	  min	  then	  centrifuged	  at	  10000	  rpm	  
for	  30	  s.	  12-­‐20	  µl	  of	  each	  sample	  and	  10	  µl	  Precision	  Plus	  Protein	  ladder	  (Biorad)	  were	  loaded	  
into	   the	  gels	   in	   separate	  wells	  and	  electrophoresed	   in	  Running	  buffer	   (2.5	  mM	  Tris	  pH	  8.3;	  
19.2	  mM	  glycine;	  0.1%	  SDS)	  at	  ~150	  V	  for	  ~2	  hr.	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Western	  blotting	  
	  
After	  PAGE,	  gel	  proteins	  were	  blotted	  onto	  PVDF	  using	   the	  Mini	   Trans-­‐Blot	  Electrophoretic	  
Transfer	   Cell	   (Biorad),	   according	   to	   the	   manufacturer’s	   instructions.	   PVDF	   was	   initially	  
washed	  in	  100%	  MeOH	  at	  RT	  then	  rinsed	  twice	  for	  5	  min	  each	  in	  1	  X	  Transfer	  buffer	  (25	  mM	  
Tris	  pH	  8.3;	  192	  mM	  glycine;	  20%	  MeOH)	  at	  4	  oC.	  Blotting	  was	  performed	   in	  pre-­‐cooled	  1	  X	  
Transfer	  buffer	  for	  1-­‐2	  hr	  at	  100	  V	  at	  4	  oC.	  
	  
After	  blotting,	  the	  PVDF	  membrane	  was	  washed	  three	  times	  for	  10	  min	  each	  in	  0.1%	  Tween-­‐
20	   in	  phosphate	  buffered	  saline	   (0.1%	  PBTw).	  PVDF	  was	  then	  blocked	   in	  WB	  Block	  solution	  
(3%	  Marvel	  Dried	  Milk	  (w/v)	  in	  0.1%	  PBTw)	  for	  1	  hr	  at	  RT.	  Blocked	  PVDF	  was	  incubated	  with	  
primary	  antibody	  (Table	  2)	  diluted	  in	  WB	  Block	  o/n	  at	  4	  oC.	  After	  primary	  antibody	  incubation,	  
PVDF	  was	  washed	  three	  times	  for	  10	  min	  each	  in	  0.1%	  PBTw	  then	  incubated	  with	  Protein	  A-­‐
HRP	  (Invitrogen)	  diluted	  1:10000	  in	  WB	  Block	  for	  1	  hr	  at	  RT.	  After	  Protein	  A-­‐HRP	  incubation,	  
PVDF	  was	  washed	  three	  times	  for	  10	  min	  each	  in	  0.1%	  PBTw.	  Western	  blot	  (HRP)	  signal	  was	  
detected	   using	   Amersham	   ECL	   Plus	   (GE	   Healthcare)	   according	   to	   the	   manufacturer’s	  
instructions	   and	   developed	   on	   Amersham	   Hyperfilm	   ECL	   (GE	   Healthcare)	   in	   an	   SRX-­‐101A	  
(Konica	  Minolta)	  radiograph	  processor	  under	  darkroom	  conditions.	  
	  
2.9	   ZEBRAFISH	  HANDLING	  
	  
Zebrafish	   were	   grown	   and	  maintained	   as	   previously	   described	   and	   according	   to	   protocols	  
approved	   by	   the	   Yale	   University	   Animal	   Care	   (Westerfield	   et	   al.,	   1995).	   The	  
Tg(sox10:mCherry)	  and	  Tg(VEGFR2:GFP)la116	   lines	  were	  used	  (Kirby	  et	  al.,	  2006;	  Anderson	  et	  
al.,	   2008).	   Embryos	  were	   raised	   and	   staged	   as	   previously	   described	   and	  when	   appropriate	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embryo	  medium	  was	  supplemented	  with	  0.003%	  phenylthiourea	  (PTU)	  from	  24	  hpf	  to	  inhibit	  
melanin	  formation	  (Kimmel	  et	  al.,	  1995;	  Westerfield	  et	  al.,	  1995).	  
	  
For	  SU5416	  treatment,	  SU5416	  was	  prepared	  at	  10	  mM	  in	  DMSO	  and	  added	  to	  fish	  water	  to	  
a	   final	   concentration	   of	   5	   µM	   from	   20	   SS.	   For	   control	   treatment,	   fish	   water	   was	  
supplemented	  with	  a	  matching	  volume	  of	  DMSO.	  
	  
For	   live	   imaging,	   zebrafish	  were	   anaesthetized	   using	   0.03%	  w/v	   tricaine	  methanesulfonate	  
(MS222)	  in	  fish	  water.	  
	  
2.10	  MOUSE	  HANDLING	  
	  
All	  mice	  were	  maintained	  on	  a	  ~12	  hour	  light-­‐dark	  cycle	  (6pm-­‐7am,	  twilight	  for	  the	  first	  and	  
the	   last	  hours).	   	   The	  day	  of	  embryonic	   conception	  was	  designated	  as	  embryonic	  day	   (E)	   0.	  	  




Olig2+/-­‐	   mice	   were	   originally	   obtained	   from	   Charles	   Stiles	   (Dana	   Farber	   Cancer	   Institute,	  
Harvard	  Medical	  School)	  and	  David	  Rowitch	  (University	  of	  California,	  San	  Francisco)	  and	  were	  
maintained	  in	  the	  WIBR	  Animal	  Facility	  (Lu	  et	  al.,	  2002).	  
	  
Olig2+/-­‐;Olig2S147A	   mice	   were	   generated	   from	   crossing	   progeny	   of	   Olig2S147A	   PAC-­‐transgenic	  
founders	  with	  Olig2+/-­‐	  mice	  and	  maintained	  in	  the	  WIBR	  Animal	  Facility	  (Li	  et	  al.,	  2011).	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Cdh5-­‐CreERT2	   mice	   were	   originally	   obtained	   from	   Ralf	   H.	   Adams	   (CRUK	   London	   research	  
Institute)	  and	  were	  maintained	  in	  the	  Yale	  CVRC	  Animal	  Facility	  (Wang	  et	  al.,	  2010).	  
	  
Notch1fl/fl	  mice	  were	  originally	  obtained	  Freddy	  Radtke	  (Ludwig	  Institute	  for	  Cancer	  Research,	  
University	  of	  Lausanne)	  and	  were	  maintained	  in	  the	  Yale	  CVRC	  Animal	  Facility	  (Wolfer	  et	  al.,	  
2001).	  
	  
VEGFR3fl/fl	  mice	  were	  originally	  obtained	  from	  Kari	  Alitalo	  (Haartman	  Institute,	  University	  of	  




To	  induce	  CreERT2	  recombinase	  activity,	  4-­‐OHT	  was	  prepared	  at	  25	  mg/ml	   in	  sunflower	  seed	  
oil.	  4-­‐OHT	  was	  administered	  via	   intra-­‐peritoneal	   injection	   into	  pregnant	  female	  mice	  at	  120	  




Pregnant	  female	  mice	  were	  exposed	  to	  hypoxia	  (FiO2	  8-­‐10%)	  for	  1	  or	  2	  d	  in	  a	  rodent	  hypoxia	  
chamber	  with	  a	  calibrated	  oxygen	  controller	  and	  sensor	  (BioSepherix).	  
	  
Mouse	  embryo	  collection	  and	  fixation	  
	  
Pregnant	   female	  mice	  were	  sacrificed	  by	  cervical	  dislocation	  at	  E9.5,	  E10.5,	  E11.5,	  E12.5	  or	  
E13.5.	   Embryos	   were	   dissected	   out	   in	   ice-­‐cold	   EBSS	   using	   a	   Leica	   Dissection	   Microscope	  
(Fisher	   Scientific)	   and	   immediately	   transferred	   to	   fixation	   solution	   (4%	   w/v	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paraformaldehyde	  in	  phosphate	  buffered	  saline	  [PBS])	  and	  incubated	  at	  4	  oC	  for	  either	  30	  min	  
(short	   fix)	   or	   o/n	   (long	   fix).	   For	   cryoprotection,	   fixation	   solution	   was	   then	   replaced	   with	  
diethylpyrocarbonate	   (DEPC)-­‐treated	  20%	  w/v	   sucrose	   in	  PBS.	  After	  o/n	   incubation	  at	   4	  oC,	  
the	   embryos	  were	   embedded	   in	   Optimal	   Cutting	   Temperature	   (OCT)	  medium	   (Tissue	   Tek)	  
and	  frozen	  in	  isopentane	  on	  dry	  ice	  and	  stored	  at	  -­‐80oC.	  
	  
2.11	  TISSUE	  HISTOLOGY	  AND	  IMMUNOCYTOCHEMISTRY	  
	  
In	  situ	  hybridization	  
	  
All	   solutions	   used	   for	   preparation	   of	   the	   probe	   and	   the	   hybridization	   step	   of	   the	   protocol	  
were	   DEPC-­‐treated,	   when	   required,	   to	   ensure	   that	   they	   are	   RNase	   free	   and	   subsequently	  
autoclaved	  to	  removed	  traces	  of	  DEPC.	  
	  
Probe	  synthesis:	  To	  prepare	  the	  probes	  for	   in	  situ	  hybridisation	  either	  plasmid	  DNA	  or	  DNA	  
clones	   from	   the	   IMAGE	   consortium	  were	   used	   as	   a	   template.	   10	   µg	   of	   template	  DNA	  was	  
linearized	  at	  an	  appropriate	  point	  by	   restriction	  enzyme	  digestion	  at	  37	  	  oC	   for	  4	  hours	   in	  a	  
total	   volume	   of	   100μl.	   	   Linearized	   template	   DNA	   was	   visualized	   by	   agarose	   gel	  
electrophoresis	   and	   purified	   using	   the	   QIAquick	   Gel	   Extraction	   Kit	   (see	   above).	   	   The	   RNA	  
probe	  transcription	  reaction	  was	  carried	  out	  using	  20	  units	  of	  promoter-­‐specific	  T3,	  T7	  or	  SP6	  
RNA	   polymerase,	   1	   μg	   template	   DNA,	   1	   X	   transcription	   buffer	   (Promega),	   30	   mM	  
dithiothreitol	   (DTT),	   1	   X	   RNA	   labeling	   mixture	   (DIG	   labeling;	   Roche),	   1	   X	   RNase	   inhibitor	  
(Promega)	  in	  a	  total	  volume	  of	  25	  μl.	  	  The	  reaction	  mixture	  was	  incubated	  at	  37	  oC	  for	  2.5	  hr.	  	  
Probe	   synthesis	   was	   evaluated	   by	   agarose	   gel	   electrophoresis	   using	   1	   µl	   of	   transcription	  
reaction	  mix.	  The	  remaining	  24	  µl	  of	  RNA	  probe	  was	  diluted	  with	  76	  μl	  of	  hybridization	  buffer	  
(50%	  deionized	  formamide,	  10%	  w/v	  dextran	  sulphate	  (Fluka),	  0.1	  mg/ml	  yeast	  tRNA	  (Roche),	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1	  X	  Denhardt’s	  solution	  (Sigma),	  and	  1	  X	  salt	  solution	  (10	  X	  salt	  stock:	  2	  M	  NaCl,	  50	  mM	  EDTA,	  
100	  mM	  Tris-­‐HCl	  pH	  7.5,	  50	  mM	  NaH2PO4.2H2O,	  50	  mM	  Na2HPO4,	  DEPC-­‐treated)	  and	  stored	  
as	  5	  µl	  aliquots	  at	  -­‐80	  oC.	  
	  
RNA	  probe	  hybridization:	   From	  OCT-­‐embedded	   and	   frozen	  mouse	   embryonic	   tissue,	   spinal	  
cord	  cross-­‐sections	  of	  15-­‐20	  μm	  were	  cut	  on	  a	  Bright	  OTF5000	  Leica	  cryostat	  and	  collected	  on	  
SuperFrost®	  Plus	  slides	  (VWR	  International)	  then	  dried	  for	  2	  hr	  at	  RT.	  	  RNA	  probe	  was	  diluted	  
1:1000	  in	  hybridisation	  buffer.	  	  The	  diluted	  probe	  was	  denatured	  at	  70	  oC	  for	  5-­‐10	  min,	  mixed	  
by	   vortexing	   and	   immediately	   applied	   to	   the	   tissue	   sections.	   The	   sections	   were	   then	  
incubated	   in	   a	   sealed	   and	   hybridization	   buffer-­‐humidified	   chamber	   at	   65	   oC.	   	   After	   o/n	  
hybridization,	   slides	   were	   washed	   3	   times	   in	   pre-­‐warmed	   (65	   oC)	   Wash	   solution	   (50%	  
formamide,	  1	  X	  SSC,	  0.1%	  Tween-­‐20)	  for	  30	  min	  each	  at	  65	  oC.	  After	  65	  oC	  washes,	  sections	  
were	  washed	  twice	  in	  1	  X	  MABT	  (5	  X	  stock:	  0.5	  M	  maleic	  acid,	  0.75	  M	  NaCl,	  1	  M	  NaOH	  pH	  7.5,	  
0.5%	   v/v	   Tween-­‐20)	   for	   30	  min	   each	   at	   RT.	   	   The	   sections	   were	   then	   blocked	   in	   ISH	   Block	  
solution	  (2%	  blocking	  reagent	  (Roche)	  1	  X	  MABT,	  20%	  heat-­‐incativated	  sheep	  serum)	  for	  1	  hr	  
at	   RT.	   	   Anti-­‐digoxigenin	   (DIG)	   alkaline	   phosphatase	   (AP)-­‐conjugated	   antibody	   (Roche)	   was	  
diluted	  1:1500	  in	  ISH	  Block	  solution	  and	  applied	  to	  the	  sections	  in	  a	  humidified	  chamber	  at	  4	  
oC.	  After	  o/n	  incubation,	  the	  sections	  were	  washed	  5	  times	  in	  1	  X	  MABT	  for	  20	  min	  each	  at	  
RT,	  then	  twice	  in	  staining	  buffer	  (0.1	  M	  NaCl,	  0.05	  M	  MgCl2,	  0.1	  M	  Tris	  pH	  9.5,	  0.1%	  Tween-­‐
20)	  for	  10	  min	  each	  at	  RT.	  	  	  
	  
NBT/BCIP	  chromogenic	  detection:	  The	  staining	  was	  developed	  in	  20	  ml	  staining	  buffer,	  1	  ml	  1	  
M	  MgCl2,	  87	  μl	  NBT	  (1	  g	  4-­‐nitroblue-­‐tetrazolium	  chloride	  crystals	  in	  7	  ml	  dimethyl-­‐formamide	  
and	  3	  ml	  distilled	  water),	  67	  μl	  BCIP	   (1	  g	   in	  20ml	  dimethyl-­‐formamide)	  and	  20	  ml	  of	  a	  10%	  
polyvinylalcohol	   (PVA)	   solution	   (10%	  w/v	   PVA	   in	   0.1	  M	   NaCl,	   0.1	  M	   Tris	   pH	   9.5	   and	   0.1%	  
Tween-­‐20).	  	  Reactions	  were	  protected	  from	  light	  and	  incubated	  at	  37	  oC.	  	  Signal	  development	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was	  assessed	  under	  a	  Leica	  dissection	  microscope.	  After	  development	  of	  sufficient	  signal,	  the	  
development	  reaction	  was	  stopped	  by	  rinsing	  the	  slides	  with	  water.	   	  Stained	  sections	  were	  
dehydrated	  by	  sequential	  washing	  in	  30%,	  60%,	  80%,	  95%	  and	  100%	  ETOH	  for	  30	  s	  each	  at	  RT	  
then	  rinsing	   twice	  with	  xylene.	  Finally,	   sections	  were	  mounted	  under	  a	  coverslip	  using	  DPX	  
mountant	  (Fluka).	  
	   	  
Immunohistochemistry	  
	  
From	  OCT-­‐embedded	  and	  frozen	  mouse	  embryonic	  tissue,	  spinal	  cord	  cross-­‐sections	  of	  15-­‐20	  
μm	  were	   cut	   on	   a	   Bright	   OTF5000	   Leica	   cryostat	   and	   collected	   on	   SuperFrost®	   Plus	   slides	  
(VWR	  International)	  then	  dried	  for	  2	  hr	  at	  RT.	  Sections	  were	  washed	  3	  times	  in	  PBS	  for	  5	  min	  
each	  at	  RT	  then	  permeabilized	  with	  0.1%	  v/v	  Triton	  X-­‐100	  in	  PBS	  (0.1%	  PBX)	  for	  15	  min	  at	  RT.	  
Sections	  were	  blocked	  using	  Antibody	  Block	  (10%	  v/v	  sheep	  or	  cow	  serum	  in	  0.1%	  PBX)	  for	  1	  
hour	  at	  RT.	  	  Primary	  antibodies	  and	  Isolectin	  B4	  were	  diluted	  in	  Antibody	  Block	  (Table	  2)	  and	  
the	  primary	  antibody	  solution	  applied	  to	  the	  sections.	  After	  o/n	  incubation	  at	  4	  oC,	  sections	  
were	  washed	  3	  times	  in	  PBS	  for	  10	  min	  each	  at	  RT.	  	  Secondary	  antibodies	  and	  DAPI	  (Sigma)	  
were	   diluted	   in	   Antibody	   Block	   and	   applied	   for	   1	   hr	   at	   RT.	   After	   secondary	   antibody	  
incubation,	  sections	  were	  washed	  3	  times	  in	  PBS	  for	  10	  min	  each	  at	  RT.	  	  Finally,	  sections	  were	  
mounted	  using	  fluorescent	  mounting	  medium	  (Dako),	  coverslipped	  and	  stored	  in	  the	  dark	  at	  




For	   immunocytochemistry,	   NSCs	   were	   cultured	   on	   poly-­‐D-­‐lysine-­‐coated	   10	   mm	   diameter	  
glass	  coverslips	  (BDH)	  in	  24-­‐well	  Multiwell	  plates	  (Falcon).	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NSC	  medium	  was	  aspirated	  and	  the	  adherent	  NSCs	  washed	  once	  with	   ice-­‐cold	  PBS	   for	  20	  s	  
then	  fixed	  with	  4%	  PFA	  in	  PBS	  for	  10	  min	  at	  RT.	  After	  fixation,	  the	  NSCs	  were	  washed	  3	  times	  
in	   PBS	   for	   5	   min	   and	   blocked,	   stained	   then	   mounted	   as	   described	   above	   for	  
immunohistochemistry.	  
	  
Zebrafish	  whole-­‐mount	  immunohistochemistry	  
	  
Dechorionated	  zebrafish	  embryos	  were	  collected	  at	  48	  hours	  post	   fertilization	   (48	  hpf)	  and	  
fixed	  in	  4%	  PFA	  in	  PBS	  o/n	  at	  4	  oC.	  After	  fixation,	  embryos	  were	  washed	  once	  in	  PBS	  for	  5	  min	  
at	  RT	  then	  incubated	  in	  100%	  MeOH	  o/n	  at	  -­‐20	  oC.	  Embryos	  were	  rehydrated	  through	  75%,	  
50%	  and	  25%	  MeOH	  in	  0.5%	  PBX	  for	  5	  min	  each	  at	  RT	  then	  washed	  twice	  in	  0.5%	  PBX	  for	  5	  
min	  each	  at	  RT.	  Embryos	  were	  permeabilized	  using	  10	  µg/ml	  proteinase	  K	  in	  0.5%	  PBX	  for	  15	  
min	  at	  RT	  then	  washed	  5	  times	  in	  0.5%	  PBX	  for	  5	  min	  each	  at	  RT.	  Blocking	  was	  performed	  by	  
incubation	   in	   Wholemount	   Block	   (5%	   sheep	   serum	   in	   0.5%	   PBX)	   for	   2	   hr	   at	   RT.	   Primary	  
antibody	   was	   diluted	   in	   Wholemount	   Block	   and	   primary	   antibody	   solution	   applied	   to	   the	  
embryos.	  After	  o/n	  primary	  antibody	  incubation	  at	  4	  oC,	  the	  embryos	  were	  washed	  5	  times	  in	  
0.5%	  PBX	  for	  30	  min	  each	  at	  RT.	  Secondary	  antibody	  was	  diluted	  in	  Wholemount	  Block	  and	  
applied	  o/n	  at	  4	  oC.	  After	   secondary	   incubation,	   the	  embryos	  were	  washed	  5	  times	   in	  0.5%	  
PBX	  for	  30	  min	  each	  at	  RT.	  Finally,	  embryos	  were	  mounted	  in	  1%	  low	  melting	  point	  agarose	  in	  
PBS.	  
	  
2.12	  MICROSCOPY	  AND	  IMAGE	  ANALYSIS	  
	  
Imaging	  was	  performed	  using	  either	  a	  Zeis	  Axioplan	  light	  microscope	  and	  Hamamatsu	  digital	  
camera,	   Leica	   LED	   Fluorescent	   microscope	   or	   Leica	   TCS	   SPE	   confocal	   laser	   scanning	  
microscope.	  	  For	  confocal	  microscopy,	  standard	  excitation	  and	  emission	  filters	  for	  visualizing	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DAPI,	  Alexa	  Fluor	  488,	  CY3,	  Alexa	  Fluor	  568,	  CY5	  and	  Alexa	  Fluor	  647	  were	  used.	  	  Confocal	  z	  
stacks	  were	  captured	  at	  a	  maximum	  of	  2	  μm	  increments.	  
	  
Images	  were	  assembled	  using	   ImageJ.	  All	  manipulations	  were	  performed	  solely	   to	  enhance	  
clarity	  and	  were	  applied	  equally	  across	  the	  whole	  image.	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Primer	  name	   Procedure	   Sequence	  (5'	  -­‐	  3')	  
MutGTR	   Genotyping	   ACGCATCTCTCCATCGCTTC	  
New1	   Genotyping	   AGCGGTGTCCAGCGCCTCTCTAC	  
Nkx2.1	  #3	   Genotyping	   TCGCCTTCTATCGCCTTCTTGACGAG	  
Olig2	  3'	   Genotyping	   GCATGCCGCCCCAGTGCTGGAAGCCACCGC	  
Olig2-­‐WT1	   Genotyping	   CTCGTAGCTCGGAGCTCAGCTCTGGCGGGC	  
Olig2-­‐WT2	   Genotyping	   TAGAAGGCCAGACTGCCGCGGCGTAGATGC	  
GAPDH-­‐Fw	   Quant.	  RT-­‐PCR	   ACAACTTTGGCATTGTGGAA	  
GAPDH-­‐Rev	   Quant.	  RT-­‐PCR	   GATGCAGGGATGATGTTCTG	  
Olig1-­‐Fw	   Quant.	  RT-­‐PCR	   ACCAACGTTTGAGCTTGCTT	  
Olig1-­‐Rev	   Quant.	  RT-­‐PCR	   GGTTAAGGACCAGCCTGTGA	  
Olig2-­‐Fw	   Quant.	  RT-­‐PCR	   CTGGTGTCTAGTCGCCCATC	  
Olig2-­‐Rev	   Quant.	  RT-­‐PCR	   GAGGTGCTGGAGGAAGATGA	  
PDGFRA-­‐Fw	   Quant.	  RT-­‐PCR	   CTGCAGACAACTGCAGCATT	  
PDGFRA-­‐Rev	   Quant.	  RT-­‐PCR	   GTACCGGATTCCAAGAAGGA	  
Sox10-­‐Fw	   Quant.	  RT-­‐PCR	   TAGCCGACCAGTACCCTCAC	  
Sox10-­‐Rev	   Quant.	  RT-­‐PCR	   TGTAGTCCGGATGGTCCTTT	  
Hb9-­‐ChIP-­‐Fw	   ChIP	  qpCR	   GCAACACTTCCAGGCTCAGCCAG	  
Hb9-­‐ChIP-­‐Rev	   ChIP	  qpCR	   CTGTTCTTGCAGACTAGCAGG	  
Olig1-­‐ChIP-­‐Fw	   ChIP	  qpCR	   CCACCCGGAACTCTCTTCT	  
Olig1-­‐ChIP-­‐Rev	   ChIP	  qpCR	   ACTTCATCAGCCCCTTCTTG	  
PDGFRA-­‐ChIP-­‐Fw	   ChIP	  qpCR	   GATAGGTACCGCAAGGCCAAGCTGGA	  
PDGFRA-­‐ChIP-­‐Rev	   ChIP	  qpCR	   GCCGGACTAGTGTGTCAATACAAGCAAC	  
Sox10-­‐ChIP-­‐Fw	   ChIP	  qpCR	   CGACAGCCCCTACAGCTGC	  
Sox10-­‐ChIP-­‐Rev	   ChIP	  qpCR	   GTGACTGAGAGTCTGAGAGC	  
Olig2-­‐S263A-­‐Fw	   Mutagenesis	   ACGGCCTGCTCAAGGCACCGTCGGCAG	  
Olig2-­‐S263A-­‐Rev	   Mutagenesis	   CTGCCGACGGTGCCTTGAGCAGGCCGT	  









Table	   1.	   Primer	   sequences.	   (Quant.	   RT-­‐PCR,	   quantitative	   reverse	   transcription	   PCR;	   ChIP-­‐qPCR,	  
chromatin	  immunoprecipitation	  quantitative	  PCR)	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Primary	  Antibody	   Species	   Dilution	   Conjugation	   Manufacturer	  
B-­‐Tubulin	  E3	   Mouse	   WB	  1:10	   N/A	   Richardson	  Lab,	  UCL	  
Cleaved	  Caspase	  3	   Rabbit	   IHC	  1:1000	   N/A	   Cell	  Signal	  
GFAP	   Rabbit	   IHC	  1:400	   N/A	   Dako	  
GFP	  Tag	   Rabbit	   IHC	  1:100	   Alexa	  488	   Invitrogen	  
Hb9	   Mouse	   IHC	  1:10	   N/A	   Developmental	  studies	  hybridoma	  bank	  
HIF1A	   Mouse	   WB	  1:100	   N/A	   Novus	  Biologicals	  
ICAM2	   Rat	   IHC	  1:500	   N/A	   BD	  Biosciences	  
Isolectin	  B4	   N/A	   IHC	  1:800	   Alexa	  488	   Invitrogen	  
Nestin	   Mouse	   IHC	  1:250	   N/A	   Santa	  Cruz	  
Olig1	   Rabbit	   IHC	  1:600	   N/A	   Stiles	  Lab,	  Harvard	  U.	  
Olig2	   Goat	   WB	  1:2000	   N/A	   R&D	  Systems	  
Olig2	   Rabbit	   IHC	  1:800	  /	  WB:4000	   N/A	   Millipore	  
Olig2	   Rabbit	   IHC	  1:4000	  /	  WB	  1:10000	   N/A	   Stiles	  Lab,	  Harvard	  U.	  
PDGFRA	   Rat	   IHC	  1:400	   N/A	   BD	  Biosciences	  
Phospho-­‐histone	  H3	   Rabbit	   IHC	  1:400	   N/A	   Cell	  Signal	  
PhosphoS147-­‐Olig2	   Rabbit	   WB	  1:100	   N/A	   Richardson	  Lab,	  UCL	  
Ppp1r14a	   Rabbit	   IHC	  1:400	   N/A	   Abcam	  
Sox10	   Guineau	  pig	   IHC	  1:2000	   N/A	   Wegner	  Lab,	  U.	  of	  Hamburg	  
TujI	   Mouse	   IHC	  1:500	   N/A	   Sigma	  
Zebrafish	  HuC	   Mouse	   IHC	  1:20	   N/A	   Invitrogen	  
Secondary	  antibody	   Species	   Dilution	   Conjugation	   Manufacturer	  
Guineau	  pig	  IgG	   Goat	   IHC	  1:1000	   Cy3	   Invtirogen	  
Mouse	  IgG	  H+L	   Goat	   IHC	  1:800	   Alexa	  488	   Invitrogen	  
Mouse	  IgG	  H+L	   Goat	   IHC	  1:800	   Alexa	  568	   Invitrogen	  
Mouse	  IgG	  H+L	   Goat	   IHC	  1:800	   Alexa	  647	   Invitrogen	  
Protein	  A	   N/A	   WB	  1:10000	   HRP	   Invitrogen	  
Rabbit	  IgG	   Goat	   IHC	  1:800	   Alexa	  488	   Invitrogen	  
Rabbit	  IgG	   Goat	   IHC	  1:800	   Alexa	  568	   Invitrogen	  
Rabbit	  IgG	   Goat	   IHC	  1:800	   Alexa	  647	   Invitrogen	  
Rat	  IgG	   Goat	   IHC	  1:800	   Alexa	  488	   Invitrogen	  
Rat	  IgG	   Goat	   IHC	  1:800	   Alexa	  568	   Invitrogen	  
Rat	  IgG	   Goat	   IHC	  1:800	   Alexa	  647	   Invitrogen	  
	  
Table	  2.	  Primary	  and	  secondary	  antibodies.	  (IHC,	  immunohistochemistry;	  WB.	  Western	  blot)	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CHAPTER	  3	  
SPINAL	  CORD	  ANGIOGENESIS	  AND	  THE	  MN-­‐OLP	  FATE	  SWITCH	  
	  
	  
3.1	   INTRODUCTION	  
	  
In	   the	   pMN	  domain	   of	   the	   developing	   spinal	   cord,	  Olig2-­‐expressing	  NSCs	   initially	   generate	  
MNs	   before	   switching	   to	   produce	  OLPs	   (reviewed	   by	   Rowitch,	   2004	   and	   Richardson	   et	   al.,	  
2006).	   In	  mice,	   the	  period	  of	  MN	  generation	   runs	   from	  ~E9.5-­‐E12.5,	  with	  OLP	  specification	  
beginning	   immediately	   after	   neurogenesis.	   Basic	   helix-­‐loop-­‐helix	   (HLH)	   transcription	   factor	  
(TF)	  Olig2	   is	  expressed	  through	  both	  developmental	  phases	  and	  dephosphorylation	  of	  Olig2	  
at	  serine	  147	  (S147)	   is	  known	  to	  be	  a	  key	  regulator	  of	  the	  MN	  to	  OLP	  fate	  switch	  (Lu	  et	  al.,	  
2000;	  Takebayashi	  et	  al.,	  2000;	  Zhou	  et	  al.,	  2000;	  Li	  et	  al.,	  2011).	  However,	   it	   is	  not	  known	  
what	   triggers	   dephosphorylation	   at	   S147.	   I	   aimed	   to	   examine	   whether	   neural	   tube	  
angiogenesis	   –	   a	   developmental	   landmark	   with	   major	   physiological	   consequences	   for	   the	  
surrounding	  CNS	  tissue,	  including	  the	  ventricular	  zone	  stem	  cell	  niche	  –	  might	  provide	  crucial	  
instructive	  signals	  that	  induce	  the	  MN-­‐OLP	  fate	  switch.	  
	  
In	   this	   chapter	   I	   present	   the	   results	  of	   experiments	  designed	   to	  examine	   the	   role	  of	   spinal	  
cord	   angiogenesis	   in	   OLP	   formation	   from	   pMN	   NSCs.	   The	   majority	   of	   this	   work	   was	  
conducted	   at	   the	   Yale	   Cardiovascular	   Research	   Centre,	   Yale	  University,	   Ct.	   USA,	   under	   the	  
supervision	  of	  Prof.	  Anne	  Eichmann	  and	  Prof.	  Jean-­‐Leon	  Thomas.	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3.2	   RESULTS	  
	  
Timeline	  of	  spinal	  cord	  angiogenesis	  in	  mouse	  
	  
If	   blood	   vessel	   formation	   induces	   OLP	   specification	   in	   the	   embryonic	   pMN	   domain,	  
angiogenic	   developments	  must	   occur	   in	   the	   immediate	   run	   up	   to	   the	  MN-­‐OLP	   fate	   switch	  
(approximately	   E12.5	   in	   mouse).	   In	   order	   to	   characterize	   development	   of	   the	   vasculature	  
over	   this	   critical	   period,	   I	   used	   a	   FITC-­‐conjugated	   Isolectin	   B4	   (IB4)	   that	   specifically	   labels	  
endothelial	  cell	  α-­‐D-­‐galactosyl	  residues	  to	  visualize	  the	  mouse	  spinal	  cord	  vasculature	  at	  E9.5,	  
E10.5,	   E11.5,	   E12.5	   and	   E13.5	   (Figure	   1).	   At	   E9.5,	   the	   absence	   of	   IB4	   signal	   indicates	   the	  
spinal	  cord	  is	  devoid	  of	  blood	  vessels.	  At	  E10.5,	   I	  observed	  scattered	  IB4-­‐positive	  structures	  
within	   the	   spinal	   cord.	   The	   primitive	   vascular	   structures	   continued	   to	   develop	   until	   E13.5,	  
with	  increasing	  IB4	  signal	  coverage	  and	  network	  formation.	  This	  sequence	  indicates	  that	  the	  
nascent	   spinal	   cord	   vasculature	   first	   emerges	   between	   E9.5	   and	   E10.5,	   with	   angiogenesis	  
continuing	   over	   the	   period	   of	   the	  MN-­‐OLP	   fate	   switch	   (approximately	   E12.5)	   until	   at	   least	  
E13.5,	  well	  into	  the	  period	  of	  oligodendrogenesis.	  The	  development	  of	  the	  ventral	  spinal	  cord	  
vasculature	   over	   the	   MN-­‐OLP	   fate	   switch	   period	   is	   consistent	   with	   the	   “vascular	   trigger”	  
hypothesis.	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Figure	  1.	  Time-­‐course	  of	  angiogenesis	   in	  the	  embryonic	  mouse	  spinal	  cord.	   Isolectin	  B4	  (IB4,	  green)	  
labeling	  of	  vascular	  endothelium	  in	  thoracic	  spinal	  cord	  cross-­‐sections	  at	  E9.5,	  E10.5,	  E11.5,	  E12.5	  and	  
E13.5.
	  
Effect	  of	  oxygen	  concentration	  on	  OLP	  specification	  in	  vitro	  and	  in	  vivo	  
	  
Oxygen	   and	   the	   HIF	   signaling	   pathway	   are	  major	   regulators	   of	   CNS	   development	   and	  NSC	  
function	  (Mohyeldin	  et	  al.,	  2010).	  Spinal	  cord	  angiogenesis	  might,	  therefore,	  induce	  the	  MN-­‐
OLP	  fate	  switch	  through	  changing	  tissue	  oxygen	  tension	  and	  disruption	  of	  the	  HIF	  pathway.	  
To	  explore	  the	  role	  of	  oxygen	  in	  OLP	  specification,	  I	  began	  by	  analysing	  OLP	  formation	  under	  
normal	  and	  hypoxic	  conditions	  using	  an	  in	  vitro	  cell	  culture	  model	  of	  Olig2-­‐expressing	  NSCs.	  
	  
Primary	  adherent	  Olig2-­‐expressing	  NSC	  cultures	  were	  derived	   from	  the	  dissociated	  cortices	  
of	   E13.5	  mice	   and	   expanded	   in	   a	   ‘NSC	  medium’	   containing	   EGF	   and	   FGF,	   as	   described	   by	  
Pollard	   et	   al.	   (2006).	   These	   cultures	   have	   been	   shown	   to	   retain	   neuronal	   and	   glial	   –	   both	  
astrocyte	   and	   OL	   –	   differentiation	   potential	   after	   multiple	   passages,	   and	   are	   widely	  
considered	  to	  represent	  bona	  fide	  NSCs	  (Conti	  et	  al.,	  2005;	  Pollard	  et	  al.,	  2006;	  Glaser	  et	  al.,	  
2007).	  I	  initially	  examined	  the	  character	  of	  these	  in	  vitro	  NSC	  populations	  after	  4	  days	  under	  
either	  normoxic	  (~20%	  [O2])	  or	  hypoxic	  (2-­‐4%	  [O2])	  conditions.	  In	  both	  normal	  and	  oxygen-­‐
depleted	  environments,	  cultured	  NSCs	  uniformly	  expressed	  Olig2	  and	  the	  neurofilamentous	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stem	   cell	   marker	   Nestin	   (Figure	   2A).	   Limited	   expression	   (<1%	   cells)	   of	   neuron	   (Tuj1),	   OL	  
(Sox10)	   and	   astrocyte	   (GFAP)	   lineage	   markers	   was	   observed	   in	   either	   condition	   (data	   not	  
shown).	   To	   assess	   the	   effect	   of	   hypoxic	   incubation	   on	   HIF1A	   stability	   and	   HIF	   pathway	  
activitation,	   I	  prepared	  total	  cell	   lysates	  from	  normoxic	  and	  hypoxic	  cultures,	  and	  visualized	  
HIF1A	  expression	  by	  western	  blot	  using	  a	  HIF1A-­‐specific	  antibody	   (Figure	  2B).	  As	  expected,	  
HIF1A	   protein	   was	   significantly	   more	   abundant	   in	   cells	   cultured	   in	   low	   [O2],	   indicating	  
activation	  of	  the	  HIF1-­‐mediated	  hypoxic	  response.	  
	  
Figure	  2.	  Hypoxia	  and	  OLP	   formation	   from	  cultured	  NSCs.	  A.	  Antibody	   labeling	  of	  TF	  Olig2	  (red)	  and	  the	  
filamentous	   neural	   stem	   cell	   marker	   Nestin	   (green)	   in	   NSCs	   cultured	   in	   NSC	  medium	   under	   normal	   and	  
hypoxic	   conditions.	  B.	  Western	   blot	   analysis	   of	   HIF1A	   levels	   in	   NSCs	   cultured	   under	   normal	   and	   hypoxic	  
conditions.	  C.	  Antibody	  labeling	  of	  Olig2	  (green)	  and	  OL	  lineage	  marker	  Sox10	  (red)	  in	  NSCs	  after	  4	  days	  in	  
Differentiation	  medium	   under	   normal	   and	   hypoxic	   conditions.	  D-­‐E.	  Quantification	   of	   OLP	   formation	   and	  
relative	  cell	  density	  after	  4	  d	  in	  Differentiation	  medium	  under	  normal	  and	  hypoxic	  conditions.	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To	  analyse	  NSC	  differentiation,	  NSC	  medium	  was	  substituted	  with	   ‘Differentiation	  medium’	  
containing	   PDGF-­‐AA	   and	   increased	   FGF,	   a	   growth	   factor	   combination	   known	   to	   enhance	  
specification	   (FGF)	   and	   proliferation	   (PDGF-­‐AA)	   of	   OLPs.	   After	   4	   days	   in	   Differentiation	  
medium	   under	   either	   normoxic	   or	   hypoxic	   conditions,	   OLP	   formation	   was	   observed	   by	  
immunolabeling	   with	   Olig2-­‐	   and	   Sox10-­‐specific	   antibodies	   and	   quantified	   (Figure	   2C-­‐D).	   In	  
atmospheric	   conditions,	   4	   day	   exposure	   to	   Differentiation	   medium	   yielded	   significant	  
numbers	   (~15-­‐20%	   total	   cells)	   of	   Olig2-­‐/Sox10-­‐double	   positive	   OLPs.	   Under	   hypoxic	  
conditions,	  however,	  OLPs	  made	  up	  only	  ~1%	  total	  cell	  number.	  Significant	  differences	  were	  
also	  detected	   in	   the	   total	   cell	  numbers,	  with	  ~50%	   fewer	  cells	   in	  hypoxic	  cultures	   (Fig.	  2E),	  
though	  there	  was	  no	  evidence	  of	  substantially	  increased	  cell	  death	  based	  on	  observations	  of	  
pyknotic	  cell	  nuclei.	  This	  preliminary	  data	  indicates	  hypoxia	  inhibits	  the	  generation	  of	  OLPs	  in	  
vitro.	  
	  
In	   order	   to	   understand	   if	   hypoxia	   inhibits	   OLP	   generation	   in	   vivo,	   I	   analysed	   the	   effect	   of	  
maternal	   hypoxia	   during	   gestation	   on	   embryonic	   OLP	   development.	   The	   experimental	  
strategy	  is	  shown	  in	  Figure	  3A.	  From	  conception	  (E0)	  until	  E11.5	  (pre-­‐fate	  switch),	  pregnant	  
female	  mice	  were	  housed	  under	  normoxic	  (20%	  [O2])	  conditions.	  At	  E11.5,	  pregnant	  female	  
mice	   either	   remained	   under	   normoxic	   conditions	   (control)	   or	   were	   transferred	   to	   a	   low-­‐
oxygen	  chamber	   (8-­‐10%	  [O2];	  exposure	  of	  neonatal	  mice	  to	  10%	  [O2]	   is	  known	  to	  result	   in	  
reduced	  OL	  numbers	   in	  vivo	  [Yuen	  et	  al.,	  2014]).	  The	  pregnant	   female	  mice	  were	  sacrificed	  
and	  the	  embryos	  analysed	  at	  E12.5	  or	  E13.5	  –	  after	  1	  or	  2	  days	  hypoxic/normoxic	  incubation	  
over	  the	  MN-­‐OLP	  fate	  switch.	  At	  the	  whole-­‐embryo	  level,	  one-­‐day	  (E11.5-­‐E12.5)	  and	  two-­‐day	  
(E11.5-­‐E13.5)	   hypoxia	   did	   not	   result	   in	   a	   global	   developmental	   delay,	   assessed	   by	   the	  
appearance	  of	  stage-­‐specific	  limb	  structures	  (data	  not	  shown).	  Spinal	  cord	  angiogenesis	  and	  
OLP	  development	  was	   visualized	   in	   cross-­‐section	  by	   labeling	  with	   IB4,	   anti-­‐Sox10	   and	   anti-­‐
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Olig2	  antibodies	  (Figure	  3B-­‐C).	   It	  should	  be	  noted	  that	  the	  absence	  of	   littermate	  controls	   in	  
these	  experiments	  prevented	  quantitative	  analysis.	  	  
	  
In	  normal	  E12.5	  and	  E13.5	  embryos	  (Figure	  3B	  I-­‐I’	  &	  3C	  I-­‐I’),	  I	  observed	  multiple	  Sox10+	  OLPs	  
within	  the	  ventral	  pMN	  domain,	   itself	  delineated	  by	  focal	  Olig2	  expression.	   Individual,	  early	  
migratory	   Olig2-­‐/Sox10-­‐double	   positive	   OLPs	   were	   also	   observed	   outside	   the	   ventricular	  
zone.	   As	   expected,	   from	   E12.5	   to	   E13.5,	   the	   number	   of	   Sox10+	   OLPs	   increased	   and	   the	  
distribution	   of	   migratory	   OLPs	   expanded.	   After	   one-­‐day	   and	   two-­‐day	   hypoxic	   incubations	  
(Figure	  3B	  II-­‐II’	  &	  3C	  II-­‐II’),	  OLP	  formation	  at	  E12.5	  and	  E13.5,	  respectively,	  closely	  resembled	  
the	  age-­‐matched	  controls,	  with	  grossly	  similar	  patterns	  of	  Sox10	  and	  Olig2	  expression.	  These	  
results	  suggest	  that	  maternal	  exposure	  to	  8-­‐10%	  O2	  for	  one	  or	  two	  days	  over	  the	  period	  of	  
the	  MN-­‐OLP	   fate	   switch	   (E11.5	   –	   E12.5/E13.5)	   did	   not	   seriously	   influence	   embryonic	   pMN	  
development	   or	   OLP	   formation.	   Time	   constraints	   precluded	   the	   collection	   and	   analysis	   of	  
embryos	   from	   multiple	   litters	   that	   would	   have	   enabled	   the	   robust	   statistical	   analysis	   of	  
embryonic	  OLP	   formation	   in	  each	  of	   the	   control	   and	  hypoxic	   conditions.	   In	   the	  absence	  of	  
sufficient	  replicate	  litters,	  I	  did	  not	  quantify	  OLP	  generation	  or	  migration.	  
	  
I	   performed	   additional	   experiments	   to	   determine	   the	   effect	   of	   maternal	   hypoxia	   on	   cell	  
division,	  MN	  formation	  and	  cell	  death	  (Figure	  3D-­‐E).	  Spinal	  cords	  of	  control	  and	  hypoxic	  E12.5	  
mice	  were	   immunostained	  in	  cross-­‐section	  with	  antibodies	   labeling	  phosphorylated	  Histone	  
H3	   (ph-­‐HH3)	   (a	  mitosis-­‐specific	  marker),	   and	   Hb9	   (a	   post-­‐mitotic	  MN-­‐specific	  marker)	   and	  
Activated	  Caspase	  3	   (Casp3)	   (an	  apoptosis-­‐specific	  marker).	  As	   a	   result	  of	   antibody-­‐specific	  
fixation	   requirements,	   the	   Hb9	   and	   Casp3	   staining	   experiments	   were	   performed	   using	  
independent	   embryonic	   litters,	   distinct	   from	   the	   litters	   of	   control	   and	   hypoxic	   embryos	  
stained	  for	  ph-­‐HH3,	  Olig2	  and	  Sox10.	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Figure	  3.	  Maternal	  hypoxia	  and	  embryonic	  OLP	  development.	  A.	  Plan	  of	  the	  experimental	  strategy.	  From	  
E11.5,	   pregnant	   wild-­‐type	   female	   mice	   were	   housed	   under	   either	   normal	   (control)	   or	   oxygen-­‐depleted	  
(hypoxic)	  conditions.	  Pregnant	  females	  were	  sacrificed	  after	  1	  or	  2	  days	  (E12.5	  or	  E13.5,	  respectively)	  and	  
embryonic	  spinal	  cord	  development	  examined.	  B-­‐C.	   Isolectin	  B4	  (IB4,	  green),	  Olig2	  (red)	  and	  Sox10	  (cyan)	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labeling	   of	   spinal	   cord	   vascular	   endothelium	  and	  OLP	   formation	   at	   E12.5	   and	   E13.5	   after	   1	   or	   2	   d	   under	  
hypoxic	   conditions.	   D.	   IB4	   (green)	   and	   phospho-­‐histone	   H3	   (red)	   labeling	   of	   spinal	   cord	   vascular	  
endothelium	   and	   cell	  mitosis	   at	   E12.5	   after	   1	   d	   under	   hypoxic	   conditions.	   E.	   IB4	   (green),	   Hb9	   (red)	   and	  
activated	  Caspase	  3	  (cyan)	  labeling	  of	  spinal	  cord	  vascular	  endothelium,	  post-­‐mitotic	  MNs	  and	  cell	  apoptosis	  
at	  E12.5	  after	  1	  d	  under	  hypoxic	  conditions.	  
	  
In	   control	   E12.5	   embryos,	   ph-­‐HH3+	   dividing	   cells	   appeared	   tightly	   clustered	   along	   the	  
lumenal	  walls	  of	  the	  dorsal	  spinal	  cord	  (Figure	  3D	  I).	  In	  the	  ventral	  spinal	  cord,	  ph-­‐HH3+	  cells	  
were	  also	  found	  in	  the	  ventricular	  zone,	  though	  at	  a	  significantly	  reduced	  density	  compared	  
to	  the	  dorsal	  region.	  This	  spatial	  pattern	  of	  cell	  division	  was	  also	  observed	  in	  the	  spinal	  cords	  
of	  hypoxic	  E12.5	  embryos,	  indicating	  that	  gestation	  at	  8-­‐10%	  [O2]	  from	  E11.5	  to	  E12.5	  did	  not	  
significantly	  affect	  regulation	  of	  cell	  division	  in	  the	  embryonic	  spinal	  cord.	  
	  
In	  both	  control	  and	  hypoxic	  E12.5	  embryos,	  Hb9-­‐expressing	  post-­‐mitotic	  MNs	  were	  primarily	  
observed	  in	  the	  ventral	  horns	  of	  the	  developing	  cord,	  with	  small	  numbers	  of	  migratory	  Hb9+	  
cells	  found	  between	  the	  pMN	  and	  ventral	  horn	  regions	  (Figure	  3E).	  Robust	  Casp3	  signal	  –	  an	  
indicator	  of	   cell	   apoptosis	  –	  was	  observed	   in	  ventral	  horn	  cell	  populations	  of	   control	  E12.5	  
embryos,	   probably	   marking	   the	   early	   stages	   of	   developmental	   cell	   death	   of	   excess	   MNs	  
(Sendtner	  et	  al.,	  2000).	  In	  contrast,	  only	  relatively	  sparse	  Casp3	  labeling	  was	  detected	  in	  the	  
same	   region	   of	   hypoxic	   embryos,	   indicating	   reduced	   cell	   death.	   The	   data	   indicate	   that	  
incubation	   from	   E11.5	   –	   E12.5	   in	   8-­‐10%	   [O2]	   did	   not	   markedly	   impact	   formation	   and	  
migration	  of	  Hb9+	  post-­‐mitotic	  MN	  precursors,	  but	  might	  affect	  physiological	  MN	  cell	  death.	  
Considering	  the	  smaller	  cross-­‐sectional	  area	  of	  the	  hypoxic	  spinal	  cord	  relative	  to	  the	  control,	  
however,	  the	  observed	  difference	   in	  Casp3	   labeling	   is	   likely	  to	  be	  an	  artefact	  of	  an	  age	  gap	  
and	  not	  a	  consequence	  of	  maternal	  exposure	  to	  an	  oxygen-­‐depleted	  environment.	  	  
	  
In	   summary,	   the	   experiments	   performed	   on	   normoxic	   and	   hypoxic	   differentiating	   NSC	  
cultures	   suggested	   that	   oxygen	   concentration	   regulated	   OLP	   generation	   in	   vitro.	   In	   vivo	  
analysis	   of	   embryos	   harvested	   from	   control	   or	   hypoxic	   pregnant	   females	   (housed	   at	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atmospheric	  (20%)	  or	  8-­‐10%	  [O2]	  over	  the	  period	  of	  the	  MN-­‐OLP	  switch),	  however,	  did	  not	  
support	  the	  in	  vitro	  findings.	  Gestation	  under	  low	  [O2]	  from	  E11.5	  to	  E12.5	  or	  E13.5	  had	  no	  
discernible	  qualitative	  effect	  on	  MN	  or	  OLP	  development.	  
	  
	  Transgenic	  manipulation	  of	  angiogenesis	  and	  OLP	  formation	  
	  
In	   the	   absence	   of	   in	   vivo	   evidence	   for	   oxygen-­‐dependent	   OLP	   production,	   I	   aimed	   to	   use	  
vascular	   mutant	   mouse	   lines	   to	   establish	   the	   effect	   of	   premature	   (hypervascular)	   and	  
delayed	   (hypovascular)	   angiogenesis	   on	   OLP	   development.	   The	   transgenic	   mouse	   lines	  










The	   Cdh5-­‐CreERT2	   transgene	   consists	   of	   the	   CreERT2	   coding	   sequence	   inserted	   into	   the	   VE-­‐
Cadherin	   (Cdh5)	   P1	   artificial	   chromosome	   (PAC)	   (Feil	   et	   al.,	   1996;	   Benedito	   et	   al.,	   2009;	  
Sorensen	  et	   al.,	   2009).	   The	   construct	  provides	   tamoxifen-­‐inducible,	   endothelial	   cell-­‐specific	  
Cre	  recombinase	  activity.	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Figure	  4.	  VEGF	  &	  Notch	  signaling	  in	  tip/stalk	  endothelial	  cell	  specification.	  	  
	  
Hypovascular	  transgenic	  mutants	  
In	   sprouting	   angiogenesis,	   endothelial	   cells	   adopt	   two	   distinct	   cellular	   phenotypes:	   	   leader	  
“tip”	  cells	  and	  follower	  “stalk”	  cells	  (Gerhardt	  et	  al.,	  2003).	  Tip	  cells	  extend	  chemoresponsive	  
filopodia	   and	   guide	   the	   nascent	   vessel	   towards	   hypoxic	   regions	   of	   the	   surrounding	   tissue.	  
Proangiogenic	   VEGF-­‐A	   –	   expressed	   and	   secreted	   from	  hypoxic	   cells	   in	   a	   HIF1/2-­‐dependent	  
manner	  –	  interacts	  with	  the	  endothelial	  tip	  cell	  surface	  receptor	  VEGFR2	  (Figure	  4)	  (reviewed	  
by	  Blanco	  &	  Gerhardt,	  2013).	  VEGF	  ligand-­‐receptor	  binding	  triggers	  VEGFR2	  dimerization	  and	  
successive	   activation	   of	   downstream	   signaling	   pathways	   that	   regulate	   the	   angiogenic	  
program.	  The	  cell	  surface	  glycoprotein	  Neuropilin1	  (Nrp1)	  acts	  as	  a	  critical	  non-­‐kinase	  VEGF	  
co-­‐receptor	   that	   enhances	   the	   VEGF/VEGFR	   interaction	   and	   modulates	   VEGF	   signaling	  
output.	   In	   Cdh5-­‐CreERT2:VEGFR2fl/fl	   and	   Cdh5-­‐CreERT2:Nrp1fl/fl	   mice,	   endothelial	   cell-­‐specific	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deletion	  of	  Nrp1	  and	  VEGFR2	   therefore	  disrupts	  transduction	  of	  extracellular	  proangiogenic	  
VEGF	  signals	  and	  results	  in	  severely	  reduced	  vascular	  development	  in	  the	  embryonic	  mouse	  
brain	  (Fantin	  et	  al.,	  2013).	  
	  
Hypervascular	  transgenic	  mutants	  
The	  cell	   contact-­‐dependent	  Notch	  signaling	  pathway	  has	  been	   implicated	   in	   the	  angiogenic	  
regulation	  of	  endothelial	  cell	  specification	  and	  differentiation	  (Blanco	  &	  Gerhardt,	  2013).	   In	  
developing	  vessels,	  VEGF/VEGFR2	  signaling	  triggers	  upregulation	  of	  the	  Notch1	  ligand	  Dll4	  in	  
tip	  cells.	  Dll4-­‐expressing	  tip	  cells	  activate	  the	  Notch1	  signaling	  pathway	   in	  adjacent	  ECs	  and	  
induce	   the	   stalk	   cell	   phenotype	   (Figure	   4)	   (Hellstrom	   et	   al.,	   2007;	   Lobov	   et	   al.,	   2007;	  
Siekmann	  et	  al.,	  2007;	  Suchting	  et	  al.,	  2007;	  Tammela	  et	  al.,	  2008).	  Selection	  of	  the	  stalk	  cell	  
phenotype	   involves	   down-­‐regulation	   of	   tip	   cell-­‐dominant	   VEGFR2	   and	   thereby	   prevents	  
excess	  sprout	  formation.	   In	  Cdh5-­‐CreERT2:Notch1fl/fl	  mice,	  endothelial	  cell-­‐specific	  deletion	  of	  
Notch1	  therefore	  results	  in	  excessive	  tip	  cell	  numbers	  and	  vessel	  hyperplasia	  (Tammela	  et	  al.,	  
2011).	  In	  contrast	  to	  Notch1,	  VEGFR3	  is	  highly	  expressed	  on	  endothelial	  tip	  cells	  and	  blocking	  
VEGFR3	   with	   antibodies	   inhibits	   postnatal	   angiogenesis	   (Tammela	   et	   al.,	   2008).	   Genetic	  
deletion	   of	   VEGFR3	   in	   Cdh5-­‐CreERT2:VEGFR3fl/fl	   mice,	   however,	   triggers	   excessive	   vessel	  
sprouting	   and	   branching	   and	   generates	   a	   hypervascular	   phenotype	   closely	   resembling	   the	  
Notch1	  mutant	  mice	  described	  above	  (Tammela	  et	  al.,	  2011).	  	  
	  
Over	   the	  course	  of	  my	  project,	   I	  was	  unable	   to	  analyse	  either	  of	   the	  selected	  hypovascular	  
mutant	  mouse	  lines.	  In	  this	  section,	  I	  present	  the	  results	  of	  analysis	  of	  both	  the	  Notch1	  and	  
VEGFR3	  conditional	  knockout	  mice.	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1.	   Cdh5-­‐CreERT2:Notch1fl/fl	  
	  
I	  crossed	  Cdh5-­‐CreERT2:Notch1fl/+	  males	  with	  Notch1fl/fl	  females.	  Cre	  recombinase	  activity	  was	  
induced	  in	  embryos	  by	  intraperitoneal	  (IP)	  administration	  of	  4-­‐hydroxytamoxifen	  (4-­‐OHT)	  to	  
pregnant	   females	  at	  E9.5	  and	  E10.5.	  Biological	   replicate	   litters	  were	  collected	  at	  E12.5	  and	  
individual	   embryos	   genotyped	   by	   PCR	   from	   genomic	   DNA	   preparations.	   I	   compared	   spinal	  
cord	  angiogenesis	  and	  OLP	  development	  in	  Cdh5-­‐CreERT2:Notch1fl/fl	  (Cre+)	  and	  Notch1fl/fl	  (Cre-­‐	  
control)	  littermates	  by	  labeling	  cross-­‐sections	  of	  cervical	  spinal	  cord	  with	  IB4,	  anti-­‐Olig2	  and	  
anti-­‐Sox10	  antibodies.	  
	  
In	  both	  litters	  #1	  and	  #2,	  the	  pattern	  of	  spinal	  cord	  IB4	  staining	  appeared	  similar	  in	  Cre+	  and	  
control	  littermate	  embryos	  (Figure	  5A	  &	  5C),	  and	  this	  was	  confirmed	  by	  ImageJ	  quantification	  
of	   IB4	   signal	   	   (Figure	  5B	  &	  5D),	   indicating	   the	   vascular	  phenotype	   in	  Cre+	  embryos	  was	  no	  
different	   to	   Cre-­‐	   controls.	   This	  might	   be	   the	   result	   of	   low	   recombination	   efficiency	   or	   the	  
inefficacy	  of	  endothelial	  cell-­‐specific	  Notch1	  deletion	  for	  stimulating	  spinal	  cord	  angiogenesis.	  
As	  expected,	  given	  the	  lack	  of	  vascular	  defects	  in	  Cre+	  mutant	  mice,	  Sox10+/Olig2+	  OLPs	  and	  
Sox10-­‐/Olig2+	   NSCs	   were	   observed	   in	   both	   Cre+	   and	   control	   littermate	   embryos	   with	  
qualitatively	   similar	  distributions	   (Figure	  5A	   III-­‐IV’	  &	  5B	   III-­‐IV’).	   In	   the	  absence	  of	  a	  vascular	  
phenotype,	  I	  did	  not	  quantify	  OLP	  generation.	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Figure	  5.	  Spinal	  cord	  angiogenesis	  and	  OLP	  development	  in	  Cdh5-­‐CreERT2:Notch1fl/fl	  E12.5	  mice.	  A	  &	  C.	  
Isolectin	  B4	  (IB4,	  green),	  Olig2	  (red)	  and	  Sox10	  (cyan)	  labeling	  of	  spinal	  cord	  vascular	  endothelium	  and	  
OLP	   formation	   in	   E12.5	   control	   and	   Cre+	   littermate	   embryos.	   B	   &	   D.	   ImageJ	   quantification	   of	   the	  
relative	  vascular	  density	  in	  spinal	  cords	  of	  control	  and	  Cre+	  littermate	  embryos.	  
CHAPTER	  3	  Spinal	  cord	  angiogenesis	  and	  the	  MN-­‐OLP	  fate	  switch	   	  
	   102	  
2.	   Cdh5-­‐CreERT2:VEGFR3fl/fl	  
	  
I	  crossed	  Cdh5-­‐CreERT2:VEGFR3fl/fl	  males	  with	  VEGFR3fl/fl	  females.	  4-­‐OHT	  was	  administered	  by	  
IP	   injection	   into	  pregnant	  females	  at	  E9.5	  and	  E10.5.	  Two	  replicate	   litters	  were	  collected	  at	  
E12.5	  and	  one	  at	  E11.5	   spinal	   cord	  angiogenesis	  and	  OLP	  development	  was	  analysed	  using	  
IB4	  and	  anti-­‐Olig2	  and	  anti-­‐Sox10	  antibodies.	  
Figure	   6.	   Spinal	   cord	   angiogenesis	   and	  OLP	  development	   in	  Cdh5-­‐CreERT2:VEGFR3fl/fl	   E11.5	  mice.	  A.	  
Isolectin	  B4	  (IB4,	  green),	  Olig2	  (red)	  and	  Sox10	  (cyan)	  labeling	  of	  spinal	  cord	  vascular	  endothelium	  and	  
OLP	  formation	   in	  E11.5	  control	  and	  Cre+	   littermate	  embryos.	  B.	   ImageJ	  quantification	  of	  the	  relative	  
vascular	  density	  in	  spinal	  cords	  of	  control	  and	  Cre+	  littermate	  embryos.	  
	  
If	   angiogenesis	   triggers	   the	   MN-­‐OLP	   fate	   switch,	   a	   hypervascular	   phenotype	   would	   be	  
expected	  to	  induce	  premature	  OLP	  formation.	  I	  therefore	  initially	  examined	  blood	  vessel	  and	  
OLP	   development	   in	   E11.5	   mutant	   embryos	   (Figure	   6).	   In	   control	   and	   Cre+	   embryos,	   the	  
pattern	   of	   IB4	   signal	   within	   the	   spinal	   cord	   appeared	   similar.	   ImageJ	   quantification	   of	   IB4	  
signal	   confirmed	   Cre+	   embryos	   did	   not	   exhibit	   a	   vascular	   phenotype.	   In	   both	   Cre+	   and	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control	   E11.5	   embryos,	   clustered	  Olig2	   labeling	   delineated	   the	   ventral	   pMN	  domain,	  while	  
negligible	   anti-­‐Sox10	   signal	   within	   the	   spinal	   cord	   indicated	   OLPs	   were	   absent	   and	  
oligodendrogenesis	  had	  not	  begun.	  
	  
At	  E12.5,	   IB4	  signal	  coverage	  within	  the	  embryonic	  spinal	  cord	  was	  visibly	  greater	  –	  tracing	  
larger	   and	   more	   abundant	   vessel-­‐like	   structures	   –	   in	   Cre+	   embryos	   compared	   to	   control	  
littermates	   (Figure	   7A	   &	   7E).	   ImageJ	   quantification	   confirmed	   a	   25-­‐30%	   increase	   in	   spinal	  
cord	  IB4	  signal	  in	  VEGFR3-­‐deficient	  Cre+	  embryos	  in	  both	  Litters	  #1	  and	  #2	  (Figure	  7B	  &	  7F).	  
The	   difference	   in	   IB4	   staining	   indicates	   the	   induction	   of	   Cre	   recombinase	   activity	   at	   E9.5-­‐
E10.5	  and	  resultant	  VEGFR3	  deletion	  in	  vascular	  endothelial	  cells	  stimulated	  excessive	  spinal	  
cord	  angiogenesis	  and	  generated	  a	  hypervascular	  phenotype	  by	  E12.5.	  
	  
In	  view	  of	  the	  clear	  and	  consistent	  vascular	  phenotype,	  I	  examined	  OLP	  formation	  in	  Cre+	  and	  
control	  embryos.	  Preliminary	  qualitative	  analysis	  did	  not	  reveal	  any	  obvious	  OLP	  phenotype.	  I	  
quantified	   both	   OLP	   specification	   and	   migration.	   OLP	   specification	   was	   calculated	   as	   the	  
percentage	   of	   Olig2-­‐/Sox10-­‐double	   positive	   OLPs	   relative	   to	   the	   total	   number	   of	   Olig2-­‐
expressing	   cells	   (both	   OLPs	   and	   pMN	   domain	   NSCs).	   The	   average	   fold-­‐change	   in	   the	  
percentage	  of	  OLPs	  in	  Cre+	  versus	  Cre-­‐	  control	  embryos	  is	  shown	  in	  Figure	  7C	  &	  7G	  for	  Litter	  
#1	   and	   Litter	   #2,	   respectively.	   The	   data	   indicated	   there	   was	   no	   significant	   impact	   on	   OLP	  
formation	  in	  the	  hypervascular	  Cre+	  embryos.	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Figure	   7.	   Spinal	   cord	   angiogenesis	   and	   OLP	   development	   in	   hypervascular	   Cdh5-­‐CreERT2:VEGFR3fl/fl	  
E12.5	   mice.	   A	   &	   E.	   Isolectin	   B4	   (IB4,	   green),	   Olig2	   (red)	   and	   Sox10	   (cyan)	   labeling	   of	   spinal	   cord	  
vascular	  endothelium	  and	  OLP	  formation	  in	  E12.5	  control	  and	  Cre+	  littermate	  embryos.	  B	  &	  F.	  ImageJ	  
quantification	  of	  the	  relative	  vascular	  density	  in	  spinal	  cords	  of	  control	  and	  Cre+	  littermate	  embryos.	  C	  
&	   G.	   Quantification	   of	   the	   relative	   OLP	   formation	   in	   spinal	   cords	   of	   control	   and	   Cre+	   littermate	  
embryos.	  D	   &	   H.	  Histogram	   plots	   of	   the	   percentages	   of	   OLPs	   at	   different	   distances	   from	   the	   pMN	  
domain.	   The	   asterisk	   and	   arrowhead	   in	   E	   IV’	   mark	   the	   centre	   of	   the	   pMN	   domain	   (origin)	   and	   a	  
migratory	  OLP,	  respectively.	  
	  
	  
OLP	  migration	  was	  measured	  by	  straight-­‐line	  distance	  of	  parenchymal	  OLPs	  from	  the	  centre	  
of	  the	  pMN	  domain	  (asterisk	  Figure	  7E	  IV’).	  For	  each	  litter,	  the	  distribution	  of	  migratory	  OLPs	  
is	   presented	   as	   a	   percentage	   frequency	   distribution.	   For	   Litter	   #1	   (Figure	   7D),	   33.3%	   and	  
34.6%	  of	  migratory	  OLPs	  were	  observed	  in	  the	  20-­‐40	  µm	  range	  in	  Cre+	  and	  control	  embryos,	  
respectively.	   Outside	   the	   40	   µm	   boundary,	   over	   50%	   of	   OLPs	   in	   control	   embryonic	   spinal	  
cords	   resided	   in	   the	   40-­‐60	   µm	   range,	   with	   ~12%	   beyond	   60	   µm.	   In	   contrast,	   in	   the	   Cre+	  
littermates,	   37.5%	  were	   40-­‐60	   µm	   from	   the	   pMN	   domain,	   with	   ~30%	   beyond	   60	   µm.	   For	  
Litter	   #2,	   no	   substantial	   differences	   (>10%)	  were	   observed	   in	   the	   proportion	   of	  migratory	  
OLPs	   within	   a	   given	   distance	   from	   the	   pMN	   domain.	   In	   both	   Cre+	   and	   control	   embryos,	  
roughly	   40%	   were	   observed	   in	   the	   40-­‐80	   µm	   range,	   with	   steadily	   decreasing	   percentages	  
over	  successive	  ranges	  and	  >99%	  migratory	  OLPs	  within	  280	  µm	  of	  the	  pMN	  domain	  centre.	  
To	  determine	  whether	  the	  distributions	  of	  migratory	  OLPs	  in	  Cre+	  and	  control	  embryos	  were	  
different	   to	  a	   statistically	   significant	  degree,	   I	   independently	  analysed	   the	  distribution	  data	  
for	   both	   litters	   using	   the	   Kolmogorov-­‐Smirnov	   (KS)	   non-­‐parametric	   test.	   The	   p	   values	  
generated	  were	  0.102	  (Litter	  #1)	  and	  0.848	  (Litter	  #2),	  indicating	  the	  distribution	  of	  migratory	  
OLPs	   in	   Cre+	   embryos	  was	   not	   significantly	   different	   from	  Cre-­‐	   littermates.	   Combined,	   the	  
data	   suggests	   that	   the	   hypervascular	   spinal	   cord	   phenotype	   observed	   in	   Cre+	   VEGFR3-­‐
deficient	  embryos	  does	  not	  affect	  either	  OLP	  specification	  or	  migration.	  	  
	  
IB4	   labeling	   and	   quantification	   confirmed	   that	   Cre+	   spinal	   cords	   are	   hypervascular.	   IB4	  
staining,	   however,	   does	   not	   reveal	   vessel	   patency	   and	   therefore	   might	   not	   represent	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functionality.	  In	  order	  to	  establish	  if	  vessel	  patency	  differed	  in	  VEGFR3-­‐deficient	  and	  control	  
E12.5	  spinal	  cords,	   I	  co-­‐labeled	  spinal	  cord	  cross-­‐sections	  of	  Litter	  #1	  and	  Litter	  #2	  with	   IB4	  
and	  an	  antibody	  specific	  to	  intracellular	  adhesion	  molecule	  2	  (ICAM2),	  a	  marker	  of	  lumenized	  
vessels	  (Figure	  8).	  With	  very	  few	  exceptions	  (arrowheads	  Figure	  8A),	  spinal	  IB4+	  endothelial	  
structures	  were	  co-­‐labeled	  for	  ICAM2	  in	  the	  Cre+	  and	  control	  embryos	  of	  both	  E12.5	  litters.	  
This	  indicated	  that	  the	  vessels	  in	  hypervascular	  spinal	  cords	  were	  lumenized,	  and	  suggested	  
that	   the	   vascular	   phenotype	  will	   generate	   differences	   in	   tissue	   perfusion.	   In	   light	   of	   these	  
data	  and	  the	  analysis	  of	  OLP	  specification	  and	  migration	  performed	   in	   the	  same	  specimens	  
(Figure	   7),	   it	   appeared	   that	   the	   additional	   patent	   vasculature	   in	   Cre+	   spinal	   cords	   did	   not	  
affect	  OLP	  development.	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Figure	   8.	   Spinal	   cord	   angiogenesis	   and	   vessel	   lumenization	   in	   hypervascular	   Cdh5-­‐
CreERT2:VEGFR3fl/fl	   E12.5	   mice.	   A	   &	   B.	   Isolectin	   B4	   (IB4,	   green)	   and	   lumenized	   vessel	  
marker	   ICAM2	   (cyan)	   labeling	   of	   spinal	   cord	   vascular	   endothelium	   in	   E12.5	   control	   and	  
Cre+	   littermate	   embryos.	   Arrowheads	   in	   A	   mark	   ICAM2-­‐negative,	   IB4-­‐positive	   vascular	  
endothelium.	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Summary	  
	  
I	   have	   described	   a	   series	   of	   experiments	   designed	   to	   establish	   whether	   spinal	   cord	  
angiogenesis	  influences	  development	  in	  the	  embryonic	  spinal	  cord,	  in	  particular	  the	  MN-­‐OLP	  
fate	  switch	  of	  PMN	  domain-­‐resident	  NSCs.	  In	  culture,	  differentiation	  of	  multipotent	  NSCs	  to	  
Sox10+	   OLPs	   was	   inhibited	   by	   hypoxia,	   indicating	   that	   oxygen	   delivery	   by	   the	   nascent	  
vasculature	  might	  in	  principle	  be	  able	  to	  trigger	  OLP	  formation	  in	  the	  embryonic	  spinal	  cord.	  
In	  vivo,	  however,	  hypoxic	   incubation	  over	   the	  period	  of	   the	   fate	  switch	   (mid	  gestation)	  did	  
not	   grossly	   affect	  OLP	  development.	  Moreover,	   transgenic	  manipulation	  of	   angiogenesis	   in	  
Cdh5-­‐CreERT2:VEGFR3fl/fl	  mice	   generated	   a	   hypervascular	   spinal	   cord	   phenotype	   but	   this	   did	  
not	   alter	   OLP	   formation	   or	   migration.	   Unfortunately,	   analysis	   of	   a	   hypovascular	   mutant	  
mouse	  line	  was	  not	  possible	  during	  my	  project.	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3.3	   DISCUSSION	  
	  
In	   the	   developing	   spinal	   cord,	   OLP	   formation	   is	   tightly	   regulated,	   both	   spatially	   and	  
temporally.	  The	  vast	  majority	  of	  OL	   lineage	  cells	  arise	   from	  a	  discrete	   region	   in	   the	  ventral	  
ventricular	   zone,	   the	  pMN	  domain,	   also	   the	  birthplace	  of	   all	   spinal	   cord	  MNs.	  Neural	   stem	  
cells	   resident	   in	   the	   pMN	   domain	   generate	   MN	   progenitors	   before	   switching	   abruptly	   –	  
around	  E12.5	  in	  mice	  –	  to	  generate	  OLPs.	  The	  underlying	  developmental	  changes	  that	  trigger	  
the	   fate	  switch	  are	  not	  known.	  One	   interesting	  possibility	   is	   that	  angiogenesis	   in	   the	  spinal	  
cord	   could	   alter	   NSC/OLP	   development	   through	   one	   or	   a	   combination	   of	   oxygen	   delivery,	  
systemic	  hormone	  signaling	  and	  short-­‐range	  EC-­‐NSC	  signaling	  mechanisms.	  In	  this	  chapter,	  I	  
explored	   how	  manipulating	   oxygen	   tension	   and	   angiogenesis	   affected	   generation	   of	   OLPs.	  
My	  results	  suggested	  that	  hypoxia	  inhibited	  OLP	  differentiation	  from	  NSCs	  in	  vitro;	  however,	  
incubation	   of	   pregnant	   wild	   type	   mice	   in	   low	   oxygen	   conditions	   did	   not	   disrupt	   OLP	  
development	  in	  the	  embryonic	  spinal	  cord	  in	  vivo.	  In	  addition,	  hypervascular	  development	  in	  
transgenic	  mice	  did	  not	  detectably	   influence	  OLP	   formation.	  The	   results	   therefore	   failed	   to	  
establish	  a	  regulatory	  role	  for	  blood	  vessel	  development	  in	  spinal	  OLP	  specification	  in	  vivo.	  
	  
Spinal	  cord	  angiogenesis	  
	  
Labeling	  thoracic	  spinal	  cord	  cross-­‐sections	  of	  E9.5,	  E10.5,	  E11.5,	  E12.5	  and	  E13.5	  wild-­‐type	  
spinal	  cords	  with	  EC	  marker	  IB4	  revealed	  the	  time-­‐course	  of	  vascular	  development.	  Primitive	  
vascular	   structures	   first	   emerge	   between	   E9.5	   and	   E10.5.	   From	   E10.5-­‐E13.5,	   the	   vascular	  
network	   continues	   to	   develop,	   with	   increasing	   vessel	   size,	   coverage	   and	   complexity.	   OLPs	  
arise	  around	  E12.5,	  during	  a	  period	  of	  significant	  vascular	  growth.	  The	  dynamic	  state	  of	  the	  
blood	   vessel	   network	   in	   the	   run	   up	   to	   the	   MN-­‐OLP	   fate	   switch	   is	   consistent	   with	   an	  
instructive	  role	  for	  angiogenesis	  in	  regulating	  pMN	  NSC	  fate.	  The	  vascular	  development	  prior	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to	  the	  pMN	  fate	  switch	  might,	  for	  example,	  facilitate	  delivery	  of	  a	  fate	  switch-­‐inducing	  agent	  
such	  as	  oxygen.	  
	  
Oxygen	  and	  MN/OLP	  development	  
	  
To	  address	  the	  potential	  role	  of	  oxygen	  in	  OLP	  specification,	  I	  analyzed	  OLP	  formation	  under	  
normal	  and	  oxygen-­‐depleted	  conditions	  both	   in	  vitro	  and	   in	  vivo.	   In	  differentiating	  NSCs	   in	  
culture,	   hypoxia	   inhibited	   OLP	   development	   and	   cell	   proliferation	   without	   inducing	  
widespread	   apoptosis.	   The	   scarcity	   of	   OLPs	   in	   hypoxic	   cultures	   could,	   therefore,	   be	   the	  
consequence	  of	  decreased	  OLP	  proliferation	  and	  not	  OLP	  specification.	  However,	   in	  a	  study	  
examining	  the	  effect	  of	  oxygen	  tension	  on	  human	  OLP	  progenitors,	  low	  O2	  has	  actually	  been	  
shown	  to	  enhance	  PDGFRA+	  cell	  proliferation	  (Pistollato	  et	  al.,	  2007).	  Regardless	  of	  whether	  
due	   to	   its	   effect	   on	   specification	   or	   proliferation	   or	   a	   combination	   of	   the	   two,	   hypoxia	  
effectively	   inhibits	   OLP	   generation	   in	   my	   differentiating	   NSC	   cultures.	   This	   is	   in	   direct	  
opposition	   to	   recent	   research	   into	   the	   effect	   of	   oxidative	   stress	   on	   oligodendrogenesis	   in	  
primary	  rat	  neural	  progenitor	  cell	  cultures	  (Perez-­‐Estrada	  et	  al.,	  2014).	  In	  these	  experiments,	  
exposure	  to	  the	  reactive	  oxygen	  species	  hydrogen	  peroxide	  (normally	  produced	  in	  cells	  under	  
hypoxic	   stress)	   significantly	   increased	   the	   OL	   yield	   in	   differentiating	   neural	   progenitor	   cell	  
cultures.	  The	  disparity	   in	  the	  observations	  reported	  here	  and	  by	  Perez-­‐Estrada	  et	  al.	   (2014)	  
might	   be	   explained	   by	   differences	   in	   cell	   culture	   –	   adult	   rat	   neural	   progenitors	   versus	  
embryonic	  mouse	   neural	   progenitors	   –	   or	  more	   likely	   the	   contrasting	   effects	   of	   hydrogen	  
peroxide	  treatment	  and	  hypoxic	  incubation.	  
	  
In	  line	  with	  the	  anti-­‐OLP	  effects	  of	  hypoxia	  I	  describe,	  pro-­‐OL	  differentiation	  roles	  for	  oxygen	  
have	  previously	  been	  reported	  in	  several	  studies.	  In	  vitro,	  when	  OLPs	  were	  differentiated	  at	  
20%	   O2	   as	   opposed	   to	   5%	   O2,	   oligodendrocyte	   maturation	   was	   significantly	   enhanced	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(Pistollato	  et	  al.,	  2007).	  More	  recently,	   it	  has	  been	  reported	  that	  oxygen	  tension,	  mediated	  
via	  effects	  in	  OLP-­‐intrinsic	  HIF,	  is	  an	  essential	  regulator	  of	  postnatal	  myelination	  (Yuen	  et	  al.,	  
2014).	   HIF	   pathway	   activation	   inhibits	   OLP	  maturation,	   and	   HIF	   degradation	   –	   induced	   by	  
oxygen	  delivery	   –	   is	   required	   for	  OL	  differentiation	   and	  myelination	   in	   the	   early	   post-­‐natal	  
mouse	   brain.	   Finally,	   oxidative	   stress	   –	   induced	   chemically	   using	   cobalt	   chloride	   in	   OLP	  
culture	   and	  by	  hypo-­‐perfusion	   in	  mice	  –	   similarly	   results	   in	   a	   reduction	   in	  mature	  OLs	   and	  
myelination	   (Miyamoto	   et	   al.,	   2013).	   My	   results	   suggest	   that	   oxygen	   tension	   might,	   in	  
addition	   to	   regulating	   OLP	   differentiation	   into	   myelinating	   OLs,	   also	   regulate	   the	   initial	  
specification	  of	  NSCs	   to	  OLPs.	   This	   could	   time	   the	  MN-­‐OLP	   fate	   switch	   in	  embryonic	   spinal	  
cord,	   and	   might	   be	   necessary	   to	   accommodate	   the	   increased	   metabolic	   requirements	   of	  
OLPs.	  
	  
I	  did	  not	  examine	  specification	  of	  other	  neural	  cell	   types	  –	  neurons	  and	  astrocytes	  –	  under	  
normal	  and	  hypoxic	  conditions.	  It	  would	  be	  interesting	  to	  know	  if	  the	  observed	  effect	  on	  OLP	  
formation	  is	  cell	  type-­‐specific	  or	  the	  result	  of	  an	  all-­‐round	  differentiation	  block.	  In	  the	  mouse	  
retina,	   for	   example,	   tissue	   hypoxia	   is	   accompanied	   by	   an	   increase	   in	   the	   proliferation	   of	  
immature	   astrocytes	   and	   delayed	   astrocyte	   differentiation	   (West	   et	   al.,	   2005).	   As	   regards	  
neuronal	   development,	   if	   oxygen	   delivery	   to	   the	   ventral	   ventricular	   zone	   by	   the	   newly	  
formed	  vasculature	  halts	  MN	  generation	  and	   initiates	  OLP	  development	   in	   vivo,	  one	  might	  
expect	  to	  observe	  enhanced	  neuron	  formation	  under	  hypoxic	  conditions.	  While	  this	  is	  yet	  to	  
be	   examined	   with	   the	   NSC	   culture	   system	   described	   here,	   there	   are	   published	   reports	   of	  
oxygen	  concentration	  differentially	  affecting	   the	  generation	  of	   specific	  neuronal	   lineages	   in	  
vitro	  (reviewed	  by	  Panchision,	  2009).	  For	  example,	   low	  oxygen	  tension	  promotes	  formation	  
of	  tyrosine	  hydroxylase-­‐positive	  dopaminergic	  neurons	  (Studer	  et	  al.,	  2000).	  Conversely,	  low	  
[O2]	   has	   also	   been	   shown	   to	   repress	   differentiation	   of	   Tuj1+	   neurons	   (Gustaffson	   et	   al.,	  
2005).	   Taken	   together,	   the	   evidence	   suggests	   that	   oxygen	   tension	   can	   regulate	   neural	   cell	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development	   in	   a	   lineage-­‐specific	   manner	   (Panchision,	   2009).	   	   Prior	   to	   spinal	   cord	  
angiogenesis,	   low	   oxygen	   tension	   in	   the	   pMN	   domain	   of	   the	   embryonic	   spinal	   cord	  might	  
promote	  MN	  production	  before	  blood	  vessel-­‐mediated	  oxygen	  delivery	  induces	  the	  MN-­‐OLP	  
fate	  switch.	  
	  
To	  explore	  the	  effect	  of	  hypoxia	  on	  embryonic	  OLP	  formation	  in	  the	  spinal	  cord,	  I	  incubated	  
pregnant	  wild-­‐type	  female	  mice	  in	  a	  hypoxic	  chamber	  (8-­‐10%	  O2)	  at	  E11.5	  and	  characterized	  
the	  effect	  on	  spinal	  OLP	  development	  at	  E12.5	  (1	  d	  hypoxia)	  and	  E13.5	  (2	  d	  hypoxia).	  After	  1	  
or	   2	   d	   hypoxia,	   no	   substantial	   differences	   were	   observed	   in	   the	   patterns	   of	   angiogenesis	  
(revealed	   by	   labeling	   for	   IB4),	   NSC/OLP	   development	   (Olig2	   &	   Sox10),	   cell	   proliferation	  
(phospho-­‐histone	   H3),	   MN	   production	   (Hb9)	   or	   cell	   death	   (cleaved	   Casp3)	   compared	   to	  
control	  embryos.	  Hypoxic	   incubation	  did	  not,	   therefore,	  grossly	  affect	  any	  examined	  aspect	  
of	   spinal	   cord	   development.	   It	   should	   be	   noted	   that	   the	   experimental	   design	   required	  
comparison	   between	   embryos	   of	   different	   litters	   as	   opposed	   to	   within	   the	   same	   litter,	  
introducing	   potential	   variation	   in,	   for	   example,	   the	   precise	   age	   of	   the	   embryos	   being	  
compared.	   Nevertheless,	   my	   data	   suggest	   that	   maternal	   hypoxia	   does	   not	   have	   a	   major	  
effect	  on	  cell	  fate	  determination	  in	  the	  pMN	  domain	  of	  the	  embryonic	  spinal	  cord.	  
	  
An	  additional	  consideration	  is	  the	  physiological	  effect	  of	  the	  maternal	  hypoxic	  incubation	  in	  
utero.	  Over	  the	  course	  of	  my	  research,	  I	  did	  not	  demonstrate	  that	  gestation	  under	  low	  [O2]	  
(8-­‐10%)	  altered	  tissue	  oxygen	  tension	  in	  the	  spinal	  cords	  of	  the	  developing	  embryos.	  As	  such,	  
the	   lack	   of	   an	   observable	   phenotype	  might	   be	   due	   to	   the	   insufficiency	   of	   this	   strategy	   for	  
inducing	  hypoxia	  in	  the	  embryonic	  spinal	  cord.	  A	  number	  of	  viable	  methods	  have	  previously	  
been	   described	   to	   detect	   tissue	   hypoxia,	   including	   HIF1A	   immunohistochemistry,	   VEGF-­‐A	  
RNA	  in	  situ	  hybridization	  and/or	  nitroimidazole	  markers	  of	  hypoxia	  such	  as	  pimonidazole	  and	  
EF5,	  which	  generate	  adducts	  with	  thiol	  containing	  proteins	  specifically	  in	  hypoxic	  cells	  (Lord	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et	   al.,	   1993;	   Arteel	   et	   al.,	   1995;	   Varia	   et	   al.,	   1998;	  Ozaki	   et	   al.,	   1999;	   Schoch	   et	   al.,	   2002).	  
However,	  I	  found	  both	  HIF1A	  immunolabeling	  and	  nitroimidazole	  markers	  EF5/pimonidazole	  
labeling	   methods	   intractable,	   failing	   to	   detect	   hypoxia	   in	   the	   spinal	   cord	   at	   E9.5,	   prior	   to	  
angiogenesis	  (data	  not	  shown).	  	  
	  
Spinal	  angiogenesis	  in	  E12.5	  Cdh5-­‐CreERT2:Notch1fl/fl	  mice	  
Over	  and	  above	  examining	  the	  specific	  role	  of	  oxygen,	  I	  intended	  to	  establish	  whether	  spinal	  
angiogenesis	   regulates	   OLP	   development	   by	   analysis	   of	   hypervascular	   transgenic	   mice.	   I	  
initially	  examined	  spinal	  cord	  angiogenesis	  in	  E12.5	  Cdh5-­‐CreERT2:Notch1fl/fl	  mice	  after	  4-­‐OHT-­‐
inducible	  deletion	  of	  Notch1	   specifically	   in	  Cdh5+	  endothelial	   cells.	   IB4	  staining	  and	   ImageJ	  
quantification	   indicated	   the	   vasculature	   in	   Cre+	   embryos	   was	   not	   significantly	   over-­‐
developed	   compared	   to	   controls.	   There	   are	   several	   possible	   explanations	   for	   the	   lack	   of	   a	  
spinal	  vascular	  phenotype.	  The	  transgenic	  mice	  did	  not	  contain	  a	  transgenic	  reporter	  of	  Cre-­‐
recombination,	  such	  as	  ROSA26-­‐YFP.	  	  In	  the	  absence	  of	  such	  a	  reporter,	  I	  could	  not	  estimate	  
the	   recombination	   efficiency	   and,	   although	   the	   Cdh5-­‐CreERT2	   is	   a	   well-­‐established	   and	  
validated	   transgenic	   tool,	   it	   is	  possible	   that	   the	   IP	  administration	  of	  4-­‐OHT	   failed	   to	   induce	  
efficient	  Notch	  deletion	  in	  endothelial	  cells.	  Indeed,	  low	  efficiency	  of	  Cre	  recombination	  has	  
been	  previously	  reported	  for	  the	  same	  transgenic	  embryos	  after	  injection	  at	  E11.5	  (Cristofaro	  
et	  al.,	  2013).	  
	  
An	   alternative	   possibility	   is	   that	   endothelial-­‐specific	   genetic	   deletion	   of	   Notch	   does	   not	  
trigger	   vascular	   overgrowth	   in	   the	   developing	   spinal	   cord.	   The	   existing	   model	   of	   Notch1	  
regulation	  of	  angiogenesis	  involves	  VEGFR2-­‐induced	  upregulation	  of	  Notch	  ligand	  Delta-­‐like	  4	  
(Dll4)	   in	   endothelial	   cells	   (Tung	   et	   al.,	   2012).	   Membrane	   bound	   Dll4	   interacts	   with	   and	  
activates	  Notch	  1	   receptors	  expressed	  on	  neighboring	  endothelial	   cells,	  ultimately	   inducing	  
down-­‐regulation	   of	   VEGFR2	   expression	   in	   Notch-­‐activated	   cells.	   This	   signaling	   cascade	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generates	   VEGFR2-­‐/Dll4-­‐expressing	   tip	   cells	   and	   adjacent	   stalk	   cells.	   The	   research	   that	  
revealed	  this	  tip	  versus	  stalk	  cell	   fate	  selection	  mechanisms	  was	  performed	  using	  the	  same	  
transgenic	   approach	   (Cdh5-­‐CreERT2	   x	   Notch1fl/fl)	   and	   examining	   retinal	   angiogenesis	   post-­‐
natally,	  where	   endothelial	  Notch1	   ablation	   generates	   a	   profound	  hypervascular	   phenotype	  
(Hellstrom	  et	  al.,	  2007).	   In	  a	  subsequent	  study	  of	  arteriolar	  network	   formation,	  endothelial	  
cell-­‐specific	  Notch1	  deletion	  also	  generated	  a	  clear	  vascular	  phenotype	  in	  the	  mouse	  brain	  at	  
E13.5	   (Cristofaro	   et	   al.,	   2013).	   To	   date,	   however,	   there	   has	   been	   no	   published	   analysis	   of	  
Notch	   signaling	   in	   embryonic	   spinal	   cord	   angiogenesis	   and	   it	   remains	   possible	   that	   an	  
alternative	   tip/stalk	   fate	   selection	  mechanism	   is	   active	   there.	   Tammela	   et	   al.	   (2011)	   have	  
shown,	  for	  example,	  VEGFR3-­‐mediated	  control	  of	  tip-­‐stalk	  conversion	  via	  induction	  of	  Notch	  
target	  genes	   in	  endothelial	   cells	   independent	  of	   canonical	  Notch	   signaling.	  VEGF-­‐C/VEGFR3	  
signaling	  induces	  Notch	  target	  gene	  expression	  through	  phosphatidylinositol-­‐3-­‐kinase	  (PI(3)K)	  
signaling	  –	  a	  positive	  regulator	  and	  effector	  of	  the	  Notch	  pathway	  –	  and	  loss	  of	  VEGFR3	  leads	  
to	   a	   decrease	   in	   Notch	   target	   gene	   activation,	   thereby	   triggering	   tip	   cell	   dominance	   and	  
excessive	   angiogenic	   sprouting	   and	   branching	   (Takeshita	   et	   al.,	   2007).	   This	  mechanism	   for	  
driving	  differentiation	  towards	  the	  stalk	  cell	  phenotype	  might	  therefore	  dominate	  over	  Dll4-­‐
Notch1	   signaling	   in	   the	   spinal	   cord	   and	   explain	   the	   lack	   of	   a	   Cdh5-­‐CreERT2:Notch1fl/fl	  
phenotype.	  	  
	  
Unfortunately,	  over	  the	  course	  of	  my	  research,	  I	  did	  not	  have	  the	  opportunity	  to	  analyse	  the	  
retinal	   or	   brain	   vascular	   phenotype	   in	   the	   Cre+	   and	   control	   embryos.	   This	   analysis	   would	  
have	  provided	  a	  useful	   confirmation	  of	   effective	   recombination.	   For	  example,	   architectural	  
differences	  in	  the	  vasculature	  of	  these	  tissues	  in	  Cre+	  versus	  control	  embryos	  would	  suggest	  
effective	   Notch1	   deletion	   and	   imply	   regional	   variation	   in	   the	   requirement	   for	   Notch1	  
signaling	  for	  normal	  angiogenesis.	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Spinal	  angiogenesis	  &	  OLP	  development	  in	  Cdh5-­‐CreERT2:VEGFR3fl/fl	  mice	  	  
	  
In	   parallel	   with	   the	   Cdh5-­‐CreERT2:Notch1fl/fl	   embryonic	   analysis,	   I	   examined	   spinal	   vascular	  
development	   and	   OLP	   formation	   in	   Cdh5-­‐CreERT2:VEGFR3fl/fl	   embryonic	   mice	   at	   E12.5	   and	  
E11.5,	  after	  4-­‐OHT	  administration	  to	  pregnant	  females	  at	  E9.5	  and	  E10.5.	  During	  embryonic	  
development,	   VEGFR3	   is	   expressed	   in	   the	   tip	   cells	   of	   angiogenic	   sprouts	   (Tammela	   et	   al.,	  
2008).	   Similar	   to	   inactivation	   of	   Notch1	   signaling	   in	   endothelial	   cells,	   deletion	   of	   VEGFR3	  
increases	  tip	  cell	  numbers	  and	  induces	  vessel	  hyperplasia	  (Tammela	  et	  al.,	  2011).	  
	  
At	   E12.5,	   IB4	   staining	   and	   ImageJ	   quantification	   revealed	   a	   consistent	   hypervascular	  
phenotype	   across	   the	   spinal	   cords	   of	   Cdh5-­‐CreERT2:VEGFR3fl/fl	   embryos	   of	   two	   litters	  
compared	  to	  the	  littermate	  controls.	  At	  E11.5,	  no	  hypervascular	  phenotype	  was	  observed	  in	  
the	  Cre+	  embryos	  of	  the	  single	  litter	  analysed.	  The	  development	  of	  an	  observable	  difference	  
by	   E12.5	   indicated	   effective	   4-­‐OHT-­‐induced	   Cre-­‐mediated	   recombination	   in	   Cdh5+	  
endothelium.	   The	   lack	   of	   any	   vascular	   difference	   at	   E11.5	   is	   therefore	   likely	   due	   to	  
insufficient	  time	  between	  4-­‐OHT	  administration	  and	  analysis.	  
	  
If	   angiogenesis	   were	   both	   necessary	   and	   sufficient	   for	   timing	   the	   MN-­‐OLP	   fate	   switch,	  
vascular	   hyperplasia	   might	   be	   expected,	   through	   premature	   delivery	   of	   a	   diffusible	   or	  
endothelial	   cell	   surface	   signal,	   to	   induce	   precocious	   OLP	   formation.	   I	   analysed	   spinal	  
pMN/OLP	  development	  by	   immunolabeling	  with	  anti-­‐Olig2	  and	  -­‐Sox10	  antibodies.	  Antibody	  
labeling	   did	   not	   reveal	   any	   gross	   qualitative	   effect	   on	   pMN	   NSC	   (Olig2+/Sox10-­‐)	   or	   OLP	  
(Olig2+/Sox10+)	   phenotypes	   and	   quantification	   confirmed	   similar	   OLP	   formation	   in	  
hypervascular	   Cdh5-­‐CreERT2:VEGFR3fl/fl	   and	   control	   embryos.	   For	   further	   analysis,	   I	   also	  
examined	   OLP	   migration.	   Quantification	   of	   the	   distribution	   of	   OLPs	   across	   the	   transverse	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plane	   of	   the	   spinal	   cord	   revealed	   no	   significant	   differences	   between	   Cre+	   and	   control	  
embryos.	  
	  
Together	   these	   data	   indicated	   that	   the	   vascular	   hyperplasia	   observed	   in	   Cre+	   embryos	   at	  
E12.5	  was	  not	  associated	  with	  an	  effect	  on	  OLP	  development,	  potentially	  reflecting	  the	  lack	  
of	   any	   important	   role	   for	   angiogenesis	   in	   regulating	  OLP	   specification	  and	  migration	   in	   the	  
embryonic	   spinal	   cord.	   There	   are,	   however,	   a	   number	   of	   qualifications.	   For	   example,	  
development	   of	   the	   blood	   vessel	   network	  might	   be	   necessary	   but	   not	   sufficient	   to	   induce	  
OLP	   formation.	   If	   additional	   cell	   intrinsic	   or	   extrinsic	   pathways	   were	   required	   to	   regulate	  
pMN	   NSC	   differentiation,	   then	   in	   the	   absence	   of	   coordinated	   activation	   of	   all	   those	  
pathways,	  OLPs	  would	  not	  emerge	  or	  develop	  prematurely.	  	  
	  
To	   resolve	   the	   requirement	   for	   angiogenesis	   in	   OL	   development	   in	   the	   embryonic	   mouse	  
spinal	   cord,	   I	   plan	   to	   perform	   similar	   immunolabeling	   experiments	   using	   hypovascular	  
transgenic	  mutants.	  Genetic	  deletion	  of	  endothelial	  VEGFR2	  or	  Neuropilin	  1	  (Nrp1)	  results	  in	  
severely	   restricted	   blood	   vessel	   growth	   (Shalaby	   et	   al.,	   1995;	   Fantin	   et	   al.,	   2013).	   These	  
experiments	   will	   provide	   a	   critical	   test	   of	   the	   role	   of	   the	   vasculature	   in	   regulating	   OLP	  
specification;	   if	   vascular	   development	   were	   a	   necessary	   regulator	   of	   OL	   development,	  




Elucidating	   the	  mechanism(s)	   that	   time	   the	  MN-­‐OLP	   fate	   switch	   –	   and	  potentially	   regulate	  
OLP	  formation	  and	  migration	  thereafter	  –	  will	  be	  fundamental	  to	  a	  proper	  understanding	  of	  
OL	   development.	   Discovering	   the	   conditions	   under	   which	   OLPs	   develop	   in	   vivo	   will	   also	  
inform	   approaches	   to	   treating	   OL	   diseases	   such	   as	   multiple	   sclerosis,	   for	   example	   for	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optimizing	  ex	  vivo	  production	  methods	   for	  efficient	  cell	   replacement	  therapies.	   In	  addition,	  
the	   data	   might	   provide	   valuable	   insight	   into	   the	   general	   mechanisms	   regulating	   NSC	   fate	  
choice	  in	  the	  developing	  CNS.	  Here,	  I	  have	  explored	  the	  role	  of	  angiogenesis	  and	  oxygen	  on	  
OLP	  development	  both	  in	  vitro	  and	  using	  mouse	  models	   in	  vivo.	  Ultimately,	  the	  data	  I	  have	  
presented	  here	  do	  not	  conclusively	  support	  or	  oppose	  an	  involvement	  for	  spinal	  angiogenesis	  
in	   triggering	   the	   MN-­‐OLP	   fate	   switch.	   Additional	   experiments	   are	   therefore	   required	   to	  
determine	  the	  role	  of	  vascularization	  in	  regulating	  pMN	  NSC	  development.	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CHAPTER	  4	  
OLIG2	  S147	  DEPHOSPHORYLATION:	  IDENTIFYING	  THE	  PHOSPHATASE	  
	  
	  
4.1	   INTRODUCTION	  
	  
Phosphorylation	   of	   bHLH	   TF	   Olig2	   at	   S147	   critically	   regulates	   NSC	   fate	   in	   the	   developing	  
spinal	   cord	   (Li	  et	  al.,	  2011).	   In	  embryonic	  development,	  Olig2	  –	  expressed	   in	  pMN	  domain-­‐
resident	   NSCs	   –	   is	   initially	   phosphorylated,	   forming	   homodimers	   and	   inducing	   MN	  
generation.	   At	   approximately	   E12.5	   in	   mouse,	   Olig2	   S147	   dephosphorylation	   alters	   the	  
binding	  preference	  of	  Olig2	   from	  homodimerisation	   to	  heterodimerisation,	  abruptly	  halting	  
MN	  production	  and	  initiating	  a	  programme	  of	  OLP	  specification.	  	  
	  
The	   extracellular	   stimuli	   and	   intracellular	   signaling	   pathways	   that	   induce	   Olig2	   S147	  
dephosphorylation	  and	  the	  MN-­‐OLP	  fate	  switch	  are	  not	  known.	  Establishing	  the	  kinase	  and	  
phosphatase	   enzymes	   that	   catalyze	   addition/removal	   of	   a	   phosphate	   group	   at	   S147	   will	  
provide	   important	   insight	   into	   how	   Olig2	   S147	   phosphorylation	   is	   regulated	   and	   the	  
molecular	  mechanisms	   governing	   spinal	  NSC	   fate.	   	   Bioinformatic	   analysis	   of	  Olig2	   revealed	  
that	  S147	  is	  a	  predicted	  protein	  kinase	  A	  (PKA)	  substrate	  and	  the	  site	  (R[R/K]X[S/T])	  (X,	  any	  
amino	   acid)	   is	   conserved	   during	   evolution	   (Li	   et	   al.,	   2011).	   In	   addition,	   Olig2	   S147	   can	   be	  
phosphorylated	  by	  PKA	  in	  cultured	  Cos-­‐7	  cells	  and	  a	  dominant	  negative	  form	  of	  PKA	  inhibits	  
phosphorylation	   (Li	   et	   al.,	   2011).	   A	   role	   for	   PKA	   in	   Olig2	   S147	   phosphorylation	   in	   vivo,	  
however,	  has	  not	  been	  confirmed,	  and	  it	  remains	  possible	  that	  Olig2	  S147	  is	  phosphorylated	  
by	  a	  different	  protein	  kinase.	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In	  addition	  to	  the	  kinase	  pathway(s)	  responsible	  for	  phosphorylating	  Olig2,	  the	  identity	  of	  the	  
phosphatase	  that	  dephosphorylates	  Olig2	  S147	  and	  thereby	  triggers	  the	  MN-­‐OLP	  fate	  switch	  
is	   yet	   to	   be	   determined.	   In	   contrast	   to	   kinase	   prediction,	   reliable	   computational	   tools	   for	  
prediction	   of	   phosphatase	   targets	   are	   not	   yet	   available.	   In	   this	   short	   chapter	   I	   report	   the	  
results	   of	   work	   aimed	   at	   identifying	   the	   Olig2	   S147-­‐targeting	   phosphatase,	   activation	   or	  
expression	  of	  which	  might	  initiate	  OLP	  production.	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4.2	   RESULTS	  
	  
To	   identify	   candidate	   phosphatases	   that	   might	   dephosphorylate	   S147,	   Huiliang	   Li	   (a	   post-­‐
doctoral	   member	   of	   the	   Richardson	   Lab)	   examined	   the	   microarray	   data	   of	   Nielsen	   et	   al	  
(2006),	  Cahoy	  et	  al.	  (2008)	  and	  Hu	  et	  al.	  (2004)	  for	  evidence	  of	  altered	  expression	  of	  specific	  
phospho-­‐kinase/phosphatase	  pathway	  proteins	  in	  neural	  progenitors	  and	  OLPs	  (Table	  1).	  The	  
analysis	   identified	  Dual	   specificity	   phosphatase	   9	   (Dusp9)	   along	  with	   a	   number	   of	   catalytic	  
and	  regulatory	  (inhibitory)	  subunits	  of	  protein	  phosphatase	  1	  (PP1)	  and	  PP2	  (Table	  1).	  In	  the	  
case	  of	  PP1/PP2	  regulatory	  subunits,	  down-­‐regulation	  could	  in	  principle	  relieve	  inhibition	  and	  
allow	  PP1/PP2-­‐mediated	  dephosphorylation	  of	  Olig2	  S147.	  Of	  the	  candidate	  phosphorylation	  
pathway	   proteins,	   Dusp9	   and	   Ppp1r14a,	   a	   regulatory	   subunit	   of	   PP1,	   exhibited	   the	   most	  
substantial	  changes	  (+14.1	  and	  -­‐13.7	  fold,	  respectively)	  between	  neural	  progenitors	  and	  OLPs	  
and	  were	  selected	  for	  further	  analysis.	  
Gene	  symbol	  	   Gene	  name	   OLP	  versus	  NSC	  expression	  (fold	  change)	  
Dusp9	   Dual	  specificity	  phosphatase	  9	   14.1	  
Ppp1r14a	   Protein	  phosphatase	  1	  regulatory	  subunit	  14A	   -­‐13.7	  
Ppm2c	   Protein	  phosphatase	  2	  magnesium	  dependent	  catalytic	  subunit	   -­‐8.7	  
Ppp2r3a	   Protein	  phosphatase	  2	  regulatory	  subunit	  B	  alpha	  isoform	   7.9	  
Ppp1r1a	   Protein	  phosphatase	  1	  regulatory	  subunit	  1A	   -­‐7.3	  
Ppp1r1b	   Protein	  phosphatase	  1	  regulatory	  subunit	  1B	   -­‐6.3	  
Ppp2r3a	   Protein	  phosphatase	  2	  regulatory	  subunit	  B	  gamma	  isoform	   -­‐6	  
	  
Table	  1.	  Candidate	  phosphatases/phosphatase-­‐components	  with	   significantly	  altered	  expression	  OLPs	  
and	  NSCs.	  Positive/negative	  values	  indicate	  increases/decreases	  respectively.	  (H.	  Li,	  pers	  comm.)	  
	  
If	   dynamic	   expression	   of	   Dusp9	   or	   Ppp1r14a	   directly	  mediates	   dephosphorylation	   of	   Olig2	  
and	   induces	   the	  MN-­‐OLP	   fate	   switch,	   the	  expression	   level	  might	  be	  expected	   to	   change	   in	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pMN-­‐resident	   NSCs	   over	   the	   period	   of	   the	   fate	   switch.	   I	   therefore	   used	   RNA	   in	   situ	  
hybridization	   (ISH)	   to	   examine	   the	   pattern	   of	   Ppp1r14a	   and	   Dusp9	   messenger	   RNA	  
expression	  in	  embryonic	  mouse	  spinal	  cord	  at	  E11.5	  (pre-­‐fate	  switch),	  E12.5	  and	  E13.5	  (post-­‐
fate	  switch)	  (Figures	  1	  &	  2).	  As	  a	  positive	  control	  and	  in	  order	  to	  delineate	  the	  pMN	  domain,	  I	  
mapped	  Olig2	  expression	  by	  RNA	  ISH	   in	  parallel.	  Dusp9,	  Ppp1r14a	  and	  Olig2	  RNA	  antisense	  
probes	   were	   synthesized	   by	   reverse	   strand	   transcription	   from	   cDNA	   clones	   in	   vitro	   (see	  
Materials	  &	  methods;	  data	  not	  shown).	  	  
	  
1. Olig2	  (Figure	  1).	  At	  E11.5,	  E12.5	  and	  E13.5,	  focal	  signal	  at	  the	  ventral	  midline	  identified	  
the	   clustered	  Olig2+	   cells	   of	   the	   pMN	   domain.	   At	   E13.5,	   isolated	  Olig2+	   cells	   were	   clearly	  
distinguished	  outside	  the	  ventral	  pMN	  domain,	  consistent	  with	  post-­‐fate	  switch	  migration	  of	  
Olig2+	  OLPs.	  
2. Ppp1r14a	   (Figure	  1).	  Dynamic	  expression	  of	  Ppp1r14a	  was	  observed	   in	   the	  spinal	  cord	  
over	   the	  period	  of	   the	   fate	  switch.	  At	  E11.5,	  elevated	  Ppp1r14a	   signal	  was	  observed	   in	   the	  
ventral	   ventricular	   zone,	   including	   but	   not	   restricted	   to	   the	   pMN	   domain.	   Ppp1r14a	  
expression	  was	  also	  evident	  at	  the	  lateral	  edges	  of	  the	  dorsal	  ventricular	  zone	  but	  not	  in	  the	  
ventricular	   zone	   itself.	   At	   E12.5,	   a	   similar	   spatial	   pattern	   of	   Ppp1r14a	   expression	   was	  
observed,	  though	   less	  pronounced.	  Finally,	  at	  E13.5,	  elevated	  Ppp1r14a	  expression	  was	  not	  
observed	  in	  any	  region	  of	  the	  spinal	  cord,	  including	  the	  pMN	  domain.	  
3. Dusp9	   (Figure	   2).	   In	   contrast	   to	   Ppp1r14a,	   no	   discernible	   spatiotemporal	   pattern	   of	  
Dusp9	  expression	  was	  visible	  within	  the	  spinal	  cord	  over	  the	  period	  of	  the	  fate	  switch.	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Figure	  1.	  RNA	  in	  situ	  hybridization	  mapping	  of	  Olig2	  and	  Ppp1r14a	  RNA	  expression	  in	  E11.5,	  
E12.5	  and	  E13.5	  spinal	  cord.	  Focal	  Olig2	  signal	  marks	  the	  pMN	  domain	  (dashed	  boxes).	  At	  E13.5	  
scattered	  Olig2	  signal	  is	  consistent	  with	  the	  migratory	  spread	  of	  Olig2+	  OLPs.	  
	  
In	  order	   to	   confirm	   the	   specificity	  of	  dynamic	  Ppp1r14a	   expression,	   I	   performed	  additional	  
RNA	  ISH	  experiments	  for	  PP1	  subunits	  Ppp1r3g	  (regulatory)	  and	  Ppp1ca	  (catalytic)	  (Figure	  2).	  
Over	   E11.5,	   E12.5	   and	   E13.5,	   no	   spatiotemporal	   pattern	   of	   expression	   was	   observed	   for	  
these	  subunits.	  
	  
The	  early	  expression	  and	  subsequent	  down-­‐regulation	  of	  Ppp1r14a	  in	  the	  ventral	  ventricular	  
zone	  is	  consistent	  with	  a	  role	  in	  the	  MN-­‐OLP	  fate	  switch.	  To	  confirm	  this	  result	  and	  to	  relate	  
it	  to	  the	  expression	  of	  Ppp1r14a	  protein,	  I	  performed	  immunolabeling	  on	  pre-­‐	  and	  post-­‐fate	  
switch	   spinal	   cords	   (E10.5	   and	   E13.5	   respectively)	   with	   anti-­‐Ppp1r14a	   and	   anti-­‐Olig2	  
antibodies	   (Figure	  3).	  Anti-­‐Olig2	  antibody	   labeled	   the	  pMN	  domain	  at	  E10.5	  and	  E13.5	  and	  
early	  migratory	  OLPs	  at	  E13.5.	  At	  E10.5,	  Ppp1r14a	  protein	  was	  expressed	  in	  the	  nuclei	  of	  cells	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of	   the	  ventral	  ventricular	  zone,	   including	  the	  Olig2+	  cells	  of	   the	  pMN	  domain.	  Strikingly,	  by	  




Figure	  2.	  RNA	  in	  situ	  hybridization	  mapping	  of	  Dusp9,	  Ppp1ca	  and	  Ppp1r3g	  transcript	  expression	  in	  
E11.5,	  E12.5	  and	  E13.5	  spinal	  cord.	  
	  
	  
These	   data	   indicate	   that	   down-­‐regulation	   of	   nuclear	   Ppp1r14a	   might	   de-­‐repress	   PP1	   and	  
induce	  Olig2	  S147	  dephosphorylation	  and	  the	  MN-­‐OLP	  fate	  switch.	  Due	  to	  time	  constraints,	  I	  
have	  been	  unable	   to	   follow	  up	   these	  provocative	  data	  during	  my	  PhD.	  However,	   exploring	  
the	  functional	  relationship	  between	  Ppp1r14a	  expression	  and	  Olig2	  S147	  phosphorylation	  is	  
an	  important	  task	  for	  the	  future.	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Figure	   3.	   Immunolabeling	   for	   Olig2	   (red)	   and	   Ppp1r14a	   (green)	   in	   the	   ventral	  
ventricular	  zone	  of	  E10.5	  and	  E13.5	  spinal	  cord.	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4.3	   DISCUSSION	  
	  
In	  pMN	  domain	  NSCs,	  dephosphorylation	  of	  Olig2	  at	  S147	  triggers	  the	  MN-­‐OLP	  fate	  switch	  (Li	  
et	   al.,	   2011).	   At	   the	  molecular	   level,	   precisely	   how	   S147	   dephosphorylation	  modifies	  Olig2	  
function	  and	   thereby	   regulates	  NSC	   fate	  choice	   is	  only	  partially	  understood.	  Moreover,	   the	  
extra-­‐	   and	   intracellular	   signaling	   pathways	   that	   mediate	   phosphorylation	   and	  
dephosphorylation	   of	   Olig2	   have	   not	   been	   established.	   While	   computational	   and	   in	   vitro	  
analysis	  suggests	  that	  PKA	  is	  the	  kinase	  responsible	  for	  phosphate	  addition	  at	  S147,	  there	  is	  
no	  evidence	  implicating	  a	  specific	  phosphatase	  in	  S147	  dephosphorylation.	  
	  
From	   a	   list	   of	   phosphatase	   components	   displaying	   significantly	   altered	   expression	   in	   OLPs	  
versus	  NSCs,	  I	  have	  identified	  the	  Ppp1r14a	  regulatory	  subunit	  of	  PP1	  as	  a	  potential	  regulator	  
of	   Olig2	   S147	   dephosphorylation	   over	   the	   period	   of	   the	   MN-­‐OLP	   fate	   switch.	   The	   initial	  
bioinformatic	  screen,	  however,	  did	  not	  exemplify	  the	   ideal	  strategy	  for	  constructing	  the	   list	  
of	   candidate	   phosphatase	   and	   phosphatase-­‐related	   proteins.	   The	   approach	   examined	  
published	   transcriptome	   databases	   from	   independent	   microarray	   analyses	   and	   revealed	  
phosphatase	  components	  exhibiting	  differential	  expression	  in	  OLPs	  and	  NSCs.	  In	  contrast	  to	  
the	   stable	   expression	   observed	   by	   microarray	   in	   purified	   NSC	   and	   OLP	   populations,	  
dephosphorylation	  of	  Oig2	  at	  S147	  at	  the	  onset	  of	  oligodendrogenesis	  might	  require	  only	  the	  
transient	   expression	   or	   repression	   of	   the	   specific	   phosphatase	   component;	   after	   effective	  
dephosphorylation	   of	   Olig2,	   the	   expression	   might	   return	   to	   the	   pre-­‐OLP	   level.	   In	   this	  
scenario,	   the	  Olig2	  phospho-­‐regulator	  would	  not	  exhibit	   the	  differential	  expression	   in	  NSCs	  
and	   OLPs	   required	   for	   identification	   in	   the	   computational	   screen	   described	   here.	   I	   cannot	  
therefore	   exclude	   the	  possibility	   that	   the	   key	   regulator	   of	  Olig2	   S147	  dephosphorylation	   is	  
not	  among	  the	  candidate	  phosphatase	  proteins	  reported	  here.	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I	  have	  demonstrated	  dynamic	  expression	  –	  at	  both	  the	  RNA	  and	  protein	  levels	  –	  of	  Ppp1r14a	  
in	   pMN	  domain	  NSCs	   over	   the	   period	   of	   the	  MN-­‐OLP	   fate	   switch.	   Ppp1r14a	  was	   originally	  
identified	   as	   an	   inhibitory	   subunit	   of	   PP1	   in	   smooth	   muscle	   (Eto	   et	   al.,	   1997).	   PP1	   is	   a	  
serine/threonine	   (S/T)	   phosphatase	   and	   a	   member	   of	   the	   phosphoprotein	   phosphatase	  
super-­‐family	   (Peti	   et	   al.,	   2013).	   In	   contrast	   to	  protein	   kinases,	   the	   catalytic	   domains	  of	   S/T	  
phosphatases,	   including	  PP1,	  have	   limited	   intrinsic	   specificity.	  The	  mammalian	  genome,	   for	  
example,	  encodes	  only	  ~40	  S/T	  phosphatases	  to	  offset	  the	  activity	  of	  ~400	  S/T	  kinases	  (Bollen	  
et	   al.,	   2010).	   The	   phosphatase	   activity	   of	   the	   ubiquitously	   expressed	   PP1	   catalytic	   core	   is	  
instead	   regulated	   and	   directed	   toward	   specific	   target	   substrates	   via	   interaction	   with	  
additional	   protein	   subunits	   –	   so	   called	   PP1	   interacting	   proteins	   –	   of	  which	   there	   are	  more	  
than	   200	   (Peti	   et	   al.,	   2013).	   Ppp1r14a	   is	   a	   validated	   PP1	   interacting	   protein	   and	   Ppp1r14a	  
expression	   has	   previously	   been	   reported	   in	   the	   human	   and	  mouse	   CNS	   (Li	   et	   al.,	   2001).	   A	  
detailed	  understanding	  of	  exactly	  how	  Ppp1r14a	  affects	  PP1	  activity	  in	  specific	  cell	  types	  has	  
not	  been	   fully	  worked	  out.	   In	  P19	  embryonic	   carcinoma	  cells,	  Ppp1r14a	  was	   found	   to	  be	  a	  
transcriptional	  target	  of	  Ngn2,	  a	  proneural	  basic	  HLH	  TF	  that	  is	  fundamental	  in	  MN	  formation	  
and	  that	  can	  directly	   interact	  with	  Olig2	   (Lee	  et	  al.,	  2005;	  Li	  et	  al.,	  2011).	  This	   is	  consistent	  
with	  a	  role	  for	  Ppp1r14a	  in	  maintaining	  phosphorylation	  of	  Olig2	  during	  the	  period	  of	  motor	  
neuron	  production.	  
	  
Here,	  I	  show	  Ppp1r14a	  protein	  expression	  at	  E11.5	  –	  during	  MN	  production	  –	  in	  the	  nuclei	  of	  
pMN	   domain	   NSCs	   (Li	   et	   al.,	   2001).	   After	   E11.5,	   Ppp1r14a	   expression	   diminished	   and	  
disappeared	   completely	   by	   E13.5.	   The	   systematic	   down-­‐regulation	   of	   nuclear	   Ppp1r14a	   in	  
pMN	   NSCs	   over	   the	   period	   of	   the	  MN-­‐OLP	   fate	   switch	   suggests	   Ppp1r14a	   might	   regulate	  
dephosphorylation	  of	  Olig2	  S147.	  In	  this	  case,	  Ppp1r14a/PP1	  complex	  formation	  would	  alter	  
PP1	   activity	   and	  preserve	  Olig2	   S147	  phosphorylation.	   The	  observed	  decrease	   in	   Ppp1r14a	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expression	  would	   de-­‐repress	   PP1,	   triggering	   PP1-­‐mediated	   removal	   of	   the	   phosphate	   from	  
Olig2	  S147	  and	  initiating	  the	  MN-­‐OLP	  fate	  switch.	  
	  
Despite	   the	  broadly	  concordant	   in	  situ	  hybridization	  and	   immunolabeling	   results,	   there	   is	  a	  
marked	  discrepancy	   in	  the	  Ppp1r14a	  RNA	  and	  Ppp1r14a	  protein	  signals	  at	  E11.5	  and	  E10.5,	  
respectively.	  The	  robust	  co-­‐localisation	  of	  Ppp1r14a	  and	  Olig2	  protein	  in	  the	  nuclei	  of	  Olig2+	  
NSCs	   in	   the	   ventricular	   zone	   of	   the	   E10.5	   spinal	   cord	   contrasts	   with	   the	   partially	   non-­‐
overlapping	   RNA	   expression	   patterns.	   The	   Ppp1r14a	   protein	   expression	   in	   Ppp1r14a	   RNA-­‐
negative	  territory	  might	  represent	  non-­‐specificity	  in	  the	  anti-­‐Ppp1r14a	  antibody.	  In	  order	  to	  
validate	   the	   specificity	   of	   the	   primary	   antibody,	   it	   will	   be	   important	   to	   repeat	   the	  
immunolabeling	  experiments	  and	  conduct	  the	  appropriate	  absorption	  controls.	  Western	  blot	  
analysis	  of	  E10.5	  and	  E11.5	  spinal	  cord	  lysates	  will	  also	  enable	  confirmation	  of	  the	  antibody	  
specificity	   for	   an	   antigen	   migrating	   at	   the	   predicted	   molecular	   weight	   of	   Ppp1r14a.	   In	  
addition	   to	   issues	   of	   antibody	   non-­‐specificity,	   the	   differing	   Ppp1r14a	   RNA	   and	   Ppp1r14a	  
protein	  expression	  patterns	  might	  reflect	  local	  translation	  –	  and	  therefore	  sequestration	  –	  of	  
the	   Ppp1r14a	  messenger	   RNA	   in	   a	   discrete	   intracellular	   region	   away	   from	   the	   Ppp1r14a+	  
nucleus.	   Ultimately,	   however,	   the	   lack	   of	   age-­‐matched	   specimens	   in	   these	   in	   situ	  
hybridization	   (performed	   at	   E11.5)	   and	   the	   immunolabeling	   (performed	   at	   E10.5)	  
experiments,	  confounds	  the	  integration	  of	  the	  different	  results.	  
	  
In	  ordr	  to	  confirm	  an	  in	  vivo	  role	  for	  the	  Ppp1r14a	  subunit	  of	  PP1,	  it	  is	  necessary	  to	  examine	  
the	  effect	  of	  conditionally	  deleting	  this	  subunit	  in	  Olig2-­‐expressing	  NSCs.	  I	  have	  submitted	  a	  
request	   to	   the	   European	   Mammalian	   Mutant	   Cell	   Repository	   (www.eummcr.org/)	   for	  
generation	   of	   the	  Ppp1r14a	   conditional	   knockout	   stem	   cell	   line	   (Ppp1r14afl/fl).	  Ppp1r14afl/fl	  
stem	   cells	   will	   enable	   generation	   of	   Ppp1r14afl/fl	   mice.	   Using	   the	   Olig2-­‐Cre	   mouse	   line,	  
analysis	  of	  Olig2-­‐Cre;Ppp1r14afl/fl	  double-­‐transgenic	  mice	  will	  determine	  the	  requirement	  of	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Ppp1r14a	  for	  Olig2	  S147	  phosphorylation	  and	  MN	  production	  from	  pMN	  NSCs	  (Schuller	  et	  al.,	  
2008).	   In	  these	  animals,	  Cre	  recombinase	  expression	  driven	  from	  the	  Olig2	  promoter	  would	  
selectively	  eliminate	  Ppp1r14a	  in	  pMN	  NSCs	  in	  the	  spinal	  cord.	  The	  phosphorylation	  state	  of	  
Olig2	  S147	  could	  be	  determined	  by	  spinal	  Olig2	  IP	  and	  WB	  using	  our	  phospho-­‐S147-­‐specific	  
antibody,	   and	   the	   timing	   of	   the	   MN-­‐OLP	   fate	   switch	   by	   immunolabeling	   for	   MN	   and	   OL	  
lineage	  markers	   (Li	  et	  al.,	  2011).	   If	  down-­‐regulation	  of	  Ppp1r14a	  activates	  PP1	  and	   thereby	  
triggers	   S147	  dephosphorylation	   in	  wild-­‐type	  mice,	   genetic	   deletion	  of	  Ppp1r14a	  would	  be	  





Research	   into	   the	   upstream	   pathways	   and	   intracellular	   components	   mediating	   Olig2	  
dephosphorylation	  at	   the	   time	  of	   the	  MN-­‐OLP	   fate	  switch	  will	  provide	  valuable	   insight	   into	  
the	   regulation	   of	   spinal	   MN	   and	   OLP	   development.	   On	   the	   basis	   of	   its	   dynamic	   nuclear	  
expression	   in	   pMN	   cells	   over	   the	   period	   of	   the	  MN-­‐OLP	   fate	   switch,	   I	   have	   identified	   the	  
inhibitory	  Ppp1r14a	   subunit	   of	   PP1	  as	   a	  potential	   regulator	  of	  Olig2	   S147	  phosphorylation.	  
Further	   work	   is	   required	   to	   test	   the	   involvement	   of	   Ppp1r14a	   in	   regulating	   Olig2	  
phosphorylation	  in	  vivo.	  In	  addition	  to	  identifying	  the	  phosphatase,	  it	  will	  be	  fundamental	  to	  
explore	  the	  signals	  and	  molecular	  mechanisms	  governing	  phosphatase	  expression/activation.	  
Gaining	   a	   detailed	   understanding	   of	  OLP	   specification	  will	   contribute	   to	   the	   design	   of	  OLP	  
production	  methods	  for	  efficient	  cell	  replacement	  therapies	  and	  in	  vitro	  drug	  screens	  aimed	  
at	  identifying	  modulators	  of	  OL	  development.	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CHAPTER	  5	  
OLIG2	  S147	  PHOSPHORYLATION	  &	  GENE	  TARGET	  CHOICE	  
	  
	  
5.1	   INTRODUCTION	  
	  
Basic	   HLH	   transcription	   factor	   Olig2	   is	   expressed	   throughout	   the	   development	   of	   the	   OL	  
lineage	  and	  has	  been	  described	  as	  a	  master	  regulator	  of	  OLP	  specification	  and	  differentiation	  
(Rowitch,	   2004;	   Li	   &	   Richardson,	   2008;	   Meijer	   et	   al.,	   2012).	   In	   the	   pMN	   domain	   of	   the	  
embryonic	  spinal	  cord,	  Olig2	  is	  also	  expressed	  in	  multipotent	  NSCs	  over	  the	  periods	  of	  motor	  
neuron	   specification	   and	   subsequent	  OLP	   specification.	  Olig2	   knockout	   results	   in	   complete	  
failure	  to	  generate	  spinal	  cord	  MNs	  and	  OL	  lineage	  cells	  and	  highlights	  the	  critical	  importance	  
of	  Olig2	  for	  production	  of	  pMN-­‐derived	  MNs	  and	  OLs	  (Lu	  et	  al.,	  2002;	  Park	  et	  al.,	  2002;	  Zhou	  
et	  al.,	  2002).	  Research	  exploring	  the	  role	  of	  Olig2	  in	  the	  generation	  of	  both	  neuronal	  and	  glial	  
cell	  types	  revealed	  that	  dynamic	  Olig2	  phosphorylation	  is	  a	  critical	  regulator	  of	  stem	  cell	  fate	  
(Li	   et	   al.,	   2011).	   During	  MN	   specification,	  Olig2	   is	   phosphorylated	   at	   serine	   147	  within	   the	  
HLH	   domain,	   while	   S147	   dephosphorylation	   –	   modeled	   by	   phospho-­‐null	   Olig2	   S147A	  
mutation	   –	   abolishes	   MN	   production	   without	   preventing	   OLP	   production.	   Li	   et	   al.	   (2011)	  
conclude	  that	  dephosphorylation	  of	  Olig2	  at	  S147	  triggers	  the	  MN-­‐OLP	  fate	  switch.	  
	  
Examining	   the	   molecular	   mechanisms	   underlying	   Olig2	   S147	   phosphorylation-­‐dependent	  
control	   of	   stem	   cell	   fate,	   Li	   et	   al.	   (2011)	   identified	   significant	   differences	   in	   the	   cofactor	  
binding	  properties	  of	  wild-­‐type	  and	  S147A	  mutant	  Olig2.	  Compared	   to	  wild-­‐type	  Olig2,	   the	  
Olig2-­‐S147A	  mutant	  shows:	  1.	  a	  severely	  reduced	  ability	  to	  form	  Olig2:Olig2	  homodimers;	  2.	  
an	   increased	   affinity	   for	   the	   pan-­‐neuronal	   bHLH	   TF	   Ngn2.	   The	   results	   demonstrated	   that	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S147A	  mutation	  seriously	   influences	  Olig2	  cofactor	  choice	  without	  grossly	  affecting	  protein	  
structure	   or	   stability.	   Taken	   together,	   the	   data	   indicate	   that	   during	   the	   initial	   neurogenic	  
phase,	   phospho-­‐S147	   Olig2	   homodimers	   regulate	   expression	   of	   MN	   lineage	   genes	   and	  
repression	   of	   OL	   lineage	   genes.	   Dephosphorylation	   of	   Olig2	   at	   S147	   induces	   homodimer	  
dissociation	  and	  formation	  of	  heterodimers,	  abruptly	  silencing	  the	  genetic	  programme	  of	  MN	  
specification	  and	  activating	  an	  OL	  genetic	  programme.	  
	  
In	  addition	   to	  Olig2	  cofactor	  preference,	   the	  position	  of	  S147	  within	   the	  DNA-­‐binding	  basic	  
HLH	  domain	  suggests	  that	  Olig2	  S147	  dephosphorylation	  might	  affect	  gene	  target	  specificity,	  
although	   this	   has	   not	   been	   investigated	   as	   yet.	   In	   this	   case,	   phosphorylation-­‐specific	  
association	  with	  MN/OL	   lineage	  gene	  regulatory	  sequences	  would,	   in	  concert	  with	  dynamic	  
protein-­‐complex	   formation,	   coordinate	   different	   developmental	   programmes	   of	   gene	  
expression.	   In	   support	   of	   this	   hypothesis,	   genome-­‐wide	   mapping	   of	   Olig2	   gene	   targets	   in	  
OLPs	  and	  mature	  OLs	  revealed	  occupancy	  of	  stage-­‐specific	  binding	  sites	  at	  later	  stages	  of	  OL	  
differentiation	   (Yu	  et	  al.,	  2013).	  Alternatively,	  Olig2	  S147	  dephosphorylation	  might	   regulate	  
recruitment	   of	   specific	   co-­‐factors	   to	   the	   same	   set	   of	   Olig2	   gene	   targets.	   Analysis	   of	   the	  
amino-­‐terminal	   S10/13/14	   phosphorylation	   of	   Olig2	   using	   triple	   phospho-­‐null	   or	   phospho-­‐
mimetic	   Olig2	   variants	   indicated	   that	   S10/13/14	   phosphorylation	   regulates	   gene	  
transcription	   and	   neural	   progenitor	   proliferation	   but	   has	   no	  major	   impact	   on	   target	   E-­‐box	  
recognition	   (Meijer	   et	   al.,	   2014).	   In	   order	   to	   better	   understand	   how	   Olig2	   S147	  
phosphorylation	  regulates	  neuronal	  versus	  glial	  cell	  fate	  decisions	  in	  the	  pMN	  domain	  of	  the	  
developing	   spinal	   cord,	   I	   planned	   to	   identify	   the	   genomic	  binding	   sites	  of	  Olig2	   in	  NSCs	  by	  
chromatin	   immunoprecipitation-­‐sequencing	   (ChIP-­‐seq)	   and	   to	   determine	   if	   S147	  
phosphorylation	  affects	  gene	  target	  specificity.	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5.2	   RESULTS	  
	  
Derivation	  and	  characterization	  of	  NSC	  cultures	  
	  
A	  diagram	  illustrating	  the	  ChIP-­‐seq	  workflow	  is	  shown	  in	  Figure	  1.	  	  
	  
To	  obtain	  DNA	  for	   Illumina	  sequencing,	   I	  used	  primary	  adherent	  NSC	  cultures	  derived	   from	  
the	  dissociated	  cortices	  of	  E13.5	  mice	  (Figure	  2A)	  (Pollard	  et	  al.,	  2006).	  For	   identification	  of	  
phospho-­‐S147	  Olig2	   gene	   targets,	  NSCs	  were	   isolated	   from	  Olig2+/-­‐	   (Olig2-­‐WT)	   embryos.	   In	  
parallel,	   to	   identify	   the	   gene	   targets	   of	   dephosphorylated	   Olig2,	   NSCs	   were	   isolated	   from	  
Olig2-­‐/-­‐;Olig2S147A	   (Olig2-­‐S147A)	  phospho-­‐null	  mutant	   embryos	   (Li	   et	   al.,	   2011).	  As	   a	   control	  
for	   background	   ChIP	   enrichment,	   NSC	   cultures	   were	   also	   derived	   from	   Olig2-­‐/-­‐	   (Olig2-­‐null	  
mutant)	  embryos	  (Li	  et	  al.,	  2011).	  NSCs	  were	  cultured	  over	  multiple	  passages	  in	  a	  chemically	  
defined	  medium	  containing	  FGF-­‐2	  and	  EGF	  (NSC	  medium).	  	  
	  
I	  initially	  characterized	  my	  primary	  NSC	  cultures	  by	  immunolabeling	  for	  expression	  of	  a	  range	  
of	   protein	  markers	   (Figure	   2).	   Olig2-­‐WT,	  Olig2-­‐S147A	   and	  Olig2-­‐null	   cells	   all	   expressed	   the	  
filamentous	  stem	  cell	  marker	  Nestin.	  Olig2-­‐WT	  and	  Olig2-­‐S147A	  phospho-­‐null	  cells	  uniformly	  
expressed	  Olig2,	  which	  was	  as	  expected	  entirely	  absent	   from	  Olig2-­‐null	   cultures.	  Finally,	   to	  
observe	   spontaneous	   neural	   differentiation	   along	   OL,	   astrocyte	   or	   neuronal	   lineages,	   I	  
labeled	   my	   NSC	   cultures	   with	   antibodies	   against	   Sox10,	   GFAP	   and	   Tuj1,	   respectively.	   No	  
Sox10+	   cells	   were	   identified	   in	   any	   of	   the	   Olig2-­‐WT,	   Olig2-­‐S147A	   and	   Olig2-­‐null	   cultures,	  
while	  Tuj1+	  and	  GFAP+	  cells	  were	  observed	   in	  extremely	   limited	  numbers	   (<1%),	   indicating	  
negligible	  NSC	  differentiation	  in	  NSC	  medium.	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Figure	   1.	   ChIP-­‐seq	   workflow.	   A.	   Chromatin	   immunoprecipitation.	   1.	   Formaldeyde-­‐treated	   cells	   are	  
lysed.	  2.	  Crosslinked	  chromatin	  is	  sheared	  by	  sonication	  to	  generate	  200-­‐1000	  bp	  fragments.	  3.	  Target	  
protein-­‐bound	   DNA	   fragments	   are	   immunoprecipitated	   using	   a	   protein-­‐specific	   antibody.	   4-­‐5.	  
Immunoprecipitated	  DNA	  is	  eluted	  and	  purified	  for	  subsequent	  PCR	  and/or	  sequencing	  analysis.	  B-­‐D.	  
Sequencing	  workflow	  for	  ChIP	  purified	  DNA	  fragments.	  B.	   Library	  generation.	  5’	  and	  3’	  adaptors	  are	  
ligated	   to	   DNA	   fragments.	   A	   ChIP	   DNA	   library	   is	   synthesized	   by	   PCR	   amplification	   using	   adaptor-­‐
specific	  primers,	   incorporating	   terminal	   SP6	  and	  T7	  promoter	   sequences	  and	  a	  unique	  barcode	   (BC)	  
sequence	  for	  multiplexing.	  (Continued	  overleaf.)	  
A	  
B	  
CHAPTER	  5	  Olig2	  S147	  phosphorylation	  &	  gene	  target	  choice	  	   	  
	   133	  
	  





























































































































































































































































)	   	  C	  
CHAPTER	  5	  Olig2	  S147	  phosphorylation	  &	  gene	  target	  choice	  	   	  
	   134	  
	  































































































































































































































	   	  D	  
CHAPTER	  5	  Olig2	  S147	  phosphorylation	  &	  gene	  target	  choice	  	   	  
	   135	  
Olig2	  expression	  in	  Olig2-­‐WT	  and	  Olig2-­‐S147A	  mutant	  NSC	  cultures	  was	  further	  examined	  at	  
the	  RNA	  level	  by	  quantitative	  reverse	  transcription-­‐PCR	  (qRT-­‐PCR)	  and	  at	  the	  protein	  level	  by	  
whole-­‐lysate	   SDS-­‐PAGE	  and	  western	  blot	   (WB)	  analysis	   (Figure	  3A-­‐B).	   	  Quantitative	  RT-­‐PCR	  
revealed	  that	  the	  abundance	  of	  Olig2	  mRNA	  –	  relative	  to	  housekeeping	  gene	  GAPDH	  mRNA	  –	  
in	  Olig2-­‐WT	  and	  Olig2-­‐S147A	  NSCs	   is	  comparable.	  SDS-­‐PAGE	  and	  WB	  analysis	  using	  a	  rabbit	  
anti-­‐Olig2	   antibody	   showed	   similar	   levels	   of	   expression	   of	  WT	   and	  mutant	  Olig2	   protein	   –	  
relative	   to	   the	   loading	   control	   B-­‐Tubulin-­‐E7	   –	   in	   the	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   cultures.	  
Together	  the	  results	  confirmed	  that	  WT	  Olig2-­‐expressing,	  phospho-­‐null	  mutant	  Olig2-­‐S147A-­‐
expressing	  and	  Olig2-­‐null	  NSC	  cultures	  were	  suitable	  for	  Olig2	  ChIP.	  
	  
It	  was	  clearly	  important	  to	  establish	  that	  Olig2	  was	  phosphorylated	  at	  S147	  in	  Olig2-­‐WT	  NSC	  
cultures.	   In	   order	   to	   observe	   phosphorylation	   of	   WT	   Olig2	   at	   S147	   I	   immunoprecipitated	  
Olig2	   from	   the	   total	   lysates	   of	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   cultures,	   and	   visualized	   the	  
immunoprecipitates	  by	  PAGE	  and	  WB	  using	  both	  a	  rabbit	  anti-­‐Olig2	  antibody	  and	  a	  custom-­‐
made	   rabbit	   antibody	   that	   specifically	   recognizes	   the	   S147-­‐phosphorylated	   form	   of	   Olig2	  
(anti-­‐ph-­‐S147	   Olig2).	   Quantitative	   ELISA	   analysis,	   first	   published	   by	   Li	   et	   al.	   (2011),	  
demonstrated	  the	  specificity	  of	  the	  anti-­‐ph-­‐S147	  Olig2	  antibody	  for	  Olig2	  phosphorylated	  at	  
S147	   (Figure	   3C).	   Olig2	   was	   clearly	   visible	   in	   both	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   NSC	  
immunoprecipitates	  (Figure	  3D).	  WT	  Olig2	  was	  observed	  as	  two	  distinct	  bands,	  a	  major	  upper	  
band	   and	   a	   weaker	   lower	   band.	   The	   major	   band	   overlapped	   precisely	   with	   the	   phospho-­‐
S147-­‐Olig2	   signal	   observed	   with	   the	   anti-­‐ph-­‐S147	   Olig2	   antibody,	   and	   migrated	   with	   an	  
apparently	   higher	   molecular	   weight	   compared	   to	   the	   single	   Olig2-­‐S147A	   band,	   consistent	  
with	   the	  presence	  of	  a	  negatively	  charged	  phosphate	  group	  on	  S147	   (Winkler	  et	  al.,	  1993).	  
The	   lower	  WT	  band	  aligned	  with	  Olig2-­‐S147A,	   indicating	   that	   it	   comprises	  dephospho-­‐S147	  
Olig2	  and	  suggesting	  that	  dephosphorylated	  Olig2	  was	  present	  at	  low	  levels	  in	  Olig2-­‐WT	  NSC	  
cultures.	  Overall,	   the	  data	   indicated	   that	  WT	  Olig2	  was	   typically	  phosphorylated	  at	  S147	   in	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Olig2-­‐WT	  NSCs,	   and	   that	   ChIP	   from	  Olig2-­‐WT	   and	  Olig2-­‐S147A	  mutant	  NSC	   cultures	  would	  
therefore	   provide	   suitable	  material	   for	   comparison	   of	   the	   gene	   targets	   of	   phosphorylated	  
and	  dephosphorylated	  Olig2.	  
	  
Figure	   2.	   Primary	   adherent	   embryonic	   NSC	   cultures.	   A.	   NSCs	   were	   derived	  
from	  the	  dissociated	  cortices	  of	  E13.5	  mice	  and	  cultured	  in	  medium	  containing	  
EGF,	   FGF-­‐2	   and	   Laminin.	   B.	   Immunostaining	   of	   Olig2-­‐WT,	   Olig2-­‐S147A	   and	  
Olig2-­‐null	  NSC	  cultures	  using	  antibodies	  labeling	  Olig2,	  Nestin,	  Tuj1	  and	  GFAP.	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Figure	  3.	  Olig2	  expression	  and	  S147	  phosphorylation	  in	  NSC	  cultures.	  A.	  Quantitative	  RT-­‐PCR	  
analysis	  of	  Olig2	  mRNA	  expression	  in	  Olig2-­‐WT	  and	  Olig2-­‐S147A	  NSC	  cultures.	  B.	  Western	  blot	  
analysis	  of	  Olig2	  protein	  abundance	  in	  Olig2-­‐WT,	  Olig2-­‐S147A	  and	  Olig2-­‐null	  NSC	  culture	  total	  
lysates	   using	   anti-­‐Olig2	   and	   anti-­‐B-­‐Tubulin	   E7	   antibodies.	   C.	  Quantitative	   ELISA	   analysis	   of	  
phosphorylated	  and	  dephosphorylated	  Olig2	   S147	  peptide	   recognition	  by	   the	   custom-­‐made	  
anti-­‐ph-­‐S147-­‐Olig2	  antibody	  (Li	  et	  al.,	  2011).	  D.	  Olig2	  immunoprecipitation	  from	  Olig2-­‐WT	  and	  
Olig2-­‐S147A	  NSC	  cultures	  and	  WB	  analysis	  using	  anti-­‐ph-­‐S147-­‐Olig2	  and	  anti-­‐Olig2	  antibodies.	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Sonication	  and	  preliminary	  ChIP	  analysis	  
	  
Chromatin	   IP	   extraction	   of	   specific	   protein-­‐bound	   DNA	   fragments	   initially	   requires	  
formaldehyde-­‐mediated	  DNA-­‐protein	  crosslinking	  and	  the	  sonication	  of	  crosslinked	  genomic	  
DNA	  into	  200-­‐1000	  bp	  fragments	  (Figure	  1A).	  The	  sonication	  conditions	  required	  to	  generate	  
ChIP-­‐suitable	   samples	   vary	   depending	   on	   the	   cell	   type	   and	   the	   formaldehyde	   crosslinking	  
conditions.	  Under-­‐sonication	  will	  compromise	  specificity	  and	  effective	  immunoprecipitation,	  
while	   over-­‐sonication	   can	   lead	   to	   protein	   denaturation	   and	   degradation.	   To	   establish	   the	  
optimum	  parameters,	  I	  sonicated	  formaldehyde-­‐treated	  Olig2-­‐WT	  cells	  over	  10,	  20,	  30,	  40	  or	  
50	   sonication	   cycles	   and	   analysed	   the	   degree	   of	   genomic	   fragmentation	   by	   de-­‐crosslinking	  
and	   agarose	   gel	   electrophoresis	   (Figure	   5A).	   In	   the	   absence	   of	   sonication,	   crosslinked	  
genomic	  DNA	  displayed	  negligible	   gel	  mobility	   (data	  not	   shown).	   Sonication	  over	   10	   cycles	  
primarily	   produced	   fragments	   in	   the	   200-­‐600	   bp	   range,	   with	   additional	   cycles	   generating	  
shorter	  fragments	  tending	  to	  an	  observed	  lower	  limit	  of	  100-­‐200	  bp.	  The	  predicted	  minimum	  
fragment	  size	  is	  147	  bp,	  the	  length	  of	  one	  nucleosome	  DNA	  wrap.	  These	  results	   indicated	  a	  
10-­‐cycle	  sonication	  strategy	  is	  suitable	  for	  ChIP	  from	  NSCs.	  
	  
I	   performed	  preliminary	  Olig2	  ChIP	   followed	  by	  quantitative	  PCR	   (ChIP-­‐qPCR)	  analysis	   from	  
Olig2-­‐WT,	  Olig2-­‐S147A	  and	  Olig2-­‐null	  NSC	  cultures	   (Figure	  4A).	  Recovery	  of	  candidate	  Olig2	  
target	  DNA	  sequences	  was	  quantified	  as	  a	  percentage	  of	  input	  material	  by	  qPCR	  using	  target-­‐
specific	  primer	  pairs.	  Olig2	  occupancy	  was	  determined	  by	  enrichment	  versus	   the	  Olig2-­‐null	  
negative	  control.	  Enrichment	  of	  a	  known	  Olig2	  E-­‐box	   target	  site	  –	  within	   the	  conserved	  U2	  
enhancer	   in	   the	   distal	   5’	   flank	   of	   the	   OL	   lineage	   gene	   Sox10	   –	   from	   the	   Olig2-­‐WT	   ChIP	  
confirmed	  phospho-­‐S147	  Olig2	  binding	  at	   the	  Sox10	   regulatory	   sequence	  and	  validated	  my	  
ChIP	  protocol	  (Kuspert	  et	  al.,	  2011).	  In	  addition,	  I	  analysed	  Olig2	  occupancy	  of	  E-­‐box	  sites	  in	  
the	  PDGFRA,	  Olig1	   and	  Hb9	   genes	   (Figure	  4A)	   (Lee	  et	   al.,	   2005).	   The	   results	  demonstrated	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Olig2-­‐WT	  occupancy	  at	  the	  PDGFRA	  and	  Olig1	  binding	  sites,	  but	  not	  at	  the	  Hb9	  gene,	  which	  
showed	  no	   significant	  enrichment	   relative	   to	   the	  Olig2-­‐null	   control.	   The	  PDGFRA	   and	  Olig1	  
gene	  E-­‐boxes	  were	  therefore	   identified	  as	  novel	  and	  bona-­‐fide	  phospho-­‐S147	  Olig2	  binding	  
sites.	   	   In	  contrast	   to	   the	  phospho-­‐S147	  Olig2-­‐WT,	  Olig2-­‐S147A	  ChIP-­‐qPCR	  revealed	   that	   the	  
phospho-­‐null	  Olig2-­‐S147A	  mutant	  does	  not	   target	  any	  of	   the	  Sox10,	  PDGFRA,	  Olig1	   or	  Hb9	  
regulatory	   regions	   examined,	   suggesting	   that	   the	   Sox10,	   PDGFRA	   and	  Olig1	   (all	   known	  OL	  
lineage	  genes)	  are	  phospho-­‐S147-­‐specific	  Olig2	  binding	  sites.	  
	  
To	  determine	  whether	  occupancy	  of	  Olig2	  at	   the	  Sox10,	  PDGFRA	   and	  Olig1	   binding	   sites	   is	  
associated	  with	  altered	  gene	  expression,	  I	  analysed	  target	  gene	  transcription	  by	  quantitative	  
RT-­‐PCR	   from	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   phospho-­‐null	   total	   RNA	   extracts.	   Relative	   to	  
housekeeping	  gene	  GAPDH,	  Sox10,	  PDGFRA	   and	  Olig1	  mRNA	   levels	  were	   insignificant	   (≤5%	  
GAPDH	  mRNA	   abundance)	   in	   both	  Olig2-­‐WT	   and	  Olig2-­‐S147A	  mutant	  NSC	   cultures	   (Figure	  
4B).	   These	   observations	  were	   supported	   by	   the	   results	   of	   immunolabeling	   for	  Olig2	   target	  
gene	  protein	  expression.	  Sox10,	  PDGFRA	  or	  Olig1	  proteins	  were	  not	  detected	  in	  either	  Olig2-­‐
WT	  or	  Olig2-­‐S147A	  NSCs,	   indicating	   that	  changes	   in	  Olig2	  binding	  at	   these	  OL	   lineage	  gene	  
targets	  is	  not	  sufficient	  to	  activate	  transcription	  (Figure	  4C).	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Figure	   4.	   Preliminary	   Olig2	   ChIP	   qPCR	   analysis.	   A.	   ChIP	   qPCR	   analysis	   of	   Olig2	  
occupancy	  at	  putative	  binding	  sites.	  Olig2	  occupancy	  of	  specific	  putative	  binding	  sites	  
in	  the	  Sox10,	  PDGFRA,	  Olig1	  and	  Hb9	  genes	  was	  determined	  by	  fragment	  enrichment	  
in	   Olig2-­‐WT/-­‐S147A	   ChIP	   samples	   relative	   to	   the	   Olig2-­‐null	   control.	   Fragment	  
enrichment	  was	  quantified	  by	  qPCR	  using	  putative	  binding	  site-­‐specific	  primer	  pairs.	  B.	  
Olig2	   and	   Olig2	   target	   gene	   expression	   in	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   NSC	   cultures	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Figure	  4	  cont’d.	  C.	  Olig2	  target	  gene	  expression	  in	  Olig2-­‐WT	  and	  Olig2-­‐
S147A	   NSC	   cultures	   analysed	   at	   the	   protein	   level	   by	   immunostaining	  
with	  target-­‐specific	  antibodies.	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ChIP	  optimization	  
	  
In	  order	  to	  identify	  the	  full	  repertoire	  of	  phospho-­‐S147	  Olig2	  and	  Olig2-­‐S147A	  gene	  targets,	  I	  
planned	  to	  submit	  Olig2	  ChIP	  DNA	  samples	  purified	  from	  Olig2-­‐WT,	  Olig2-­‐S147A	  mutant	  and	  
Olig2-­‐null	   cultures	   for	   high-­‐throughput	   Illumina	   sequencing	   (Figure	   1).	   Illumina	   sequencing	  
requires	  library	  preparation	  from	  25	  ng	  of	  purified	  ChIP	  DNA	  at	  a	  minimum	  concentration	  of	  
1	   ng/µl	   (Source	   Bioscience,	   pers	   comm).	   The	   preliminary	   ChIP	   extractions	   did	   not	   recover	  
sufficient	  DNA	   for	   library	  preparation	   (data	  not	   shown).	   To	  optimize	   the	  protocol	   for	  Olig2	  
immunoprecipitation	  (IP)	  –	  a	  key	  stage	  in	  the	  Olig2	  ChIP	  protocol	  –	  I	  conducted	  parallel	  Olig2	  
IPs	   from	  cultured	  Olig2-­‐expressing	  P19	  cells	  with	  varying	  concentrations	  of	   two	  rabbit	  anti-­‐
Olig2	  antibodies	  and	  protein	  A-­‐conjugated	  agarose	  beads	   (Figure	  5C).	   In	   these	  optimization	  
experiments,	  an	  increase	  in	  the	  recovery	  of	  Olig2	  protein	  –	  assessed	  by	  WB	  with	  a	  goat	  anti-­‐
Olig2	  antibody	  –	  demonstrates	  an	  improvement	  in	  the	  Olig2	  IP;	  a	  direct	  measure	  of	  ChIP	  DNA	  
purification	  by	  parallel	  ChIP-­‐qPCR	  from	  Olig2-­‐expressing	  P19	  cells	  was	  not	  obtained.	  The	  anti-­‐
Olig2	   antibodies	   used	  were:	   1.	   a	   commercially	   available	  Millipore	  polyclonal	   antibody;	   2.	   a	  
custom-­‐made	   polyclonal	   antibody	   developed	   and	   generously	   provided	   by	   Charles	   D.	   Stiles	  
(Ligon	   et	   al.,	   2004).	   The	   use	   of	   multiple	   primary	   antibodies	   in	   tandem	   is	   an	   uncommon	  
strategy	   for	   improving	   the	   IP	   recovery	   of	   a	   target	   protein.	   In	   this	   case,	   however,	   the	  
published	  Millipore	   and	   Stiles	   anti-­‐Olig2	   antibodies	   were	   raised	   against	   different	   epitopes	  
within	  Olig2	  and	  might,	  I	  reasoned,	  synergistically	  improve	  the	  recovery	  of	  Olig2.	  It	  should	  be	  
noted	  that	  in	  the	  absence	  of	  parallel	  IPs	  performed	  using	  the	  Olig2	  antibodies	  individually	  as	  
well	  as	  in	  combination,	  the	  effectiveness	  of	  this	  strategy	  remains	  to	  be	  validated.	  
	  
The	   comparable	   recovery	   of	   Olig2	   from	   IPs	   1,	   3	   and	   6	   (Figure	   5C)	   –	   in	   which	   antibody	  
concentration	   remained	   unchanged	   but	   protein	   A	   bead	   concentration	   was	   altered	   –	  
indicated	   that	   increasing	   the	   concentration	   of	   protein	  A-­‐conjugated	   agarose	   beads	   did	   not	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substantially	  affect	  the	  recovery	  of	  Olig2	  protein.	  In	  contrast,	  however,	  comparison	  of	  IPs	  3,	  4	  
and	  5	  (Figure	  5C)	  –	  increasing	  antibody	  concentration	  with	  constant	  bead	  volume	  –	  indicated	  
that	  Olig2	  extraction	  improved	  significantly	  with	  increasing	  antibody	  concentration.	  The	  WB	  
indicated	  that	  maximal	  recovery	  of	  Olig2	  was	  achieved	  using	  10	  µg/ml	  Millipore	  plus	  1	  µl/ml	  
Stiles	  anti-­‐Olig2	  antibodies	  and	  50	  µl/ml	  protein-­‐A	  beads.	   It	   should	  be	  noted	   that	  although	  
further	   improvements	   in	  Olig2	  recovery	  might	  have	  been	  possible	  with	  additional	   increases	  
in	  antibody	  concentration,	  considerations	  of	  cost	  and	  reagent	  supply	  made	  this	  impractical.	  
	  
In	   addition	   to	   the	   optimization	   described	   above,	   I	   analysed	   the	   effect	   on	  
immunoprecipitation	  of	  Olig2	  of	  two	  alternative	  incubation	  protocols.	  Protocol	  1	  (Figure	  5C,	  
IP	  2)	  included	  3	  hours	  of	  antibody-­‐only	  incubation	  followed	  by	  overnight	  antibody-­‐plus-­‐bead	  
incubation.	   In	  Protocol	  2	  (Figure	  5C,	   IP	  3),	  overnight	  antibody-­‐only	   incubation	  was	  followed	  
by	   3	   hours	   of	   antibody-­‐plus-­‐bead	   incubation.	   The	   modest	   difference	   in	   Olig2	   recovery	  
between	  the	  different	  protocols	  suggested	  Protocol	  1	  was	  more	  effective.	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Figure	  5.	  Olig2	  ChIP	  optimization.	  A.	  Optimizing	  sonication.	  Crosslinked	  Olig2-­‐WT	  NSC	  culture	  
lysate	   was	   sonicated	   over	   10,	   20,	   30,	   40	   or	   50	   rounds	   (30	   s	   on,	   30	   s	   off)	   and	   chromatin	  
fragmentation	   assessed	   by	   agarose	   gel	   electrophoresis.	   B.	   Optimizing	   pre-­‐IP	   clearing.	   WB	  
analysis	  of	  Olig2	  protein	   level	   in	  Olig2-­‐expressing	  P19	  cell	   lysate	  before	   (Pre)	  and	  after	   (Post)	  
clearing	   with	   protein-­‐A-­‐conjugated	   agarose	   beads.	   C.	   IP	   optimization.	   WB	   analysis	   of	   Olig2	  
protein	   recovery	   after	  Olig2	   IP	   from	  P19	   cells	   under	   a	   range	  of	   conditions,	   including	   variable	  
antibody	  and	  protein-­‐A	  bead	  concentrations.	  Protocol	  1:	  3	  hr	  antibody-­‐only	  incubation	  followed	  
by	   overnight	   antibody-­‐plus-­‐bead	   incubation.	   Protocol	   2:	   overnight	   antibody-­‐only	   incubation	  
followed	   by	   3	   hr	   antibody-­‐plus-­‐bead	   incubation.	   (For	   more	   details	   regarding	   the	   different	  
protocols,	  please	  see	  Materials	  &	  methods.)	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The	   preliminary	   ChIP	   protocol	   included	   a	   preparatory	   ‘clearing’	   step	   for	   removal	   of	   non-­‐
specific	  bead-­‐binding	  proteins	  from	  the	  input	  lysate.	  There	  remained	  a	  possibility,	  however,	  
that	  non-­‐specific	  pull-­‐down	  of	  Olig2	  during	  the	  clearing	  phase	  might	  deplete	  the	  input	  level	  
of	  Olig2	  and	  result	  in	  diminished	  recovery	  of	  Olig2-­‐bound	  DNA	  fragments.	  Finally,	  I	  examined	  
the	   impact	  of	   clearing	  with	  protein	  A-­‐conjugated	  agarose	  beads	  on	   the	   input	   level	  of	  Olig2	  
(Figure	   5B).	   Crucially,	   I	   did	   not	   observe	   Olig2	   in	   the	   protein	   eluate	   of	   the	   clearing	   beads	  
(Figure	  5B,	  Beads)	  and	  I	  observed	  similar	   levels	  of	  Olig2	  in	  the	  input	  lysate	  before	  and	  after	  
clearing	   (Figure	   5B,	   Pre/Post).	   This	   indicated	   that	   Olig2	   did	   not	   bind	   protein	   A-­‐conjugated	  
agarose	  beads	  and	  clearing	  had	  no	  discernible	   impact	  on	   input	   levels	  of	  Olig2.	  The	  clearing	  




Under	   the	   optimized	   sonication	   and	   ChIP	   conditions,	   Olig2-­‐bound	   DNA	   fragments	   were	  
purified	  from	  three	  Olig2-­‐WT	  NSC	  cultures,	  two	  Olig2-­‐S147A	  NSC	  cultures	  and	  a	  single	  Olig2-­‐
null	  NSC	  culture	  (Figure	  6A).	  The	  sample	  concentration	  of	  ChIP-­‐purified	  DNA	  was	  quantified	  
using	  the	  high	  sensitivity	  Qubit	  Assay	  (Figure	  6B).	  For	  all	  six	  samples,	  quantification	  indicated	  
that	   sufficient	  DNA	  had	  been	   isolated	   for	   library	   construction.	   The	   six	  ChIP	  DNA	   samples	   –	  
three	   Olig2-­‐WT,	   two	   phospho-­‐null	   and	   one	   Olig2-­‐null	   –	   along	  with	   a	   single	   pre-­‐ChIP	   input	  
sample	   (from	  wild-­‐type	  NSCs)	  were	   submitted	   to	   Source	   Bioscience	   for	   library	   preparation	  
and	  multiplexed	  single-­‐end	  Illumina	  HiSeq	  sequencing.	  
	  
At	   Source	   Bioscience,	   ChIP	   DNA	   libraries	   were	   prepared	   using	   the	   standard	   protocol:	   end	  
repair	  and	  adaptor	  ligation	  followed	  by	  PCR	  amplification.	  Library	  construction	  was	  validated	  
using	   an	   Agilent	   Bioanalyzer.	   	   Agilent	   Bioanalyzer	   analysis	   (Figure	   6C)	   indicated	   successful	  
library	  generation	  with	  an	  average	  fragment	  length	  of	  622	  bp.	  The	  libraries	  were	  pooled	  and	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sequenced	   in	  a	  100	  bp	  Single	  End	   Illumina	  HiSeq	  run.	  Sequencing	  generated	  approximately	  
20	  million	  reads	  for	  each	  of	  the	  ChIP	  DNA	  samples	  and	  30	  million	  reads	  for	  the	  WT	  input	  DNA	  
sample.	   The	   raw	   sequencing	   data	  were	   analyzed	   at	   Source	   Bioscience.	   The	   Olig2-­‐WT	   ChIP	  
sequencing	  data	  were	  analysed	  in	  silico	  as	  a	  biological	  triplicate	  and	  the	  phospho-­‐null	  Olig2-­‐
S147A	   ChIP	   samples	   as	   a	   biological	   duplicate.	   The	   bioinformatics	   analysis	   included:	   read	  
mapping	  to	  the	  mouse	  reference	  genome	  (Mm10),	  peak	  calling	  and	  annotation,	  differential	  
peak	   detection	   for	   Olig2-­‐WT	   versus	   Olig2-­‐S147A	   sequence	   enrichment,	   peak	   sequence	  
extraction	   and	  motif	   discovery,	   and	   gene	  ontology.	   For	   stringency,	   both	   the	  WT	   Input	   and	  
Olig2-­‐null	  ChIP	  sequencing	   results	  were	  used	   for	  background	  subtraction.	  As	  an	  example,	  a	  
visualization	  of	  the	  ChIP-­‐seq	  data	  mapping	  to	  the	  Olig1	  gene	  locus	  is	  shown	  in	  Figure	  7A.	  The	  
pile-­‐up	   of	   Olig2-­‐WT	   ChIP	   sequence	   reads	   mapping	   to	   ~3	   kb	   upstream	   of	   the	   Olig1	   open	  
reading	   frame	   (ORF),	   which	   was	   absent	   in	   both	   the	   Olig2-­‐S147A	   and	   Olig2-­‐null	   samples,	  
identified	  a	  unique	  Olig2-­‐WT	  binding	  site	  close	  to	  the	  Olig1	  gene	  locus.	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Figure	  6.	  Olig2	  ChIP	  and	  library	  construction.	  A.	  Chromatin	  sonication.	  The	  cross-­‐linked	  lysate	  of	  three	  
Olig2-­‐WT,	  two	  Olig2-­‐S147A	  and	  a	  single	  Olig2-­‐null	  NSC	  cultures	  underwent	  sonication	  to	  yield	  200-­‐600	  
bp	  fragments.	  B.	  ChIP	  sample	  concentration.	  DNA	  concentration	  in	  the	  six	  purified	  ChIP	  samples	  and	  a	  
single	   input	   sample	   was	   quantified	   for	   Library	   preparation	   using	   a	   high	   sensitivity	   Qubit	   assay.	   C.	  
Agilent	   Bioanalyzer	   plots	   of	   the	   seven	  DNA	   libraries	   generated	   (see	   Figure	   1)	   from	   the	   six	   ChIP	   and	  
single	  input	  DNA	  samples.	  
	  
Bioinformatic	  analysis	  of	  the	  ChIP-­‐seq	  data	  identified	  861	  discrete	  WT	  Olig2	  binding	  sites	  and	  
175	  mutant	  Olig2-­‐S147A	  binding	  sites	  (Figure	  7B).	  Of	  these	  binding	  sites,	  annotation	  mapped	  
560	   Olig2-­‐WT	   binding	   sites	   and	   34	   Olig2-­‐S147A	   binding	   sites	   to	   a	   nearby	   or	   overlapping	  
genetic	   feature.	   Interestingly,	   Olig2-­‐WT	   and	   phospho-­‐null	   Olig2-­‐S147A	   shared	   no	   common	  
binding	  sites,	  indicating	  phospho-­‐S147-­‐Olig2	  and	  Olig2-­‐S147A	  target	  completely	  independent	  
sets	  of	  gene	  targets.	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To	   understand	   the	   functional	   profile	   of	   the	   genes	   associated	   with	   the	   WT	   phospho-­‐S147	  
Olig2-­‐WT	   and	   Olig2-­‐S147A	   binding	   sites	   identified	   in	   the	   ChIP-­‐seq	   analysis,	   I	   requested	  
Source	  Bioscience	  perform	  gene	  ontology	  (GO)	  analysis	  (Figure	  7C).	  The	  GO	  project	  describes	  
genes	   in	   terms	   of	   the	   normal	   biological	   processes,	   cellular	   components	   and	   molecular	  
functions	  with	  which	  the	  gene	  products	  are	  associated.	  GO	  analysis	  therefore	   identifies	  the	  
GO	   terms	   (for	   example,	   ‘mitotic	   cell	   cycle’	   or	   ‘histone	   deacetylase	   complex’)	   over-­‐
represented	  in	  a	  gene	  set;	  over-­‐representation	  is	  determined	  based	  on	  the	  probability	  that	  a	  
GO	  term	  would	  be	  observed	  by	  chance	  given	  the	  size	  of	  the	  dataset	  (total	  number	  of	  genes)	  
and	  the	  frequency	  of	  the	  GO	  term	  within	  the	  genome.	  
	  
In	  the	  Olig2-­‐WT	  dataset,	  GO	  analysis	  displayed	  a	  statistically	  significant	  (p	  <	  0.05)	  enrichment	  
of	   genes	   involved	   in	   the	   following	  biological	   processes,	   cellular	   components	   and	  molecular	  
functions	  (shown	  along	  with	  the	  corresponding	  GO	  term	  identifier):	  
	  
Biological	  processes:	  	   1.	  Nervous	  system	  development	  (GO:0007399)	  
2.	  Activation	  of	  neurological	  system	  process	  (GO:0031646)	  
3.	  Activation	  of	  nerve	  impulse	  transmission	  (GO:0051971)	  
	  
Cellular	  components:	  	   1.	  Cell	  projection	  (GO:0042995)	  
2.	  Cell	  junction	  (GO:0030054)	  
	  
Molecular	  functions:	  	   1.	  Phospholipid	  binding	  (GO:0005543)	  
2.	  GTPase	  regulator	  activity	  (GO:0030695)	  
3.	  Nucleoside-­‐triphosphatase	  regulator	  activity	  (GO:0060589)	  
4.	  Neurotransmitter:sodium	  symporter	  activity	  (GO:0005328)	  
5.	  Lipid	  binding	  (GO:0008289)	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6.	  Solute:sodium	  symporter	  activity	  (GO:0015370)	  
7.	  Actin	  binding	  (GO:0003779)	  
8.	  Neurotransmitter	  transporter	  activity	  (GO:0005326)	  
9.	  Cytoskeletal	  protein	  binding	  (GO:0008092)	  
10.	  Organic	  acid:sodium	  symporter	  activity	  (GO:0005343)	  
11.	  Guanyl-­‐nucleotide	  exchange	  factor	  activity	  (GO:0005085)	  
	  
The	   enrichment	   of	   nervous	   system	   development	   genes	   is	   consistent	   with	   the	   established	  
functions	   of	   Olig2.	   More	   broadly,	   the	   biological	   processes	   and	   cellular	   components	  
highlighted	  in	  the	  GO	  analysis	  are	  prominent	  during	  the	  later	  stages	  of	  neural	  differentiation	  
and	  not	  in	  multipotent	  NSCs.	  
	  
In	  conjunction	  with	  the	  GO	  analysis,	  basic	  empirical	  analysis	  identified	  a	  number	  of	  known	  OL	  
lineage	  genes	  in	  the	  WT	  Olig2	  ChIP-­‐seq	  dataset,	  including	  Olig1.	  For	  the	  Olig1	  gene,	  two	  Olig2	  
binding	   sites	   were	   identified	   upstream	   of	   the	   open	   reading	   frame	   (ORF),	   the	   first	   at	   a	  
distance	  of	  ~3	  kb	  (Figure	  7A)	  and	  the	  second	  at	  ~7	  kb.	  Importantly,	  the	  more	  proximal	  Olig2	  
binding	   site	   identified	  by	  ChIP-­‐seq	  overlapped	  precisely	  with	   the	  binding	   site	   that	   I	   initially	  
identified	  by	  ChIP-­‐qPCR	  (see	  Sonication	  and	  preliminary	  ChIP	  analysis	  above).	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In	  contrast	  to	  the	  clear	  results	  of	  the	  GO	  analysis	  of	  phospho-­‐S147	  Olig2-­‐WT,	  GO	  analysis	  of	  
the	   ChIP-­‐seq	   data	   for	   Olig2-­‐S147A	   identified	   no	   statistically	   significant	   (p	   <	   0.05)	   over-­‐
representation	   of	   any	   GO	   term.	   This	   indicated	   that	   the	   Olig2-­‐S147A	   target	   genes	   are	   not	  
primarily	   associated	   with	   any	   specific	   biological	   process,	   cellular	   component	   or	   molecular	  
mechanism,	  and	  are	  in	  terms	  of	  functionality	  incoherent.	  In	  line	  with	  this,	  the	  GO	  terms	  that	  
were	   represented	   at	   the	   greatest	   confidence	   level	   were	   not	   consistent	   with	   the	   known	  
functions	   of	   Olig2	   in	   the	   CNS	   (data	   not	   shown).	   For	   example,	   the	   biological	   process	   and	  
cellular	   components	   represented	   at	   the	   highest	   statistical	   significance	   were	   embryonic	  
digestive	   tract	  morphogenesis	   (GO:0048557)	   (p	  ≈	  0.10)	  and	  mitochondrial	   respiratory	  chain	  
complex	  IV	  (GO:0005751)	  (p	  ≈	  0.22),	  respectively.	  
	  
From	  the	  raw	  Olig2-­‐WT	  ChIP-­‐seq	  data,	  a	  list	  of	  candidate	  motifs	  was	  obtained.	  Of	  these,	  two	  
were	  regarded	  as	  real	  binding	  motifs	  on	  the	  basis	  of	  the	  calculated	  p	  value	  and	  the	  Gaussian	  
distribution	  of	   the	  underlying	  peaks	   (Source	  Bioscience,	  pers	  comm)	   (Figure	  7D).	  Basic	  HLH	  
proteins	   –	   such	   as	   Olig2	   –	   typically	   bind	   to	   E-­‐box	   sequences,	   and	   the	  M1	   and	  M2	  motifs	  
identified	  followed	  the	  E-­‐box	  consensus	  CANNTG,	  where	  N	  can	  be	  any	  nucleotide.	   In	  direct	  
contrast	   to	   the	   clear	   and	   consistent	   gene	   target	   E-­‐box	  motifs	   revealed	   for	  Olig2-­‐WT,	  motif	  
analysis	  of	  the	  Olig2-­‐S147A	  ChIP-­‐seq	  data	  failed	  to	  identify	  any	  Olig2-­‐S147A	  target	  motifs	  and	  
appeared	  to	  be	  weighted	  towards	  repetitive	  or	  GC-­‐rich	  DNA	  sequences.	  
	  
In	   conclusion,	  ChIP-­‐seq	  analysis	  of	   the	  Olig2	  DNA	  binding	   sites	  purified	   from	  Olig2-­‐WT	  NSC	  
cultures	   indicated	   that	   Olig2	   phosphorylated	   at	   S147	   occupied	   regulatory	   E-­‐box	   elements	  
CAGCTG	   and	   CAGATG	   of	   genes	   strongly	   linked	   to	   central	   nervous	   system	   development,	  
structure	  and	   function.	  The	   limited	  number	  of	  Olig2-­‐S147A	  binding	  sites	   identified	  by	  ChIP-­‐
seq,	   combined	   with	   the	   absence	   of	   both	   meaningful	   gene	   ontology	   and	   motif	   analysis,	  
indicated	  that	  Olig2-­‐S147A	  –	  modeling	  Olig2	  dephosphorylated	  at	  S147	  –	  does	  not	  recognize	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specific	  sequence	  motifs	  of	  a	  target	  set	  of	  genes	  and	  probably	  does	  not	  bind	  DNA	  selectively	  
in	  NSCs.	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5.3	   DISCUSSION	  
	  
In	   the	  developing	   spinal	   cord,	   transcription	   factor	  Olig2	   is	   uniquely	   expressed	   in	  NSCs	   that	  
reside	   in	   a	   discrete	   region	   of	   the	   ventral	   ventricular	   zone,	   the	   pMN	   domain.	   Olig2+	   NSCs	  
divide	   and	   differentiate	   to	   produce	   MNs	   before	   switching	   to	   produce	   OLPs,	   and	   Olig2	   is	  
essential	  for	  both	  the	  neurogenic	  and	  oligodendrogenic	  phases.	  Research	  into	  precisely	  how	  
Olig2	   regulates	   the	   two	   very	   different	   developmental	   programmes	   has	   revealed	   that	  
reversible	   phosphorylation	   of	   a	   specific	   serine	   residue	   (S147)	   within	   Olig2	   is	   a	   critical	  
regulator	   of	   Olig2	   function	   and	   NSC	   fate	   (Li	   et	   al.,	   2011).	   S147	   is	   located	   within	   the	  
dimerization	   and	   DNA-­‐binding	   basic	   helix-­‐loop-­‐helix	   (bHLH)	   motif	   and	   is	   highly	   conserved	  
among	   vertebrates.	   During	   the	   early	   patterning	   and	  MN-­‐producing	   periods	   of	   spinal	   cord	  
development,	  Olig2	  S147	  is	  phosphorylated.	  Olig2	  S147	  is	  dephosphorylated	  over	  the	  period	  
of	  the	  MN-­‐OLP	  fate	  switch	  and	  analysis	  in	  cultured	  P19	  cells	  and	  in	  mouse	  and	  chick	  embryos	  
indicates	   that	   S147	   dephosphorylation	   acts	   as	   an	   instructive	   signal,	   inducing	   NSCs	   to	   stop	  
becoming	  MNs	  and	  instead	  generate	  OLPs	  (Li	  et	  al.,	  2011).	  	  
	  
S147	  dephosphorylation	  alters	  the	  protein	  binding	  properties	  of	  Olig2.	  Phosphorylated	  Olig2	  
preferentially	   forms	   homodimers,	   while	   dephosphorylated	   Olig2	   –	   modelled	   using	   the	  
phospho-­‐null	  mutant	  Olig2-­‐S147A	  –	  heterodimerizes	  with	  other	  cofactors	  such	  as	  Ngn2.	  Olig2	  
S147	  dephosphorylation	  is	  proposed	  to	  mediate	  the	  fate	  switch	  through	  dynamic	  changes	  in	  
Olig2	   cofactor	   choice	   (Li	   et	   al.,	   2011).	   In	   concert	   with	   the	   specific	   protein-­‐protein	  
interactions,	  basic	  HLH	  transcription	  factors	  directly	  regulate	  the	  expression	  of	  target	  genes	  
via	  occupancy	  of	  discrete	  genomic	  binding	  sites.	  Olig2	  has	  been	  shown	  to	  bind	  to	  a	  number	  
of	   target	   genes	   and	   to	   regulate	   target	   gene	   expression	   (Kuspert	   et	   al.,	   2011;	  Weng	   et	   al.,	  
2012;	  Yu	  et	  al.,	  2013;	  Mateo	  et	  al.,	  2015).	  The	  effect	  of	  S147	  phosphorylation	  on	  Olig2	  gene	  
target	  selection,	  however,	  remains	  to	  be	  established.	  In	  this	  chapter,	  I	  have	  explored	  the	  DNA	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binding	   activity	   of	   Olig2-­‐WT	   phosphorylated	   at	   S147	   and	   the	   Olig2-­‐S147A	   phospho-­‐null	  
mutant	   form	  of	  Olig2.	  Understanding	   the	   role	  of	  Olig2	  gene	   target	   choice	   in	   regulating	   the	  
MN-­‐OLP	   fate	   switch	   will	   provide	   important	   insights	   into	   the	   molecular	   mechanisms	  
underpinning	  NSC	  specification	  in	  the	  pMN	  domain	  and	  possibly	  cell	  fate	  specification	  more	  
broadly.	  
	  
The	  primary	  NSC	  strategy	  
	  
My	  experimental	   strategy	   involved	  derivation	  of	   primary	   adherent	  NSC	   cultures	   expressing	  
either	   endogenous	   wild-­‐type	   Olig2	   or	   the	   transgenic	   Olig2-­‐S147A	   mutant	   isoform.	   I	  
confirmed	   that	   Olig2-­‐WT	   was	   phosphorylated	   at	   S147	   and	   analysed	   Olig2-­‐WT	   and	   Olig2-­‐
S147A	   gene	   target	   association	   by	   ChIP	   and	   quantitative	   PCR/high	   throughput	   Illumina	  
sequencing.	  Here,	  I	  discuss	  the	  reasoning	  behind	  my	  approach.	  	  
	  
In	  order	  to	  obtain	  sufficient	  material	  from	  the	  Olig2	  ChIP	  for	  Illumina	  sequencing	  analysis,	  an	  
expandable	   in	  vitro	  platform	  was	  necessary.	   In	  theory,	  Olig2	  ChIP	  could	  be	  performed	  from	  
the	   dissected	   and	   dissociated	   spinal	   cords	   of	   wild-­‐type	   E11.5	   (pre-­‐fate	   switch)	   and	   E13.5	  
(post-­‐fate	  switch)	  mice.	  This	  method	  should	  identify	  the	  Olig2	  targets	  in	  bona	  fide	  pMN	  NSCs	  
during	   neurogenesis	   and	   oligodendrogenesis.	   Realistically,	   however,	   the	   time	   and	   effort	  
necessary	   to	   collect	   sufficient	   numbers	   of	   embryonic	   spinal	   cords	   renders	   this	   approach	  
unworkable.	   In	  addition,	   the	  presence	  of	  Olig2-­‐expressing	  OLPs	   in	   the	  spinal	  cords	  of	  E13.5	  
mice	  would	  confound	  the	  identification	  of	  Olig2	  gene	  targets	  specifically	  in	  NSCs.	  In	  contrast,	  
forced	  expression	  of	  Olig2	  by	  transient	  transfection	  of	  a	  stable	  cell	  line	  would	  enable	  simple	  
ChIP	   purification	   of	   sufficient	   quantities	   of	   genetic	   material	   for	   sequencing	   analysis.	   The	  
biological	   relevance	  of	   this	   approach,	   however,	  would	   need	   to	   be	  questioned.	   The	  protein	  
milieu	   and	   chromatin	   landscape	  will	   vary	   substantially	   between	  pMN	  NSCs	   in	   vivo	   and	   the	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cells	   of	   a	   stable	   cell	   line	   and	   might	   affect	   occupancy	   of	   genomic	   binding	   sites.	   The	  
methodology,	   therefore,	   required	   a	   trade-­‐off	   between	   the	   experimental	   viability	   and	   the	  
fidelity	  to	  the	  in	  vivo	  situation.	  On	  that	  basis,	  I	  decided	  to	  use	  primary	  NSCs	  derived	  from	  the	  
cortices	  of	  embryonic	  mice	  and	  expanded	   in	   vitro,	  as	  previously	  described	  by	  Pollard	  et	  al.	  
(2006).	  These	  cells	  express	  Olig2	  naturally,	  retain	  neuronal	  and	  glial	  differentiation	  potential	  
and	  are	  widely	  regarded	  as	  a	  reliable	  model	  of	  endogenous	  NSCs	  (Conti	  et	  al.,	  2005;	  Pollard	  
et	  al.,	  2006;	  Glaser	  et	  al.,	  2007).	  The	  cortical	  source	  of	  these	  primary	  NSC	  cultures	  is	  clearly	  
distinct	   to	   the	   ventral	   ventricular	   zone	   of	   the	   embryonic	   spinal	   cord,	   the	   in	   vivo	   region	   of	  
interest.	  The	  fidelity	  of	  the	  cortical	  NSC	  culture	  strategy	  to	  model	  pre	  and	  post	  MN-­‐OLP	  fate	  
switch	   NSCs	   of	   the	   spinal	   pMN	   domain	   might	   also	   therefore	   be	   called	   into	   question.	   In	  
defense	  of	  my	  approach,	  I	  would	  contest	  that	  the	  ex	  vivo	  culture	  systems	  often	  necessary	  for	  
high-­‐throughput	   sequencing	   analysis	   will	   invariably	   alter	   cell	   character.	   In	   this	   case,	   the	  
cortical	  culture	  system	  generates	  uniform	  populations	  of	  multipotent	  Olig2-­‐expressing	  NSCs,	  
with	   medium	   supplements	   FGF2	   and	   EGF	   acting	   as	   potent	   mitogens	   to	   promote	   NSC	  
proliferation,	   as	  well	   as	   inducing	   a	   ventral	  molecular	   phenotype	   and	   blocking	   neuronal/OL	  
lineage	  commitments,	   respectively	   (Guillemot,	  2007;	  Bithell	  et	  al.,	  2008).	  Overall,	  given	  the	  
inevitable	   limitations	  of	   in	   vitro	   cell	   culture	   systems	   for	  modeling	   in	   vivo	  development,	  my	  
Olig2+	  primary	  NSC	  cultures	  balance	  the	  methodological	  requirements	  for	  expandability	  and	  
tractability	  with	  a	  useful	  degree	  of	  biological	  relevance.	  
	  
I	  performed	  Olig2	  ChIP	  from	  parallel	  cultures	  of	  NSCs	  derived	  from	  embryonic	  mice	  carrying	  
either	   the	   Olig2-­‐WT	  or	   the	   Olig2-­‐S147A	   gene.	   An	   alternative	   strategy	   using	   the	   same	   NSC	  
cultures	  would	  be	  to	  compare	  wild-­‐type	  NSCs	  that	  have	  either	  been	  maintained	  as	  stem	  cells	  
or	  differentiated	   into	  OLPs.	  This	  would	  be	  an	  excellent	  strategy	  for	  analysing	  the	  activity	  of	  
Olig2	   in	  NSCs	   and	  OLPs.	  However,	   I	   set	   out	   to	   address	   a	   different	   question:	   how	  does	   the	  
activity	  of	  phosphorylated	  versus	  dephosporylated	  Olig2	  in	  NSCs	  regulate	  commitment	  to	  the	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neuronal	   versus	   glial	   lineages?	   Chromatin	   IP	   of	   phosphorylated	   wild-­‐type	   Olig2	   and	   the	  
phospho-­‐null	   mutant	   Olig2-­‐S147A	   from	   NSCs	   under	   uniform	   conditions	   would,	   therefore,	  
enable	   the	   effect	   of	   S147	   phosphorylation	   on	   Olig2	   gene	   target	   choice	   to	   be	   analysed	   in	  




NSC	  cultures	  were	  derived	  from	  the	  dissociated	  cortices	  of	  E13.5	  mice	  and	  characterized	  by	  
immunolabeling	   for	   Nestin,	   Sox10,	   GFAP	   and	   Tuj1.	   The	   ubiquitous	   expression	   of	   the	  
intermediate	  filament	  protein	  and	  NSC	  marker	  Nestin	  combined	  with	  the	  near	  absence	  of	  the	  
OL,	  astrocyte	  and	  neuron	  lineage	  markers	  Sox10,	  GFAP	  and	  Tuj1,	  indicated	  that	  the	  cultures	  
retained	   neural	   stem	   cell-­‐like	   character	   (Lendahl	   et	   al.,	   1990).	   These	   stem-­‐like	   properties	  
common	   to	   both	   the	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   cultures	   indicated	   that	   Olig2	  
dephosphorylation	  was	  not	  by	   itself	   sufficient	   to	   induce	   spontaneous	  OLP	   formation	   in	  my	  




I	  performed	  preliminary	  Olig2	  ChIP	  from	  Olig2-­‐WT,	  Olig2-­‐S147A	  and	  Olig2-­‐null	  NSC	  cultures	  
and	   examined	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   DNA	   binding	   at	   specific	   genomic	   loci	   by	  
quantitative	  PCR.	  The	  results	  revealed	  that	  Olig2-­‐WT	  occupied	  the	  regulatory	  regions	  of	  the	  
Sox10,	  PDGFRA	  and	  Olig1	  genes,	  identifying	  two	  novel	  Olig2	  binding	  sites	  in	  the	  PDGFRA	  and	  
Olig1	   genes.	   ChIP-­‐qPCR	   from	   Olig2-­‐S147A	   cultures	   revealed	   that	   the	   phsopho-­‐null	   Olig2-­‐
S147A	  did	   not	   occupy	   these	   binding	   sites	   in	  NSCs,	   indicating	   that	   occupancy	   of	   the	  Sox10,	  
PDGFRA	  and	  Olig1	  gene	  targets	  requires	  Olig2	  phosphorylation	  at	  S147.	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Interestingly,	   the	  5’	  U2	  enhancer	  of	  gene	  Sox10	  –	   identified	  here	  as	  a	  phospho-­‐S147	  Olig2-­‐
specific	  binding	  site	  in	  NSCs	  –	  was	  first	  established	  as	  an	  Olig2	  gene	  target	  in	  committed	  OLPs	  	  
(Kuspert	  et	  al.,	  2011).	  Olig2	  binds	  the	  U2	  enhancer	   in	  OLPs	   in	  vivo,	  and	  mutation	  of	  the	  U2	  
sequence	   abolishes	  Olig2	   binding	   and	   diminishes	   enhancer	   activity.	   It	   is	   therefore	   perhaps	  
surprising	   that	   I	   did	   not	   observe	   Olig2-­‐S147A	   occupancy	   of	   the	   U2	   enhancer	   of	   Sox10	   in	  
cultured	   NSCs.	   This,	   however,	   assumes	   that	   the	   activity	   of	   Olig2	   is	   constant	   in	  
oligodendrogenic	   NSCs	   and	   committed	   OLPs.	   In	   NSCs,	   dephosphorylation	   at	   S147	   instead	  
appears	  to	  trigger	  dissociation	  of	  Olig2	  from	  the	  U2	  binding	  site,	  before	  Olig2	  reoccupies	  the	  
same	  U2	  binding	   site	  and	  drives	  Sox10	   expression	   in	   committed	  OLPs.	   	  Re-­‐association	  with	  
the	  U2	  binding	  site	  might	  coincide	  with	  re-­‐phosphorylation	  of	  S147,	  although	  this	  remains	  to	  
be	  established.	  	  
	  
In	   addition	   to	   the	   U2	   enhancer	   of	   Sox10,	   I	   examined	   occupancy	   of	   another	   previously	  
reported	  Olig2	  binding	  site,	  the	  upstream	  M250	  enhancer	  of	  the	  motor	  neuron-­‐specific	  gene	  
Hb9	   (Lee	   et	   al.,	   2004;	   Lee	   et	   al.,	   2005).	   The	  M250	   enhancer	   contains	   two	   evolutionarily	  
conserved	   E-­‐boxes	   –	   the	  M50	   E-­‐box	   and	   the	  M100	   E-­‐box	   –	   and	  mediates	   both	  Hb9	   gene	  
activation	   and	   repression	   (Lee	   et	   al.,	   2004).	   Olig2	   occupancy	   of	   the	  M250	   enhancer	   was	  
confirmed	   in	   transfected	   P19	   cells	   by	   ChIP	   of	   Flag-­‐tagged	  Olig2,	   and	   in	   HEK293	   cells	   Olig2	  
repressed	   the	   activity	   of	   an	  M250	   reporter	   construct	   (Lee	   et	   al.,	   2005).	   In	   contrast	   to	   the	  
results	  of	  Lee	  et	  al.,	  however,	  I	  detected	  no	  significant	  recovery	  of	  the	  M250	  enhancer	  after	  
Olig2	  ChIP	  from	  either	  Olig2-­‐WT	  or	  Olig2-­‐S147A	  NSCs,	  indicating	  Olig2	  did	  not	  occupy	  either	  
the	   M50	   or	   M100	   E-­‐boxes	   in	   cultured	   NSCs.	   The	   different	   observations	   could	   relate	   to	  
differences	   between	   the	   primary	   NSC	   and	   P19	   cells	   used,	   as	   well	   as	   to	   the	   properties	   of	  
endogenous	  versus	  exogenous	  Flag-­‐tagged	  Olig2.	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ChIP-­‐seq	  analysis	  
	  
To	   identify	   the	   full	   repertoire	   of	   phospho-­‐S147	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   gene	   targets,	   I	  
analysed	   ChIP-­‐purified	   DNA	   samples	   from	   Olig2-­‐WT	   and	   mutant	   NSC	   cultures	   by	   high-­‐
throughput	  Illumina	  sequencing.	  The	  ChIP-­‐seq	  generated	  more	  than	  25	  million	  100	  bp	  reads	  
per	   sample.	   The	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   sequencing	   data	   were	   analysed	   in	   silico	   for	  
sequence	   enrichment	   relative	   to	   input	   and	   Olig2-­‐null	   background	   controls.	   The	  
computational	  analysis	  identified	  871	  and	  175	  discrete	  binding	  sites	  for	  phospho-­‐S147	  Olig2	  
and	  Olig2-­‐S147A	  respectively,	  with	  no	  individual	  site	  common	  to	  both	  datasets.	  The	  number	  
of	  Olig2	  binding	  sites	  identified	  here	  is	  considerably	  lower	  than	  has	  previously	  been	  reported	  
in	   published	   high-­‐throughput	   studies	   of	   Olig2	   gene	   target	   binding:	   Weng	   et	   al.	   (2012)	  
identified	   5439	  Olig2	   binding	   sites	   using	   purified	   rat	  OLs,	   Yu	   et	   al.	   (2013)	   identified	   21901	  
Olig2	   binding	   sites	   in	   cultured	   OLPs	   isolated	   from	   neonatal	   rats,	   and	   Mateo	   et	   al.	   (2015)	  
identified	   16067	  Olig2	   gene	   targets	   in	   cultured	  NSCs.	   The	   total	   number	   of	   ChIP-­‐seq	   peaks,	  
however,	   is	   contingent	   on	   the	   thresholds	   set	   for	   peak	   calling	   and	   is	   therefore	   difficult	   to	  
interpret	   across	   independent	   ChIP-­‐seq	   datasets.	   Indeed,	   ChIP-­‐seq	   performed	   using	  mouse	  
neural	  progenitor	  cells	  transduced	  with	  wild-­‐type	  Olig2	  identified	  fewer	  than	  400	  Olig2	  target	  
genes	  (Meijer	  et	  al.,	  2014).	  In	  the	  future,	  it	  will	  nonetheless	  be	  interesting	  to	  explore	  whether	  
the	  Olig2	  binding	  sites	  identified	  here	  represent	  a	  set	  of	  high-­‐affinity	  targets	  revealed	  under	  
more	  stringent	  peak	  calling	  conditions.	  
	  
Basic	   HLH	   TFs	   such	   as	   Olig2	   typically	   bind	   to	   E-­‐box	   sequences	   (Murre	   et	   al.,	   1989).	  Motif	  
analysis	   performed	   on	   the	   phospho-­‐S147	  Olig2-­‐WT	   ChIP-­‐seq	   data	   identified	   two	   hexamers	  
conforming	  to	  the	  canonical	  CANNTG	  E-­‐box	  motif:	  CAGCTG	  and	  CAGATG.	  The	  CAGATG	  Olig2	  
target	   DNA	   motif	   has	   not	   previously	   been	   identified.	   The	   CAGCTG	   Olig2	   binding	   motif,	  
however,	   was	   previously	   identified	   by	   Yu	   et	   al.	   (2013),	   indicating	   that	   this	   Olig2	   target	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sequence	  is	  common	  to	  NSCs	  and	  differentiating	  OLPs.	  Furthermore,	  cross	  comparison	  with	  
the	   Yu	   et	   al.	   (2013)	  OLP	   gene	   target	   list	   revealed	   that	   75%	  of	   the	  phospho-­‐S147	  Olig2-­‐WT	  
gene	   targets	   in	  NSCs	  are	  also	  Olig2	   targets	   in	  OLPs.	   The	  degree	  of	  overlap	   in	  NSC	  and	  OLP	  
Olig2	   gene	   targets,	   combined	   with	   the	   discovery	   of	   a	   conserved	   binding	   motif	   mediating	  
target	  occupancy,	  suggests	  Olig2	  primarily	  associates	  with	  a	  stable	  set	  of	  gene	  targets	  in	  both	  
neurogenic	  NSCs	  and	  committed	  OLPs	  (Yu	  et	  al.,	  2013).	  	  
	  
ChIP-­‐seq	   identified	   175	   Olig2-­‐S147A	   binding	   sites,	   none	   of	   which	   was	   common	   to	   the	  
phospho-­‐S147	  Olig2-­‐WT	  dataset.	  The	  majority	  (~80%)	  of	  the	  Olig2-­‐S147A	  binding	  sites	  were	  
not	  affiliated	  with	  any	  known	  genomic	  feature,	  and	  motif	  analysis	  failed	  to	  identify	  an	  Olig2-­‐
S147A	   target	  DNA	   sequence.	   In	   addition,	  while	  GO	  analysis	   of	   the	  phospho-­‐S147	  Olig2-­‐WT	  
gene	   targets	   revealed	   significant	   over-­‐representation	   of	   a	   number	   of	   related	   GO	   terms,	  
including	  nervous	  system	  development,	  GO	  analysis	  of	  the	  Olig2-­‐S147A	  ChIP-­‐seq	  data	  did	  not	  
establish	   enrichment	   of	   any	   GO	   term.	   In	   other	   words,	   there	   was	   no	   significant	   over-­‐
representation	  of	  genes	  performing	  any	  specific	  molecular	  function,	  comprising	  any	  specific	  
cellular	   component	   or	   involved	   in	   any	   specific	   biological	   process;	   the	   dataset	   as	   a	   whole	  
exhibited	  no	  discernible	  functional	  profile.	  Finally,	  a	  correlation	  plot	  and	  principal	  component	  
analysis	   (PCA)	   demonstrated	   the	   two	   replicate	   Olig2-­‐S147A	   mutant	   peak	   sets	   show	   low	  
concordance	   (data	   not	   shown).	   In	   fact,	   PCA	   indicated	   the	   individual	   Olig2-­‐S147A	   datasets	  
show	  less	  concordance	  with	  one	  another	  than	  they	  do	  with	  the	  highly	  concordant	  phospho-­‐
S147	  Olig2	  datasets,	  suggesting	  the	  replicate	  Olig2-­‐S147A	  datasets	  are	  essentially	  unrelated.	  
Overall,	  the	  ChIP-­‐seq	  analysis	  indicated	  Olig2-­‐S147A	  did	  not	  bind	  DNA	  in	  a	  specific	  manner	  in	  
NSCs.	  
	  
On	  the	  basis	  of	  the	  ChIP-­‐seq	  experiments	  presented	  here,	  it	  appears	  that	  phospho-­‐S147	  Olig2	  
homodimers	   –	   expressed	   in	   pMN	   domain-­‐resident	   NSCs	   during	   motor	   neurogenesis	   –	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specifically	   target	  CAGCGT/CAGATG	   E-­‐box	  binding	   sites	  of	  neural	  development	  genes.	  Over	  
the	   NSC	   fate	   switch,	   S147	   dephosphorylation	   triggers	   Olig2-­‐gene	   target	   dissociation,	  
heterodimer	   formation	   and	   induction	   of	   the	   OL-­‐specific	   genetic	   programme.	   Later,	   in	  
differentiating	   OLPs,	   Olig2	   re-­‐occupies	   the	   phospho-­‐S147-­‐specific	   binding	   sites	   targeted	   in	  
neurogenic	  NSCs	  (Yu	  et	  al.,	  2013).	  In	  OLPs,	  Olig2	  occupancy	  of	  the	  upstream	  U2	  enhancer	  of	  
Sox10	  has	  been	  shown	  to	  upregulate	  Sox10	  transcription	  after	  the	  initial	   induction	  of	  Sox10	  
expression	  and	  commitment	  to	  the	  OL	  lineage	  (Kuspert	  et	  al.,	  2011).	  This	  delay	  between	  the	  
initial	   activation	   of	   Sox10	   expression	   and	   Olig2-­‐mediated	   activation	   of	   Sox10	   expression	  
might,	   therefore,	   reflect	   the	   timeline	   of	   re-­‐occupancy	   of	   specific	   gene	   targets	   by	   Olig2	   in	  
committed	   OLPs.	   Moreover,	   the	   re-­‐association	   of	   Olig2	   with	   its	   earlier	   phosphorylation-­‐
dependent	  NSC	  gene	  targets	  might	  itself	  be	  dependent	  on	  the	  re-­‐phosphorylation	  of	  S147	  in	  
OLPs.	   The	   transient	   dissociation	   of	   dephosphorylated	   Olig2	   from	   its	   gene	   targets	   and	  
phosphorylation	  dependent	  re-­‐occupancy	  of	  the	  same	  gene	  targets	  in	  stable	  OLPs,	  however,	  
is	  yet	  to	  be	  confirmed.	  Tracking	  the	  phosphorylation	  state	  of	  Olig2	  S147	  along	  the	  OL	  lineage,	  
and	  examining	  the	  ability	  of	  Olig2-­‐S147A-­‐expressing	  NSCs	  to	  generate	  mature	  OLs	  will	  reveal	  
the	   dynamics	   of	   Olig2	   phosphorylation	   and	   its	   requirement	   over	   the	   full	   course	   of	   OL	  
development.	  
	  
The	   precise	   molecular	   activity	   of	   dephosphorylated	   Olig2	   in	   NSCs	   remains	   to	   be	   fully	  
elucidated.	   Li	   et	   al.	   (2011)	   propose	   that	   one	   function	   of	   S147	   dephosphorylation	   is	   to	  
dissociate	  Olig2	  homodimers,	   allowing	  monomeric	  Olig2	   to	  bind	   and	   sequester	  Ngn2	  away	  
from	  the	  regulatory	  regions	  of	  MN	  genes,	  thus	  halting	  MN	  gene	  expression	  and	  facilitating	  OL	  
lineage	  gene	  expression.	  Consistent	  with	  this	  model,	  the	  Olig2-­‐S147A	  ChIP-­‐seq	  data	  reported	  
here	  suggest	  entirely	  DNA-­‐independent	  roles	  for	  dephosphorylated	  Olig2	  in	  NSCs.	  There	  are,	  
however,	   in	   addition	   to	   DNA-­‐independent	   functions	   for	   Olig2,	   a	   number	   of	   alternative	  
interpretations	   of	   the	   Olig2-­‐S147A	   ChIP-­‐seq	   data.	   For	   instance,	   the	   lack	   of	   a	   detectable	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sequence-­‐specific	  DNA-­‐binding	  activity	  of	  Olig2-­‐S147A	  might	  represent	  an	  artefact	  of	  the	   in	  
vitro	  culture	  system.	  The	  protein	  complement	  of	  pMN	  domain	  NSCs	   in	  vivo	  will	  differ	   from	  
that	  of	  cultured	  NSCs	  and	  might	  include	  an	  additional	  bHLH	  protein	  cofactor	  that	  is	  absent	  in	  
cultured	  NSCs	  and	  necessary	  for	  Olig2-­‐S147A	  dimerization	  and	  DNA	  binding.	  In	  WT	  NSCs,	  the	  
capacity	   of	   phospho-­‐S147	   Olig2	   to	   form	   homodimers	   would	   bypass	   the	   requirement	   for	  
expression	   of	   this	   cofactor.	   Validatation	   of	   the	   NSC	  model	   and	   the	   ChIP-­‐seq	   results	   that	   I	  
report	  here	  will	  require	  comparative	  transcriptome	  analysis	  of	  genuine	  post-­‐fate	  switch	  pMN	  
domain	  NSCs	  and	  cultured	  NSCs,	  along	  with	  follow-­‐up	  DNA	  binding	  studies	  of	  Olig2-­‐S147A	  in	  
alternative	  model	  systems.	  	  
	   	  
CHAPTER	  5	  Olig2	  S147	  phosphorylation	  &	  gene	  target	  choice	  	   	  
	   163	  
Olig2	  regulation	  of	  target	  gene	  activity	  
	  
Olig2	  has	  been	  reported	  to	  act	  as	  both	  a	  transcriptional	  repressor	  during	  neurogenesis	  and	  as	  
a	  transcriptional	  activator	  during	  oligodendrogenesis	  (Mizugutchi	  et	  al.,	  2001;	  Novitch	  et	  al.,	  
2001;	  Ligon	  et	  al.,	  2007;	  Kuspert	  et	  al.,	  2011;	  Lee	  et	  al.,	  2005;	  Weng	  et	  al.,	  2012;	  Yu	  et	  al.,	  
2013).	  Indeed,	  Mateo	  et	  al.	  (2015)	  revealed	  that	  Olig2	  simultaneously	  activates	  stem	  cell/self	  
renewal	   genes	   and	   represses	   neuronal	   differentiation	   and	   quiescence	   genes	   in	   cultured	  
NSCs.	  To	  determine	  whether	  phospho-­‐S147	  Olig2	  acts	  as	  either	  an	  activator	  or	  a	  repressor	  at	  
the	  Sox10,	  PDGFRA	  and	  Olig1	  gene	  targets,	  I	  analysed	  gene	  target	  expression	  at	  the	  protein	  
and	  RNA	  levels	  in	  Olig2-­‐WT	  and	  phospho-­‐null	  Olig2-­‐S147A	  mutant	  NSC	  cultures.	  If	  Olig2	  were	  
acting	   to	   repress	   expression	   of	   these	   genes,	   dissociation	   of	   Olig2	   from	   these	   DNA	   binding	  
sites	   might	   be	   expected	   to	   de-­‐repress	   and	   thereby	   activate	   gene	   expression.	   For	   Sox10,	  
PDGFRA	  and	  Olig1,	   I	   found	  extremely	  low	  RNA	  abundance	  (≤5%	  GAPDH)	  and	  no	  observable	  
protein	   in	   both	   Olig2-­‐WT	   and	   Olig2-­‐S147A	   cultures.	   This	   suggests	   that	   S147	  
dephosphorylation-­‐dependent	   dissociation	   of	   Olig2	   is	   not	   sufficient	   to	   regulate	   OL	   lineage	  
target	   gene	   expression.	   In	   vivo,	   OLP	   formation	   from	   pMN	   NSCs	   might	   require	   Olig2	  
dissociation-­‐dependent	  de-­‐repression	  of	  OL	   lineage	  gene	  targets	  combined	  with	  expression	  
and/or	  activation	  of	  additional	  factors	  that	  are	  suppressed	  under	  the	  NSC	  culture	  conditions	  
described	  here.	   In	   this	   case,	   S147	  dephosphorylation-­‐induced	   changes	   in	  Olig2	  binding	   site	  
occupancy	  would	  represent	  a	  ‘priming’	  step	  in	  the	  NSC-­‐OLP	  transition.	  
	  
In	  the	  absence	  of	  high-­‐throughput	  gene	  expression	  analysis,	  such	  as	  RNAseq	  or	  microarray,	  
the	   genome-­‐wide	   impact	   on	   Olig2	   gene	   target	   expression	   of	   dynamic	   Olig2	   gene	   target	  
occupancy	   in	   phospho-­‐S147	   and	   phospho-­‐null	   mutant	   Olig2-­‐expressing	   NSCs	   cannot	   be	  
established.	  The	  ChIP-­‐seq	  data	  nevertheless	  imply	  a	  repressor	  function	  for	  Olig2.	  GO	  analysis	  
revealed	  that	  a	  significant	  number	  of	  Olig2	  target	  genes	  are	   involved	  in	   late-­‐stage	  neuronal	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processes,	   such	   as	   Activation	   of	   nerve	   impulse	   transmission	   (GO:0051971),	   which	   are	   not	  
associated	  with	  undifferentiated	  NSCs.	  Empirical	  analysis	  of	  the	  ChIP-­‐seq	  data	  also	  identified	  
a	   number	   of	   established	   late-­‐stage	   neuron,	   OL-­‐	   and	   astrocyte-­‐lineage	   markers,	   including	  
Cplx2,	  Nrxn1,	  Nrxn2,	  GFAP,	  Olig1,	  Tenm4	  and	  Opalin	  (Raff	  et	  al.,	  1979;	  Ushkaryov	  et	  al.,	  1992;	  
Lee	  et	  al.,	  2005;	  Kippert	  et	  al.,	  2008;	  Suzuki	  et	  al.,	  2012).	  In	  line	  with	  this,	  a	  number	  of	  studies	  
have	   described	   gene	   repressor	   functions	   for	   Olig2	   in	   CNS	   development	   (Mizuguchi	   et	   al.,	  
2001;	  Novitch	  et	  al.,	  2001;	  Zhou	  et	  al.,	  2001;	  Lee	  et	  al.,	  2005;	  Ligon	  et	  al.,	  2007;	  Mateo	  et	  al.,	  
2015).	  
	  
Transcriptional	   activator	   functions	   for	   Olig2	   have	   also	   previously	   been	   reported	   in	   OLPs	  
(Kuspert	  et	  al.,	  2011;	  Yu	  et	  al.,	  2013).	  My	  results	  indicate	  that	  phosphorylated	  Olig2	  binds	  the	  
U2	  enhancer	   of	  Sox10	   previously	   identified	  as	   an	  Olig2	   gene	   target	   in	  OLPs	   (Kuspert	   et	   al.,	  
2011).	   In	   committed	   OLPs,	   Olig2	   occupancy	   of	   the	   U2	   enhancer	   was	   shown	   to	   activate	  
expression	  of	  Sox10.	   If	  Olig2	  binding	  of	   the	  U2	  enhancer	   inhibits	  Sox10	  expression	   in	  NSCs,	  
Olig2	   would	   repress	   gene	   expression	   in	   NSCs	   and	   activate	   gene	   expression	   in	   OLPs	   via	  
occupancy	  of	  a	  single	  binding	  site.	   In	  this	  case,	  the	  dual	  functionality	  might	  be	  regulated	  by	  
NSC-­‐/OLP-­‐specific	  recruitment	  of	  off/on	  transcriptional	  machinery.	  	  
	  
In	  NS5	  NSC	  cultures,	  Olig2	  occupancy	  activates	  transcription	  of	  cell	  cycle	  and	  DNA	  replication	  
genes,	  promoting	  NSC	  proliferation	  and	   self-­‐renewal	   (Mateo	  et	   al.,	   2015).	   It	   remains	   to	  be	  
established,	   however,	  whether	  Olig2	  displays	   the	   same	  dual	   functionality	   and	   concurrently	  
performs	  gene	  activator	  and	  repressor	   functions	   in	   the	  primary	  NSC	  cultures	  analysed	  here	  
(Pollard	  et	  al.,	  2006).	  It	  should	  be	  noted	  that	  proliferation-­‐/stem	  cell	  maintenance-­‐related	  GO	  
terms	  such	  as	  “Cell	  cycle”	  were	  not	  statistically	  over	  represented	  in	  the	  phospho-­‐S147	  Olig2-­‐
WT	  ChIP-­‐seq	  dataset.	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Summary	  and	  further	  work	  
	  
In	  this	  chapter,	  I	  have	  presented	  the	  results	  of	  ChIP	  analyses	  of	  Olig2	  gene	  target	  selection	  in	  
cell	  culture	  models	  of	  neurogenic	  (Olig2-­‐WT)	  and	  gliogenic	  (Olig2-­‐S147A)	  pMN	  NSCs.	  I	  report	  
phospho-­‐S147-­‐specific	  occupancy	  of	  CAGCGT	  and	  CAGATG	  E-­‐box	  binding	  sites	  at	  a	  range	  of	  
gene	   targets,	   including	   multiple	   critical	   regulators	   of	   neural	   development	   such	   as	   Foxp1,	  
Tulp3,	  Notch1,	  Nkx6.2	  and	  Sox10	  (Kuhlbrodt	  et	  al.,	  1998;	  Wang	  et	  al.,	  1998;	  Ikeda	  et	  al.,	  2001;	  
Genoud	  et	  al.,	  2002;	  Pattyn	  et	  al.,	  2003;	  Wegner	  &	  Stolt,	  2005;	  Vallstedt	  et	  al.,	  2005;	  Cai	  et	  
al.,	   2010;	   Hisaoka	   et	   al.,	   2010).	  Quantitative	   RT-­‐PCR,	   as	  well	   as	  GO	   and	   empirical	   analysis,	  
suggest	  that	  Olig2	  gene	  target	  occupancy	  was	  associated	  with	  limited	  target	  gene	  expression	  
and	  might	  represent	  gene	  target	  repression.	  Olig2-­‐S147A	  ChIP-­‐seq	  revealed	  that	  Olig2-­‐S147A	  
and	  phospho-­‐S147	  Olig2	  shared	  no	  binding	  sites	  and	  that	  Olig2-­‐S147A	  did	  not	  bind	  genomic	  
DNA	  with	  any	   specificity	  or	   to	  perform	  any	  discernible	   function.	  However,	  quantitative	  RT-­‐
PCR	   indicates	   that	   the	   absence	   of	   Olig2	   from	  OL-­‐lineage	   gene	   targets	   Sox10,	  PDGFRA	   and	  
Olig1	   was	   not	   associated	  with	   any	   significant	   change	   in	   gene	   expression.	   This	   implies	   that	  
dynamic	  Olig2	  DNA	  binding	  was	  not	  sufficient	  to	  affect	  transcriptional	  regulation	  and	  might	  
act	  as	  a	  necessary	  but	  insufficient	  prelude	  to	  gene	  activation.	  
	  
In	  ChIP-­‐seq	  experiments	  performed	   from	  cultured	  OLPs	  by	  Yu	  et	   al.	   (2013),	   the	  Olig2	  gene	  
targets	  are	  highly	  concordant	  with	  those	  reported	  here	  for	  phospho-­‐S147	  Olig2	  in	  NSCs.	  The	  
phospho-­‐S147	  Olig2	  gene	  target	  CAGCTG	  E-­‐box	  binding	  motif	  identified	  here	  is	  also	  identical	  
to	   the	   Olig2	   target	   motif	   established	   in	   OLPs	   (Yu	   et	   al.,	   2013).	   I	   identified	   an	   additional	  
related	   binding	   motif	   in	   NSCs	   (CAGATG)	   that	   was	   not	   reported	   in	   OLPs.	   The	  
dephosphorylation-­‐induced	  dissociation	  of	  Olig2	   from	   its	  gene	  targets	   therefore	  appears	   to	  
be	   a	   transient	   state	   interposed	   between	   the	   NSC	   and	   OLP	   states.	   It	   will	   be	   intriguing	   to	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explore	   the	   potential	   mechanisms	   (S147	   re-­‐phosphorylation,	   for	   example)	   inducing	   Olig2	  
DNA	  binding	  at	  the	  same	  target	  genes	  in	  OLPs.	  
	  
In	   future,	   the	   phosphorylation	   state	   of	   Olig2	   S147	   in	   cultured	  OL	   lineage	   cells	   at	   different	  
stages	  of	  differentiation	   can	  be	  examined	  by	  western	  blot	  using	   the	  phospho-­‐S147-­‐specific	  
antibody	  developed	  by	  Li	  et	  al.	   (2011).	  Moreover,	  the	  capacity	  of	  mutant	  Olig2-­‐S147A	  NSCs	  
to	   generate	   myelinating	   OLs	   could	   be	   addressed	   in	   vivo	   by	   crossing	   the	  Olig2-­‐S147A	   and	  
Sox10-­‐Cre	   PAC	   transgenes	  onto	   the	  Olig2fl/fl	   background.	   In	   these	  mice,	  expression	  of	  wild-­‐
type	  Olig2	  in	  NSCs	  during	  embryonic	  development	  would	  allow	  normal	  MN	  development	  and	  
postnatal	   survival	  of	   these	   transgenic	  mice,	  while	  Sox10-­‐linked	  Cre-­‐recombinase	  expression	  
would	   ablate	   the	  Olig2fl/fl	   in	   OL	   lineage	   cells	   leaving	   only	   the	   mutant	  Olig2-­‐S147A.	   In	   this	  
system,	  the	  ability	  of	  the	  recombined	  OLPs	  to	  become	  myelinating	  OLs	  in	  vivo	  would	  reveal	  
the	  requirement	  for	  Olig2	  S147	  phosphorylation	  for	  OL	  differentiation.	  	  
	  
Exploring	  how	  Olig2	  affects	  target	  gene	  expression	  will	  also	  be	  fundamental	  to	  understanding	  
the	  molecular	  regulation	  of	  CNS	  development.	  Gene	  expression	  profiling	  of	  NSCs	  and	  OLPs	  by	  
RNA-­‐seq	   and/or	   RNA	   polymerase	   II	   ChIP-­‐seq	   will	   enable	   comparison	   of	   Olig2	   gene	   target	  
transcription.	  For	  those	  Olig2	  gene	  targets	  common	  to	  NSCs	  and	  OLPs	  that	  show	  significantly	  
different	  expression	  levels	  in	  NSCs	  and	  OLPs,	  determining	  precisely	  how	  Olig2	  contributes	  to	  
the	   regulation	   of	   transcription	   will	   be	   fascinating.	   Opposing	   effects	   on	   gene	   target	  
transcription	  in	  NSCs	  and	  OLPs	  would	  presumably	  be	  mediated	  by	  recruitment	  of	  specific	  co-­‐
regulator	   proteins,	   such	   as	   histone	   modifiers	   and	   chromatin	   remodelers.	   Olig2	   has	   been	  
shown	   to	   recruit	   the	   SWI-­‐SNF	   chromatin	   remodeler	   Brg1	   to	   E-­‐box	   enhancer	   elements	   in	  
immature	   OLs,	   and	   regulate	   gene	   expression	   and	   OL	   differentiation	   (Yu	   et	   al.,	   2013).	   A	  
combination	   of	   ChIP-­‐seq	   analysis	   for	   enrichment	   of	   regulatory	   histone	   marks	   (H3K9	  
acetylation,	  for	  example)	  at	  Olig2	  target	  sites	  and	  protein-­‐protein	  interaction	  assays,	  such	  as	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yeast-­‐two-­‐hybrid	  and	  co-­‐IP	  experiments,	  could	  identify	  important	  candidate	  mechanisms	  for	  
further	  analysis.	  
	  
Overall,	  I	  have	  revealed	  DNA-­‐binding	  preferences	  for	  wild-­‐type	  Olig2	  phosphorylated	  at	  S147	  
and	   the	   constitutively	   dephosphorylated	   Olig2-­‐S147A	   mutant	   in	   cultured	   NSCs.	   My	   data	  
suggest	   a	   variety	   of	   experimental	   directions	   for	   the	   future	   that	   will	   provide	   critical	  
information	   for	   understanding	   how	   Olig2	   S147	   phosphorylation	   might	   regulate	   stepwise	  
progression	   along	   the	   OL	   lineage.	   This	   research	   might	   also	   provide	   a	   paradigm	   for	  
understanding	  how	  phosphorylation	  of	  bHLH	  proteins	  regulates	  cell	  development.	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CHAPTER	  6	  
OLIG2	  S263	  PHOSPHORYLATION	  
	  
	  
6.1	   INTRODUCTION	  
	  
Basic	  HLH	  TF	  Olig2	  has	  roles	   in	  neuron,	  OLP	  and	  astrocyte	  formation	   in	  the	  developing	  CNS	  
(Meijer	   et	   al.,	   2012).	   In	   the	   embryonic	   spinal	   cord,	  Olig2	   is	   expressed	   in	  multipotent	  NSCs	  
resident	   in	   the	  ventral	  pMN	  domain	  and	   is	  essential	   for	   the	  generation	  of	  both	  spinal	  MNs	  
and	   OLs.	   In	   addition,	   Olig2-­‐expressing	   pMN	   NSCs	   produce	   a	   subpopulation	   of	   astrocytes	  
concentrated	  at	  the	  ventral	  pial	  surface	  of	  the	  spinal	  cord,	  and	  postnatal	  Olig2	  function	  has	  
been	  reported	  to	  be	  necessary	  for	  proper	  astrocyte	  differentiation	  in	  cerebral	  white	  matter	  
(Masahira	  et	  al.,	  2006;	  Cai	  et	  al.,	  2007).	  Olig2+	  NSCs	  in	  the	  ventricular	  zone	  of	  the	  embryonic	  
ventral	  forebrain	  contribute	  to	  excitatory	  cholinergic	  and	  glutamatergic	  neuron	  populations,	  
as	   well	   as	   multiple	   subtypes	   of	   inhibitory	   interneurons,	   including	   cortical	   interneurons	  
(Furosho	   et	   al.,	   2006;	  Miyoshi	   et	   al.,	   2007;	   Ono	   et	   al.,	   2008).	   In	   OL	   development,	   Olig2	   is	  
continuously	   expressed	   from	  nascent	  OLPs	   to	  mature	  and	  myelinating	  OLs	   and	   is	   a	  master	  
regulator	  of	  OL	  differentiation	  (Li	  &	  Richardson,	  2008).	  Recent	  research	   indicates	  that	  Olig2	  
initially	   promotes	   OL	   lineage	   progression	   before	   inhibiting	   the	   final	   differentiation	   of	   pre-­‐
myelinating	   OLs	   (Mei	   et	   al.,	   2013).	   The	   involvement	   of	   Olig2	   in	   the	   generation	   of	   specific	  
astrocyte	  and	  neuron	  sub-­‐types,	  and	   its	  dynamic	   functions	  at	  different	  stages	  along	   the	  OL	  
lineage,	  indicates	  that	  Olig2	  performs	  a	  wide	  range	  of	  functions	  in	  different	  cellular	  contexts.	  
	  
The	   activities	   of	   Olig2	   in	   these	   different	   biological	   contexts	   have	   been	   explored	   at	   a	  
molecular	   level.	   During	   the	   neurogenic	   phase	   of	   pMN	   domain	   development,	   Olig2	   initially	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primes	  NSCs	   for	  neuronal	  differentiation	  by	  de-­‐repressing	  expression	  of	  pro-­‐neuronal	  TFs	  –	  
including	  Ngn2	  and	  Lim3	  –	  before	  subsequently	  antagonizing	  pro-­‐neuronal	  TF	  activity	  (Lee	  et	  
al.,	  2005).	  In	  Ngn2/Olig2	  double-­‐positive	  pMN	  NSCs,	  Olig2	  competitively	  binds	  and	  represses	  
pro-­‐MN	   gene	   targets	   such	   as	  Hb9,	   while	   at	   the	   protein	   level	   formation	   of	   Olig2:Ngn2	   and	  
Olig2:E47	  heterodimers	  inhibits	  formation	  of	  the	  functional	  pro-­‐neuronal	  Ngn2:E47	  activator	  
complex.	  High	   throughput	  ChIP-­‐seq	  and	  RNAseq	  analyses	   indicate	   that	  Olig2	  acts	  as	  both	  a	  
transcriptional	  activator	  and	  a	  repressor	  to	  inhibit	  neuronal	  differentiation	  and	  maintain	  the	  
proliferating	  stem	  cell	  state	  (Mateo	  et	  al.,	  2015).	  In	  OLPs,	  Olig2	  directly	  activates	  Sox10	  gene	  
expression	  via	   the	  conserved	  upstream	  U2	  enhancer	   (Liu	  et	  al.,	  2007;	  Kuspert	  et	  al.,	  2011).	  
The	  opposing	  functions	  of	  Olig2	   in	  promoting/inhibiting	  OL	  lineage	  progression	  at	  early	  and	  
late	   stages	   of	   differentiation	   were	   also	   observed	   to	   coincide	   with	   a	   switch	   from	   Olig2-­‐
mediated	  activation	  of	  Olig1	  gene	  expression	  in	  OLPs	  to	  repression	  of	  Olig1	  in	  immature	  OLs	  
(iOLs)	   (Mei	   et	   al.,	   2013).	   Moreover,	   ChIP-­‐seq	   revealed	   that	   Olig2	   associates	   with	   largely	  
distinct	   sets	   of	   gene	   targets	   in	   OLPs/iOLs	   and	   mature	   OLs	   (mOLs)	   (Yu	   et	   al.,	   2013).	   This	  
dynamic	  gene	  target	  choice	  is	  accompanied	  by	  stage-­‐specific	  interaction	  with	  protein	  binding	  
partner	  Brg1,	  the	  central	  ATPase	  subunit	  of	  the	  SWI/SNF	  chromatin	  remodeler	  complex.	  Brg1	  
and	  Olig2	  have	  been	  shown	  to	  interact	  physically	  and	  occupy	  common	  genomic	  binding	  sites	  
in	   iOLs	   but	   not	   in	   mOLs.	   Ultimately,	   the	   existing	   research	   highlights	   how	   the	   range	   of	  
different	  developmental	   functions	  of	  Olig2	   is	  underscored	  by	  unique	  and	  specific	  molecular	  
activities.	  	  
	  
Protein	  kinase-­‐mediated	  phosphorylation	  at	  specific	  serine	  and	  threonine	  residues	  has	  been	  
shown	  to	  alter	  key	  properties	  of	  Olig2	  and	  to	  critically	  affect	  Olig2+	  cell	  development.	  Casein	  
kinase	   2B	   (CK2B)	   phosphorylates	   Olig2	   at	   multiple	   sites	   in	   the	   serine-­‐threonine-­‐rich	   (STR)	  
domain	   in	  vitro	  and	  this	   is	  proposed	  to	  mediate	  the	  positive	  regulatory	  role	  of	  CK2B	  in	  OLP	  
specification	  from	  embryonic	  NSCs	  (Huillard	  et	  al.,	  2010).	  In	  adult	  subventricular	  zone	  NSCs,	  
CHAPTER	  6	  Olig2	  S263	  phosphorylation	   	   	  	  
	   170	  
Akt-­‐mediated	  phosphorylation	  of	   S30	   induces	  nuclear	   export	   of	  Olig2,	   an	  essential	   process	  
for	   CNTF-­‐induced	  astrocyte	  differentiation	   in	   vitro	   (Setoguchi	  &	  Kondo,	   2004).	   In	   the	  Olig2	  
amino	   terminal,	   S10/13/14	   phosphorylation	   alters	   Olig2	   target	   gene	   expression	   through	  
phosphorylation-­‐dependent	   compartmentalization	   of	   Olig2	   to	   transcriptionally	   active	   open	  
chromatin	  and	  interaction	  with	  specific	  co-­‐regulator	  proteins	  (Sun	  et	  al.,	  2011;	  Meijer	  et	  al.,	  
2014).	  Finally,	  Olig2	  phosphorylation	  at	  S147	   in	   the	  basic	  HLH	  domain	  determines	  NSC	   fate	  
choice	   in	   the	  embryonic	  pMN	  domain	   (Li	  et	  al.,	  2011).	  Olig2	  S147	  dephosphorylation	  alters	  
Olig2	   cofactor	   choice,	   and	   potentially	   gene	   target	   selection,	   to	   trigger	   the	   MN-­‐OLP	   fate	  
switch,	  abruptly	  ending	  neurogenesis	  and	  initiating	  OL	  formation.	  	  
	  
The	  diverse	  range	  of	  developmental	   functions	  of	  Olig2	   is	  underscored	  by	  specific	  molecular	  
activities	   that	   are	   in	   turn	   modulated	   through	   post-­‐translational	   modification	   –	   notably	  
reversible	  phosphorylation	  –	  of	  specific	  amino	  acid	  residues.	  Establishing	  the	  full	   repertoire	  
of	  genuine	  phosphorylation	   states	  of	  Olig2	  and	   the	  molecular	  activity	  associated	  with	  each	  
will	  be	  fundamental	  to	  understanding	  CNS	  development	  and	  will	  require	  intensive	  research.	  
In	  this	  chapter,	  I	  present	  the	  results	  of	  computational	  analysis	  of	  Olig2	  phosphorylation	  and	  
the	   early	   steps	   in	   functional	   characterization	   of	   the	  Olig2	   carboxy-­‐terminal	   S263	   phospho-­‐
acceptor	  site.	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6.2	   RESULTS	  
	  
In	   total,	   mouse	   Olig2	   contains	   over	   60	   serine/threonine	   residues,	   and	   a	   serine	   content	   of	  
approximately	   15%	   (50	   residues	   of	   323	   total).	   Computational	   analysis	   –	   performed	   by	  
Professor	  Cizhong	  Jiang	  at	  Tongji	  University,	  China	  –	  examining	  the	  serine	  content	  of	  16,403	  
distinct	   protein	   sequences	   in	  Mus	  musculus	   revealed	   that	   the	   542	   TFs	   identified	   display	   a	  
significantly	  higher	  serine	  content	  than	  the	  remaining	  non-­‐TF	  proteins	  (Figure	  1).	  Among	  this	  
set	  of	  542	  serine-­‐rich	  transcription	  factors,	  Olig2	  has	  the	  13th-­‐highest	  serine	  content	  (Figure	  
1).	   For	   any	   protein,	   each	   serine	   residue	   represents	   a	   potential	   phosphorylation	   site	   that	  
might	  alter	   its	  molecular	  properties	  and	   thereby	   regulate	   its	   function.	   In	   the	   case	  of	  Olig2,	  
the	   abundance	   of	   potentially	   phosphorylated	   serine	   residues	   could	   therefore	   provide	   the	  
mechanism	   for	   an	   individual	   TF	   to	   perform	   a	   range	   of	   functions,	   with	   specific	   multisite	  
phosphorylation	  states	  inducing	  specific	  activities	  in	  different	  cells.	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Figure	  1.	  Transcription	  factor	  serine	  content.	  A.	  Distribution	  of	  TF	  and	  non-­‐TF	  
percentage	  serine	  content.	  TF	  proteins	  carry	  a	  significantly	  higher	  percentage	  of	  
serines	   compared	   to	   non-­‐TF	   (nTF)	   proteins.	   B.	   Top	   20	   serine-­‐rich	   TFs	   ranked	  
according	   to	   serine	   content	   (#	   serines	   /	   #	   total	   amino	   acids).	   (Computational	  
analysis	  provided	  by	  Prof.	  Cizhong	  Jiang	  at	  Tongji	  University,	  China.)	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Predicted	  Olig2	  phosphorylation	  sites	  
	  
To	   identify	   putative	   phospho-­‐acceptor	   sites,	   I	   analysed	   the	   human	  Olig2	   protein	   sequence	  
using	   the	   online	   tool	   NetPhos	   2.0,	   which	   predicts	   phosphorylation	   sites	   using	   an	   ‘artificial	  
neural	   network	   algorithm’	   (Blom	   et	   al.,	   1999).	   From	   among	   the	   60	   sites,	   NetPhos	   2.0	  
predicted	   28	   are	   phosphorylated,	   including	   the	   established	   S10/13/14,	   S30,	   STR	   and	   S147	  
sites	  (Figure	  2A)	  (Setoguchi	  &	  Kondo,	  2004;	  Huillard	  et	  al.,	  2010;	  Sun	  et	  al.,	  2011).	  In	  addition	  
to	   the	  NetPhos	  2.0	  analysis,	   I	   also	  used	   the	  kinase-­‐specific	  prediction	   tool	  NetPhosK	  1.0	   to	  
identify	   the	   putative	   kinases	   targeting	   different	   sites	   (Blom	   et	   al.,	   2004).	   NetPhosK	   1.0	  
analysis	   identified	   12	   protein	   kinases	   with	   predicted	   substrate	   residues	   within	   the	   Olig2	  
protein	  sequence,	  11	  of	  which	  are	  predicted	  to	  target	  multiple	  serine/threonine	  sites	  and	  8	  
of	  which	   have	   been	  previously	   implicated	   in	  OL	   development	   and	  myelination	   (Figure	   2A).	  
Finally,	   to	   determine	   the	   evolutionary	   conservation	   of	   the	   predicted	   phospho-­‐acceptor	  
residues,	  I	  used	  the	  ClustalO	  tool	  to	  align	  the	  protein	  sequences	  of	  human,	  mouse,	  zebrafish	  
and	  chick	  Olig2.	  The	  Olig2	  sequences	  are	  >95%	  conserved	  between	  human	  and	  mouse,	  while	  
human-­‐to-­‐chick	   and	   human-­‐to-­‐zebrafish	   alignment	   of	   Olig2	   revealed	   85.9%	   and	   70.0%	  
conservation	  respectively.	  Of	   the	  28	  serine/threonine	  residues	  predicted	  by	  NetPhos	  2.0	   to	  
be	  phosphorylated	  in	  human	  Olig2,	  10	  –	  including	  the	  validated	  S10/13/14	  and	  S147	  sites	  but	  
not	   the	   S30	   and	   STR	   sites	   –	   are	   conserved	   across	   all	   species	   (Setoguchi	   &	   Kondo,	   2004;	  
Huillard	  et	  al.,	  2010;	  Li	  et	  al.,	  2011;	  Sun	  et	  al.,	  2011;	  Meijer	  et	  al.,	  2014).	  On	  the	  basis	  of	  the	  
phosphorylation	  and	  kinase	  predictions,	  and	  evolutionary	  conservation	  of	  different	  putative	  
phosphorylation	   sites,	   the	   computational	   analysis	   indicates	   that	  Olig2	   is	   phosphorylated	   at	  
multiple	  residues	  besides	  the	  known	  phospho-­‐acceptor	  serine	  sites.	   Identifying	  the	  genuine	  
phosphorylation	  sites	  within	  Olig2	  and	  analysing	  the	  contribution	  of	  each	  to	  Olig2	  function	  is	  
an	  important	  route	  to	  understanding	  the	  role	  of	  Olig2	  in	  neurodevelopment.	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Figure	   2.	   Predicted	   phosphorylation	   sites	   of	   human	  Olig2	   and	   their	   evolutionary	   conservation.	   A.	  
Distribution	   of	   predicted	   and	   confirmed	   phospho-­‐acceptor	   sites	   in	   human	  Olig2	   and	   the	   associated	  
protein	  kinases.	  B.	  ClustalO	  alignment	  of	  human,	  mouse,	  zebrafish	  and	  chick	  Olig2	  protein	  sequences.	  
Arrowheads	   mark	   predicted	   and	   confirmed	   phosphorylation	   sites	   from	   A.	   Boxes	   mark	   the	  
phosphorylation	  sites	  conserved	  across	  all	  species	  analysed.	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Carboxy-­‐terminal	  S263	  and	  P38-­‐MAPK	  
	  
In	  addition	  to	  the	  S10/13/14,	  S30,	  STR	  and	  S147	  sites,	  bona	  fide	  phosphorylation	  of	  S263	  was	  
detected	   in	  mass	  spectrometry	  analysis	  of	  Olig2	  purified	  from	  transfected	  COS	  cells	   (Sun	  et	  
al.,	  2011).	  The	  precise	  function	  of	  S263	  phosphorylation,	  however,	  has	  not	  been	  established.	  
Computational	   analysis	   of	   the	   Olig2	   carboxy	   terminal	   amino	   acid	   sequence	   revealed	   S263	  
resides	  immediately	  upstream	  of	  a	  proline	  residue	  and	  is	  predicted	  by	  NetPhosK	  1.0	  to	  be	  a	  
substrate	   of	   several	   proline-­‐directed	   protein	   kinases	  with	   known	   roles	   in	  OL	   development,	  
including	  P38-­‐MAPK.	  
	  
Mitogen-­‐activated	  protein	  kinases	  (MAPKs)	  consist	  of	  families	  of	  Ser/Thr-­‐specific	  kinases	  that	  
mediate	  the	  intracellular	  responses	  to	  extracellular	  stimuli	  through	  protein	  phosphorylation	  
signaling	  cascades.	  Four	  distinct	  subgroups	  within	  the	  MAPK	  family	  have	  been	  identified,	  one	  
of	   which	   is	   the	   P38-­‐MAPK	   group.	   P38-­‐MAPKs	   are	   activated	   by	   dual	   phosphorylation	   at	  
conserved	   residues,	   catalyzed	   by	   upstream	   MAP	   kinase	   kinases	   (Zarubin	   &	   Han,	   2005).	  
Downstream	   substrates	   of	   P38-­‐MAPK	   include	   additional	   kinases	   as	   well	   as	   transcription	  
factors	   that	   directly	   regulate	   gene	   expression	   in	   response	   to	   P38-­‐MAPK-­‐mediated	  
phosphorylation	   (Tan	  et	  al.,	  1996).	  Research	  published	   from	  a	  number	  of	   labs	  has	   revealed	  
important	   roles	  of	  P38-­‐MAPK	  signaling	   in	  OLP	  differentiation	  and	  myelination	   (Baron	  et	  al.,	  
2000;	  Fragoso	  et	  al.,	  2007;	  Hu	  et	  al.,	  2012;	  Rafalski	  et	  al.,	  2013).	  	  
	  
As	  a	  preliminary	  demonstration	  of	  the	  role	  of	  P38-­‐MAPK	  in	  OLP	  development,	  I	  analysed	  the	  
effect	   of	   anisomycin-­‐induced	   P38-­‐MAPK	   activation	   on	   OLP	   formation	   from	   NSCs	   in	   vitro.	  
Primary	  adherent	  Olig2-­‐expressing	  NSC	  cultures	  were	  derived	   from	  the	  dissociated	  cortices	  
of	   E13.5	   wild-­‐type	  mice	   and	   expanded	   in	   ‘NSC	  medium’	   (Conti	   et	   al.,	   2005;	   Pollard	   et	   al.,	  
2006).	   Under	   these	   conditions,	   the	   cultured	   NSCs	   remain	   Olig2-­‐	   and	   Nestin-­‐positive	   and	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Sox10-­‐negative,	   an	   indication	   of	   pre-­‐OL	   lineage,	   stem	   cell-­‐like	   character	   (see	   Chapter	   3:	  
Spinal	   cord	   angiogenesis	   and	   the	  MN-­‐OLP	   fate	   switch).	   To	   induce	  OL	   lineage	   commitment,	  
the	  NSC	  medium	  was	  substituted	  with	   ‘Differentiation	  medium’,	  containing	  20	  ng/ml	  FGF-­‐2	  
and	  10	  ng/ml	  PDGF-­‐AA,	  a	  growth	  factor	  combination	  known	  to	  enhance	  oligodendrogenesis.	  
NSCs	   were	   exposed	   to	   either	   unsupplemented	   Differentiation	   medium	   (control)	   or	  
Differentiation	  medium	  supplemented	  with	   the	  P38-­‐MAPK	  activator	  anisomycin	   (+Ani)	   at	  2	  
µg/ml	  final	  concentration.	  After	  24	  hrs	  in	  control	  or	  +Ani	  Differentiation	  medium,	  P38-­‐MAPK	  
activation	   was	   assessed	   by	   western	   blot.	   In	   +Ani	   medium,	   NSCs	   showed	   increased	   P38	  
phosphorylation	  (activation)	  relative	  to	  the	  level	  of	  total	  P38,	  confirming	  anisomycin-­‐induced	  
activation	   of	   P38-­‐MAPK	   (Figure	   3A).	   After	   four	   days	   in	   control	   or	   +Ani	   Differentiation	  
medium,	   OLP	   development	   was	   analysed	   by	   immunolabeling	   the	   cultures	   with	   anti-­‐Sox10	  
and	   anti-­‐Olig2	   antibodies,	   and	   the	   emergence	   of	   Sox10+/Olig2+	   OLPs	   quantified	   as	   a	  
percentage	   of	   total	   cell	   number.	   In	   untreated	   control	   cultures	   approximately	   20%	   of	   cells	  
were	  Olig2/Sox10	  double-­‐positive,	  indicating	  robust	  OLP	  generation	  from	  NSCs,	  while	  in	  +Ani	  
cultures,	  Olig2	  and	  Sox10	  co-­‐expression	  was	  observed	  in	  <2%	  of	  cells	  (Figure	  3C).	  In	  contrast	  
to	  the	  reduction	  in	  OLP	  numbers,	  an	  increase	  in	  the	  relative	  cell	  density	  was	  observed	  in	  +Ani	  
cultures	  compared	  to	  control	  (Figure	  3D),	  and	  based	  on	  observations	  of	  pyknotic	  cell	  nuclei	  
there	   was	   no	   evidence	   of	   widespread	   apoptosis	   in	   either	   condition.	   The	   results	   therefore	  
indicate	   that	   the	   P38-­‐MAPK	   activator	   anisomycin	   potently	   inhibited	   OLP	   production	   from	  
NSCs	   in	  vitro.	  Whether	  this	  effect	  of	  anisomycin	  treatment	   is	  mediated	  via	  phosphorylation	  
of	  Olig2	  at	  S263,	  however,	  has	  not	  been	  established	  but	  remains	  an	  intriguing	  hypothesis.	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Figure	   3.	   Anisomycin-­‐induced	   activation	   of	   P38-­‐MAPK	   and	   its	   effect	   on	  OLP	  
formation	   in	   cultured	   NSCs.	   A.	  Western	  blot	   analysis	   of	   phospho-­‐	   (activated)	  
P38	  and	  total	  P38	  levels	  in	  NSCs	  cultured	  for	  24	  hrs	  in	  unsupplemented	  (control)	  
or	   anisomycin-­‐supplemented	   Differentiation	   medium	   (+Ani)	   B.	   Antibody	  
labeling	  of	  TF	  Olig2	  (green)	  and	  OLP	  marker	  Sox10	  (red)	   in	  NSCs	  cultured	  for	  4	  
days	   in	   control	   or	   +Ani	   Differentiation	   medium.	   C-­‐D.	   Quantification	   of	   OLP	  
formation	  and	  relative	  cell	  density	  in	  control	  and	  +Ani	  conditions. 
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Olig2-­‐S263A	  expression	  vector	  construction	  
	  
To	   analyze	   Olig2	   S263	   phosphorylation	   in	   vitro,	   I	   generated	   expression	   vector	   constructs	  
encoding	   3xFLAG-­‐tagged	   wild-­‐type	  Olig2	   (Olig2WT)	   and	   3xFLAG-­‐tagged	   phospho-­‐null	  Olig2-­‐
S263A	  (Olig2S263A).	  The	  mouse	  Olig2	  cDNA	  had	  previously	  been	  subcloned	  into	  the	  pcDNA4.1	  
expression	   vector	   backbone	   (Figure	   4)	   (obtained	   from	   U.	   Grazini).	   I	   used	   a	   site-­‐directed	  
mutagenesis	  strategy	  to	  produce	  the	  Olig2S263A-­‐pcDNA4.1	  from	  the	  Olig2WT-­‐pcDNA4.1	  parent	  
template	   (Figure	   4).	   Briefly,	   oligonucleotide	   primers	   containing	   an	   intended	   base-­‐pair	  
mismatch	   –	   to	   produce	   a	   serine	   (TCA)	   to	   alanine	   (GCA)	   codon	   change	   –	  were	   used	   in	   the	  
mutagenic	  PCR	  reaction.	  The	  methylated	  parent	  vector	  was	  destroyed	  by	  digestion	  with	  DpnI	  
and	   the	   Olig2S263A-­‐pcDNA4.1	   vector	   transformed	   into	   competent	   cells	   for	   nick	   repair	   and	  
plasmid	   preparation.	   Sequencing	   and	   BLAST	   alignment	   with	   Mus	   musculus	   Olig2	   cDNA	  
sequence	   confirmed	   incorporation	   of	   the	   desired	   mutation	   and	   successful	   generation	   of	  
Olig2S263A-­‐pcDNA4.1	  (Figure	  4D).	  
	  
I	   replaced	   the	   3’	  Myc	   tag	   with	   a	   3xFLAG	   tag	   (Figure	   5A).	   The	   3xFLAG	   tag	   fragment	   was	  
designed	  to	   include	  5’	  XbaI	  and	  3’	  AgeI	  restriction	  sites,	  and	  was	  synthesized	  commercially.	  
The	  Myc	  tag	  was	  excised	  from	  the	  Olig2WT-­‐	  and	  Olig2S263A-­‐pcDNA4.1	  and	  substituted	  with	  the	  
3xFLAG	   tag	   using	   XbaI	   and	   AgeI	   restriction	   enzymes.	   Successful	   3xFLAG	   insertion	   was	  
confirmed	  by	  sequencing	  and	  ClustalO	  alignment	  with	  Mus	  musculus	  Olig2	  cDNA	  and	  3xFLAG	  
tag	  sequences.	  
	  
To	   confirm	   functionality	   of	   the	   constructs,	   I	   transfected	   Olig2-­‐negative	   C6	   glioma	   cells	   in	  
culture	   with	   either	   the	   Olig2WT-­‐	   or	   Olig2S263A-­‐pcDNA4.1	   expression	   vectors	   and	   analysed	  
Olig2WT/Olig2S263A	  expression	  by	  WB	  with	  a	  rabbit	  anti-­‐Olig2	  antibody	  (Figure	  5B).	  Olig2	  was	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Figure	  4.	  Olig2-­‐S263A	  mutagenesis.	  A.	  Protein	  and	  DNA	  sequences	  in	  Olig2WT	  and	  Olig2S263A.	  
B.	   Vector	   map	   of	   pcDNA4.1-­‐Olig2WT	   previously	   generated	   in	   the	   lab.	   C.	   Graphical	  
representation	  of	  the	  site-­‐directed	  mutagenesis	  strategy.	  Mutant	  Olig2-­‐S263A	  is	  synthesized	  
by	   PCR	   with	   mutagenic	   primers	   from	   the	   pcDNA4.1-­‐Olig2WT	   template.	   Methylated	  
pcDNA4.1-­‐Olig2WT	   is	   removed	   by	   digestion	  with	  DpnI,	   leaving	   only	   the	   desired	  pcDNA4.1-­‐
Olig2S263A	   for	   nick	   repair	   and	   purification.	   D.	   Olig2WT	   and	   Olig2S263A	   mutant	   construct	  
sequences	  and	  BLAST	  alignment	  with	  the	  mouse	  Olig2	  coding	  sequence.	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Figure	   5.	   Incorporation	   of	   the	   3’	   3XFLAG	   tag	   into	   Olig2
WT
-­‐	   &	   Olig2
S263A
-­‐pcDNA4.1.	   A.	   Olig2
WT
-­‐	   &	  
Olig2
S263A
-­‐pcDNA4.1	   3’	   Myc	   tag	   replaced	   with	   3xFLAG	   (FLAG)	   tag	   using	   XbaI	   and	   AgeI	   restriction	  
enzymes.	   Generation	   of	   the	   complete	  Olig2
WT
-­‐	   &	  Olig2
S263A
-­‐pcDNA4.1	   constructs	   was	   confirmed	   by	  










-­‐pcDNA4.1	  were	  transfected	  into	  cultured	  C6	  cells	  and	  Olig2	  expression	  analysed	  
by	  WB	  with	  an	  anti-­‐Olig2	  antibody.	  	  
	  
Olig2-­‐S263A	  PAC	  construction	  
	  
In	  order	  to	  examine	  the	  function	  of	  Olig2	  S263	  phosphorylation	  in	  vivo,	  I	  aimed	  to	  generate	  a	  
transgenic	   mouse	   line	   carrying	   a	   modified	   version	   of	   the	   original	   Olig2	   P1	   artificial	  
chromosome	   (PAC)	   encoding	   the	   phospho-­‐null	   mutant	   Olig2-­‐S263A	   (Olig2S263A)	   (Li	   et	   al.,	  
2011).	   Crossing	   the	   Olig2+/+;Olig2S263A	   transgenic	   mouse	   line	   with	   the	   viable	   Olig2+/-­‐	   line	  
B	  
A	  
CHAPTER	  6	  Olig2	  S263	  phosphorylation	   	   	  	  
	   181	  
maintained	   in	   the	   lab,	   it	   would	   be	   possible	   after	   two	   generations	   to	   generate	   Olig2-­‐/-­‐
;Olig2S263A	   mice.	   Endogenous	   expression	   of	   the	   phospho-­‐null	   Olig2-­‐S263A	   mutant	   on	   an	  
Olig2-­‐null	  background	  will	  enable	  functional	  analysis	  of	  S263	  phosphorylation	  at	  behavioural,	  
histological	  and	  molecular	   levels.	  Given	  Olig2	  knockout	   in	  mice	  becomes	   lethal	  at	  birth,	  the	  
Olig2-­‐/-­‐;Olig2S263A	  mice	  would	  be	  expected	   to	   survive	   through	  embryogenesis	   and	   therefore	  
provide	  a	  useful	  experimental	  tool	  for	  functional	  analysis.	  As	  a	  necessary	  control,	  I	  also	  aimed	  
to	  generate	  a	  transgenic	  mouse	  line	  carrying	  the	  corresponding	  Olig2WT	  PAC.	  	  
	  
Using	  the	  Olig2WT-­‐	  and	  Olig2S263A-­‐pcDNA4.1	  expression	  vectors,	   I	   initially	  generated	  Olig2WT-­‐
/Olig2S263A	   targeting	   vectors	   (Figure	   6).	   I	   excised	   and	   purified	   the	  Olig2WT-­‐/Olig2S263A-­‐FLAG	  
cassette	   using	   restriction	   enzymes	   KpnI	   and	   AgeI	   and	   agarose	   gel	   purification.	   In	   parallel,	  
using	   restriction	   enzymes	   KpnI	   and	  BglII,	   I	   excised	   the	   5’	  Olig2	   homology-­‐Olig2	  ORF-­‐CreERT2	  
cassette	   from	   the	  pBlueScript-­‐Olig2	   targeting	   vector	   and	  purified	   the	  pBlueScript	   backbone	  
by	   agarose	   gel	   purification.	   The	  Olig2WT/Olig2S263A-­‐FLAG	   cassette	  was	   ligated	   using	   T4	  DNA	  
ligase	  into	  the	  pBlueScript-­‐Olig2	  targeting	  vector	  backbone,	  and	  electroporated	  into	  XL1-­‐Blue	  
E.	   coli	   for	   plasmid	   preparation.	   Sequencing	   and	   ClustalO	   alignment	   confirmed	   successful	  
generation	  of	  Olig2WT	  and	  Olig2S263A	  targeting	  vectors.	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Figure	   6.	   Generation	   of	  Olig2WT	   &	   	  Olig2S263A	   targeting	   vectors.	   The	  Olig2WT	  &	   	  Olig2S263A	   cassettes	  
were	  excised	  from	  pcDNA4.1	  using	  restriction	  enzymes	  KpnI	  and	  AgeI,	  and	  cloned	  into	  the	  pBlueScript	  
targeting	   vector	   backbone	   using	   KpnI	   and	   BglII.	   Generation	   of	   the	   Olig2WT	   &	   	   Olig2S263A	   targeting	  
vectors	  was	  confirmed	  by	  sequencing	  and	  ClustalO	  sequence	  alignment	  with	  the	  known	  FLAG	  tag	  and	  
chloramphenicol	  resistance	  (ChlorR)	  cassette	  sequences.	  	  
	  
	  
Finally,	   in	  order	   to	   visualize	  expression	  of	   the	  Olig2WT-­‐/Olig2S263A-­‐FLAG	   transgenes	   in	   vivo,	   I	  
incorporated	  an	   IRES-­‐mCherry	   cassette	   immediately	  downstream	  of	   the	  Olig2WT-­‐/Olig2S263A-­‐
FLAG	   sequence	   (Figure	   7).	   The	   IRES-­‐mCherry	   cassette	   was	   excised	   from	   the	   commercially	  
available	  pmCherry	  C1	   vector	  using	   restriction	  enzymes	  NheI	   and	  XbaI	   and	   ligated	   into	   the	  
Olig2WT/Olig2S263A	  targeting	  vector.	  Sequencing	  and	  ClustalO	  alignment	  confirmed	  successful	  
generation	  of	  the	  complete	  Olig2WT	  and	  Olig2S263A	  targeting	  vectors,	  including	  a	  3’	  3xFLAG	  tag	  
and	  IRES-­‐mCherry	  cassette.	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Figure	  7.	  Incorporation	  of	  the	  IRES-­‐mCherry	  cassette	  into	  Olig2WT	  &	  	  Olig2S263A	  targeting	  vectors.	  The	  
IRES-­‐mCherry	  cassette	  was	  excised	  from	  the	  pmCherryC1	  parent	  vector	  using	  restriction	  enzymes	  NheI	  
and	   XbaI,	   and	   cloned	   into	   Olig2WT	   &	   	   Olig2S263A	   targeting	   vectors	   using	   NheI.	   Generation	   of	   the	  
complete	  Olig2WT	  &	  	  Olig2S263A	  targeting	  vectors	  was	  confirmed	  by	  sequencing	  and	  ClustalO	  sequence	  
alignment	  with	  the	  known	  FLAG	  tag	  and	  IRES-­‐mCherry	  cassette	  sequences.	  	  
	  
The	   complete	   and	   validated	   targeting	   vectors	   were	   used	   for	   homologous	   recombination-­‐	  
(HR-­‐)	  mediated	  modification	   of	   the	   original	  Olig2	   PAC	   in	   Escherichia	   coli	   (Figure	   8).	   E.	   coli	  
strain	   EL250	   carries	   a	   bacteriophage	   lambda	   prophage	   encoding:	   1.	   the	   double-­‐stranded	  
break	  repair	  recombinase	  proteins	  Exo	  and	  Beta	  under	  the	  control	  of	  a	  temperature-­‐sensitive	  
cI	  repressor;	  2.	  arabinose-­‐inducible	  Flp	  recombinase	  for	  site-­‐specific	  recombination	  between	  
frt	   sites	   (Lee	   et	   al.,	   2001).	   In	   electrocompetent	   E.	   coli	   EL250	   bacteria,	   heat-­‐shock	   at	   42oC	  
induced	   recombinase	   protein	   expression.	   I	   introduced	   either	   the	   complete	   Olig2WT	   or	  
Olig2S263A	   linearized	   targeting	   vectors	   by	   electroporation.	   Homologous	   recombination	  
between	  the	  5’	  Olig2	  ORF	  and	  3’	  homology	  region	  (Olig2	  3’	  Hom)	  generated	  the	  Olig2WT-­‐	  and	  
Olig2S263A-­‐PACs.	   PAC-­‐containing	   EL250	   bacteria	   were	   selected	   using	   the	   insert-­‐specific	  
chloramphenicol	   resistance	   (ChlorR)	   and	   pPAC4	   backbone-­‐specific	   kanamycin	   resistance	  
(KanR)	   cassettes.	   The	   frt-­‐ChlorR-­‐frt	   cassette	   was	   removed	   by	   arabinose-­‐inducible	   Flp	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expression	   and	   frt	   recombination	   (Figure	   9A).	   	   At	   this	   stage,	   Olig2WT-­‐	   or	   Olig2S263A-­‐PAC	  
generation	   and	   subsequent	   Flp/frt-­‐mediated	   ChlorR	   excision	   was	   assessed	   by	   colony	   PCR	  
using	  a	  forward	  primer	  that	  specifically	  annealed	  within	  the	  mCherry	  sequence	  and	  a	  reverse	  
primer	   that	   specifically	  annealed	  downstream	  of	   the	   inserted	  construct,	  within	   the	  original	  
Olig2	  PAC	  sequence	  (Figure	  9B).	  Agarose	  gel	  analysis	  of	  the	  PCR	  products	  indicated	  successful	  
Exo/Beta	   and	   Flp/frt	   recombination.	   The	   Olig2WT-­‐	   and	   Olig2S263A	   PACs	   were	   purified	   then	  
linearized	  with	  PvuI.	  The	  digests	  were	  resolved	  by	  pulse	  field	  gel	  electrophoresis	  (Figure	  9C)	  
and	  the	  linearized	  Olig2WT	  and	  Olig2S263A	  PACs	  purified	  for	  pronuclear	  injection	  in	  mice.	  
	  
Over	   the	   course	   of	   the	   project,	   the	   Olig2WT	   and	   Olig2S263A	   PAC-­‐transgenic	   lines	   were	   not	  
established	   with	   time	   for	   generation	   of	  Olig2-­‐/-­‐;Olig2WT/S263A	   mice	   and	   phenotypic	   analysis,	  
primarily	   because	   of	   building	  works	   that	   disrupted	   transgenic	   production	   across	   the	   board	  
for	  more	  than	  a	  year.	  This	  work	  is	  continuing	  as	  a	  high	  priority	  in	  the	  lab,	  and	  will	  –	  we	  expect	  
–	  produce	  robust	  and	  informative	  data	  regarding	  the	  function	  of	  Olig2	  S263	  phosphorylation	  
in	  vivo.	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6.3	   DISCUSSION	  
	  
Transcription	   factor	   Olig2	   is	   expressed	   in	   multiple	   discrete	   populations	   of	   neurogenic	   and	  
gliogenic	  NSCs	  and	  in	  OL	  lineage	  cells	  for	  the	  duration	  of	  OL	  development	  and	  myelination.	  In	  
its	   different	   cellular	   environments,	   Olig2	   has	   been	   shown	   to	   perform	   a	   broad	   range	   of	  
functions,	  underscored	  by	  an	  array	  of	  specific	  molecular	  activities	  (Meijer	  et	  al.,	  2012).	  Post-­‐
translational	   modification	   is	   a	   well-­‐known	   mediator	   of	   Olig2	   function.	   Serine	  
phosphorylation,	   for	   example,	   critically	   regulates	   NSC	   proliferation	   and	   differentiation	   by	  
altering	  Olig2	  intracellular	  localisation	  and	  cofactor	  choice	  (Setoguchi	  &	  Kondo,	  2004;	  Sun	  et	  
al.,	  2011;	  Li	  et	  al.,	  2011;	  Meijer	  et	  al.,	  2014).	  
	  
Computational	  analysis	  of	  Olig2	  phosphorylation	  	  
	  
Of	   the	  annotated	  Mus	  musculus	  protein	  sequences,	   I	   report	  known	  TFs	  have	  a	   significantly	  
higher	   percentage	   serine	   content	   than	   non-­‐TFs.	  Moreover,	  with	   50	   serine	   residues	   among	  
323	  amino	  acids	  (15%),	  Olig2	  reveals	  itself	  as	  an	  exceptionally	  serine-­‐rich	  transcription	  factor,	  
ranking	   13th	   of	   542	   TFs	   in	   total.	   Given	   that	   serine	   phosphorylation	   is	   a	   widespread	  
mechanism	   for	   regulating	   protein	   function,	   the	   high	   serine	   content	   of	   Olig2	   suggests	   an	  
abundance	   of	   potential	   phosphorylation	   states	   and	   complex	   modulation	   of	   activity	  
(Whitmarsh	  &	  Davis,	  2000).	  Two-­‐dimensional	  PAGE	  has	  previously	  revealed	  a	  wide	  range	  of	  
differently	  electrically	  charged	  isoforms	  of	  wild-­‐type	  Olig2	  (Li	  et	  al.,	  2011).	  Critically,	  after	  calf	  
intestinal	   alkaline	   phosphatase	   treatment,	   the	   Olig2	   signal	   collapsed	   to	   a	   single	   isoelectric	  
point,	   indicating	  that	  the	  charge	  variants	  corresponded	  to	  different	  phospho-­‐forms	  of	  Olig2	  
(Li	  et	  al.,	  2011).	  I	  used	  the	  online	  tool	  NetPhos	  2.0	  to	  predict	  phosphorylation	  sites	  within	  the	  
human	  Olig2	  primary	  sequence.	  NetPhos	  2.0	  identified	  25	  putative	  phospho-­‐acceptor	  serines	  
in	   human	  Olig2.	   In	   addition,	   ClustalO	   alignment	   indicates	   96%	  of	   these	   serine	   residues	   are	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conserved	   in	   mouse,	   68%	   in	   chick	   and	   40%	   in	   zebrafish,	   with	   the	   degree	   of	   evolutionary	  
conservation	  providing	  evidence	  of	  potential	  functionality.	  Together,	  the	  published	  2D	  PAGE	  
and	   computational	   analysis	   suggest	   that	  Olig2	   can	  be	  phosphorylated	  at	  multiple	   sites	   and	  
that	  the	  phospho-­‐acceptor	  residues	  are	  critical	  to	  Olig2	  function.	  
	  
Combinatorial	   (de)phosphorylation	  would	  alter	  the	  molecular	  properties	  of	  Olig2	  and	  might	  
enable	  precise	  modification	  of	  Olig2	   function	  under	  different	  conditions.	  Generation	  of	   the	  
multiple	   phospho-­‐forms	   of	   Olig2	   would	   be	   determined	   by	   signaling	   pathway-­‐induced	  
activation	  of	  downstream	  kinase/phosphatase	  enzymes.	  Serine-­‐rich	  TFs	  such	  as	  Olig2	  could	  
therefore	  act	  as	  signal	  integration	  hubs,	  with	  multiple	  pathways	  converging	  on	  a	  single	  TF	  to	  
mediate	   the	   appropriate	   cellular	   response.	   To	   predict	   the	   kinases	   and	   upstream	   signaling	  
pathways	  that	  target	  those	  sites	   identified	  by	  NetPhos	  2.0,	   I	  used	  the	  online	  tool	  NetPhosK	  
1.0.	  This	  indicated	  that	  the	  predicted	  phospho-­‐acceptor	  serine	  residues	  are	  substrates	  for	  an	  
assortment	  of	  different	   intracellular	   kinases	   (Pearce	  et	  al.,	   2010;	  Varjosalo	  et	  al.,	   2013).	  Of	  
the	   predicted	   kinases,	   several	   have	   been	   linked	   to	   oligodendrocyte	   development	   and	  
myelination,	  with	  PKA	  and	  CK2	  previously	  implicated	  in	  direct	  phosphorylation	  of	  Olig2	  (Azim	  
&	  Butt	  et	  al.,	  2011;	  Tang	  et	  al.,	  1998;	  Fragoso	  et	  al.,	  2007;	  Li	  et	  al.,	  2011;	  Baron	  et	  al.,	  2000;	  
Huillard	   et	   al.,	   2010).	   It	  will	   be	   interesting	   to	   explore	  whether	   the	   reported	   roles	   of	   these	  
kinases	  in	  OL	  lineage	  cells	  are	  mediated	  through	  direct	  phosphorylation	  of	  Olig2.	  
	  
Ultimately,	  on	  top	  of	  the	  computational	  analysis	  presented	  here,	  establishing	  the	  bona	  fide	  
phosphorylation	  of	  amino	  acid	  residues	  in	  Olig2	  will	  be	  crucial	  to	  understanding	  the	  role	  and	  
regulation	   of	   Olig2	   in	   different	   cells	   and	   at	   different	   stages	   of	   development.	   Mass	  
spectrometry	   and/or	   Edman	   degradation	   analysis	   of	   Olig2	   extracted	   from	   specific	   sources	  
(NSCs	  or	  OLPs,	  for	  example),	  in	  conjunction	  with	  in	  vitro	  phosphorylation	  assays,	  will	  provide	  
robust	   evidence	   for	   the	   genuine	   phospho-­‐modification	   of	   the	   as	   yet	   unvalidated	   phospho-­‐
CHAPTER	  6	  Olig2	  S263	  phosphorylation	   	   	  	  
	   189	  
acceptor	   residues.	   	   Furthermore,	   phospho-­‐null	   (and	   potentially	   phospho-­‐mimetic)	  
mutagenesis	   studies	   –	   both	   in	   vivo	   and	   in	   vitro	   –	   will	   elucidate	   the	   impact	   of	   acquiring	  
different	   reversible	   phosphorylation	   states	   on	   the	   molecular	   activity	   and	   developmental	  
function	  of	  Olig2.	  
	  
Olig2	  Serine	  263	  
	  
Of	   the	   novel	   phosphorylation	   sites	   predicted	   by	   computational	   analysis,	   I	   selected	   the	  
carboxy	   terminal	  S263	   for	   further	  analysis.	  Mass	  spectrometry	  performed	  on	  Olig2	  purified	  
from	  transfected	  COS	  cells	  mapped	  a	  high	  confidence	  phosphorylation	  site	   to	  S263	   (Sun	  et	  
al.,	   2011).	   In	   contrast	   to	   the	   typical	   nuclear	   localization	   of	   Olig2,	   however,	   ectopic	   Olig2	  
expressed	  in	  COS	  cells	  was	  primarily	  cytoplasmic.	  In	  addition,	  S263	  phosphorylation	  was	  not	  
seen	   in	   MS	   analysis	   of	   endogenous	   Olig2	   isolated	   from	   mouse	   neurosphere	   cultures	   and	  
grafted	  human	  glioma	  cells.	  As	  such,	  phospho-­‐S263	  was	  initially	  reported	  by	  Sun	  et	  al.	  (2011)	  
as	   a	   potentially	   artefactual	   by-­‐product	   of	   the	   in	   vitro	   COS	   system.	   Nonetheless,	   the	  
observation	   of	   S263	   phosphorylation	   by	  MS	   confirms	   S263	   is	   a	   genuine	   phospho-­‐acceptor	  
and	   it	   remains	  possible	   that	  S263	  phosphorylation	  occurs	   in	  vivo,	  potentially	   regulating	   the	  
nuclear/cytoplasmic	  localisation	  of	  Olig2.	  
	  
Computational	   analysis	   revealed	   that	   S263	   is	   a	   predicted	   P38-­‐MAPK	   target.	   Mitogen-­‐
activated	  protein	  kinases	  (MAPKs)	  consist	  of	  families	  of	  Ser/Thr-­‐specific	  kinases	  that	  mediate	  
the	  intracellular	  responses	  to	  extracellular	  stimuli	  through	  protein	  phosphorylation	  signaling	  
cascades.	  Four	  distinct	  subgroups	  within	  the	  MAPK	  family	  have	  been	  identified,	  one	  of	  which	  
is	  the	  P38-­‐MAPKs.	  P38-­‐MAPKs	  are	  activated	  by	  dual	  phosphorylation	  at	  conserved	  residues,	  
catalyzed	  by	  upstream	  MAP	  kinase	  kinases	  (Zarubin	  &	  Han,	  2005).	  Downstream	  substrates	  of	  
P38-­‐MAPK	   include	   additional	   kinases,	   as	  well	   as	   transcription	   factors	   that	   directly	   regulate	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gene	   expression	   in	   response	   to	   P38-­‐MAPK-­‐mediated	   phosphorylation,	   such	   as	   Cyclic	   AMP	  
response	  element-­‐binding	  protein	  (CREB)	  and	  Activating	  transcription	  factor	  1	  (ATF1)	  (Tan	  et	  
al.,	  1996).	  	  
	  
Research	  from	  a	  number	  of	  labs	  has	  revealed	  important	  roles	  of	  P38-­‐MAPK	  signaling	  in	  OLP	  
differentiation	   and	   myelination	   (Baron	   et	   al.,	   2000;	   Fragoso	   et	   al.,	   2007;	   Hu	   et	   al.,	   2012;	  
Rafalski	   et	   al.,	   2013).	   I	   analyzed	   the	   effect	   of	   the	  potent	   P38-­‐MAPK	   agonist	   anisomycin	   on	  
OLP	  specification	  from	  NSCs	  in	  vitro	  (Zinck	  et	  al.,	  1995).	  Using	  wild-­‐type	  primary	  NSC	  cultures,	  
I	  confirmed	  that	  anisomycin	  activates	  P38-­‐MAPK	  and	  observed	  a	  near-­‐complete	  ablation	  of	  
OLP	   formation	   in	   anisomycin-­‐treated	   cultures.	   It	   should	   be	   acknowledged,	   however,	   that	  
these	  data	  do	  not	  prove	  a	  causal	  link	  between	  P38-­‐MAPK	  activation	  and	  NSC	  differentiation.	  
Anisomycin	   is	   a	   translational	   inhibitor	   of	   protein	   synthesis	   that	   activates	   kinase	   pathways	  
besides	  P38,	  including	  the	  ribosomal	  S6	  kinases	  (RSKs)	  and	  stress-­‐activated	  c-­‐Jun	  N-­‐terminal	  
kinases	  (JNKs)	  (Kardalinou	  et	  al.,	  1994;	  Hazzalin	  et	  al.,	  1998).	   It	  remains	  possible,	  therefore,	  
that	  the	  effect	  of	  anisomycin	  treatment	  on	  generation	  of	  OLPs	  from	  primary	  NSCs	  in	  culture	  
occurs	  via	  a	  non-­‐P38-­‐mediated	  pathway.	  Indeed,	  the	  anti-­‐OL	  effects	  of	  anisomycin	  treatment	  
described	   here	   contrast	   with	   the	   published	   data	   on	   P38	   activity	   and	   OL	   development.	  
Selective	   P38	   inhibition	   using	   small	   molecule	   antagonists	   indicates	   that	   P38	   activity	   is	  
necessary	   for	  myelin	   formation,	   and	   the	   expansion	   and	   differentiation	   of	   OLPs	   (Cui	   et	   al.,	  
2014;	  Hu	  et	  al.,	  2012;	  Rafalski	  et	  al.,	  2013;	  Haines	  et	  al.,	  2008;	  Bhat	  et	  al.,	  2007;	  Fragoso	  et	  
al.,	   2007).	   Understanding	   the	   results	   shown	   here	   will	   require	   distinguishing	   the	   critical	  
factor(s)	   mediating	   the	   anisomycin-­‐induced	   inhibition	   of	   oligodendrogenesis.	   If	   P38	   were	  
isolated	  as	  a	  key	  component	  of	  the	  anti-­‐OLP	  specification	  pathway	  activated	  in	  anisomycin-­‐
treated	   NSCs,	   this	   would	   demonstrate	   opposing	   functions	   for	   P38	   in	   NSCs	   and	   OLPs,	  
inhibiting	  and	  promoting	  OL	  lineage	  progression,	  respectively.	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Research	  exploring	  the	  mechanisms	  of	  P38-­‐mediated	  regulation	  of	  rodent	  OLP	  differentiation	  
revealed	   that	   P38	   regulates	   the	   DNA-­‐binding	   activity	   of	   OL	   lineage	   TF	   Sox10	   (Chew	   et	   al.,	  
2010).	   Activated	   P38	   is	   proposed	   to	   induce	   Sox10	   occupancy	   of	   and	   thereby	   transcription	  
from	  myelin	  gene	  promoters,	   including	  MBP.	  It	  should	  be	  noted	  that	  Chew	  et	  al.	  (2010)	  did	  
not	   confirm	  direct	   phosphorylation	   of	   Sox10	   by	   P38-­‐MAPK,	   so	   the	   reported	   impact	   of	   P38	  
activation/inhibition	  on	  Sox10	  activity	  might	  occur	  via	  regulation	  of	  an	  additional	  factor,	  such	  
as	   Olig2.	   In	   fact,	   analysis	   of	   Sox	   protein	   cofactor	   choice	   indicated	   that	   mouse	   Sox10	   can	  
physically	   interact	   with	   Olig2	   (Wissmuller	   et	   al.,	   2006;	   Li	   et	   al.,	   2007).	   Moreover,	   the	  
computational	  prediction	  of	  kinase	  substrate	  residues	  in	  human	  Olig2,	  shown	  here,	  identified	  
S263	  –	  conserved	  in	  mouse	  and	  chick	  –	  as	  a	  P38-­‐MAPK	  target.	  P38-­‐induced	  phosphorylation	  
of	   Olig2	   S263	   might	   regulate	   Olig2/Sox10	   complex	   formation	   and	   thereby	   alter	   the	   DNA-­‐
binding	  activity	  of	  Sox10	   in	  mammalian	  OLPs.	   In	  zebrafish,	  by	  contrast,	  Olig2	  and	  Sox10	  do	  
not	  associate	  and	  –	  on	   the	  basis	  of	  protein	  sequence	  alignment	  –	  human	  Olig2	  S263	   is	  not	  
conserved	  (Li	  et	  al.,	  2007).	  The	  correlation	  between	  the	  presence	  or	  absence	  of	  S263	  and	  the	  
ability	   of	   Sox10	   and	   Olig2	   to	   interact	   in	   zebrafish	   versus	   mouse	   is	   consistent	   with	   S263	  
facilitating	  Olig2/Sox10	   complex	   formation.	   In	   any	   case,	   P38-­‐MAPK	   signaling	  has	   important	  
consequences	  for	  OL	  development,	  the	  roles	  of	  Olig2	  in	  which	  remain	  to	  be	  fully	  established.	  
	  
In	   addition	   to	   P38-­‐MAPK,	  Olig2	   S263	   is	   a	   predicted	   target	   of	   other	   kinases	  with	   important	  
functions	   in	   OL	   development,	   including	   CDK5	   and	   GSK3.	   Below	   is	   a	   brief	   summary	  
highlighting	  the	  various	  roles	  of	  CDK5	  and	  GSK3	  in	  the	  OL	  lineage:	  
	  
Cyclin	  dependent	  kinase	  5	  (CDK5)	  
The	  cyclin-­‐dependent	  kinases	  (CDKs)	  are	  a	  family	  of	  protein	  kinases	  predominantly	  involved	  
in	  cell	  cycle	  regulation.	  However,	  CDK5	  –	  related	  to	  CDK1	  –	  has	  not	  been	  implicated	  in	  control	  
of	   cell	   cycle	   progression.	   CDK5	   is	   activated	   exclusively	   in	   the	   nervous	   system	   by	   the	   CNS-­‐
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specific	   co-­‐activators	   P35	   and	   P39,	   and	   critically	   regulates	   certain	   aspects	   of	   neural	  
development	   including	  OL	  migration,	  differentiation	  and	  myelination	   (Lew	  et	  al.,	  1994;	  Tsai	  
et	  al.,	  1994;	  Tang	  et	  al.,	  1998;	  Miyamoto	  et	  al.,	  2007;	  Miyamoto	  et	  al.,	  2008;	  He	  et	  al.,	  2011;	  
Yang	   et	   al.,	   2013;	   Luo	   et	   al.,	   2014).	   Research	   from	   Tang	   et	   al.	   (1998)	   reported	   that	  
differentiation	  of	  OLs	   in	  culture	   is	  accompanied	  by	   increasing	  CDK5	  activity,	  suggesting	  that	  
CDK5	   plays	   a	   role	   in	   OL	   differentiation	   (Tang	   et	   al.,	   1998).	   In	   vitro,	   inhibition	   of	   CDK5	  
impaired	  OL	  differentiation	  and	   reduced	  OLP	  migration	   in	   response	   to	  PDGF	   (Miyamoto	  et	  
al.,	   2007;	   Miyamoto	   et	   al.,	   2008).	   In	   addition,	   Emx1-­‐Cre-­‐	   and	   Olig1-­‐Cre-­‐mediated	   CDK5	  
knockout	   in	   mice	   impairs	   OL	   differentiation	   in	   vivo	   and	   generates	   a	   hypomyelination	  
phenotype	  (He	  et	  al.,	  2011;	  Yang	  et	  al.,	  2013).	  In	  CNP-­‐Cre;CDK5fl/fl	  conditional	  knockout	  mice,	  
myelin	   repair	   is	   also	   significantly	   reduced	   in	   response	   to	   focal	   demyelinating	   lesions	  
compared	   to	  wild-­‐type	   animals,	   despite	   increased	   numbers	   of	   Olig2-­‐expressing	   OL	   lineage	  
cells	  (Luo	  et	  al.,	  2014).	  With	  regard	  to	  the	  mechanisms	  of	  CDK5-­‐mediated	  regulation	  of	  OLP	  
migration	   and	   differentiation,	   direct	   phosphorylation	   of	   WAVE2	   and	   Paxillin	   have	   been	  
proposed	   respectively	   (Miyamoto	  et	   al.,	   2007;	  Miyamoto	  et	   al.,	   2008).	   It	   remains	   possible,	  
however,	   that	  Olig2	   is	   itself	  a	  downstream	  target	  of	  CDK5	  and	   is	   responsible	   for	  mediating	  
CDK5	  function	  in	  OL	  development.	  
	  
Glycogen	  synthase	  kinase	  3	  (GSK3)	  
Initially	  classified	  as	  a	  kinase	  exclusively	  involved	  in	  glycogen	  metabolism,	  glycogen	  synthase	  
kinase	  3	  has	  since	  been	  established	  as	  a	  critical	  mediator	  of	  multiple	  cell	  signaling	  pathways,	  
including	   proliferation	   and	   differentiation	   signals	   (Cohen	   &	   Frame,	   2001).	   Indeed,	   GSK3B	  
mediates	  signaling	  by	  insulin-­‐growth	  factor	  1	  (IGF-­‐1),	  fibroblast	  growth	  factor	  2	  (FGF-­‐2),	  Wnt	  
and	   Notch,	   all	   of	   which	   have	   established	   and	   important	   roles	   in	   OL	   specification	   and/or	  
development	  (Wang	  et	  al.,	  1998;	  Baron	  et	  al.,	  2000;	  Zeger	  et	  al.,	  2007;	  Langseth	  et	  al.,	  2010).	  
Exploring	   the	   role	   of	   GSK3B	   in	   OL	   differentiation	   in	   the	   developing	   white	   matter	   by	  
CHAPTER	  6	  Olig2	  S263	  phosphorylation	   	   	  	  
	   193	  
intraventricular	  administration	  of	  GSK3B	  inhibitors	  revealed	  that	  GSK3B	  is	  a	  potent	  negative	  
regulator	  of	  OL	  differentiation	  in	  vivo	  (Azim	  &	  Butt,	  2011).	  In	  experiments	  aimed	  at	  analysing	  
the	  role	  of	  GSK3	  signaling	  on	  OLP	  generation	  in	  the	  postnatal	  subventricular	  zone,	  inhibition	  
of	  GSK3B	  robustly	  stimulated	  NSC	  proliferation	  and	  oligodendrogenesis	  (Azim	  et	  al.,	  2014).	  In	  
addition,	  CDK5	  modulation	  of	  OL	  development	  and	  myelination	  is	  mediated	  in	  part	  through	  
CDK5-­‐induced	  inactivation	  of	  GSK3B	  (Luo	  et	  al.,	  2014).	  The	  protein	  substrates	  of	  GSK3B	  that	  
mediate	   its	   inhibitory	   role	   in	   OL	   differentiation	   have	   not	   been	   established.	   Olig2	   might,	  
therefore,	   be	   an	   important	   phosphorylation	   target	   and	   downstream	   effector	   of	   GSK3	  
signaling,	  with	  S263	  the	  target	  phospho-­‐acceptor	  residue	  within	  Olig2.	  
	  
Olig2-­‐S263A	  expression	  vector	  and	  PAC	  analysis	  
	  
The	  identification	  by	  Sun	  et	  al.	  (2011)	  of	  Olig2	  S263	  phosphorylation	  by	  MS,	  combined	  with	  
its	   evolutionary	   conservation	   and	   the	   computational	   prediction	   of	   S263	   as	   a	   substrate	   for	  
several	   protein	   kinases	   with	   known	   roles	   in	   OL	   lineage	   cell	   development/function	   justifies	  
further	  analysis	  of	  Olig2-­‐S263	  phosphorylation.	   I	  have	  reported	  successful	  construction	  of	  a	  
phospho-­‐null	   mutant	   Olig2-­‐S263A-­‐encoding	   expression	   vector	   and	   PAC	   for	   effective	  
examination	  of	  S263	  phosphorylation	  in	  vitro	  and	  in	  vivo.	  Here	  I	  will	  outline	  how	  these	  tools	  
can	  be	  used	  to	  yield	  information	  about	  regarding	  S263	  phosphorylation	  and	  its	  involvement	  
in	  OL	  development.	  
	  
The	  Olig2WT-­‐	   and	  Olig2S263A-­‐pcDNA	  4.1	   expression	   vectors	  will	   enable	   confirmation	   of	  Olig2	  
S263	  phosphorylation	  by	   P38/CDK5/GSK3	   in	   vitro.	   In	  Olig2WT-­‐transfected	  C6	   glioma	   cells	   in	  
culture,	  Olig2	   IP	   and	  WB	  using	  Olig2-­‐	   and	   phospho-­‐serine-­‐specific	   antibodies	  would	   detect	  
dynamic	   Olig2	   phosphorylation	   after	   drug-­‐induced	   activation	   or	   inhibition	   of	   the	  
P38/CDK5/GSK3	   signaling	   pathways.	   In	   this	   approach,	   altered	   Olig2/phospho-­‐serine	   WB	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signal	  under	  different	  conditions	  would	  indicate	  P38-­‐/CDK5-­‐/GSK3-­‐mediated	  phosphorylation	  
of	  wild-­‐type	  Olig2.	  Parallel	  experiments	  performed	  with	  Olig2S263A-­‐transfected	  C6	  cells	  would	  
indicate	  whether	  S263	  is	  a	  target	  phospho-­‐acceptor	  site	  under	  these	  conditions.	  
	  
Generation	  of	  Olig2WT	  and	  Olig2S263A	   PAC-­‐transgenic	  mice	  will	   enable	   in	   vivo	  analysis	  of	   the	  
developmental	   requirement	   for	   Olig2	   S263	   phosphorylation.	   Using	   the	  Olig2+/-­‐	   mouse	   line	  
maintained	   in	   the	   lab	   it	   will	   be	   possible	   to	   generate	  Olig2-­‐/-­‐;Olig2WT	   and	  Olig2-­‐/-­‐;Olig2S263A	  
mice.	   The	   complement	   of	   a	   single	   copy	   of	   wild-­‐type	   Olig2	   –	   expressed	   from	   a	   modified	  
version	   of	   the	   original	   Olig2	   PAC	   –	   is	   expected	   to	   be	   sufficient	   for	   Olig2-­‐/-­‐;Olig2WT	   PAC-­‐
transgenic	  mice	   to	   develop	   and	   survive	   normally	   (Li	   et	   al.,	   2011).	   In	  Olig2-­‐/-­‐;Olig2S263A	   PAC-­‐
transgenic	  mice,	  Olig2-­‐S263A	  expression	  will	  model	  constitutive	  dephosphorylation	  of	  Olig2	  
at	   S263.	   Deficits	   in	   CNS	   development	   and	   behaviour	   in	   Olig2-­‐/-­‐;Olig2S263A	   mice	   versus	   the	  
Olig2-­‐/-­‐;Olig2WT	  controls	  will	  therefore	  reveal	  the	  biological	  readouts	  of	  S263	  phosphorylation.	  
At	   a	   cellular	   level,	   inclusion	   of	   the	   IRES-­‐mCherry	   reporter	   construct	   will	   enable	  
straightforward	   analysis	   of	   Olig2	   expression	   and	   Olig2+	   cell	   number,	   character	   and	  
distribution	   at	   different	   stages	   of	   embryonic	   and	   post-­‐natal	   development.	   In	   addition	   to	  
supporting	  direct	  in	  vivo	  analysis,	  the	  Olig2-­‐/-­‐;Olig2S263A	  mice	  might	  provide	  a	  useful	  source	  of	  
cellular	  material	   for	   ex	   vivo	  molecular	   analysis	   of	  Olig2-­‐S263A,	   such	   as	   protein	   cofactor	   or	  




Computational	  examination	  indicates	  that	  Olig2	  contains	  multiple	  phospho-­‐acceptor	  residues	  
and	   that	   these	   residues	   are	   the	   targets	   of	   a	   number	   of	   different	   protein	   kinases.	   Of	   the	  
putative	   phosphorylation	   sites	   revealed	   in	   silico,	   S263	   –	   conserved	   in	   chick,	   mouse	   and	  
human	  –	  has	  previously	  been	  validated	  as	  a	  genuine	  phospho-­‐acceptor	  by	  MS	  analysis	  (Sun	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et	  al.,	  2011).	  Olig2	  S263	  is	  a	  predicted	  substrate	  for	  P38-­‐MAPK,	  GSK3	  and	  CDK5,	  kinases	  with	  
established	  roles	  in	  OL	  formation	  and	  myelination.	  An	  attractive	  hypothesis,	  therefore,	  is	  that	  
S263	   phosphorylation	   modifies	   Olig2	   function	   and	   directly	   mediates	   the	   effects	   of	   kinase	  
activity	  in	  OL	  lineage	  cells.	  A	  combination	  of	  in	  vitro	  and	  in	  vivo	  approaches	  using	  the	  Olig2-­‐
S263A	   expression	   and	   PAC	   constructs	   I	   have	   generated	   will,	   I	   anticipate,	   produce	   useful	  
information	  regarding	  Olig2	  S263	  phosphorylation.	  Ultimately,	  identifying	  the	  bona	  fide	  Olig2	  
phosphorylation	  sites,	  and	  determining	  the	  regulation	  of	  each	  modification	  and	  its	  impact	  on	  
Olig2	  function,	  will	  be	  fundamental	  to	  a	  detailed	  understanding	  of	  CNS	  development.	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CHAPTER	  7	  
SUMMARY	  &	  CONCLUSIONS	  
	  
	  
In	  the	  developing	  CNS,	  OLPs	  arise	   in	  discrete	  regions	  and	  at	  specific	  stages	  of	  development	  
(reviewed	  by	  Richardson	  et	  al.,	  2006).	   In	   the	   forebrain,	   the	   first	  OLPs	  emerge	   from	  ventral,	  
MGE-­‐resident	   NSCs	   at	   approximately	   E11.5	   in	   mouse.	   Successive	   waves	   of	  
oligodendrogenesis	  then	  occur	  from	  the	  LGE/CGE	  at	  ~E15	  and	  finally	  from	  the	  cortex	  at	  early	  
post-­‐natal	  stages.	  In	  the	  spinal	  cord,	  the	  majority	  (~80%)	  of	  OLPs	  derive	  from	  NSCs	  resident	  
in	   the	   ventral	   pMN	   domain,	   with	   the	   first	   pMN-­‐derived	   OLPs	   appearing	   at	   ~E12.5.	   The	  
remaining	  fraction	  is	  born	  later	  –	  from	  ~E15	  –	  from	  more	  dorsal	  regions	  of	  the	  spinal	  cord.	  In	  
terms	   of	   function,	   the	   different	   populations	   of	   OL	   lineage	   cells	   –	   defined	   according	   to	  
developmental	  origin	  –	  are	  typically	  redundant,	  although	  specific	  patterns	  of	  migration	  and	  
myelination	  have	  been	  described	  for	  the	  ventral	  and	  dorsal	  spinal	  OL	  populations	  (Kessaris	  et	  
al.,	   2006;	   Tripathi	   et	   al.,	   2011).	   The	   mechanisms	   underlying	   the	   precise	   spatio-­‐temporal	  
regulation	  of	  OLP	  formation	  during	  development,	  however,	  remain	  only	  partially	  understood.	  	  
	  
In	  the	  embryonic	  spinal	  cord,	  graded	  Shh	  signaling	  –	  emanating	  from	  the	  ventral	  notochord	  
and	  floorplate	  –	  induces	  combinatorial	  expression	  of	  specific	  TFs	  in	  ventricular	  zone	  NSCs	  at	  
different	   distances	   from	   the	   ventral	   midline	   (Dessaud	   et	   al.,	   2008).	   Specific	   TF	   expression	  
profiles	   define	   distinct	   progenitor	   domains,	   the	   NSC	   populations	   of	   which	   sequentially	  
generate	   characteristic	   neuronal	   and	   glial	   subtypes	   (Jessel,	   2000).	   In	   the	   case	   of	   the	   pMN	  
domain,	  the	  NSCs	  form	  MNs	  before	  switching	  to	  form	  OLPs.	  Expression	  of	  the	  bHLH	  TF	  Olig2	  
is	   specific	   to	   pMN	  NSCs	   and	   is	   essential	   for	   both	  MN	  and	  OLP	  production	   (Lu	   et	   al.,	   2000;	  
Zhou	  et	  al.,	  2000;	  Lu	  et	  al.,	  2002;	  Park	  et	  al.,	  2002;	  Zhou	  et	  al.,	  2002).	  Recent	  research	  from	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the	  Richardson	  lab	  has	  revealed	  a	  crucial	  role	  for	  Olig2	  phosphorylation	  in	  the	  MN-­‐OLP	  fate	  
switch	   (Li	   et	   al.,	   2011).	   Initially,	   during	   the	   patterning	   and	   neurogenic	   phases	   of	   spinal	  
development,	  Olig2	  is	  phosphorylated	  at	  S147.	  Dephosphorylation	  of	  S147	  profoundly	  alters	  
the	  molecular	  properties	  of	  Olig2	  and	  induces	  the	  switch	  in	  NSC	  fate.	  	  
	  
Regulation	  of	  Olig2	  phosphorylation	  and	  NSC	  fate	  
	  
At	   both	   molecular	   and	   cellular	   levels,	   the	   upstream	   signals	   that	   trigger	   Olig2	   S147	  
dephosphorylation	  and	   the	   fate	   switch	   are	  not	   known.	   In	   research	   focused	  on	  establishing	  
the	  developmental	  cues	  that	  govern	  the	  timing	  of	  the	  MN	  to	  OLP	  fate	  switch,	  I	  examined	  the	  
role	   of	   angiogenesis	   in	   pMN	   NSC	   development.	   Constructing	   a	   timeline	   of	   spinal	   cord	  
angiogenesis,	   the	  observed	  expansion	  of	   the	   vascular	   network	  over	   the	  period	  of	   the	  MN-­‐
OLP	  switch	  is	  consistent	  with	  an	  instructive	  role	  for	  angiogenesis	  in	  regulating	  pMN	  NSC	  fate.	  
The	   vasculature	   could,	   I	   hypothesized,	   directly	   induce	   the	   fate	   switch	   through	   one	   or	   a	  
combination	   of	   three	   signaling	  mechanisms:	   1.	  Oxygen	   signaling;	   2.	   Endocrine	   signaling;	   3.	  
EC-­‐NSC	  contact	  signaling.	  The	  results	  reported	  here	  indicate	  oxygen	  is	  an	  important	  regulator	  
of	  OLP	  specification	  in	  vitro.	  Research	  performed	  in	  mice,	  however,	  did	  not	  clearly	  establish	  
any	  regulatory	  function	  for	  oxygen	  or	  vascular	  development	  in	  spinal	  OLP	  formation	  in	  vivo.	  
Further	   research	   is	   required	   to	   establish	   if	   angiogenesis	   is	   necessary	   for	   timely	   OLP	  
production.	  
	  
In	   addition,	   fundamental	   to	   understanding	   the	   regulation	   of	   the	   fate	   switch	   will	   be	  
elucidating	   the	   intracellular	   signaling	   pathways	   that	   culminate	   in	   the	  dephosphorylation	  of	  
Olig2	  at	   S147.	   In	  order	   to	   identify	   candidate	  phosphatases	   responsible	   for	   S147	  phosphate	  
removal,	   I	   analysed	   published	   microarray	   data	   for	   phosphatases	   and	   phosphatase	  
components	   with	   differential	   expression	   in	   NSCs	   and	   OLPs.	   RNA	   ISH	   and	   immunolabeling	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experiments	  confirmed	  down-­‐regulation	  of	  the	  inhibitory	  Ppp1r14a	  subunit	  of	  PP1	  in	  Olig2-­‐
expressing	  pMN	  NSCs	  over	  the	  fate	  switch.	  This	  data	  suggests	  in	  pre-­‐fate	  switch	  pMN	  NSCs,	  
Olig2	   S147	   phosphorylation	  might	   be	   preserved	   through	   Ppp1r14a-­‐mediated	   regulation	   of	  
PP1	  activity.	  Repression	  of	  Ppp1r14a	   in	  pMN	  NSCs	  –	   induced	  by	  as	  yet	  unknown	  upstream	  
signals	   –	   would	   activate	   PP1	   and	   induce	   Olig2	   S147	   dephosphorylation.	   Analysis	   of	   a	  
conditional	   Ppp1r14a-­‐null	   mouse	   line	   will	   reveal	   the	   in	   vivo	   requirement	   of	   dynamic	  
Ppp1r14a	  expression	  for	  normal	  MN/OLP	  production.	  To	  date,	  however,	  attempts	  to	  recover	  
Ppp1r14a-­‐null	   embryonic	   stem	   cell	   clones	   from	   the	   EUCOMM	   repository	   have	   been	  
unsuccessful.	   I	  have	  received	  the	  Ppp1r14a	  targeting	  vector	  from	  EUCOMM	  but	  sequencing	  
indicates	  it	  does	  not	  contain	  the	  correct	  features.	  
	  
Molecular	  mechanisms	  of	  Olig2	  function	  
	  
Dimerization	  is	  critical	  for	  bHLH	  TF	  activity	  and	  phosphorylation	  of	  S147	  is	  known	  to	  alter	  the	  
protein	   binding	   properties	   of	   Olig2	   (Li	   et	   al.,	   2011).	  Moreover,	   S147	   is	   located	   within	   the	  
DNA-­‐binding	  HLH	  domain,	  suggesting	  the	  phosphorylation	  state	  of	  S147	  could	  influence	  Olig2	  
occupancy	  of	  specific	  genomic	  binding	  sites.	  In	  addition	  to	  the	  developmental	  and	  molecular	  
regulation	  of	  Olig2	  dephosphorylation	  and	  the	  MN-­‐OLP	  fate	  switch,	   I	  explored	  the	  effect	  of	  
S147	  phosphorylation	  on	  Olig2	  gene	  target	  choice.	  Performing	  ChIP-­‐qPCR	  and	  ChIP-­‐seq	  from	  
primary	  Olig2-­‐expressing	  NSC	  cultures,	  I	  have	  identified	  an	  array	  of	  phospho-­‐S147	  Olig2	  gene	  
targets.	  Using	  the	  phospho-­‐null	  Olig2-­‐S147A	  mutant	  model,	  I	  have	  revealed	  a	  critical	  effect	  of	  
S147	  dephosphorylation	  on	  Olig2	  gene	  target	  binding	  activity.	  Phospho-­‐S147	  Olig2	  occupied	  
E-­‐box	   sequences	   of	   genes	   linked	   to	   neural	   development	   and	   function.	   I	   found	   the	   set	   of	  
phospho-­‐Olig2	  gene	  targets	   in	  the	  NSCs	  was	  highly	  concordant	  with	  a	  published	  Olig2	  ChIP-­‐
seq	  dataset	  from	  cultured	  OLPs,	  suggesting	  that	  Olig2	  gene	  target	  choice	  is	  similar	  in	  pre-­‐fate	  
switch	  NSCs	  and	  OLPs	  (Yu	  et	  al.,	  2013).	  In	  contrast,	  however,	  Olig2-­‐S147A	  expressed	  in	  NSCs	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–	  modeling	   post-­‐fate	   switch	   NSCs	   –	   did	   not	   display	   any	   specific	   DNA-­‐binding	   activity.	   This	  
suggests	   that	   dephosphorylated	   Olig2	   vacates	   its	   gene	   target	   binding	   sites	   in	  
oligodendrogenic	   NSCs,	   before	   reoccupying	   the	   majority	   of	   sites	   in	   committed	   OLPs.	   It	  
remains	   to	   be	   established	   whether	   the	   observed	   transience	   of	   Olig2/DNA	   dissociation	  
coincides	  with	   rephosphorylation	   at	   S147.	   Ultimately,	   this	   data	   offers	   valuable	   insight	   into	  
the	   highly	   dynamic	   molecular	   activity	   of	   Olig2	   and	   will	   provide	   a	   useful	   foundation	   for	   a	  
detailed	  understanding	  of	  how	  Olig2	  regulates	  NSC	  fate	  in	  the	  developing	  spinal	  cord.	  
	  
Additional	  phospho-­‐regulation	  of	  Olig2	  
	  
In	   addition	   to	   pMN	   domain-­‐resident	   NSCs,	   Olig2	   is	   expressed	   throughout	   the	   OL	   lineage,	  
from	  nascent	  OLPs	   to	   fully	  mature	   and	  myelinating	  OLs,	   as	  well	   as	   in	   a	   number	  of	   distinct	  
neurogenic	   and	   gliogenic	   stem	   cell	   populations	   (reviewed	   in	   Meijer	   et	   al.,	   2013).	  
Accompanying	  the	  broad	  expression	  of	  Olig2	  is	  a	  diverse	  array	  of	  cell-­‐type-­‐specific	  functions.	  
For	   TFs	   such	   as	   Olig2,	   post-­‐translational	   modifications	   of	   specific	   amino	   acids	   frequently	  
direct	   TF	   function	   in	   specific	   cellular	   contexts	   (Benayoun	  &	  Veitia,	   2009;	   Filtz	   et	   al.,	   2014).	  
Phosphorylation	  of	  Olig2	  at	  specific	  serine	  residues	  –	  the	  most	  common	  phospho-­‐amino	  acid	  
–	   alters	   intracellular	   and	   intranuclear	   localisation,	   cofactor	   choice	   and	   gene	   target	  
recognition,	   and	   profoundly	   regulates	   neural	   progenitor	   proliferation	   and	   neural	   lineage	  
development	  in	  vitro	  and	  in	  vivo	  (Setoguchi	  &	  Kondo,	  2004;	  Li	  et	  al.,	  2011;	  Sun	  et	  al.,	  2008;	  
Meijer	   et	   al.,	   2014).	   I	   report	   that,	   in	  mouse,	   TFs	   have	   a	   significantly	   higher	   serine	   content	  
relative	   to	   non-­‐TF	   proteins,	   and	   Olig2	   is	   one	   of	   the	   most	   serine-­‐rich	   TFs.	   The	   range	   of	  
expression	  and	  developmental	  functions	  described	  for	  Olig2	  could,	  I	  propose,	  be	  dependent	  
on	   the	   modification	   of	   multiple	   phospho-­‐acceptor	   residues,	   the	   status	   of	   which	   would	  
determine	  Olig2	  activity	  and	  function.	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I	  have	  also	  generated	  expression	  vector	  and	  PAC	  constructs	  for	  in	  vitro	  and	  in	  vivo	  analysis	  of	  
Olig2	  S263	  phosphorylation.	  MS	  previously	  identified	  S263	  as	  a	  genuine	  phosphorylation	  site	  
(Sun	  et	  al.,	  2011).	  S263	  is	  a	  putative	  substrate	  of	  P38-­‐MAPK,	  GSK3	  and	  CDK5,	  and	  the	  genetic	  
tools	   described	   here	   should	   enable	   confirmation	   of	   kinase-­‐mediated	   S263	   phosphorylation	  
and	  examination	  of	  the	  physiological	  requirement	  of	  S263	  phosphorylation	  for	  proper	  Olig2	  
function	  in	  vivo.	  	  
	  
The	   data	   presented	   here	   provides	   valuable	   insight	   into	   potentially	   important	   phospho-­‐
acceptor	   sites	   in	   Olig2	   and	   will	   be	   a	   useful	   resource	   for	   future	   research.	   Ultimately,	  
establishing	  the	  bona	  fide	  phosphorylation	  sites	  on	  Olig2	  and	  the	  kinases	  acting	  on	  each,	  as	  
well	  as	  the	  molecular	  and	  developmental	  function	  of	  each	  modification,	  will	  be	  vital	  for	  our	  




Oligodendrocytes	  are	  the	  myelinating	  cells	  of	  the	  central	  nervous	  system,	  ensheathing	  axons	  
and	  facilitating	  rapid	  saltatory	  conduction	  of	  action	  potentials.	   In	  evolution,	   the	  emergence	  
of	   CNS	  myelin	   was	   critical	   to	   the	   formation	   of	   larger	   and	  more	   complex	   neural	   networks	  
(Hartline	   &	   Coleman,	   2007).	   Moreover,	   myelination	   has	   recently	   been	   revealed	   to	   be	  
necessary	   for	   the	  acquisition	  of	  new	  skills	   in	  a	  mouse	  model	  of	  motor	   learning,	  and	   loss	  of	  
myelin	  is	  a	  pathophysiology	  associated	  with	  several	  major	  neurodegenerative	  diseases,	  most	  
significantly	   multiple	   sclerosis	   (Compston	   &	   Coles,	   2002;	   McKenzie	   et	   al.,	   2014).	   The	  
involvement	   of	   OLs	   in	   fundamental	   neurological	   processes	   and	   disease	   has	   stimulated	  
intense	   scientific	   interest	   in	   these	   cells.	   In	   animal	   models	   of	   demyelinating	   diseases	   and	  
spinal	   cord	   injury,	   proof-­‐of-­‐concept	   studies	   have	   demonstrated	   robust	   remyelination	   with	  
cell	   replacement	   strategies,	   though	   OL-­‐/myelin-­‐linked	   cell-­‐based	   treatments	   remain	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unavailable	   in	  the	  clinic	   	   (Yasuda	  et	  al.,	  2011;	  Huang	  &	  Franklin,	  2012).	  At	  the	   level	  of	  basic	  
research,	   modern	   imaging	   and	   genetic	   tools	   combined	   with	   next	   generation	   sequencing	  
technologies	  have	  brought	  significant	  advances	  in	  our	  understanding	  of	  OL	  development	  and	  
function.	   In	   the	   research	   reported	   here,	   I	   have	   applied	   a	   range	   of	   methods	   to	   address	  
important	   outstanding	   questions	   and	   provide	   experimental	   resources	   for	   future	   research.	  
Ultimately,	  examining	  OL	  formation	  and	  myelination	  in	  vivo	  and	  in	  vitro	  and	  integrating	  the	  
knowledge	   into	   robust	   models	   of	   OL	   development	   will	   inform	   the	   future	   generation	   of	  
clinically	  viable	  treatments	  for	  demyelinating	  diseases.	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